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Abstract 
 
Sepsis is a pathological syndrome that leads to unique physiological changes in critically ill 
patients, and can affect antibiotic pharmacokinetics. Acute kidney injury (AKI) is common in 
critically ill patients. The commencement of renal replacement therapy (RRT) in the management of 
AKI can further affect antibiotic pharmacokinetics. RRT prescription within intensive care units 
(ICUs) worldwide is highly variable as it depends on availability, speciality and cost. Thus, 
antibiotic pharmacokinetic studies in RRT derived from one type of RRT are not readily 
transferrable to another type of RRT. The major challenge caused by RRT is altered antibiotic 
clearance by the extracorporeal circuit, which will vary depending on the RRT modality and 
settings. It follows, that standardisation of antibiotic dosing regimens is not advisable. Clinically, 
when prescribing antibiotic doses for critically ill patients on RRT, various factors require 
consideration including; RRT mode and settings, patient characteristics (body size and other organ 
function), and the likely bacterial pathogen susceptibility. Whilst numerous pharmacokinetic studies 
have been published on various classes of antibiotics to optimize dosing, continuous infusion (CI) 
as a method to optimise antibiotic activity, has rarely been studied in these patients. Certainly, there 
has been much recent interest in this alternative mode of administration for beta-lactam antibiotics 
(e.g penicillin, cephalosporin, carbapenem antibiotics), as a mechanism to achieve sustained 
antibiotic concentrations in plasma, as well as optimal pharmacokinetic/pharmacodynamics 
(PK/PD) indices.  
 
This Thesis aims to describe the pharmacokinetics of two commonly used beta-lactam antibiotics in 
intensive care unit (ICU) setting, namely meropenem and piperacilllin/tazobactam during 
continuous RRT (CRRT) using ex vivo and clinical pharmacokinetic data. Specifically this work 
will characterise the pharmacokinetics and the probability of PK/PD attainment of beta-lactam 
dosing by two methods of antibiotic administration, CI and intermittent bolus (IB) in critically ill 
patients receiving a common form of CRRT, continuous venovenous haemofiltration (CVVH).  
 
This Thesis comprises of nine chapters. Chapter one is an introductory chapter where it provides an 
overview on the literatures on the Thesis topic. The discussion section in Chapter one outlines a 
theoretical framework behind the objectives of this Thesis, as well as the specific aims of this 
Thesis. 
 
Chapter two incorporates a published review article that systemically analysed the current 
literatures on different classes of antibiotic pharmacokinetics in special situations in the ICU 
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including patients receiving different types of RRT, burn patients and extracorporeal membrane 
oxygenation (ECMO). This chapter describes the frequency with which current antibiotic dosing 
regimens achieve the therapeutic targets or the PK/PD targets and outlines alternative dosing 
strategies that may optimise antibiotic dosing in these populations. 
 
Chapter three includes a published review article that summarizes the pharmacokinetic parameters 
of different classes of antibiotics in critically ill patients receiving different types of RRT. This 
chapter also reviews the frequency that current antibiotic dosing regimens achieve the PK/PD 
targets of different classes of antibiotic, and outlines alternative antibiotic dosing strategies to 
optimise antibiotic dosing in this population 
 
Chapter four, five, six, seven and eight are original research articles that report the research projects 
undertaken. Each of these chapters begin with a short sypnosis of the work, followed by the 
published or submitted manuscript, and the chapter ends with a final conclusion on the main 
finding(s) of the study and its contribution to the knowledge in this area of research. 
 
Chapter four describes the impact of variations in RRT settings on piperacillin, meropenem and 
vancomycin drug clearance in critically ill patients, an analysis of published literature on 
pharmacokinetic parameters and dosing regimens. Effluent flow rate was found to be the most 
reliable predictor of antibiotic clearance despite the significantly altered pharmacokinetics in these 
patients. It was concluded that higher dosing regimens maybe required in critically ill patients 
receiving RRT, in the presence of high effluent flow rates and/or the presence of poorly susceptible 
pathogens, particularly for vancomycin. 
 
Chapter five describes findings of a national survey on prescribing practice of RRT in Malaysian 
ICUs. This survey aims to also compare the results to previously published data from other regions. 
It was found that CRRT was the preferred form of RRT to treat AKI in critically ill patients. CVVH 
was the most common RRT modality with other RRT settings variable.  The RRT practices were 
overall similar to those observed in other regions although the modality and settings utilised were 
slightly different, due to local availability. 
 
Chapter six describes the findings of a prospective pharmacokinetic trial on meropenem 
pharmacokinetics administered by CI and IB in Malaysian critically ill patients receiving CVVH. 
This study also aimed to evaluate the frequency of achieving targeted PK/PD indices of meropenem 
by CI and IB administration. CI resulted a higher meropenem steady-state concentrations (Css) on 
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occasion 1 (day 1-3 of treatment) compared to the minimum concentration (Cmin) observed for IB 
patients. The meropenem doses administered resulted in plasma drug concentrations that were 
above 4 times the targeted susceptibility breakpoint (2 mg/L) for 100% of the dosing interval, for 
both groups, throughout the treatment days. CI could be an alternative to IB for meropenem 
administration in critically ill patients receiving CVVH, particularly for less susceptible pathogens. 
 
Chapter seven describes piperacillin pharmacokinetics administered by CI and IB in critically 
patients receiving CVVH. This study also aimed to describe the frequency of achieving targeted 
PK/PD indices of piperacillin by CI and IB administration. Significantly higher Css were observed 
in CI patients. Total clearance (CLtotal) and clearance not mediated by CVVH (CLnon-CVVH) were 
also significantly higher with CI administration. The estimated unbound piperacillin concentrations 
were 4 times above the target susceptibility breakpoint (16 mg/L) for the entire dosing interval 
(100% fT>4xMIC), in more patients who received CI administration (occasion 1 of sampling), as 
compared to IB patients. Compared to IB dosing, and despite similar CVVH settings, CI 
administration of piperacillin results in a pharmacokinetic profile that may optimize outcomes for 
less susceptible pathogens. 
 
Chapter eight describes the pharmacokinetic findings from an experimental study of meropenem 
and piperacillin during continuous haemofiltration. This ex-vivo study used a modified RRT system 
circulated with a blood-crystalloid mixture, which aimed to characterise the adsorption and 
clearance of meropenem and piperacillin. The study also aimed to compare the parameters observed 
during the ex vivo pharmacokinetic study with data observed from the clinical studies in Chapters 6 
and 7. Meropenem and piperacillin appear to be rapidly adsorbed onto the CRRT circuit, however 
the amount of adsorption is likely to be clinically insignificant. No significant differences were 
observed for meropenem and piperacillin clearance with pre- or post-dilution during continuous 
haemofiltration in this ex vivo study. Further, no clinically significant differences were observed 
between meropenem and piperacillin parameters obtained from the ex vivo study compared to those 
observed from clinical data. The experimental method studied here could be a surrogate approach 
for future clinical pharmacokinetic studies of CRRT.  
 
Chapter nine is the final chapter of this Thesis and which includes a final summary of the findings, 
as well as a discussion on potential future research in this area. 
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Chapter 1 
 
Introduction and literature review 
 
1.1 Introduction 
 
Antibiotic dosing in critically ill patients is challenging. The severity and progression of critical 
illness leads to pathophysiologic changes, which can significantly affect antibiotic pharmacokinetic 
parameters. In critically ill patients with severe sepsis and septic shock, treating physicians can 
struggle to successfully treat infection, particularly in an era of emerging resistance where there are 
limited new antibiotic agents entering clinical practice. Optimization of antibiotic 
pharmacokinetic/pharmacodynamics (PK/PD) has therefore been recommended to increase the 
chances of clinical success, and limit the development of bacterial resistance. However, there are 
variable factors that can affect antibiotic dosing in this population, and most importantly these 
factors vary between intensive care units (ICUs) worldwide.  Patient characteristics, intensive care 
unit (ICU) management, and the likely causative pathogens, significantly contribute to the 
complexity of antibiotic dosing in critically ill patients. Many studies have sought to describe the 
best approach to antibiotic dosing in this setting, however as variations exist between critically ill 
populations and ICU settings worldwide, dosing regimens that are individualised for patients 
remain the best approach. 
 
Commencement of renal replacement therapy (RRT) further complicates antibiotic prescription in 
critically ill patients. Variable RRT settings lead to varying dosing requirements, not easily 
determined from previously published data. Therefore, the main focus in this research is to evaluate 
the pharmacokinetic of two commonly used antibiotics in critically ill patients, meropenem and 
piperacillin/tazobactam, in a significantly different population from those previously studied. Both 
antibiotics share a similar PK/PD characteristic - time-dependent killing. Previous studies have 
demonstrated that continuous infusion (CI) is advantageous in optimizing the PK/PD of these 
antibiotics in critically ill patients. However, currently there is a lack of data describing the use of 
this dosing strategy in critically ill patients receiving RRT, particularly continuous RRT (CRRT).  
In this research, the pharmacokinetic parameters of CI and intermittent bolus (IB) administration of 
meropenem and piperacillin/tazobactam in critically ill patients concurrently treated with CRRT, 
specifically the continuous venovenous haemofiltration (CVVH) mode, will be determined. 
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1.2 Sepsis 
 
Sepsis was the 11th leading cause of death in the United States as reported by the Center for Disease 
Control and Prevention (CDC) in 2010, with an incidence 11.3 per 100,000 population [1]. For 
septic patients, 50% received ICU treatment, with 17.3% requiring mechanical ventilation or care in 
a coronary care unit [2]. The costs associated with sepsis and its management in critical care rose 
from $56.6 billion to $81.7 billion, from 2000 to 2005 in United States [3]. Mortality related to 
sepsis reported worldwide is variable, with mortality rates up to 44.5% in Asian ICUs [4].  In a 
study of prevalence of infection in ICU patients, 71% of patients were receiving antibiotic therapy.  
A prolonged ICU stay increased the likelihood of infection in the studied population [5]. Early and 
appropriate antibiotic therapy is recommended, and has been shown to increase survival in patients 
with severe sepsis or septic shock [6].  
 
1.3 The importance of antibiotic therapy in sepsis 
 
The importance of timely and adequate use of antibiotics in sepsis has been previously reviewed 
and discussed [7]. In a retrospective review of patients with bacterial meningitis [8], mortality was 
lower in patients administered antibiotic in the emergency department (7.9%), as compared to those 
who received antibiotics as an inpatient (29%). Iregui and colleagues [9] reported a similar outcome 
in critically ill patients administered early antibiotic treatment for ventilator-associated pneumonia 
(VAP). Delay in the initiation of antibiotic treatment is reported as a risk factor for hospital 
mortality [9]. In a retrospective study of critically ill patients with septic shock, Larché and 
colleagues [10] addressed the importance of time to antibiotic treatment.  Specifically, mortality 
was shown to be higher when the time to antibiotic treatment is more than 2 hours [10]. All these 
studies highlight the importance of early and adequate antibiotic treatment in septic patients.                                                                                    
 
1.4 Pathophysiological changes in critically ill patients that can affect drug 
pharmacokinetics 
 
In sepsis, depression of myocardial function, in addition to microvascular circulatory failure, may 
lead to reduction in organ perfusion that can eventually result in end-organ failure. This may 
progress to multiple organ dysfunction syndrome (MODS) in severe sepsis or septic shock [11]. 
The importance of these pathophysiological changes in the critically ill patient, relate to alterations 
in the two main pharmacokinetic parameters that describe dosing requirements, the apparent 
volume of distribution (Vd) and clearance [12]. Clearance may decrease, as determined by the 
	   3 
effects of the underlying pathological process on kidney, gut and/or liver function [13]. Tissue 
distribution of antibiotics may also be impaired during critical illness. 
 
1.5 Optimisation of antibiotic in critically ill patients: pharmacokinetic/pharmacodynamic 
consideration 
 
Given the potential for either suboptimal dosing or overdosing of antibiotics in critically ill patients 
with sepsis, PK/PD optimization of antibiotics is being increasingly recognised as a tool to improve 
dosing regimens for critically ill patients. PK/PD relates pharmacokinetic parameters to 
pharmacodynamic indices, which describe antibiotic activity at different concentrations [12, 13]. 
Different classes of antibiotics exhibit different PK/PD indices, which have been defined through 
previous in vitro and in vivo studies in animals and humans [14-22]. 
 
The goal of dosing time-dependent antibiotics is to maximize the time that free plasma 
concentrations exceed the minimum inhibitory concentration (MIC) of causative pathogens 
(fT>MIC). The optimal percentage of fT>MIC (%fT>MIC) is variable for different agents, although is 
largely between 40-80% [17-19]. As the goal of any dosing regimen is to achieve the optimal 
PK/PD target, more frequent dosing or prolongation of antibiotic administration (e.g extended 
infusion (EI) or CI provides a rational way to ensure longer exposure of higher free plasma 
concentrations. The ability of EI or CI to provide better PK/PD target attainment, compared to IB 
administration for beta-lactam antibiotics have been shown previously in many studies [23-28].  
 
For concentration-dependent antibiotics (e.g aminoglycosides), dosing regimens that maximize the 
peak plasma concentration, ideally 8-10 times higher than the MICs (Cmax/MIC 8-10) of causative 
pathogens [15, 17], is generally the aim. Such a target could be rationally achieved through a higher 
dose, with less frequent administration, as there is an advantage in utilising these agent’s post 
antibiotic effect (PAE). This refers to the persistent suppression of bacterial growth following 
exposure to an antibiotic. Certain antibiotics (e.g fluoroquinolones, glycopeptides, colistin) exhibit 
both time- and concentration dependent killing [14, 16, 21, 22]. The goal of dosing regimens in 
these circumstances would be to achieve a higher 24-hour area under the concentration-time curve  
(AUC0-24) to MIC ratio. Figure 1.1 illustrates the basic PK/PD indices for different class of 
antibiotics. 
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Figure 1.1: Basic concept of pharmacodynamic targets of antibiotics (adapted from Roberts & 
Lipman [13]) 
 
 
 
 
 
 
 
 
 
 
 
 
1.6 Renal replacement therapy in intensive care unit setting 
 
Acute kidney injury (AKI) is a frequent problem in the ICU, and has been reported to affect up to 
67% of critically ill patients [29]. Up to 70% of patients with AKI may require RRT [30]. Sepsis 
and septic shock can cause AKI [31]. The ‘Risk, Injury, Failure, Loss and End-stage kidney 
disease’ (RIFLE) classification for AKI is used to stage the severity of renal injury, varying from 
minor changes in renal function, to the requirement for RRT [32]. Using the RIFLE classification, 
ICU mortality is greatest among patients with classification ‘F’ (74.5%), compared to those 
classified ‘I’ (50%) and ‘R’ (38.3%) [33]. Given the increased mortality rates seen with worsening 
severity of AKI, commencement of RRT is considered an essential component in the management 
of AKI in the ICU.  
 
RRT modalities such as intermittent haemodialysis (IHD), CRRT (e.g CVVH, continuous 
venovenous haemodialysis (CVVHD), continuous venovenous haemodiafiltration (CVVHDF)) and 
prolonged intermittent renal replacement therapy (PIRRT) (e.g sustained low efficiency dialysis 
(SLED) and extended daily dialysis (EDD)) are commonly used in ICU. Many RRT modalities 
employ ultrafiltration.  In this process, water moves across a semi-permeable membrane because of 
differences in hydrostatic pressure across the membrane.  Solute is ‘dragged’ with water, resulting 
in removal of waste products such as creatinine and urea. This mechanism for waste removal is 
often referred to as convection. Table 1.1 summarises the differences between the types of RRT 
commonly available [34, 35].  
Cmax/MIC - concentration-dependent  
 (e.g aminoglycoside) 
T>MIC  - time-dependent (e.g β-
lactam) 
AUC/MIC  - concentration and time-
dependent  
    (e.g fluoroquinolones) 
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Table 1.1: The differences between intermittent haemodialysis, continuous renal replacement 
therapy and prolonged intermittent renal replacement therapy 
 IHD CRRT PIRRT 
Characteristics • Empirically delivered 
3 to 6 times a week 
• 3 to 4 hours per 
session 
• Blood flow rate of 
200-300 mL/min and 
a dialysate flow rate 
of 500 – 800 mL/min 
• Occurs 24 hours a day 
• Blood flow of 100-200 
mL/min and dialysate 
flow of 17-40 mL/min 
(diffusive) 
• Classified by vascular 
access and method of 
solute clearance 
• 6-14 hours per session 
• Blood flow rate of 
200 mL/min and a 
dialysate flow rate of 
100-300 mL/min 
Solute & 
Volume 
clearance 
Solute removal by 
diffusion 
• Different modalities 
can use diffusion, 
convection or 
combination of both 
• Gradual solute and 
volume removal as in 
CRRT, high solute 
clearance as in IHD 
Advantage(s) • Rapid solute and 
volume removal 
• Decreased need for 
anticoagulation 
because of faster 
blood flow and 
shorter duration of 
treatment 
• Better haemodynamic 
tolerability 
• Can remove toxins with 
a large volume of 
distribution 
• Ability to remove large 
molecule weight (up to 
30,000 dalton) through 
the convective process. 
• Less expensive 
compare to CRRT, 
can be done 
intermittently thus 
avoid the interruption 
of therapy 
• Allows for patient 
mobility when RRT 
not being used 
Disadvantage(s) • Risk of systemic 
hypotension 
• Access and filter 
clotting and the 
consequent need for 
anticoagulation 
• Limited by greater cost, 
demand trained staff 
• Infrastructure for 
effluent is expensive 
IHD = intermittent haemodialysis; CRRT = continuous renal replacement therapy; PIRRT = prolonged 
intermittent renal replacement therapy and RRT = renal replacement therapy 
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The use of RRT between ICUs can vary significantly [36-38]. Ideally, the aims of treatment are to 
control fluid volume, correct acid-base abnormalities, improve uraemia, promote renal recovery and 
improve survival without causing complications [34]. 
 
1.7 The importance of continuous renal replacement therapy during antibiotic therapy 
 
The influence of CRRT on antibiotic pharmacokinetic in critically ill patients is well described 
worldwide. For example, studies of meropenem during CRRT reported highly variable 
pharmacokinetic parameters, as well as divergent dosing recommendations, when targeting optimal 
PK/PD indices [39-46]. Within the same mode of CRRT, such as CVVH [39, 41], significant 
differences in meropenem clearance are observed, possibly related to different settings of CVVH, 
such as the filter material employed (polysulfone vs polyacrylonitrile (PAN) membranes) and 
variable blood flow (150-170 mL/min) and ultrafiltration rates (50-150 mL/min). 
 
In a study using modeled continuous haemofiltration circuit by Lam and colleagues [47], the 
authors demonstrated that more than 90% of gentamicin and 99% of netilmicin was adsorbed by 
PAN filters, whereas adsorption by polyamide filters was substantially less. In another study, 
adsorption of amikacin to PAN filters was significant and not reversible [48], thus suggesting the 
potential need for routine amikacin monitoring in patients receiving CRRT with PAN haemofilters. 
Similar findings were seen in another study of modeled RRT circuit on vancomycin, where 
irreversible adsorption onto filters was greater with PAN than polyamide and polysulfone type 
filters [49]. Choi and colleagues [50] found that levofloxacin sieving coefficients (Sc) are not 
related to variations in the point of dilution (pre-dilution or post-dilution) or membrane type, but 
most probably variations in other factors such as patient population, transmembrane pressure, filter 
age, blood flow rate and blood viscosity. It was suggested that with higher rates of fluid 
replacement, the point of dilution would probably significantly influence clearance during 
haemofiltration [51]. In a study by Uchino and colleagues [52], the amount of pre-dilution 
replacement fluid significantly influenced the Sc and clearance of vancomycin. 
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1.8 The modeled (ex vivo) versus clinical study design 
 
Unique data concerning antibiotic pharmacokinetic during CRRT can be derived not only from a 
clinical setting, but potentially also from the experimental methods, using ex vivo CRRT models. 
Table 1.2 summarises the advantages and disadvantages of clinical and ex vivo study designs.	  
Importantly, each study design complements each other, with both investigations likely to 
contribute to the knowledge base regarding antibiotic pharmacokinetics in this context.  Practically, 
not every aspect of CRRT can be evaluated during clinical study. For example the effects of 
different filter materials or surface area are unlikely to be assessable by clinical investigation alone, 
due to clinical impracticality. However, ex vivo studies can provide concurrent or repeated intensive 
data collection, which would be more accurate for performing such comparisons. 
 
Table 1.2: Advantages and disadvantages of clinical and ex vivo study designs 
 Clinical study Ex vivo study 
Advantage(s) • Data from patient group that 
doses will be used in 
• More expensive 
• Can assess effect of different filter 
material, surface areas and 
dialysate flow rate 
• Able to control the blood flow 
rate, ultrafiltration rate and 
dialysate flow rate throughout the 
study 
• No consent required 
• Shorter time to complete study 
• More easily repeatable 
 
Disadvantage(s) • Variability in RRT setting is 
difficult to standardize given 
clinical needs of patients 
• Limited sample size available 
• Prolonged data collection period 
• High costs with repeating a 
study 
• May not identically resemble the 
characteristics of critically ill 
patients  
 
RRT = renal replacement therapy 
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1.9 Conclusions 
 
Meropenem and piperacillin/tazobactam share basic characteristics of beta-lactams antibiotics. Both 
are hydrophilic, with many studies demonstrating these antibiotics are significantly removed from 
plasma during CRRT, with the degree of elimination being variable, and dependent on several 
factors. These factors include; CRRT mode and settings, as well as the effect of patient 
characteristics. As such, antibiotic pharmacokinetics in critically ill patients receiving CRRT can be 
highly variable, and therefore a singular dosing regimen will not be universally applicable. 
Published data are not presently translatable to other CRRT settings or patient populations.  
 
CI has been shown to be superior to IB in many previous clinical studies in terms of establishing 
and maintaining plasma concentration above the MIC, throughout the dosing interval. CI also offers 
a distinct advantage when dealing with more resistant pathogens (those with a higher MIC). A 
landmark study of CI in CRRT by Mariat and colleague [53] has shown that the administration 
ceftazidime by CI during CVVHDF resulted in sustained serum concentrations four times above the 
MIC, throughout the course of therapy. This finding confirms that CI of meropenem and 
piperacillin/tazobactam might also be advantageous in critically ill patients receiving CRRT. To 
date limited data are available on the pharmacokinetic of meropenem and piperacillin administered 
as CI in patients receiving CRRT, thus unique findings are expected. It is expected that there will be 
different pharmacokinetic parameters between CI and IB administration for both antibiotics. 
 
Describing these pharmacokinetic parameters in a significantly different population such as in 
Asians is important as this population has a significantly smaller body size compared with 
European or American patients, and could result in significantly different findings. To address this 
issue, a study that measures the pharmacokinetic of meropenem and piperacillin/tazobactam in 
Malaysian critically ill patients receiving CRRT was conducted. Data from this study was compared 
to previously published studies in non-Malaysian patients. 
 
As there are possible limitations to the clinical study, particularly in describing the effects of 
different settings in CRRT, the ex vivo study of the CRRT circuit was carried out to complement 
these data.  
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AIMS 
 
This Thesis aims to further characterize the pharmacokinetics of beta-lactam antibiotics during 
CVVH in a critically ill population, in order to determine the frequency of achievement PK/PD 
targets when administered by CI and IB. 
 
The specific aims of this Thesis are: 
1. To perform a systematic review of the published literature on antibiotic pharmacokinetics 
and dosing requirements in critically ill patients receiving different RRT modalities 
2. To determine the factors within RRT settings that can affect antibiotic clearance 
3. To report the prescribing practice of RRT in Malaysian ICUs as a baseline for future 
potential multinational research in this area 
4. To describe the pharmacokinetic parameters of meropenem when administered by CI and IB 
in critically ill patients receiving CVVH 
5. To describe the pharmacokinetic parameters of piperacillin when administered by CI and IB 
in critically ill patients receiving CVVH 
6. To further characterize the effect of the RRT circuit on meropenem and piperacillin 
pharmacokinetics during an experimental continuous haemofiltration circuit 
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Chapter 2 
 
Antibiotic pharmacokinetics in special situations in the intensive care unit: Burns, renal 
replacement therapy and extracorporeal membrane oxygenation 
 
2.1  Sypnosis 
 
Antibiotic dosing in critically ill patients receiving organ support treatments including RRT and 
extracorporeal membrane oxygenation (ECMO) is likely to be suboptimal. These patients can be 
exposed to significant antibiotic pharmacokinetic changes, particularly in terms of drug volume of 
distribution and clearance.  Special ICU populations such as burn patients would add further to the 
complexity to delivering optimal antibiotic treatment, particularly due to the pathophysiological 
changes and interventions associated with burn injury management. This chapter aims to review 
published literature describing antibiotic pharmacokinetics and dosing regimens of different classes 
of antibiotics in critically ill patients with burn injuries, and those receiving extracorporeal therapies 
including CRRT, SLED and ECMO. 
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2.2 Published review article entitled, “Improving antibiotic dosing in special situations in 
the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation” 
 
The manuscript entitled, “Improving antibiotic dosing in special situations in the ICU: burns, renal 
replacement therapy and extracorporeal membrane oxygenation” has been accepted for publication 
by Current Opinion in Critical Care (2012; 18(5): 460-471). 
 
The co-authors contributed to the manuscript as follows: the literature review was performed by the 
PhD candidate, Janattul-Ain Jamal, and Mr. Caleb Economou, under the supervision of Prof. Jason 
A. Roberts. The PhD candidate, Janattul-Ain Jamal, and Mr. Caleb Economou, were responsible for 
data extraction from cited articles. Analysis of data was performed by the PhD candidate, Janattul-
Ain Jamal and Mr. Caleb Economou, under guidance of Prof. Jason A. Roberts and Prof. Jeffrey 
Lipman. The PhD candidate, Janattul-Ain Jamal, took the leading role in manuscript preparation 
and writing. 
 
The manuscript is presented as published, except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted to 
fit the overall style of the Thesis. The references are found alongside to the other references of the 
Thesis, in the section ‘References’. 
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2.2.1 Abstract 
 
Purpose of review: Antibiotic dosing for critically ill patients that is derived from other patient 
groups is likely to be suboptimal because of significant antibiotic pharmacokinetic changes, 
particularly in terms of drug volume of distribution and clearance. Organ support techniques 
including RRT and ECMO increase the pharmacokinetic variability. This article reviews the 
recently published antibiotic pharmacokinetic data associated burns patients, those receiving CRRT, 
SLED and ECMO.  
 
Recent findings: These groups develop increases in volume of distribution that necessitate the use 
of higher initial doses to rapidly achieve therapeutic antibiotic concentrations. Burns patients have 
supranormal drug clearances requiring more frequent administration of antibiotics. Patients 
receiving CRRT or SLED have variable drug clearances related to different equipment and RRT 
settings at different institutions. ECMO presents a different challenge because there is such a dearth 
of data with higher than standard doses potentially required, even in the presence of end-organ 
failure.  
 
Summary: In the context of such variable pharmacokinetics, a guideline approach to dosing 
remains elusive because of insufficient available data and therefore use of therapeutic drug 
monitoring should be considered advantageous where possible. 
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2.2.2 Introduction 
 
The healthcare system burden associated with infections in critical care units remains high. Given 
that as many as 70% of patients may be receiving antibiotics at any one time and with 50% of 
patients deemed infected, antibiotic prescription is a very common part of care of the critically ill 
patient [5]. However, the types of patients, infections and antibiotics can vary significantly and an 
individualized approach to patient care should be a focus of patient care plans. Clinicians will 
initially identify the likely source of the infection, then determine the likely pathogen and 
commence an appropriate antibiotic to treat the infection. To further optimize antibiotic therapy, 
individualization of antibiotic dosing is important – that is, to prescribe a dose which will ensure a 
pharmacokinetic exposure of the drug likely to maximize bacterial killing and clinical outcome 
[54]. 
 
A challenge for critical care clinicians however, is the variation in organ function of the critically ill 
patient [11]. Although some patients may be hyperdynamic with elevated cardiac outputs and renal 
and hepatic blood flows predisposing to supranormal drug clearances, other patients may develop 
single or multiple organ dysfunction leading to very low drug clearances and corresponding high 
drug concentrations [55]. Patients with burns injuries and those receiving extracorporeal therapies 
including ECMO [56], CRRT [57] and SLED [58] can develop profoundly altered 
pharmacokinetics and will have varying antibiotic dosing requirements for which little data are 
presently available. Achieving timely and appropriate antibiotic exposures in these patients is 
essential as has been shown to improve patient outcomes in previous studies [59-61]. 
 
The aim of this review is to examine the recently published data describing the altered 
pharmacokinetics and dosing requirements for critically ill patients with burn injuries and those 
receiving extracorporeal therapies including ECMO, CRRT and SLED. 
 
2.2.3 Methods 
 
A Pubmed search using relevant keywords was undertaken to identify relevant recently published 
English language articles. Journal articles referenced in the primary article identified if appropriate 
were also cited.  
 
 
 
	   15 
2.2.4 Pharmacokinetics and pharmacodynamics in critical illness 
 
PK/PD optimization of antibiotics is being increasingly seen as a tool to improve dosing regimens 
for critically ill patients. PK/PD relates pharmacokinetic parameters to pharmacodynamic indices 
which describe antibiotic activity at different concentrations [12, 13]. Different classes of 
antibiotics exhibit different PK/PD indices which have been defined through previous in-vitro and 
in-vivo studies in animals and humans (Table 2.1) [14-22]. 
 
Table 2.1: Antibiotic killing characteristics and pharmacokinetic/pharmacodynamic target 
Antibiotic 
classification Definition of PK/PD target PK/PD target 
Concentration-
dependent 
Ratio of the peak antibiotic 
concentration to the MIC of the 
pathogen (Cmax/MIC) 
 
Aminoglycoside: Cmax/MIC 8-10 [15] 
Daptomycin: Cmax/MIC 8-10, AUC0-
24/MIC 100 [17, 20] 
Time-dependent 
 
Percentage of time during dosing 
interval for which the free plasma 
concentration of the antibiotic 
remains more than the MIC of the 
pathogen (%fT>MIC) 
β-lactams: 50-70%fT>MIC [17] 
Carbapenems:  ≥40%fT>MIC [17] 
Linezolid: 40-80%fT>MIC [18, 19] 
Concentration- with 
time-dependent 
 
Ratio of the area under the 
concentration-time curve (AUC) 
during a 24-h period to the MIC 
of the pathogen (AUC0-24/MIC) 
Fluoroquinolones: Cmax/MIC 10, 
AUC0-24/MIC 125a (Gram negatives) 
[14, 16] 
Glycopeptides: AUC0-24/MIC ≥400b 
(Staphyloccoccus aureus) [21] 
Colistin: AUC0-24/MIC 53-141 
(Pseudomonas aeruginosa) [22] 
AUC = area under the curve; Cmax = maximum concentration; fT>MIC = unbound plasma concentration above 
the minimum inhibitory concentration of the pathogen; MIC = minimum inhibitory concentration and PK/PD 
= pharmacokinetic/pharmacodynamics. 
aCiprofloxacin 
bVancomycin 
 
Critically ill patients may develop unique pathophysiological changes which can affect antibiotic 
pharmacokinetics, thus necessitating different doses so that the pharmacokinetic exposures 
associated with optimal activity can be achieved. The interrelationship between pathophysiological 
changes in critically ill patients and how these affect antibiotic pharmacokinetic parameters has 
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been reviewed elsewhere [11]. Two main pharmacokinetic parameters that are commonly affected 
due to these changes are the Vd and clearance. An increase in the Vd typically affects hydrophilic 
antibiotics and may warrant an increase in the initial dosing requirements (i.e. loading doses or 
front-loaded doses) to produce target drug concentrations. In contrast, clearance will affect the day-
to-day dosing requirements for patients with those patients developing very high clearance 
requiring more frequent dosing than those that develop low clearance from organ dysfunction. 
Alterations in protein binding can affect both Vd and clearance. In critical illness, albumin is 
redistributed disproportionately from intravascular to extravascular compartments resulting in low 
plasma albumin concentrations [62]. This causes decreases in drug-albumin binding resulting in an 
increased proportion of unbound drug which will distribute extravascularly or be eliminated from 
the body causing low plasma drug concentrations toward the end of a dosing interval. Predicting 
such pharmacokinetic changes is essential for developing appropriate antibiotic dosages and may be 
undertaken with knowledge of the physicochemical characteristics of the antibiotic as described in 
Fig 2.1.  
 
Figure 2.1: The association between antibiotic physicochemical characteristics and possible 
pharmacokinetic parameters alteration during critical illness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PK = pharmacokinetic; Vd = volume of distribution and CL = clearance 
Examples: 
• Aminoglycoside 
• β-lactams 
• Carbapenems 
• Linezolid 
• Glycopeptides 
• Colistin 
• Daptomycin 
 
General PK parameters 
• Low Vd 
• Predominant renal CL 
• Low intracellular 
penetration 
General PK parameters 
• High Vd 
• Predominant hepatic CL 
• Good intracellular 
penetration 
Hydrophilic antibiotics Lipophilic antibiotics 
Examples: 
• Fluoroquinolones 
• Macrolides 
• Lincosamides 
• Tigecycline 
• Clindamycin 
 
PK 
changes in 
critically ill	  
• ↑Vd,  
• ↑ or ↓ in CL (dependent 
on renal function),  
• ↓ interstitial penetration 	  
•  ↔ Vd 
• ↑ or ↓ in CL (dependent 
on hepatic function) 
• ↔ interstitial penetration 	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Significant pharmacokinetic changes are common to many critically ill patients, although there have 
been increasing data published for special critical care populations which have extreme 
pharmacokinetic changes, burns patients and patients receiving ECMO, CRRT and SLED. Below, 
we describe the latest data describing the altered pharmacokinetics in these patient groups and we 
interpret the clinical relevance to antibiotic dosing. 
 
2.2.5 Burns patients   
 
Critically ill burns patients develop complex haemodynamic changes such as hypovolemia, 
hypoalbuminemia and low (or high) [63] glomerular filtration rates during the early phase post burn 
injury [64]. In later phase postburn injury (> 48-72 hours), the patients can exhibit hyperdynamic 
states that can cause increased cardiac output, increases in renal and nonrenal clearance, significant 
decreases in plasma albumin concentrations and liver dysfunction [64]. Protein binding may be 
affected in these patients partly contributing to increases in Vd and clearance. The efficacy of highly 
protein bound antibiotics (ertapenem, daptomycin, ceftriaxone, the ‘oxacillins’) in light of 
hypoalbuminemia is particularly important as small changes in protein binding result in a 
disproportionately greater amount of unbound drug available for activity; however the 
consequential increase in clearance decreases the time that the unbound concentration of antibiotic 
remains above the minimum inhibitory concentration of the pathogen (MIC, fT>MIC) leading to 
potential therapeutic failure if dosing is not adjusted in line with the altered pharmacokinetics. The 
recent studies published on antibiotic PK/PD in burns patients are summarized in Table 2.2 [65-72]. 
 
2.2.5.1 Aminoglycosides 
Recent studies have confirmed that amikacin pharmacokinetic parameters are significantly different 
in burns patients compared with nonburns patients [65, 66]. Amikacin penetrates into eschar tissue 
during early burn injury [65]; however, concentrations in one study did not reach the desired 
maximum concentration in a dosing interval (Cmax) to MIC (Cmax/MIC) ratio of 8-10. However, a 
very low amikacin dose (400 mg; <10 mg/kg) was used in this study suggesting that higher doses of 
20-30 mg/kg may enable achievement of PK/PD targets in eschar tissue. In order to achieve PK/PD 
targets, that is, high Cmax, a dose that is significantly higher than usual is required in burns patients 
particularly when the isolated pathogens have high MICs (e.g. gentamicin and tobramycin 7 mg/kg 
or amikacin 30 mg/kg). In renally impaired patients, less frequent aminoglycoside dosing is 
suggested (24-48 hourly dosing). Where clearance is excessively high, as seen in some patients 
such as in those with augmented renal clearance, more frequent dosing may be appropriate (e.g. 18 
h). 
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2.2.5.2 β-lactams  
Changes in β-lactam pharmacokinetic parameters in burns patients have been well described in 
recent studies [67, 68, 73]. The magnitude of burn injury as well as early treatment in burn patients 
could alter the pharmacokinetic parameters [67]. Usual β-lactam doses are unlikely to achieve target 
plasma concentrations above the MIC [17] of causative pathogens [68, 73, 74]. Increasing the dose, 
infusion time or frequency of administration would be required in this population to optimise drug 
therapy, that is, to increase the fT>MIC [73]. Therapeutic drug monitoring (TDM) may also be useful 
for these patients [75]. 
 
2.2.5.3 Glycopeptide 
Recent studies have described increases in clearance and Vd of vancomycin in burns patients [69, 
70]. Vancomycin appears to extensively penetrate burnt tissue during the early phase of burn 
injuries with concentrations sustained in tissue for longer periods than that observed in plasma [65]. 
Standard doses of 1g intravenous 12 h rarely achieve PK/PD targets [21] in these patients [69, 70]. 
A larger loading dose subsequently followed by a large total maintenance dose such as that 
previously shown necessary for critically ill patients with conserved organ function is required [76]. 
Routine TDM is recommended to maintain adequate concentrations in light of potential 
supranormal clearance or alternatively acute kidney injury both known to occur in burns patients. 
 
2.2.5.4 Other drugs  
Standard linezolid doses were found to be inadequate to achieve PK/PD targets [18, 19] in burns 
patients [71]. Similarly, a higher than standard dose of colistin [72] is required to optimize PK/PD 
targets [22] in burns patients, although the clinical consequences of this altered approach are yet to 
be clarified.  
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Table 2.2: Antibiotic pharmacokinetic parameters in burn patients 
Drug /  
Reference Population 
Number of 
patients Study design Dose 
PK parameters (mean ± SD, unless otherwise stated) 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24  
(mg.h/L) 
CLtotal 
(L/h) 
Vd 
(L) 
CLcr 
(mL/min) 
Aminoglycoside           
Amikacin                      
[65] 
Early stage 
severe burn 
(TBSA 68.39 ± 
17.85) 
20 Prospective, 
open-label, non-
randomized 
400 mg 24 h 
after burn 
 
30.2 ± 2.8 14.4 ± 1.5 1802.5 ± 
285.7 
0.2 ± 0.04 13.2 ± 1.3 95.5 ± 23.1 
Amikacin                      
[66] 
Mean TBSA 38.4 
± 21.8% 
60 Retrospective 
study 
Single daily 
dose 15 mg/kg 
32.7b 
 
1.6b 226.9b 8.3b 64.2b 134.0 ± 35.0  
(no CRRT) 
β-Lactam           
Cephalothin                 
[67] 
Severely burned 
patients (mean 
42 ± 9% burn) 
9 Open-label, 
single centre 
Single dose 
1000 mg 
38.7 ± 
19.4 
NA NA 95.2 ± 32.0 50.4 ± 12.8b 148.0 ± 75.0 
Cefepime                     
[68] 
Severe thermal 
burn injury 
(45.5% TBSA) 
1 Case report 1 g every 6 h 
 
25.8 3.9 358.0 10.7 28.9 136.0 
Glycopeptide           
Vancomycin                 
[65] 
Early stage 
severe burn 
(TBSA 
68.39±17.85) 
20 Prospective, 
open-label, non-
randomized 
500 mg 24 h 
after burn 
 
20.0 ± 3.4 7.9 ± 0.9 1279.4 ± 
256.1 
0.4 ± 0.08 25.6 ± 5.7 95.5 ± 23.1 
Vancomycin                 
[69] 
Severe burn 
injury 
(≥10%TBSA) 
37 Retrospective 
case-control 
study 
 NA 6.4b NA 5.4b,c 129.5b NA 
Vancomycin                 
[70] 
Adult patients 
with new thermal 
injury (34±17% 
TBSA) 
49 Retrospective 
chart review 
 NA NA 137.5 
(≤14 days 
after burn)           
194.2 
(≥14 days 
after burn) 
7.9 
(≤14 days 
after burn) 
5.7 
(≥14 days 
after burn) 
70.3 
(≤14 days 
after burn) 
58.2 
(≥14 days 
after burn) 
NA 
Others           
	   20 
Drug /  
Reference Population 
Number of 
patients Study design Dose 
PK parameters (mean ± SD, unless otherwise stated) 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24  
(mg.h/L) 
CLtotal 
(L/h) 
Vd 
(L) 
CLcr 
(mL/min) 
Linezolid                      
[71] 
Major thermal 
injuries (>20% 
TBSA) 
8 Open-label, 
multicentre 
Single dose 600 
mg 
 
12.5 ± 4.4 NA 85 20.9 ± 12.4 50.8 ± 16.8 NA 
Colistin                         
[72] 
Adolescent with 
71% TBSA, 
Acinetobacter 
baumanii (MIC 
0.5 mg/L) burn 
wound sepsis / 
septic shock 
1 Case report 2.5 mg/kg 
every 24 h 
3.6 ±1.0 0.9 ± 0.5 47.1 ± 14.4 NA NA NA 
AUC0-24 = area under the concentration-time curve from 0-24 h; CLcr = creatinine clearance; Cmax = peak drug concentration during a dosing interval; Cmin = 
minimum drug concentration during a dosing interval; CRRT = continuous renal replacement therapy; MIC = minimum inhibitory concentration; NA = data not 
available; PK = pharmacokinetic; TBSA = total burn surface area and Vd = volume of distribution.  
a Data reported as median 
b Data calculated based on the reported PK parameters 
c Data calculated using estimated body weight = 70 kg 
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2.2.6 Continuous renal replacement therapy 
 
Commencement of RRT in critically ill patients is common [11]. There are different types of RRT 
used in critically ill patients including continuous, intermittent and hybrid modalities (e.g. SLED). 
CRRT can be performed in different modes, CVVH, CVVHD and CVVHDF. Presently, there are 
no clinical data supporting one mode over another, meaning that hospitals use different modes and 
settings according to local needs causing the extreme variability of RRT practices worldwide. 
Advancing technology has meant that these techniques are very efficient at removing not only 
metabolic waste products such as creatinine and urea, but also hydrophilic antibiotics, especially 
those with low plasma protein binding [77]. However, the amount of antibiotic eliminated will 
depend on the mode of RRT, dose of RRT delivered, blood flow rate, filter material and surface 
area, each of which should be considered when dosing during RRT [51]. The following are the 
recent antibiotic pharmacokinetic studies in critically ill patients receiving CRRT with their 
pharmacokinetic parameters summarized in Table 2.3 [66, 78-92]. 
 
2.2.6.1 Aminoglycosides  
The pharmacokinetic of aminoglycosides in CRRT have been well described recently [66, 78]. 
These studies suggest that standard approaches to dosing do not achieve PK/PD targets due to an 
increased clearance and Vd. Given that high Cmax/MIC ratios of 8-10 are associated with better 
clinical outcome [15], higher doses to account for the higher Vd and less frequent dosing to account 
for the decreased clearance in this patient population may provide better aminoglycoside exposures 
[15]. Subsequent dose adjustment using TDM remains appropriate. 
 
2.2.6.2 β-lactam 
Seyler et al. [79] recently suggested that β-lactam doses of piperacillin-tazobactam, cefepime and 
ceftazidime administered during CRRT inadequately achieved PK/PD targets for Pseudomonas 
aeruginosa during early phase (first 24-48 hours) of severe sepsis or septic shock. The conclusions 
of this study support the use of higher doses or extended infusions of β-lactams to maintain 
adequate serum concentrations during the dosing interval [77]. Further studies have described how 
different CRRT modes result in variable β-lactam clearance [81-83] and that variable antibiotic 
doses are required to achieve PK/PD targets during different forms of CRRT [80], thus 
demonstrating that dose standardization for β-lactams in CRRT is not possible with current data.  
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2.2.6.3 Glycopeptides 
In recent studies, CRRT has been reported responsible for up to 50% of total glycopeptide clearance 
[84, 85]. Similar to other hydrophilic antibiotics, dose standardization across different CRRT modes 
and settings for glycopeptides is difficult. Standard dosing regimens do not achieve PK/PD targets 
[80, 84, 85]. Administration of a loading dose (e.g. 20 mg/kg) would enable faster attainment of 
target vancomycin exposures with subsequent dosing based on local vancomycin pharmacokinetic 
data or TDM. The high protein binding of teicoplanin makes dosing in CRRT challenging, 
particularly in patients with hypoalbuminemia [93], in which higher clearance of the unbound 
fraction can be expected. In these patients, supplemental dosing or higher doses should be 
considered given the good safety profile. 
 
2.2.6.4 Fluoroquinolones 
Recent pharmacokinetic studies have reported that varied doses are required for different CRRT 
settings [80, 86-88]. Ciprofloxacin dose requirements remain moderate in the presence of renal 
dysfunction and/or CRRT because of hepatic metabolism (contributes approximately on-third of 
ciprofloxacin elimination [94]). It follows that hepatic dysfunction will be associated with 
decreased ciprofloxacin elimination and, thus, in patients with concurrent renal and hepatic 
dysfunction, significantly decreased ciprofloxacin dosing and perhaps TDM should be considered 
to optimize antibiotic exposure [95] and achieve PK/PD targets [14, 16]. 
  
2.2.6.5 Other drugs 
Recent studies have recommended varied dosing regimens for daptomycin in CRRT [89-91]. Even 
though similar CRRT characteristics are reported [89, 90], none of these are superior from the other 
because of differences in study design, and most importantly the intervariability of critically ill 
patients. The hydrophilicity, high protein binding and predominant renal excretion can lead to 
different rates of daptomycin clearance through extracorporeal circuits. The association between 
Cmax/MIC and the ratio between the area under the concentration-time curve from 0-24 h (AUC0-24) 
to MIC (AUC0-24/MIC) for optimal bactericidal effect for daptomycin [20] suggest that initial high 
dosing (6-8 mg/kg IV daily) is required to achieve the targeted Cmax. Maintenance dosing based on 
likely CRRT clearance should then be used. A higher than usual dose is also recommended for 
other drugs, such as fluconazole, during CRRT [92].	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Table 2.3: Antibiotic pharmacokinetic parameters during continuous renal replacement therapy 
Drug / 
Reference 
Mode of 
CRRT  
(n) 
 
Study 
design 
 
Dose 
PK parameters (mean ± SD, unless otherwise stated) CRRT filters and settings 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24 
(mg.h/L) 
CLtotal 
(L/h) 
CLdialysis 
(L/h) 
Vd 
(L) 
Filter material/ 
surface area 
(m2) 
Qb 
(mL/min), 
Qf, Qd (L/h) 
Replacement 
fluid 
Aminolgycoside            
Amikacin                      
[66] 
CVVH              
(n=12) 
Retros-
pective 
medical 
records 
review 
Single 
daily dose 
15 mg/kg 
29.1 ± 
14.5 
1.5 ± 1.6 214.8 ± 113.8 8.8 ± 8.9 NA 69.7 ± 88.0 Polyarylether-
sulfone  
(1.4), 
Polyether-
sulfone  
(1.5) 
Qf: 2.5 ± 1.1 NA 
Amikacin                          
[78] 
CVVHDF               
(n=13) 
 LD 25 
mg/kg 
70.0a 9.6a NA 5.3c NA 35.0c Poly-
acrylonitrile/ 
Polysulphone 
 
Qb:150.0 
Qf:2.3c, 
Qd:2.0c 
NA 
β-Lactam            
Ceftazidime                     
[79] 
CVVHD/                
CVVHDF         
(n=15) 
Obser-
vational, 
prospective 
2 g 12h 78.0a 24.0a 536.0a 2.2a,c NA 25.9a,c Poly-
acrylonitrile 
Qb:150.0± 
24.0 
Qf:1.5±0.8c            
Qd:1.6±0.6c 
NA 
Cefepime                         
[79] 
CVVHD/              
CVVHDF         
(n=11) 
Obser-
vational, 
prospective 
2 g 12h 43.0a 11.0a 379.0a 4.4a,c NA 38.5a,c Poly-
acrylonitrile 
Qb:150.0± 
24.0 
Qf:1.5±0.8c            
Qd:1.6±0.6c 
NA 
Piperacillin-
tazobactam       
[79] 
CVVHD/                
CVVHDF      
(n=21) 
Obser-
vational, 
prospective 
4.5 g 6h 138.0a 60.0a 527.0a 4.8a,c NA 30.8a,c Poly-
acrylonitrile 
Qb:150.0± 
24.0 
Qf:1.5±0.8c            
Qd:1.6±0.6c 
NA 
Piperacillin-
tazobactam     
[80] 
CVVHDF               
(n=7) 
Obser-
vational, 
prospective, 
multicentre 
4.5 g 
6-12h 
NA 105.0a NA NA NA NA Poly-
acrylonitrile 
(1.2) 
NA Post-dilution 
Carbapenem            
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Drug / 
Reference 
Mode of 
CRRT  
(n) 
 
Study 
design 
 
Dose 
PK parameters (mean ± SD, unless otherwise stated) CRRT filters and settings 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24 
(mg.h/L) 
CLtotal 
(L/h) 
CLdialysis 
(L/h) 
Vd 
(L) 
Filter material/ 
surface area 
(m2) 
Qb 
(mL/min), 
Qf, Qd (L/h) 
Replacement 
fluid 
Meropenem                     
[79] 
CVVHD/                
CVVHDF         
(n=22) 
Obser-
vational, 
prospective 
1 g 12h 26.0a 6.0a 134.0a 4.8a,c NA 31.5a,c Poly-
acrylonitrile 
Qb:150.0± 
24.0       
Qf:1.5±0.8c            
Qd:1.6±0.6c 
NA 
Meropenem                     
[80] 
CVVHDF               
(n=17) 
Obser-
vational, 
prospective, 
multicentre 
0.5-1 g 
8-12h 
NA 12.1a NA NA NA NA Poly-
acrylonitrile 
(1.2) 
NA Post-dilution 
Meropenem                 
[81] 
CVVHF                  
(n=10) 
Prospective, 
observational 
1 g 8h 56.6a 7.6a 499.5b 6.0a 3.5a 25.9b Poly-
acrylonitrile  
(2.15) 
Qb:250.0, 
Qf:4.0-6.0 
Pre-dilution 
Doripenem                  
[82] 
CHDF             
(n=6) 
Prospective, 
open-label 
250 mg 
12/24h 
 
13.2 ± 
4.1 
NA NA 3.5 ± 0.8 0.8 ± 0.1 33.0 ± 15.8 Polysulfone  
(1.0) 
Qb:100.0, 
Qf:0.3, 
Qd:0.5 
NA 
Doripenem                  
[83] 
CHDF             
(n=2) 
 Single 
dose     
250 mg 
NA NA NA 7.1 2.5 NA Polysulfone  
(1.0) 
Qb:100.0 
Qf:0.9, 
Qd:1.5 
NA 
Glycopeptide            
Vancomycin                     
[80] 
CVVHDF               
(n=10) 
Obser-
vational, 
prospective, 
multicentre 
1 g o.d. NA 12.0b NA NA NA NA Poly-
acrylonitrile 
(1.2) 
NA Post-dilution 
Vancomycin 
[84] 
CVVH              
(n=7) 
Prospective, 
open-label 
1 g NA NA NA 1.6 ± 0.5 0.7 ± 0.2 24.7 ± 11.0 NA Qb:200.0-
250.0 
Qf:0.8-1.2 
Pre-dilution 
Teicoplanin                      
[85] 
CVVH              
(n=15) 
 LD 1.2 g 
followed 
by MD 
target 
trough 
level 15-
25 mg/L 
55.4 ± 
15.9 
(LD)  
81.2 ± 
28.6  
(MD) 
6.4 ± 1.7 
(LD) 
21.3 ± 
5.6 (MD) 
291.0 ± 49.0 
(LD)  
706.7 ± 142.0 
(MD) 
3.1b 
(LD)           
0.8c 
(MD) 
NA 65.7b 
(LD)        
32.9c 
(MD) 
Polysulfone  
(1.2) 
Qb:180.0, 
Q:2.5c 
Pre-dilution 
and Post-
dilution 
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Drug / 
Reference 
Mode of 
CRRT  
(n) 
 
Study 
design 
 
Dose 
PK parameters (mean ± SD, unless otherwise stated) CRRT filters and settings 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24 
(mg.h/L) 
CLtotal 
(L/h) 
CLdialysis 
(L/h) 
Vd 
(L) 
Filter material/ 
surface area 
(m2) 
Qb 
(mL/min), 
Qf, Qd (L/h) 
Replacement 
fluid 
Quinolone            
Ciprofloxacin 
[80] 
CVVHDF               
(n=6) 
Obser-
vational, 
prospective, 
multicentre 
0.2-0.4 g    
8-12h 
NA 3.7a NA NA NA NA Poly-
acrylonitrile 
(1.2) 
NA Post-dilution 
Ciprofloxacin 
[86] 
CVVHDF               
(n=3) 
 0.6 g/day NA NA 54.9±12.8 8.8±5.1 1.8±0.03 89.2±8.7 Cellulose 
triacetate 
hollow fiber 
(1.1) 
Qb:100.0 
Qf:1,Qd:1 
Post-dilution 
Ciprofloxacin 
[87]) 
CVVHDF               
(n=1) 
Case report 0.8 g 12h 13 4.8 192 8.3 1.6 90 Poly-
acrylonitrile 
Qb:100.0-
130.0 
Qf:1.25-1.5 
Qd:1.0 
NA 
Ciprofloxacin 
[88]) 
CVVHDF               
(n=7) 
Open 
prospective 
0.4 g b.d, 
0.4 mg 
o.d, 
0.2 mg b.d 
5.8±1.0 NA 83.0±11.1 8.6±2.7 2.5±0.3 125b Poly-
acrylonitrile 
Qb:200.0, 
Qf:2.0 
Qd:1.0/2.0 
NA 
Others            
Daptomycin                 
[89] 
CVVHD           
(n=8) 
Prospective 
open label 
PK 
8 mg/kg 81.2±19.
0 
NA NA 0.7±0.3 3.3±1.6 18.9b Polysulfone 
(1.5) 
Qb:181.0± 
26.0 
Qf:0.6b, 
Qd:2.1b 
NA 
Daptomycin 
[90] 
CVVHD           
(n=8) 
Open label, 
prospective 
trial, single 
center 
LD 8 
mg/kg, 
then 4 
mg/kg 48h 
87.5±15.0 
(LD)  
41.8±5.0 
(MD) 
5.0±2.6 
(LD)       
2.5±1.0 
(MD) 
537.0±97.0 
(LD)        
302.0± 43.0 
(MD) 
0.8±0.2 
(LD)  
0.7±0.1 
(MD) 
NA 19.5±6.0  
(LD)       
16.1±3.0 
(MD) 
Polyamix  
(1.4) 
Qb:100.0 
Qd:2.0 
NA 
Daptomycin                 
[91] 
CVVHDF               
(n=9) 
 6 mg/kg 
o.d 
68.9b 17.9b 578.0±224.0 0.4±0.3 4.7±4.2 6.3c Acrylonitrile 
hollow fiber 
(0.9) 
Qd:150.0± 
48.0 
Qf:1.0, 
Qd:1.0 
Pre-dilution 
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Drug / 
Reference 
Mode of 
CRRT  
(n) 
 
Study 
design 
 
Dose 
PK parameters (mean ± SD, unless otherwise stated) CRRT filters and settings 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24 
(mg.h/L) 
CLtotal 
(L/h) 
CLdialysis 
(L/h) 
Vd 
(L) 
Filter material/ 
surface area 
(m2) 
Qb 
(mL/min), 
Qf, Qd (L/h) 
Replacement 
fluid 
Fluconazole 
[92] 
CVVHDF 
(n=10) 
 0.2 g b.d NA NA NA 2.7 1.7 53.6 Poly-
acrylonitrile 
Qf:2.0, 
Qd:1.0 
Pre-dilution 
AUC0-24 = area under the concentration-time curve from 0-24 h; CHDF = continuous hemodiafiltration; CLdialysis = dialysis clearance; CLtotal = total clearance; Cmax = 
peak drug concentration during a dosing interval; Cmin = minimum drug concentration during a dosing interval; CRRT = continuous renal replacement therapy; 
CVVH = continuous venovenous hemofiltration; CVVHD = continuous venovenous hemodialysis; CVVHDF = continuous venovenous hemodiafiltration; LD = 
loading dose; MD = maintenance dose; NA = data not available; PK = pharmacokinetic; Qb = blood flow rate; Qd = dialysate flow rate; Qf = ultrafiltrate flow rate 
and Vd = volume of distribution.  
a Data reported as median 
b Data calculated based on the reported PK parameters 
c Data calculated using estimated body weight = 70 kg 	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2.2.7 Sustained low-efficiency dialysis 
 
Although SLED was first successfully utilised in 1945 by Willem J. Kolff [96], there are 
surprisingly few antibiotic pharmacokinetic data [97, 98]. Available studies have shown that the 
removal of antibiotics occurs more efficiently during SLED in comparison to standard CRRT and 
intermittent hemodialysis modalities [58, 99-110]. SLED is called a ‘hybrid modality’ because each 
treatment typically only lasts 8-12 hours. Recently, Bogard et al [58] reviewed the studies 
describing antibiotic pharmacokinetics in SLED. The authors found higher antibiotic clearance 
during SLED for hydrophilic drugs without high protein binding (<90%) or weak protein binding 
(as with daptomycin), those of small molecular size and those with significant renal clearance in the 
presence of normal renal function [58]. Like CRRT, antibiotic pharmacokinetics in SLED should be 
interpreted with knowledge of blood and dialysate flow rates, treatment duration and filter surface 
area [58]. The frequency and duration of SLED administration must also be borne in mind when 
considering dosing adjustments. As SLED has been shown to more effectively remove time-
dependent antibiotics such as the β-lactams, it may be necessary to provide supplemental doses of 
antibiotics during or following SLED treatments, or prolong infusion times to maintain the desired 
fT>MIC. In a recent study of linezolid in septic patients on SLED, the authors suggested that because 
of the altered pharmacokinetic resulting from sepsis and the effects of SLED, TDM should be 
considered useful for dose optimization [107]. More recently, Lorenzen et al. [101] investigated the 
pharmacokinetics of ampicillin/sulbactam in critically ill patients on SLED in which they found 
patients would be significantly underdosed if dosing for regular hemodialysis were to be 
implemented. The authors found that >75% removal of both ampicillin and sulbactam during an 8-h 
SLED session, and recommended 3 g IV 12-h dosing of ampicillin/sulbactam for patients on 
comparable SLED specifications [101]. Burkhardt et al. [110] reported that SLED does not affect 
the pharmacokinetics of voriconazole; however, accumulation of the toxic solubilizing agent was 
observed. Therefore, the use of voriconazole in this setting cannot be supported at this time. 
Variability in SLED parameters as noted by Bogard et al. [58] and residual renal function make 
recommendations regarding antibiotic prescribing during SLED problematic. Table 2.4 [99-110] 
displays the pharmacokinetic data described for various antibiotics in patients undergoing SLED.	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Table 2.4: Antibiotic pharmacokinetic parameters in patients on sustained low-efficiency dialysis 
Drug 
(reference) 
Mode of 
SLED 
Study design 
(n) Dose 
Pharmacokinetic (PK) Parameters SLED filters and Settings 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24 
(mgh/L) 
CLtotal 
(L/h) 
CLdialysis 
(L/h) 
Vd 
(L) 
Filter type/ 
surface area (m2) 
Qb; Qf; Qd 
(mL/ min) 
Aminoglycoside           
Gentamicin  
[99] 
Slow daily 
home HD 
7-9h/day 
Outpatient 
single dose 
PK (n=8) 
0.6mg/kg 
postdialysis 
NA NA NA 6.5 ± 2.6a 4.6 ± 2.3a 19.6 Polysulfone  
high-flux 
(F50NR;0.5m2) 
Qb 200; 
Qd 300 
Gentamicin 
[100] 
EDD-f Single and 
multi-dose 
PK study 
(n=12) 
3-7 mg/kg >10d 1.5e 48.4-122.0c NA 2.5 38.5 Fresenius 
(AV600S;0.6m2) 
Qb 300; 
Qd 300 
β-Lactams           
Ampicillin / 
sulbactam 
[101] 
SLED 
(6 h) 
Single dose 
PK study 
(n=12) 
2g/1g 75-360/  
74-157 
NA 847.5 ± 499.5 3.7 ± 3.3/  
4.9 ± 4.9 
4.8 ± 0.5/  
5.0 ± 0.7 
13.1±11.1 Polysulfone  
high-flux 
(F60S;1.3m2) 
Qb 160; 
Qd 160 
Carbapenems           
Meropenem 
[102] 
SLED 
(8 h) 
Single dose 
PK study 
(n=10) 
1g 6 h 
predialysis 
 
NA NA NA NA 2.3 (0.7-3.7)/ 
5.1 (4.3-5.7) 
50.4±74.2 Polysulfone  
high-flux 
(F60S; 1.3m2) 
Qb 160; 
Qd 160 
Ertapenem  
[103] 
SLED 
(8 h) 
Single dose 
PK (n=6) 
1g 81.3 ± 12.1 NA NA NA 3.0 ± 0.7 15.9±3.2 Polysulfone  
high-flux 
(F60S; 1.3m2) 
Qb 160; 
Qd 160 
Cyclic lipopetides           
Daptomycin 
[104] 
SLED 
(8 h) 
Single dose 
PK study 
(n=10) 
6mg/kg 8 h 
pre-SLED 
 
69.6 ± 17.7 NA NA 1.0 ± 0.3 NA 11.4±2.9 Polysulfone  
high-flux 
(F60S; 1.3m2) 
Qb 160; 
Qd 160 
Daptomycin  
[105] 
SLED 
(12 h) 
Case report, 
single dose 
PK study 
(n=1) 
6mg/kg 
ABW 
121.7 NA 588.7 0.92 NA 12.5 Polysulfone  
high-flux 
(F60S; 1.3m2) 
Qb 200; 
Qd 100 
Fluoroquinolone           
Levofloxacin  
[106] 
SLED 
(8 h) 
PK study 
(n=5) 
250/500 mg 
up to 12 h 
predialysis 
NA NA NA NA 3.0-3.2f 74-155 Polysulfone  
high-flux 
(F60S;1.3m2) 
Qb 160; 
Qd 160 
Moxifloxacin  SLED PK study 400mg NA NA NA NA 2.6-4.3f 154.0-514.0 Polysulfone  Qb 160; 
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Drug 
(reference) 
Mode of 
SLED 
Study design 
(n) Dose 
Pharmacokinetic (PK) Parameters SLED filters and Settings 
Cmax 
(mg/L) 
Cmin 
(mg/L) 
AUC0-24 
(mgh/L) 
CLtotal 
(L/h) 
CLdialysis 
(L/h) 
Vd 
(L) 
Filter type/ 
surface area (m2) 
Qb; Qf; Qd 
(mL/ min) 
[106] (8 h) (n=10) infusion 8 h 
predialysis 
high-flux 
(F60S;1.3m2) 
Qd 160 
Glycopeptide           
Vancomycin 
[102] 
SLED 
(8 h) 
Single dose 
PK study 
(n=10) 
1g 12 h 
predialysis 
 
NA NA NA NA 3.8 ± 1.7 
2.1 ± 1.0 
39.9±149.1 Polysulfone  
high-flux 
(F60S;1.3m2) 
Qb 160; 
Qd 160 
Oxazolidinone           
Linezolid  
[107] 
SLED 
(19 h) 
PK study 
(n=10) 
600mg 7.9-22.0 <0.1-8.8 115.2 ± 70.6 12.8 ± 6.5 3.7 ± 0.8 38.1 Polysulfone  
high-flux 
(F60S;1.3m2) 
Qb 110-150 
Linezolid  
[108] 
SLED 
(8-9 h) 
Prospective 
single dose 
PK (n=5) 
600 mg 
infusion 
predialysis 
10.5-19.9 NA NA NA 1.998b 30.2 Polysulfone  
low-flux 
(F7HPS;1.6m2) 
Qb 200; 
Qd 100 
Antimycotics           
Anidulafungin 
[109] 
SLED 
(8 h) 
Case report, 
single dose 
PK (n=1) 
200mg 5.3 1.6 55.2 29.5 NA 64 Polysulfone  
high-flux 
(F60S;1.3m2) 
Qb 180; 
Qd 180 
Voriconazole  
[110] 
SLED 
(8 h) 
PK study 
(n=4) 
4mg/kg 2.1-5.0 NA NA NA NA NA Polysulfone  
high-flux 
(F60S;1.3m2) 
Qb 180; 
Qd 180 
ABW = actual body weight; AUC0-24 = area under the concentration-time curve from 0-24 h; CLdialysis = dialysis clearance; CLtotal = total clearance; Cmax = peak drug 
concentration during a dosing interval; Cmin = minimum drug concentration during a dosing interval; EDD-f = extended daily diafiltration; Qb = blood flow rate; Qd 
= dialysate flow rate; SLED = sustained low-efficiency dialysis and Vd = volume of distribution. 
bValue calculated from one patient in the study group  
cAUC0-24 range for 6 mg/kg every 48-h dose. 
dCmax in 99.9% of simulated patients. 
eMinimized Cmin of simulated patients prescribed 6 mg/kg every 48h. 
fEstimation of drug sample concentrations from samples taken before and after the dialysis machine.	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2.2.8 Extracorporeal membrane oxygenation 
 
ECMO is a highly invasive intervention that assists critically ill patients with severe lung and/or 
heart dysfunction. Generally, ECMO may cause increases in Vd for certain drugs as well as the 
possible binding of drugs in the ECMO circuit [111]. However, the variable characteristics of 
ECMO technologies and settings (e.g. composition of tubing, flow rates and machine 
specifications) make comparisons between different pharmacokinetic studies challenging. The 
pharmacokinetics of antibiotics in ECMO has recently been reviewed in detail [56]. Adsorption of 
lipophilic drugs to ECMO membranes and tubing appears common and likely to rapidly reduce 
plasma concentrations [56]. Problematic to this issue is that not all drugs are affected and the extent 
of sequestration is not consistent [112]. The final challenge in providing adequate antibiotic doses 
for critically ill patients receiving ECMO is the presence of RRT which also need to be considered 
as a source of potentially significant drug clearance in the presence of renal dysfunction. From the 
available data, we agree with the findings of a systematic review from Mousavi et al. [113] and 
suggest that individualizing drug regimens in patients receiving ECMO using TDM is necessary 
until further data become available to guide dosing. 
 
2.2.9 Conclusion 
 
In conclusion, antibiotic dosing in critically ill patients is challenging especially in the era of 
emerging antibiotic resistance. The best approach for optimal dosing of antibiotics in critically ill 
patients is through an understanding of the relationship between the pharmacodynamics and the 
extent to which pharmacokinetics are altered by illness. Variability of patient characteristics, 
disease state management by individual units and variable pathogen susceptibility favour 
individualized dosing regimens in this population. To this end, the increase in Vd common to 
aminoglycosides, β-lactams and glycopeptides supports the use of higher doses in the first 24-48 h 
of therapy. In patients such as burns patients with apparently higher clearance for most antibiotics, 
more frequent administration appears necessary to ensure the equivalent exposure in critically ill 
patients to that observed in noncritically ill patients. In patients receiving extracorporeal circuits 
(CRRT, SLED and ECMO), significant pharmacokinetic variability makes a guideline approach to 
dosing not possible with the available data.  All of the above lead us to believe TDM should be used 
wherever available. 
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2.3 Conclusion 
 
This chapter has described the available pharmacokinetic data of different classes of antibiotics and 
their dosing regimen in special ICU populations, such as those receiving different types of 
extracorporeal treatment (e.g CRRT, SLED and ECMO) and burn patients. In the context of such 
variable pharmacokinetics in these patients, establishing standard antibiotic dosing guiedlines is not 
possible due to insufficient data. Understanding of the relationship between pharmacodynamics and 
the extent to which pharmacokinetics are altered by critical illness is essential. This scenario 
compels the clinician to consider alternative dosing strategies, in order to deliver optimal doses. The 
increase in Vd is common to aminoglycosides, β-lactams and glycopeptides, thus supports the use of 
higher doses in the first 24-48 h of therapy. In patients such as burns patients with apparently higher 
clearance for most antibiotics, more frequent administration appears necessary to ensure the 
equivalent exposure in critically ill patients to that observed in non-critically ill patients. TDM 
should be used wherever available. 
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Chapter 3 
 
Antibiotic dosing in critically ill patients receiving different types of renal replacement 
therapy 
 
3.1 Sypnosis 
 
The prescribing of RRT in ICU setting worldwide is unstandardized and heterogenous, particularly 
due to availability and cost. Therefore identifying changes in antibiotic pharmacokinetics in 
critically ill patients receiving different RRT modalities is complex. Translating the possible 
changes using existed data derived from different RRT modalities is difficult. Adding to this 
complexity is the existence of profound clinical and arthopometric patient variability, as well as 
ICU management, worldwide. This chapter aimed to describe the published pharmacokinetic data 
of frequently used antibiotics in critically ill patients receiving different RRT modalities, and to 
identify the alternative dosing strategies that could be applied to increase the likelihood of 
achieving targeted antibiotic exposures. Furthermore, this chapter is also aimed to identify possible 
knowledge gaps in dosing, and discuss future research approaches in this area in order to establish 
robust dosing guidelines for critically ill patients receiving RRT.  
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3.2 Manuscript entitled, “How can we ensure effective antibiotic dosing in critically ill 
patients receiving different types of renal replacement therapy?” 
 
The manuscript entitled, “How can we ensure effective antibiotic dosing in critically ill patients 
receiving different types of renal replacement therapy?” has been accepted for publication by 
Diagnostic Microbiology and Infectious Disease (25th January 2015). 
 
The co-authors contributed to the manuscript as follows: All study design and data collection was 
performed by the PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. 
Roberts and the PhD candidate, Janattul-Ain Jamal, was responsible for data extraction from cited 
articles. Analysis of data was performed by the PhD candidate, Janattul-Ain Jamal, under the 
guidance of Prof. Jason A. Roberts, Dr. Gordon Y.S. Choi, Prof. Jeffrey Lipman and Dr. Bruce A. 
Mueller. The PhD candidate, Janattul-Ain Jamal, took the leading role in manuscript preparation 
and writing. 
 
The manuscript is presented as the revised manuscript was submitted, except figures and tables 
have been inserted into the text at slightly different positions. Also, the numbering of pages, figures 
and tables has been adjusted to fit the overall style of the Thesis. The references are found alongside 
the other references of the Thesis, in section ‘References’. 
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3.2.1 Abstract 
 
Determining appropriate antibiotic dosing for critically ill patients receiving RRT is complex. 
Worldwide unstandardized and heterogeneous prescribing of RRT as well as altered patient 
physiology and pathogen susceptibility all cause drug disposition to be much different to that seen 
in non-critically ill patients. Significant changes to pharmacokinetic parameters, including volume 
of distribution and clearance, could be expected, in particular, for antibiotics that are hydrophilic 
with low plasma protein binding and that are usually primarily eliminated by the renal system. 
Antibiotic clearance is likely to be significantly increased when higher RRT intensities are used. 
The combined effect of these factors that alter antibiotic disposition is that non-standard dosing 
strategies should be considered to achieve therapeutic exposure. In particular, an aggressive early 
approach to dosing should be considered and this may include administration of a ‘loading dose’, to 
rapidly achieve therapeutic concentrations and maximally reduce the inoculum of the pathogen. 
This approach is particularly important given the pharmacokinetic changes in the critically ill as 
well as the increased likelihood of less susceptible pathogens. Dose individualization that applies 
knowledge of the RRT and patient factors causing altered pharmacokinetics remains the key 
approach for ensuring effective antibiotic therapy for these patients. Where possible, therapeutic 
drug monitoring should also be used to ensure more accurate therapy. A lack of pharmacokinetic 
data for antibiotics during the PIRRT and IHD currently limits evidence-based antibiotic dose 
recommendations for these patients. 
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3.2.2 Introduction 
 
AKI is a serious problem in critically ill patients and is commonly complicated by severe sepsis or 
septic shock. The incidence of AKI in the ICU varies between 16-65% [114, 115]. Initiating RRT is 
common in this population, with approximately 70% of these patients being treated with RRT 
[115]. Importantly, the mortality rate of critically ill patients with AKI is high, approximately 49% 
[114], and may exceed 60% in those concurrently treated with RRT [116]. Optimised antibiotic 
therapy in this population should be considered a key intervention to reduce mortality [117].  
 
Treating infection in critically ill patients with severe sepsis receiving RRT is highly challenging as 
the use of the extracorporeal circuit may cause alterations in antibiotic pharmacokinetics. In fact, 
standard antibiotic dosing is frequently suboptimal [79]. Rapidly achieving therapeutic antibiotic 
PK/PD targets at the site of infection is likely to increase treatment efficacy. These targets are 
different for different antibiotic classes (Figure 3.1), with most targets robustly defined through in-
vitro and in-vivo studies in animals and humans [17, 19].  
 
Varied approaches to RRT prescribing in ICUs and decreased pathogen susceptibility complicate 
the defining of optimal antibiotic dosing regimens in this population. However, a comprehensive 
understanding of RRT modalities and settings (e.g. modes, blood flow rate, effluent flow rate, filter 
material and size) and knowledge of antibiotic characteristics such as molecular size, 
hydrophilicity, plasma protein binding and altered pharmacokinetics in critical illness (organ 
dysfunction and altered fluid balance) can help the clinicians to predict changes in pharmacokinetic 
parameters. These data can be used to subsequently guide empiric antibiotic dosing in critically ill 
patients with AKI receiving RRT. 
 
This paper aimed to review the published pharmacokinetic data of frequently used antibiotics in 
critically ill patients receiving RRT and to describe dosing strategies that could be applied to 
increase the likelihood of achieving targeted antibiotic exposures for these patients. 
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Figure 3.1: The pharmacokinetics/pharmacodynamics indices of different classes of antibiotics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          
 
 
 
 
 
 
 
 
 
Cmax = maximum concentration; fCmax = unbound maximum concentration; MIC = 
minimum inhibitory concentration; %T>MIC = percentage of time in one dosing 
interval for which the total concentration remain above the MIC of the pathogen; 
%fT>MIC = percentage of time in one dosing interval for which the unbound 
concentration remain above the MIC of the pathogen; AUC = area under a total 
concentration-time curve; fAUC = area under an unbound concentration-time curve 
and PK/PD = pharmacokinetics/pharmacodynamics.	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3.2.3 Methods 
 
A PubMed search using relevant keywords was undertaken to identify relevant published English 
language articles. Journal articles referenced in the primary article were also included where 
appropriate. Search terms included; ‘antibiotic’, ‘antibacterial’, ‘antimicrobial’, ‘beta-lactam’, 
‘carbapenem’, ‘fluoroquinolone’, ‘aminoglycoside’, ‘oxazolidinone’, ‘macrolide’, ‘colistin’, 
‘daptomycin’, ‘pharmacokinetic’, ‘pharmacodynamic’, ‘renal replacement therapy’, 
‘h(a)emodialysis’ ‘h(a)emofiltration’, ‘h(a)emodiafiltration’, ‘extended daily dialysis’, ‘prolonged 
intermittent renal replacement therapy’, ‘sustained low efficiency dialysis’, ‘intermittent 
h(a)emodialysis’, ‘critically ill’ and ‘intensive care’. Only articles with detailed information on 
RRT settings and pharmacokinetic parameters were included.  
 
Where relevant, we compared the available pharmacokinetic data (using published mean or median 
parameter estimates) with the associated PK/PD indices of the antibiotic with susceptibility 
breakpoints of common ICU pathogens (using the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) 2014; [118]) to estimate the likelihood of achieving targeted 
antibiotic exposures with standard doses. 
 
3.2.4 Renal replacement therapy in intensive care unit 
 
There are various approaches to the use RRT in the ICU setting [119-124].  IHD is prescribed in the 
same manner as it is used for end-stage renal disease (ESRD) outpatients as a 4-hour treatment. 
However, IHD is often delivered more frequently, up to six sessions per week, to meet solute and 
fluid removal goals [125, 126]. CRRT is by far the most common RRT used in the ICU and is given 
as a 24-hour treatment. PIRRT, a hybrid of CRRT and IHD, lasts for 6-18 hours and provides 
convenience in patient care by having time during the day for when the patient is not attached to the 
RRT machine [127].  
 
Solute removal during RRT occurs by convection and/or diffusion processes. IHD and CVVHD 
apply diffusion for solute removal, whereas hemofiltration techniques such as CVVH use the 
process of convection. In some cases, a clinician may choose to combine both diffusion and 
convection, as in CVVHDF, because of its greater capacity for solute removal. The selection of 
RRT modality for solute removal varies widely in clinical practice [38, 116], as data for survival 
benefit of one modality to another are still lacking [128]. 
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Variations in RRT settings, such as type of filter material, blood flow rate and effluent flow rate 
settings can result in changes to antibiotic pharmacokinetics, [39, 41, 47, 50]. In general, when 
higher RRT intensities are used (i.e. higher effluent flow rates), greater drug clearance is expected, 
requiring higher doses in order to achieve the same exposure observed with the lower RRT 
intensity. The enhanced removal of compounds like antibiotics has been proposed as one of the 
reasons for the failure of benefit seen in critically ill patients with septic shock who received higher 
RRT intensities which had initially been hypothesized to improve clinical outcomes [129, 130].  
 
3.2.5 Pathophysiological changes in critically ill patients with severe sepsis or septic shock 
 
Haemodynamic changes during severe sepsis or septic shock can lead to changes in antibiotic 
pharmacokinetics. Reduced organ perfusion is common and if prolonged, will eventually lead to 
MODS. MODS is associated with alterations in antibiotic Vd and clearance, two parameters that are 
significant determinants of dosing [11].  
 
Indeed, the physicochemical characteristics of the antibiotics such as hydrophilicity, protein binding 
and molecular size can be used to estimate the significance of these pharmacokinetic changes. 
Hydrophilic drugs (e.g. beta-lactams, aminoglycosides, glycopeptides) are more likely to be cleared 
by RRT and have increases in Vd that are associated with increasing levels of sickness severity. 
Lipophilic drugs (e.g. quinolones) distribute out of the vascular compartment significantly and as 
such, RRT is less likely to result in high drug clearance with Vd changes also less likely in critical 
illness. 
 
For antibiotics with high protein binding (e.g daptomycin, ertapenem), the presence of low serum 
albumin concentrations is also likely to be associated with increases in Vd and drug clearance [93]. 
In addition, returning native renal function in patients receiving RRT will increase the clearance of 
renally cleared antibiotics; thus, this difficult-to-predict total clearance (RRT, renal and non-renal) 
supports use of frequent antibiotic concentration monitoring where possible for more accurate 
dosing.  
 
3.2.6 Pharmacokinetics and pharmacodynamics of antibiotics 
 
Given the potential subtheraputic dosing or overdosing of antibiotics in critically ill patients 
receiving RRT [79, 131], achieving the optimal PK/PD indices at the target site of infection (e.g 
blood, tissue), is essential to maximise antibiotic effects. Figure 3.1 describes the PK/PD 
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classifications and suggested targets for various antibiotics. These classifications can help inform an 
effective approach to dose adaptation of the antiiobitic where necessary. For concentration-
dependent antibiotics, maximizing the peak concentration (Cmax), ideally between 8-10 times higher 
than the MIC of causative pathogens (Cmax/MIC 8-10) [15, 17], is likely to result in maximal 
bacterial killing. For time-dependent antibiotics, dose adjustment using more frequent drug dosing 
or alternatively using extended or continuous infusions to maximize the percentage of time in a 
dosing interval that the concentration exceeds the MIC (%T>MIC) is recommended. On the other 
hand, for antibiotics with both time and concentration-dependent killing characteristics, achieving a 
sufficient ratio of the area under the concentration-time curve to MIC (AUC/MIC) is required to 
optimize the killing activity. The data supporting the association of the PK/PD indices with 
favorable clinical and/or microbiological cure for the various classes has emerged mostly from 
retrospective analyses of pharmacokinetic data [15, 16, 60, 61, 132-136].   
 
Altered dosing approaches due to the pharmacokinetic reasons listed above are required, but also 
for pharmacodynamics reasons. Higher initial dosing (e.g. ‘loading doses’) could help reduce the 
inoculum of the pathogen early in the course of treatment which would make it easier for the host’s 
immune system to clear the remaining pathogens [137]. Furthermore, the increased presence of less 
susceptible pathogens in the critically ill often requires higher antibiotic exposures to ensure 
optimal PK/PD targets can still be achieved [138].  
 
3.2.7 Antibiotic pharmacokinetic studies in critically ill patients receiving different type of 
renal replacement therapy 
 
Widely varying antibiotic pharmacokinetic parameters have been published in patients receiving all 
forms of RRT (Table 3.1). It remains unclear whether commonly used dosing regimens are able to 
meet PK/PD targets during RRT in the ICU setting. In this section, EUCAST susceptibility 
breakpoints for common ICU pathogens were used to estimate the frequency of achievement of 
desired PK/PD targets for the different classes of antibiotics [118], using reported mean or median 
values of the pharmacokinetic estimates. Numerically, far more antibiotic pharmacokinetic studies 
have been performed during CRRT than for PIRRT or IHD in critically ill patients. In particular, 
the available PIRRT studies suggest that conventional antibiotic dosing is unlikely to meet PK/PD 
targets [103, 139, 140].  
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3.2.7.1 Aminoglycosides  
Amikacin and gentamicin were significantly eliminated by CVVH and CVVHDF (effluent flow 
rates 40-68 mL/min), with CRRT accounting for up to 80% of the total clearance [66, 78, 141, 142]. 
Both drugs had a Sc of approximately 0.8, suggesting that they freely cross the semipermeable 
CRRT filter. The Vd of aminoglycosides is also likely to increase in the presence of critical illness 
and RRT due to gross fluid balance alterations [66, 143, 144].  
 
Administration of a higher initial dose of amikacin (e.g 25 mg/kg) [78], has been reported to help 
achieve a target Cmax/MIC ratio. However little data exists to define which doses are required to 
achieve target aminoglycoside AUC/MIC ratios [136, 145]. Indeed with the presence of the post-
antibiotic effect, the administration of higher less frequent doses (e.g. 36-48-hourly dosing) should 
be considered to better achieve PK/PD targets. Dosing that is higher than doses that are traditionally 
used must be balanced against the risk of potential drug toxicities. To this end, frequent antibiotic 
concentration monitoring, although expensive, should always be considered. In the setting of IHD 
or PIRRT, pre-dialysis administration of aminoglycosides (30-minutes prior to RRT) may allow for 
the attainment of PK/PD targets without resulting in excessive drug exposure [100, 139, 146].  
 
3.2.7.2 Cephalosporins 
The Sc for ceftazidime is reported to be between 0.7-1.0, when CVVH/CVVHDF techniques were 
used (effluent flow rates 20-50 mL/min) [53, 79, 147, 148]. RRT contributes more than 50% of 
total clearance (CLtotal) of ceftazidime, particularly when higher intensities of CRRT are used 
(effluent flow rate >25 mL/min) [53, 148]. Similarly, the cefepime Sc is reported to be high (0.7-
0.9), in studies with varied CRRT settings (effluent flow rate = 16-42 mL/min) [149, 150]. In these 
studies, the cefepime clearance by RRT (CLRRT) was between 20-50% of the CLtotal in those CRRT 
settings.  
 
Doses ranging between 4-8 g per day and 2-6 g per day, for ceftazidime and cefepime respectively 
provided a mean or median minimum concentration (Cmin) above the susceptibility breakpoint of 8 
mg/L [53, 79, 147-150]. However higher doses may be required when treating pathogens with 
higher MICs. CI could be considered to better achieve the cephalosporin PK/PD target (antibiotic 
concentration above targeted MIC for at least 50% of time in the dosing interval [50% T>MIC]) [53]. 
However, when higher cephalosporin doses are used, frequent serum concentration monitoring is 
recommended to prevent any unwanted adverse events [151].  In many centres, serum concentration 
monitoring is not available for beta-lactams and therefore clinical monitoring is required (i.e. for 
encephalopathy, or use of electro-encephalogram (EEG) monitoring). Alternatively, less neurotoxic 
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agents should be considered where doubt for dosing exists as seizures are being increasingly 
reported for some agents (e.g. cefepime) [152, 153]. 
 
3.2.7.3 Penicillins  
High protein binding penicillin (e.g flucloxacillin, 90-95% protein binding) is associated with a 
lower Sc (0.2) compared to piperacillin (30% protein binding) (Sc between 0.4-0.8) during different 
CRRT settings (effluent flow rates 27-57 mL/min) [154-156]. CVVH has been shown to be 
responsible for approximately 10% of flucloxacillin CLtotal (Meyer et al., 2003), whilst data for 
piperacillin is more variable with between 2% to 42% of CLtotal occurring during CVVH/CVVHDF 
(effluent flow rates 10-50 mL/min) [79, 154-157]. This wide pharmacokinetic variability suggests 
that drug clearance is influenced by RRT intensity and patient characteristics such as residual renal 
function. PIRRT is also associated with significant drug clearances. By way of example, 87% of a 
2g ampicillin dose was removed during a single PIRRT session, although robust data to describe the 
ramifications for dosing remains elusive [101].  
 
Doses of 8/1-16/2 g per day of piperacillin/tazobactam ensure that piperacillin trough 
concentrations exceed the susceptibility breakpoint of 16 mg/L for varied RRT settings (effluent 
flow rates 10-40 mL/min) [79, 157, 158]. However, such doses lead to tazobactam accumulation 
[155, 159]. This cautionary tale of dosing with fixed antibiotic combinations is highly important for 
drug combinations that have different RRT clearances and half lives. Thus, any alteration of dosing 
for these products requires close clinical or concentration monitoring for potential toxicities of both 
chemical entities in the combination. Previous studies in critically ill patients without RRT [160-
162], have showed CI to be advantageous for achieving PK/PD targets for piperacillin (at least 
50%T>MIC), and as such CI has been suggested to be an alternative option for patients receiving 
CRRT. However, more data is still required to confirm these hypotheses and whether these 
potential benefits extend to other RRT modalities such as PIRRT and IHD. 
 
3.2.7.4 Carbapenems  
The effect of CRRT settings on meropenem clearance has been shown to vary for effluent flow 
rates between 10-70 mL/min. In these studies, CRRT caused more than 50% of meropenem CLtotal 
when a higher CRRT intensity was used (effluent flow rate >70 mL/min) [39-46, 79, 81, 102, 163]. 
Substantial clearance of meropenem was also observed during PIRRT [102, 164]. Imipenem data is 
similar to that reported for meropenem for effluent flow rates between 20-37 mL/min where CRRT 
contributed to 20-30% of the CLtotal [165-167]. Limited data is available for other carbapenems, 
with continuous hemodiafiltration (effluent flow rate 13.3-33.3 mL/min) accounting for ~20-30% of 
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doripenem clearance [82, 168]. PIRRT and CRRT are also likely to significantly affect ertapenem 
clearance [103, 169]. 
 
Doses between 2-3 g per day have resulted in mean or median meropenem trough concentrations 
that were above the susceptibility breakpoint of 2 mg/L in patients receiving CRRT [40, 43, 45, 46, 
79, 81]. Higher dosing would be expected to be necessary for pathogens with higher MICs. As for 
other beta-lactams, CI could be an alternative strategy to better achieve meropenem PK/PD target 
(>40% T>MIC) in patients receiving CRRT [46, 170]. The usual imipenem doses (1-2 g per day) did 
not consistently achieve the desired PK/PD targets for effluent flow rates ~20 mL/min [165-167]. 
Alterations in non-renal clearance that have been described for imipenem in critically ill patients 
with different levels of native renal function receiving CRRT [171], supports the need for higher 
doses in these scenarios. 
 
3.2.7.5 Quinolones 
The pharmacokinetics of levofloxacin and ciprofloxacin are the most commonly studied of all 
quinolones in critically ill patients receiving RRT. CVVH/CVVHDF studies have included effluent 
flow rates between 20-37 mL/min and a PIRRT study which included an effluent flow rate ~160 
mL/min. In these studies RRT was responsible for ~40% of levofloxacin CLtotal [172, 173]. While 
studies for ciprofloxacin have used CVVH/CVVHDF with effluent flow rates between 19-60 
mL/min, the effect of RRT on CLtotal was modest at ~20% [88, 173, 174].  
 
Based on the published data, we believe that if treatment is aimed at a gram negative pathogen, 
levofloxacin doses between 0.25 – 0.5 g per day would minimally achieve the PK/PD target, 
AUC/MIC >125 [16], for an MIC of 1 mg/L in critically ill patients receiving CRRT [172, 173], 
and thus higher doses may be necessary, particularly pathogens with higher MICs. For 
ciprofloxacin, 0.4 – 0.8 g per day sufficiently achieved the desired PK/PD target for pathogens with 
a MIC ≤0.5 mg/L) [88, 173]. Frequent clinical (electrocardiogram (ECG) monitoring) or therapeutic 
drug monitoring should be considered where possible to minimize the advent of any unwanted 
adverse events such as prolongation of QT interval [175, 176] that could be caused by high 
quinolone concentrations. 
 
3.2.7.6 Glycopeptides 
Numerous pharmacokinetic studies of vancomycin in critically ill patients receiving varying types 
of RRT have been published [84, 102, 177-181]. The vancomycin Sc is reported to be between 0.7-
0.9 during CVVH/CVVHDF for effluent flow rates between 20-50 mL/min [84, 178, 179]. RRT 
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can significantly affect vancomycin clearance with large increases expected when higher effluent 
flow rates are used (>65 mL/min) [179, 182]. PIRRT also substantially increases vancomycin 
clearance [102, 180].  
 
More aggressive dosing regimens that include the use of a loading dose (e.g 25 mg/kg for high 
volume CRRT) would be necessary in this population to achieve PK/PD targets. Indeed such dosing 
has been validated in one study [181], to increase the achievement of the PK/PD target, AUC/MIC 
ratio ≥400 [21]. Therapeutic drug monitoring to guide dosing is essential, as returning native renal 
function can increase vancomycin clearance in the presence of CRRT [177]. CRRT is associated 
with varied removal of the highly protein bound glycopeptide, teicoplanin (between 15-50% of 
CLtotal) [85, 183, 184]. This variability could be due to differences in the CRRT intensities 
prescribed or the effect of different levels of hypoalbuminemia on unbound teicoplanin 
concentrations. 
 
3.2.7.7 Lipopeptides  
Few pharmacokinetic studies on daptomycin in critically ill patients receiving RRT are available 
[89-91, 139]. Daptomycin is reported to have a Sc of approximately 0.2 during CRRT in studies 
that have used effluent flow rates between 33-45 mL/min [89, 91]. This low Sc is mostly due to 
daptomycin’s high protein binding (ca. 90%). CVVHD has been shown to be responsible for 30% 
of daptomycin CLtotal [89], while PIRRT has also been shown to influence daptomycin clearance 
(~23% removed in one dialysis session, effluent flow rate = 160 mL/min) [139].  
 
Based on published data of mean pharmacokinetic parameter estimates, doses between 4-6 
mg/kg/day appear to achieve the desired PK/PD targets (Cmax/MIC >8 and the AUC/MIC ratio of 
100) [17, 20], for susceptible pathogens (e.g MIC 1 mg/L) in critically ill patients receiving 
CVVHD/CVVHDF with an effluent flow rate of 33 mL/min [90, 91]. Administration of a loading 
dose (e.g 8 mg/kg) is reported to increase the likelihood of better achieving the desired PK/PD 
target [90]. Drug concentration monitoring of daptomycin appears to be becoming more widespread 
[89-91, 139], although the appropriateness of measuring total concentrations in patients with altered 
protein binding remains uncertain. Measuring the unbound concentration of daptomycin could be 
advantageous, although we are unaware of any reports of this approach to date. 
 
3.2.7.8 Oxazolidinones  
The clearance of linezolid is variably affected by different RRT modalities [107, 108, 185, 186]. 
The effect of RRT on linezolid CLtotal was between 8-40% during CVVH and CVVHD with 
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effluent flow rates of 17-40 mL/min [107, 185, 186]. PIRRT is also reported to significantly affect 
the clearance of linezolid [107].   
 
From the available data, we interpret that usual doses (e.g 1.2 g per day) will not consistently 
achieve the desired PK/PD target (AUC/MIC ratio >50) [18, 19], for a MIC of 4 mg/L [107, 185, 
186] and thus higher doses may be required with pathogens of this reduced susceptibility. 
 
3.2.7.9 Colistin  
Limited pharmacokinetic studies have been performed for colistin in critically ill patients receiving 
RRT [187-189]. Garonzik et al has provided the most useful paper on this topic which included a 
dosing guideline for colistin in CRRT and IHD [190]. Administration of both a higher loading dose 
and maintenance doses of colistin is required for this group of patients [191].	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Table 3.1: Pharmacokinetic parameters of different class of antibiotics in critically ill patients receiving different renal replacement therapy modalities 
Drug / 
(Reference) 
Type of 
RRT/  
No. of 
patients (n) 
RRT settings 
Dose 
Pharmacokinetic parametersa 
Qb  
(mL/min) 
Qe 
(mL/min) 
Filter material/ 
surface area (m2) 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) 
Vd 
(L) 
AUC0-τ  
(mg.h/L) 
CLtotal 
(mL/min) 
CLRRT  
(mL/min) Sc 
Aminoglycosides             
Amikacin* 
[66] 
CVVH  
(n=12)             
NA  41.7±18.7 Polysulfone 
(1.4, 1.5) 
15mg/kg 24H 29.1±14.5 1.5±1.6 70.0±88.3 214.8±113.8h 146.7±148.3 NA NA 
Amikacin  
[78] 
CVVHDF 
(n=13)                
150.0  
 
61.0 Polyacrylonitrile/ 
Polysulfone  
(NA) 
25mg/kg  
(first dose) 
70.0b  
(38.3-94.6) 
9.6b  
(4.1-29.9) 
35.0b,f 
(15.4-283.5) 
NA 88.2b,f 
(7.0-231.0) 
NA NA 
Amikacin  
[141] 
CVVHDF 
(n=5) 
200.0 
 
50.0-66.7 Polyacrylonitrile 
(0.6) 
0.3-1.5g  
12-54H 
48.2b  
(7.6-68.3) 
3.0b  
(2.1-16.1) 
31.4 ± 3.3 NA 58.0±12.3 47.7±6.8 0.8±0.1 
Gentamicin 
[142] 
CVVH 
(n=7) 
 
200.0 
 
67.5 Polysulfone  
(1.4/1.8) 
0.24g (LD), 
0.24-0.32g 
24H 
8.8b  
(5.6-12.5) 
0.5b  
(0.4-1.3) 
42.3b 
(39.6-49.5) 
NA 61.2b  
(44.1-107.1) 
28.8b  
(27.9-30.6) 
0.8 
Cephalosporins             
Ceftazidime 
[147] 
CVVH 
(n=12) 
143.0±13.0 
 
47.0±7.0 Polysulfone  
(0.7) 
2g 8H 58.2 ± 11.6 14.0 ± 3.2 36.4±6.4 344.0±51.6g 98.7±13.2 32.1±7.9 0.7±0.2 
Ceftazidime 
[53] 
CVVHDF 
(n=7) 
150.0 
 
41.7 Polyacrylonitrile 
(0.6) 
2g (LD), 
3g/day (CI) 
NA 33.5±2.4 18.9±6.0 838.1±70.6h 62.4±4.8 33.6±4.0 0.8±0.1 
Ceftazidime  
[79] 
CVVH/ 
CVVHDF 
(n=12) 
150.0± 24.0  25.6±52.5f   Polyacrylonitrile 
(NA) 
2g 12H 78.0d 
[54.0-118.0] 
24.0d 
[5.0-46.0] 
25.9d,f 
[15.4-58.8] 
536.0d 
[258.0-906.0] 
36.4d,f 
[9.1-112.7] 
NA NA 
Cefepime 
[149] 
CVVHD 
(n=6) 
150.0 16.7 Polyacrylonitrile 
(0.6) 
2g 12H 53.0±21.3 17.7±8.3 56.2±29.3 NA 22.1 
(14.3-36.5) 
NA 0.7±0.1 
Cefepime 
[150] 
CVVH 
(n=5) 
150.0 
 
16.0±4.0 Polyacrylonitrile 
(0.6) 
1-2g  
12-24H 
71.0±20.0 25.8±13.5 41.4±12.6 1153.1± 332.5h 36.0±6.0 13.0±4.0 0.9±0.0 
Cefepime 
[150] 
CVVHDF 
(n=7) 
150.0 
 
33.7 Polyacrylonitrile 
(0.6) 
1-2g  
12-24H 
59.0±24.0 10.4±5.7 34.0±12.0 813.3 ± 325.0h 47.0±0.1 26.0±5.0 0.8±0.1 
Cefepime 
[79] 
CVVHD/ 
CVVHDF 
(n=8) 
150.0± 24.0  25.6±52.5f      Polyacrylonitrile 
(NA) 
2g 12H 43.0d 
[28.0-83.0] 
11.0d 
[3.0-12.0] 
38.5d,f 
[23.1-65.8] 
379.0d 
[148.0-483.0] 
72.8d,f 
[30.1-207.9] 
NA NA 
Penicillins             
Flucloxacillin 
[154] 
CVVH 
(n=10) 
169.0±24.0 
 
57.0±9.0 Polyamide 
(0.7) 
4g 8H 143.8±65.0 59.5±36.8 48.1±36.4 568.0 ± 285.9g 117.2±79.1 10.3±4.5 0.2±0.1 
Ampicillin* 
[101] 
PIRRT 
(7.4H) 
(n=12) 
162.0±6.0 
 
162.0±6.0 Polysulfone 
(1.3) 
3g (2/1g) 
 (single dose) 
280.9±174.9 NA 13.1±11.1 847.5 ± 499.5g 61.1±55.2  80.1±7.7  NA 
Piperacillin* CVVH NA 25.9±9.8 NA 4g 8H NA NA 25.9±17.8 NA 42.0±23.0 NA NA 
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Drug / 
(Reference) 
Type of 
RRT/  
No. of 
patients (n) 
RRT settings 
Dose 
Pharmacokinetic parametersa 
Qb  
(mL/min) 
Qe 
(mL/min) 
Filter material/ 
surface area (m2) 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) 
Vd 
(L) 
AUC0-τ  
(mg.h/L) 
CLtotal 
(mL/min) 
CLRRT  
(mL/min) Sc 
[159] (n=9)  
Piperacillin* 
[158] 
CVVH 
(n=6) 
150.0 
 
14.0±1.0 Polysulfone 
(0.5) 
4g  
(first dose) 
125.0±21.0 48.0±8.0 35.5±17.8 964.0±342.0 79.2±23.7 NA NA 
Piperacillin* 
[158] 
CVVH 
(n=4) 
150.0 
 
10.8±0.8 Polysulfone 
(0.5) 
4g 8H 470.0±127.0 188.0±71.
0 
9.7±4.8 3352.0±1750.0 24.8±13.1 NA NA 
Piperacillin* 
[155] 
CVVHD 
(n=8) 
150.0 
 
25.3 Polyacrylonitrile 
(NA) 
2-4g 8-24H NA NA 20.8±4.7 NA 47.0b 
(26.0-220.0) 
22.0±5.0 0.8±0.2 
Piperacillin* 
[156] 
CVVH 
(n=4) 
150.0-220.0 
 
27.1±7.8 Polyacrylonitrile 
(0.9) 
4g 6-8H 365.6 ± 232.3 NA 21.0±11.7 76143.0±49748 50.0±53.0 11.5±6.5 0.4±0.3 
Piperacillin* 
[156] 
CVVH 
(n=5) 
150.0-220.0 
 
30.3±4.3 Polyacrylonitrile 
(0.9) 
4g 6-8H 244.5 ± 122.1 NA 26.8±19.8 45445 ± 25525 90.6±29.9 12.2±13.2 0.4±0.4 
Piperacillin* 
[156] 
CVVH 
(n=5) 
150.0-220.0 
 
20.0±7.5 Polyacrylonitrile 
(0.9) 
4g 6-8H 160.6 ± 93.2 NA 44.9±20.4 17328 ± 11134 265.2±152.2 4.8±3.3 0.2±0.1 
Piperacillin* 
[79] 
CVVH/ 
CVVHDF 
(n=8) 
150.0±24.0        25.6±52.5f      Polyacrylonitrile 
(NA) 
4g 6H 138.0d 
[36.0-262.0] 
60.0d 
[4.0-
155.0] 
30.8d 
[15.4-120.4] 
527.0d 
[62.0-1378.0] 
80.5d 
[18.9-438.2] 
NA NA 
Piperacillin* 
[157] 
CVVHD/ 
CVVHDF 
(n=42) 
NA 40.7±25.0 Polyacrylonitrile/ 
Polyethersulfone 
(0.6,0.9,1.5) 
2-3g 6-12H 115.0d 
[62.1] 
54.8d 
[35.2] 
38.2d 
[26.5] 
NA 78.6d 
[62.2] 
33.2d 
[14.9] 
NA 
Carbapenems             
Imipenem* 
[165] 
CVVHD 
(n=6) 
60.0 20.0 Polyacrylonitrile 
(0.5) 
0.5g  32.5±6.7 1.1±0.5 19.3±6.0 95.3±19.6 89.4±17.5 18.7±1.2 NA 
Imipenem* 
[166] 
CVVH 
(n=12) 
150.0-170.0 
 
18.3-20.0 Polyacrylonitrile 
(NA) 
0.5g 6-8H 26.5-30.2 2.3-4.1 24.3±7.7 NA 122.2±28.6 22.9±2.5 1.2±0.1 
Imipenem* 
[167] 
CVVH 
(n=6) 
150.0 
 
20.0 Polyacrylonitrile 
(0.6) 
0.5g 8-12H 17.8±3.9 1.4±1.0 35.5±9.9 147.4±35.8h 145.0±18.0 36.0±13.0 1.2±0.1 
Imipenem* 
[167] 
CVVHDF 
(n=6) 
150.0 
 
36.7 Polyacrylonitrile 
(0.6) 
0.5g 8-12H 15.6±3.5 1.1±1.1 36.4±12.8 125.4±24.3h 178.0±18.0 57.0±28.0 1.3±0.2 
Meropenem 
[39] 
CVVH 
(n=9) 
150.0 
 
50.0 Polysulfone 
(0.4) 
1g 
(single dose) 
28.1±2.7 6.6±1.5 29.5±2.7 118.0±15.8g 143.7±18.6 49.7±8.3 1.1±0.1 
Meropenem  
[40] 
CVVHDF 
(n=9) 
100.0 
 
55.7 Polyacrylonitrile 
(0.9) 
1g 12H 103.2±45.9 9.6±3.8 18.0±6.2 344.0±114.4 53.1±16.8 30.4±2.0 1.1 
Meropenem 
[41] 
CVVH 
(n=9) 
150.0-170.0 
  
18.3-19.2 Polyacrylonitrile 
(NA) 
0.5g 8-12H 38.9±9.7 7.3±1.3 12.4±1.8 NA 52.0±8.4 22.0±4.7 1.2±0.1 
Meropenem 
[43] 
CVVH / 
CVVHDF 
(n=10) 
150.0 
  
33.3 Polyacrylonitrile 
(0.9) 
1g 12H 55-128 
(range) 
9.6±5.4 27.3±9.8 246.0±97.1 70.6±24.2 32.7±11.2 0.9±0.1 
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Drug / 
(Reference) 
Type of 
RRT/  
No. of 
patients (n) 
RRT settings 
Dose 
Pharmacokinetic parametersa 
Qb  
(mL/min) 
Qe 
(mL/min) 
Filter material/ 
surface area (m2) 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) 
Vd 
(L) 
AUC0-τ  
(mg.h/L) 
CLtotal 
(mL/min) 
CLRRT  
(mL/min) Sc 
Meropenem 
[45] 
CVVHDF 
(n=13) 
119.0±15.0 
  
28.3 Polyacrylonitrile 
(0.9) 
0.5-1g 8-12H 34.7(0.5g), 
59.4 (1g) 
4.1 (0.5g), 
7.6 (1g) 
33.2c 
(18.5-45.6) 
NA 74.7c 
(46.0-128.5) 
27.0c 
(14.8-46.5) 
0.7 
Meropenem 
[44] 
CVVH 
(n=8) 
100 
  
26.7 Polyacrylonitrile 
(0.9) 
0.5g 12H 39.5±10.5 2.4±1.5 22.3±5.6 105.3±21.7 82.9±21.6 24.4±8.0 0.9±0.1 
Meropenem 
[163] 
CVVHDF 
(n=7) 
100.0-180.0 
  
25.0 Polyacrylonitrile/ 
Polysulfone 
(0.9,1.4) 
0.5-1g 6-8H 30.4±10.3 7.7±5.4 42.8±21.8 NA 150.3±75.8 27.0±6.9 0.8±0.1 
Meropenem 
[163] 
CVVH / 
CVVHDF 
(n=7) 
150.0-220.0 
  
36.0 Polyacrylonitrile/ 
Polysulfone 
(0.9,1.4) 
0.5-1g 6-8H 43.3±20.1 4.4±2.3 25.9±7.0 NA 134.4±57.2 32.2±7.2 0.9±0.1 
Meropenem 
[163] 
CVVH 
(n=6) 
120.0-180.0 
  
16.7 Polyacrylonitrile 
(0.9) 
1-2g 6-8H 34.5±18.6 1.0±1.6 91.7±63.0 NA 1064.8± 
662.3 
16.4±6.7 NA 
Meropenem 
[46] 
CVVHDF 
(n=6) 
150.0 
  
31.3 Polysulfone 
(1.4) 
LD 0.5g,  
1g 12H (IB)  
62.8d 
[51.4-85.0] 
 
8.2d 
[5.4-10.1] 
 
32.2d 
[28.9-40.7] 
 
NA 72.0d 
[65.5-82.7] 
 
NA 1.0 
 
Meropenem 
[46] 
CVVHDF 
(n=6) 
150.0 
  
31.3 Polysulfone 
(1.4) 
LD 0.5g,  
2g 24H (CI) 
20.0d 
[19.1-24.8] 
15.7d 
[12.6-
18.5] 
NA NA 73.3d 
[59.7-93.0] 
NA 0.9 
Meropenem 
[81] 
CVVH 
(n=10) 
275.0 
  
73.3 Polyacrylonitrile 
(2.15) 
1g 8H 56.6d 
[49.7-65.7] 
7.6d 
[6.2-12.9] 
25.9d 
[22.4-32.2] 
166.5d 
[160.5-193.1] 
100.0d 
[86.7-103.3] 
58.3d 
[56.7-65.0] 
0.9 
Meropenem 
[79] 
CVVH/ 
CVVHDF 
(n=17) 
150.0±24.0         25.6±52.5f      Polyacrylonitrile 
(NA) 
1g 12H 26.0d 
[15.0-67.0] 
6.0d 
[2.0-11.0] 
31.5d,f 
[14.0-212.1] 
134.0d 
[61.0-291.0] 
80.5d,f 
[37.8-235.90] 
NA NA 
Doripenem 
[82] 
CVVHDF             
(n=6) 
100.0 
  
13.3 Polysulfone  
(1.0) 
0.25g (single 
dose) & 12H 
13.2±4.1 NA 33.0±15.8 74.6±15.6g 58.0±12.7 13.5±1.6 NA 
Ertapenem 
[169] 
CVVHD/ 
CVVHDF 
(n=8) 
181.0±26.0 48.0±6.5 Acrylonitrile/ 
Polyarylethy- 
sulfone (1.5, 1.4) 
1g 24H NA NA NA NA 48.0e 
(10.0) 
36.0e 
(13.0) 
0.2±0.1 
Ertapenem 
[103] 
PIRRT 
(8.0H) 
(n=6) 
160.0 
  
160.0 Polysulfone   
(1.3) 
1g 
(single dose) 
81.3 ± 12.1 NA 15.9 ± 3.2 687.4±212.0g 49.5±10.9 38.5±14.2 NA 
Glycopeptides             
Vancomycin 
[178] 
CVVHDF 
(n=10) 
200.0 
  
50.0 Polyacrylonitrile 
(NA) 
0.75g 12H 45.4±10.1 19.2±5.2 49.7±29.1 262.5±79.5 41.7±11.7 30.0±6.7 0.7±0.1 
Vancomycin 
[84] 
CVVH 
(n=7) 
200.0-250.0       13.3-20.0 Triacetate 
(NA) 
1g  
(single dose) 
NA NA 24.7±11.0 671.1±181.1g 26.5±7.8 12.1±3.5 0.7±0.1 
Vancomycin CVVH 200.0 67.5 Polysulfone 1g (1st dose), 21.3b 10.0b 36.9b 347.4h 49.5b 45.0b 0.7 
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Drug / 
(Reference) 
Type of 
RRT/  
No. of 
patients (n) 
RRT settings 
Dose 
Pharmacokinetic parametersa 
Qb  
(mL/min) 
Qe 
(mL/min) 
Filter material/ 
surface area (m2) 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) 
Vd 
(L) 
AUC0-τ  
(mg.h/L) 
CLtotal 
(mL/min) 
CLRRT  
(mL/min) Sc 
[179] (n=17)   (1.4, 1.8) 1g 12H (13.3-36.4) (6.4-16.6) (30.6-70.2) (27.0-96.3) (45.0-54.0) 
Vancomycin 
[180] 
PIRRT 
(6.0H) 
(n=5) 
200.0 
  
500.0 Polysulfone 
(1.3) 
~11mg/kg NA 11.7b 
(7.3-12.0) 
28.0b 
(22.4-44.0) 
324.0b,h 
(208.5-345.1) 
NA 29.0 NA 
Vancomycin 
[180] 
PIRRT 
(6.0H) 
(n=4) 
200.0 
  
500.0 Polysulfone 
(1.5) 
~11mg/kg NA 21.6b 
(12.6-
26.6) 
40.0b 
(15.2-44.8) 
555.5b,h 
(318.1-623.7) 
NA 60.3 NA 
Vancomycin 
[181] 
CVVH/ 
CVVHDF 
(n=32) 
150.0 45.3 Polyacrylonitrile/ 
Polysulfone 
(NA) 
35 mg/kg 
(LD), 14 
mg/kg 12H 
44.0d 
[38.0-58.0] 
23.0d 
[19.0-
26.0] 
NA 652.0d,h 
[596.0-789.0] 
33.2d 
[30.0-33.7] 
NA NA 
Teicoplanin 
[85] 
CVVH 
(n=11) 
180.0 40.8f Polysulfone 
(1.2) 
1.2g (1st 
dose) 
55.4±15.9  6.4±1.7  
 
58.6±15.1f           
 
291.0±49.0h  45.5±14.0f           
 
6.7±1.6 0.1±0.0 
Teicoplanin 
[85] 
CVVH 
(n=4) 
180.0 40.8f Polysulfone 
(1.2) 
MD: Daily - 
trough level 
15-25 mg/L 
81.2±28.6  21.3±5.6 33.3±6.3f 706.7±142.0h 12.8±4.7f 7.1±4.6 0.2±0.1 
Quinolones             
Levofloxacin 
[172] 
CVVH 
(n=6) 
150.0 
  
21.7 Polyacrylonitrile 
(0.9) 
0.5g  
(first dose) 
6.4±2.4 2.0±1.3 112.8±33.7 202.0±120.0g 52.1±24.4 21.2±4.8 1.0±0.1 
Levofloxacin 
[172] 
CVVH 
(n=6) 
150.0 
  
21.7 Polyacrylonitrile 
(0.9) 
 0.25g 24H 8.2±2.3 2.9±0.8 82.8±50.1 109.0±33.0h 41.9±14.7 20.1±2.9 0.9±0.1 
Levofloxacin 
[173] 
CVVH 
(n=4) 
150.0 
  
20.0 Polyacrylonitrile 
(0.6) 
0.25-0.5g 
24-48H 
6.4b 
(4.3-7.6) 
2.0b 
(1.6-3.1) 
89.4b 
(72.9-134.1) 
101.6b,h 
(69.2-155.3) 
40.0b 
(35.0-54.0) 
12.0b 
(6.0-16.0) 
0.7 
Levofloxacin 
[173] 
CVVHDF 
(n=6) 
150.0-200.0 
  
36.7 Polyacrylonitrile 
(0.6) 
0.25-0.5g 
24-48H 
6.1b 
(3.5-7.7) 
1.4b 
(1.2-2.1) 
80.5b 
(62.6-125.2) 
90.6b 
(57.6-105.5) 
50.5b 
(45.0-60.0) 
20.5b 
(15.0-36.0) 
0.6 
Ciprofloxacin 
[173] 
CVVH 
(n=5) 
150.0 
  
19.0 
 
Polyacrylonitrile 
(0.6) 
0.4g 24H 5.8b 
(3.2-7.2) 
1.5b 
(0.7-4.7) 
106.5b 
(77.4-135.5) 
84.3b,h 
(46.8-138.0) 
65.0b 
(34.0-151.0) 
13.0b 
(9.0-20.0) 
0.7 
Ciprofloxacin 
[173] 
CVVHDF 
(n=5) 
150.0 
  
33.7 Polyacrylonitrile 
(0.6) 
0.4g 12-24H 4.8b 
(3.2-7.5) 
1.3b 
(0.3-2.4) 
87.1b 
(48.4-135.5) 
76.6b,h 
(40.3-96.6) 
131.0b 
(121.0-208.0) 
21.0b 
(19.0-24.0) 
0.6 
Ciprofloxacin 
[174] 
CVVHDF 
(n=6) 
200.0 
  
50.0 Polyacrylonitrile 
(NA) 
0.2g 8H 3.3b 
(1.9-3.9) 
0.7±0.3 135.0±27.0 11.3b 
(7.0-16.4) 
203.0±72.0 37.0±7.0 0.7±0.1 
Ciprofloxacin 
[88] 
CVVHDF 
(n=7) 
200.0 
  
50.0-66.7 Polyacrylonitrile 
(NA) 
0.2-0.4g  
12-24H 
5.8±1.0 NA 125.0b 
(79.5-554.0) 
83.0±11.1h 143.3±45.0 41.2±4.8 0.7±0.1 
Lipopeptides             
Daptomycin 
[139] 
PIRRT 
(7.6H) 
(n=10) 
166.0±5.0 
  
166.0±5.0 Polysulfone 
(1.3) 
6mg/kg 
(single dose) 
69.6±17.7 NA 11.4 ± 2.9 531.1±177.4g 17.2±4.8 63.0±9.0 NA 
Daptomycin CVVHD 100.0 33.3 Polyamix  8mg/kg (LD) 87.5±15.0        5.0±2.6        19.5±6.0       537.0±97.0h        12.5±3.3 NA NA 
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(mL/min) Sc 
[90] (n=8)   (1.4)      
Daptomycin 
[90] 
CVVHD 
(n=8) 
100.0 
  
33.3 Polyamix  
(1.4) 
4mg/kg 48H 41.8±5.0 2.5±1.0 16.1±3.0 302.0±43.0h 11.7±1.5 NA NA 
Daptomycin 
[89] 
CVVHD 
(n=8) 
181.0±26.0,      45.3±6.9 Polysulfone  
(1.5) 
8mg/kg 48H 81.2±19.0 NA 16.1±6.6 NA 10.7±3.3 3.3±1.6 0.1±0.1 
Daptomycin 
[91] 
CVVHDF 
(n=9) 
150.0±48.0       
  
33.3 Polycrylonitrile 
(0.9) 
6mg/kg 24H 66.1±17.3 17.2±8.8 6.3±2.1f 578.0±224.0h 5.3±4.1f NA 0.2 
Oxazolidinones             
Linezolid 
[185] 
CVVH 
(n=13) 
186.0±15.0 
  
40.0±8.0 Polysulfone 
(0.9) 
0.6g 12H 16.9±3.8 2.0±1.9 46.3±11.0 85.7±55.1g 145.7±50.5 27.2±8.3 0.7±0.1 
Linezolid 
[185] 
CVVH 
(n=7) 
186.0±15.0 
  
40.0±8.0 Polysulfone 
(1.2) 
0.6g 12H 12.4±2.3 1.7±1.2 60.5±8.6 67.6±26.7g 172.5±66.2 39.0±15.7 0.8±0.1 
Linezolid 
[107] 
PIRRT 
(19.5H) 
(n=10) 
110.0-150.0 
  
NA Polysulfone 
(1.3) 
0.6g 12H 14.1±4.9 1.0±2.7 NA 115.2±70.6h 213.3±108.3 61.7±13.3 NA 
*Data based on ampicillin or piperacillin or imipenem component 
PK = pharmacokinetic; H = hourly; IB = intermittent bolus; CI = continuous infusion; CVVH = continuous venovenous hemofiltration; CVVHDF = continuous 
venovenous hemodiafiltration; PIRRT = prolonged intermittent renal replacement therapy; Qb = blood flow rate; Qf = ultrafiltration rate; Qd = dialysate flow rate; 
Qe = effluent flow rate, Cmax = maximum concentration; Cmin = minimum concentration; Css = concentration at steady state; AUC0-τ = area under the concentration-
time curve in one dosing interval; CLtotal = total clearance; CLRRT = clearance by RRT; Vd = volume of distribution; Sc = sieving coefficient and NA = not available  
aData reported as mean ± standard deviation unless otherwise stated 
bData presented as median (range) 
cData presented as mean (range) 
dData presented as median [interquartile range] 
eData presented as population estimate (relative standard error %)  
fData calculated using estimated body weight = 70kg 
gData reported as area under the concentration-time curve from t=0 until infinity (AUC0-∞) 
hData reported as area under the concentration-time curve from t=0 to t=24 hours (AUC0-24) 	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3.2.8 Clinical ramifications of the altered antibiotic pharmacokinetics during the different 
forms of renal replacement therapy in the intensive care unit setting 
 
Published pharmacokinetic studies in the critically ill have provided insight into possible changes to 
pharmacokinetic parameters of different classes of antibiotics during different types of RRT 
modalities. Such changes will affect dosing requirements in these already challenging patients. 
Significant changes to the pharmacokinetic parameters during RRT, particularly clearance, would 
support alternative antibiotic dosing strategies, especially when aiming for higher drug exposures 
because of the presence of less susceptible pathogens (Figure 3.2).  
 
Establishing a standard antibiotic dosing regimen in this population remains a challenge because of 
the complex inter- and intra-patient pharmacokinetic variability during the various forms of RRT. 
During commencement of CRRT, it is expected that clearance would be constant, however there are 
many instances when CRRT is interrupted, which leads to diminished overall solute removal [192, 
193]. This would also affect the antibiotic clearance, which particularly would be significant for 
septic critically ill patients. Therefore, antibiotic concentration monitoring remains essential 
whenever possible to guide dosing and prevent excessive antibiotic exposures that may lead to 
toxicity.  
 
Administration of an initial ‘loading’ dose with subsequent drug concentration monitoring is the 
preferred strategy to rapidly achieve and maintain desired serum concentrations in critically ill 
patients receiving RRT. We suggest that a loading dose that is an additional 50-100% of standard 
dose during a dosing interval is required for hydrophilic antibiotics because of an increased Vd 
caused by altered fluid balances in these patients. 
 
For antibiotics where therapeutic drug monitoring is not available, use of doses informed by 
pharmacokinetic software could be very useful. Using a robust pharmacokinetic model, dose 
estimation could be performed and proper individualized dosing regimens could be established, for 
different critically ill populations receiving variable types of RRT. Whilst theoretically useful, this 
approach has not been investigated in detail previously.  
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Figure 3.2: The factors supporting a potential need for altered dosing strategies to ensure rapid 
achievement of therapeutic concentrations  
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RRT = renal replacement therapy and PK = pharmacokinetic 
 
3.2.9 Future directions: What is needed to improve antibiotic dosing in renal replacement 
therapy 
 
Larger well-designed trials are required to describe the overall variability of prescribed RRT 
settings and the associated effects on antibiotic pharmacokinetics. Such studies are required to 
determine whether guideline based dosing is possible or whether only a therapeutic drug monitoring 
approach can be recommended to ensure accurate dosing in critically ill patients receiving RRT. 
The SMARRT (SaMpling Antibiotics in Renal Replacement Therapy) study, is a large multi-centre 
prospective pharmacokinetic study, registered with Australian New Zealand Clinical Trial Registry 
(ACTRN) that is underway. This study seeks to define the magnitude of the influence of patient and 
RRT factors on antibiotic pharmacokinetics. Using pharmacokinetic models and a simulation 
approach, the SMARRT Study aims to identify the statistical distribution of pharmacokinetic 
parameters, such as Vd and clearance, during different forms of RRT, as well as patient 
Significant PK changes likely & 
alternative dosing strategy suggested: 
♦ Aggressive initial dose (or 
loading dose) 
♦ Higher maintenance doses 
♦ Frequent administration or 
extended/continuous infusion for 
time dependent antibiotics 
 
 
High RRT 
intensity 
Changes in plasma protein 
binding  -­‐ low serum albumin -­‐ high α-1-acid glycoprotein 
Hydrophilic 
Less 
susceptible 
pathogen 
Low molecular 
weight 
Primarily 
renal 
elimination  
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characteristics. These data will then be analysed to determine the appropriate doses for various 
antibiotics during different RRT forms and settings. 
 
Another form of study that can help improve our understanding of antibiotic dosing in RRT is the 
use of in-vitro and ex-vivo laboratory studies of RRT. By using this approach to study antibiotic 
clearances associated with changes in RRT in a controlled setting, relationships that are not 
confounded by patient factors may be possible. These laboratory-based investigations may be able 
to rapidly provide the urgently needed antibiotic pharmacokinetic data during PIRRT and IHD in 
the ICU where clinical pharmacokinetic studies are currently grossly lacking.  
 
3.2.10 Conclusion 
 
Numerous pharmacokinetic studies for different classes of antibiotics in critically ill populations 
receiving different types of CRRT techniques are available. However those studies mostly include 
only small numbers of patients and observe wide inter-patient differences in antibiotic 
pharmacokinetics. Indeed the lack of standardization of CRRT techniques is partly responsible for 
the significant variations in results described and makes development of a robust dosing guideline 
very difficult. Pharmacokinetic data collected during other types of RRT such as PIRRT and IHD is 
still limited and thus, current data does not reliably inform antibiotic dosing requirements during 
these RRT modalities. Given this uncertainty, the individualization of antibiotic dosing regimens 
through the application of pharmacokinetic principles is the best approach to increase the likelihood 
of achieving PK/PD targets. Where possible, therapeutic drug monitoring should be used to guide 
dosing. We also suggest that particularly for hydrophilic antibiotics, the administration of ‘front 
loaded’ doses could be advantageous to ensure PK/PD targets are more rapidly achieved. 
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3.3 Conclusion 
 
This chapter has described the effect of RRT on antibiotic pharmacokinetics. Hydrophilic 
antibiotics, those that primariy eliminated by the kidneys, and those with low plasma protein 
binding would have significant changes in pharmacokinetic. Greater clearance would be expected 
when higher intensity RRT is used. Individualization of antibiotic dosing regimens is essential in 
patients receiving RRT and therapeutic drug monitoring should be considered as the best tool to 
guide dosing. In particular, more data is still required to understand the pharmacokinetic changes 
during PIRRT. Larger well-designed pharmacokinetic studies are required to describe the effect of 
variations of prescribed RRT settings and the associated effects on antibiotic dosing requirements.  	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Chapter 4 
 
The impact of renal replacement therapy settings on antibiotic clearance 
 
4.1 Sypnosis 
 
The primary aim of this chapter is to describe the effect of different RRT modalities and settings on 
the clearance of antibiotics commonly used in the ICU setting, meropenem, piperacillin and 
vancomycin. The correlation between RRT settings and pharmacokinetic parameters were assessed 
to identify possible predictors of dose modifications during different RRT settings. This chapter 
also evaluated the frequency that commonly used dosing regimens of meropenem, piperacillin and 
vancomycin in patients receiving RRT achieve therapeutic targets against pathogens commonly 
encountered in the ICU.  
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4.2 Manuscript entitled, “The impact of variation in renal replacement therapy settings on 
piperacillin, meropenem and vancomycin drug clearance in the critically ill: An analysis of 
published literature and dosing regimens” 
 
The manuscript entitled, “The impact of variation in renal replacement therapy settings on 
piperacillin, meropenem and vancomycin drug clearance in the critically ill: An analysis of 
published literature and dosing regimens” has been accepted for publication by Critical Care 
Medicine (2014; 42(7): 1640-1650). 
 
The co-authors contributed to the manuscript as follows: All literature review and analysis was 
performed by the PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. 
Roberts, Dr. Andrew A. Udy and Prof. Jeffrey Lipman. The PhD candidate, Janattul-Ain Jamal, 
took the leading role in manuscript preparation and writing. 
 
The manuscript is presented as published; except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted to 
fit the overall style of the Thesis. The references are found alongside the other references of the 
Thesis, in the section ‘References’. 
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4.2.1 Abstract 
 
Objectives: To describe the effect of different RRT modalities and settings on the clearance of 
meropenem, piperacillin and vancomycin in critically ill patients, and to evaluate the frequency 
with which current dosing regimens achieve therapeutic concentrations.  
 
Design: Regression analyses of published pharmacokinetic data. 
 
Setting: Pubmed was searched for relevant articles published between 1952 and 2013. 
 
Subjects: Original research articles describing the pharmacokinetics of meropenem, piperacillin 
and vancomycin, in critically ill patients receiving RRT. 
 
Interventions: None 
 
Measurement and Main Results: Data from 30 studies were analysed. The mean age of the patient 
groups involved in studies of meropenem, piperacillin and vancomycin, were 55.3, 60.3 and 56.9 
years respectively. The mean blood and effluent flow rates used for each antibiotic were 151.3 and 
33.8 mL/min, 131.8 and 27.3 mL/min, and 189.3 and 35.6 mL/min, respectively in CRRT studies. 
Correlations existed between effluent flow rate in CRRT and extracorporeal clearance for 
meropenem (rs = 0.43; P = 0.12), piperacillin (rs = 0.77; P = 0.10), and vancomycin (rs = 0.90; P = 
0.08). Current dosing regimens achieved target concentrations for meropenem (89%), piperacillin 
(83%) and vancomycin (60%), against susceptible pathogens. 
 
Conclusions: Effluent flow rate appears be a reliable predictor of antibiotic clearance in critically 
ill patients despite significantly altered pharmacokinetics in these patients. Higher dosing regimens 
maybe be required in critically ill patients receiving RRT, in the presence of high effluent flow rates 
and/or the presence of poorly susceptible pathogens, particularly for vancomycin. 
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4.2.2 Introduction 
 
AKI in the ICU is encountered in 16-65% of patients [114, 115], often in association with severe 
sepsis or septic shock. Initiation of RRT is common in this population, with up to 70% of these 
patients requiring this intervention [115]. Not only is AKI common, the associated mortality rate is 
high, at around 50% [114]. In those needing RRT, mortality increases to 60% [31]. Further 
complicating ICU management is the high prevalence of gram-negative and gram-positive 
infections (62% and 47% respectively) [194]. Of these, Pseudomonas spp (20%) and 
Staphylococcus aureus (20%) are among the most commonly isolated pathogens in the ICU [194].  
As such, anti-pseudomonal beta-lactam antibiotics (such as meropenem and piperacillin), and 
vancomycin for resistant gram-positive infections are commonly used for both empirical and 
directed therapy [195].  Importantly, adequate antibiotic treatment in this population is considered a 
key intervention to reduce mortality [59], although the delivery of RRT will alter the concentrations 
of many agents.  
 
Designing drug-dosing regimens that produce therapeutic antibiotic concentrations at the site of 
infection is challenging in critically ill patients. This process should aim to ensure that the PK/PD 
indices correlated with maximal antibiotic activity are achieved.  However, many factors can 
influence drug exposure, least of which is the potential impact of extracorporeal modalities. In this 
respect, the global heterogeneity of RRT prescription within ICU, is likely to significantly impact 
antibiotic pharmacokinetics. Of concern, most data on antibiotic concentrations during RRT are 
from single centre studies, where consistent RRT settings are applied to all study participants. 
Despite this, many of these studies show that dosing is presently insufficient [79, 196]. Clearly, 
recommending a single antibiotic dose for all forms of RRT is therefore flawed, while currently 
there is little data quantifying how varying modes and settings influence antibiotic 
pharmacokinetics. As such, an improved understanding of the influence of differing modalities and 
settings (e.g modes, blood flow rate, effluent flow rate, filter material and size) would likely greatly 
improve the prescription of antibiotics in critically ill patients concurrently receiving RRT [51, 98, 
197].   
 
The primary aim of this paper was to describe the effect of different renal replacement therapy 
modalities and settings on the clearance of the antibiotics most commonly used in ICU setting, 
meropenem, piperacillin and vancomycin [195]. We also aimed to evaluate if the dosing regimens 
utilized were likely to achieve the necessary PK/PD targets associated with maximal antibiotic 
efficacy, against commonly encountered pathogens in the ICU. 
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4.2.3 Methods 
 
4.2.3.1 Search strategy  
We searched the Pubmed database (1951 – 2013) for relevant articles using the following terms, 
‘meropenem’, ‘piperacillin’, ‘vancomycin’, ‘h(a)emofiltration’, ‘h(a)emodiafiltration’, 
‘h(a)emodialysis’, ‘renal replacement therapy’, ‘continuous renal replacement therapy’, ‘extended 
daily dialysis’, ‘sustained low efficiency dialysis’, ‘pharmacokinetic’, ‘critically ill’ and ‘intensive 
care’ (Figure 4.1). The reference lists of articles selected were also searched. Original prospective 
studies, reporting on the pharmacokinetics of meropenem, piperacillin and vancomycin in critically 
ill patients receiving RRT were included. Articles that did not provide qualitative or quantitative 
data on RRT settings used and/or associated pharmacokinetic parameters, were from non-critically 
ill populations, or were retrospective, were excluded.  	  
         Figure 4.1: Study selection process 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
RRT = renal replacement therapy 
 
 
 
Articles identified and screened in 
PubMed database 
(N=132) 
Full-text articles accessed for 
eligibility 
(N=58) 
Articles excluded (N = 33) -­‐ Review articles (N=13) -­‐ Not in RRT (N=11) -­‐ Not in critically ill 
population (N=1) -­‐ Retrospective studies (N=1) -­‐ Duplicate publication (N=7) 
Relevant citations from 
references retrieved 
(N=5) 
Studies included in the 
analysis 
(N=30) 
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4.2.3.2 Data extraction  
For all included studies, the following data were extracted: first author’s name, year of publication, 
sample size, baseline patient characteristics (age, weight, acute physiology and chronic health 
evaluation (APACHE) II score [198], sequential organ failure assessment (SOFA) score [199], 
creatinine clearance), antibiotic dosing, RRT settings (mode, blood flow rate, ultrafiltration rate, 
dialysate flow rate, haemofilter material and surface area), pharmacokinetic parameters (peak 
concentration - Cmax; trough concentration - Cmin; area under the concentration-time curve - AUC; 
total body clearance - CLtotal, extracorporeal clearance - CLRRT; volume of distribution - Vd and 
sieving coefficient - Sc) and dosing regimens. The effluent flow rate was determined from the 
reported ultrafiltration rate in CVVH or dialysate flow rate in CVVHD. Data from hybrid RRT 
techniques (EDD or SLED) were also included.  The sum of ultrafiltration and dialysate flow rates 
was used for defining the RRT dose in CVVHDF.  For quantitative analysis, only mean or median 
data of the patient cohorts were extracted. 
 
4.2.3.3 Pharmacokinetic calculations  
Pharmacokinetic parameters were calculated using the following equations where reported data 
were not available.  The elimination half-life was calculated as t1/2 = ln2/ke, where ke is the 
elimination rate constant. Vd was calculated as Vd = CLtotal/ke, where CLtotal is the total clearance. 
The CLRRT was estimated based on previously described calculation [51]. An estimated body 
weight of 70kg was used when mean or median data for patient weight were not available. 
 
4.2.3.4 Pharmacodynamic calculations  
PK/PD target attainment for reported dosing regimens was determined for each antibiotic.  For 
meropenem and piperacillin, the PK/PD target [the percentage of time during the dosing interval 
that the drug concentration is in excess of the MIC of the targeted pathogen (%T>MIC)] was 
determined according to previously established calculations [200].  Target MIC values of 2 mg/L 
and 16 mg/L were chosen for meropenem and piperacillin respectively, as these represent 
susceptibility breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa [201]. For 
vancomycin, an AUC to MIC ratio (AUC0-24/MIC) of at least 400 over a 24 hours dosing interval 
was considered as the optimal PK/PD target [21].  A susceptibility breakpoint of 1 mg/L, 1.5 mg/L 
and 2mg/L for Staphylococcus spp. were used in the vancomycin analysis [201]. 
  
4.2.3.5 Statistical analysis  
Statistical analyses were performed using Prism (GraphPad, version 6.0; San Diego, CA) and 
Microsoft Excel (Microsoft Office 2011; Redmond, WA). Data are presented as the mean ± 
	   63 
standard deviation (SD) or median (interquartile range, IQR) of the group data that were reported in 
individual studies.  The relationship between summary data was determined by Spearman’s rank 
correlation coefficient (rs). The relationship (line of best fit) between blood flow rate or effluent 
flow rate and CLtotal or CLRRT, as dependent variables, was determined by simple linear regression. 
A P value <0.05 was considered statistically significant. 
 
4.2.4 Results 
 
Thirty original articles describing the pharmacokinetic of meropenem, piperacillin and vancomycin 
inclusive of 349 critically ill patients concurrently treated with varying types of RRT were reviewed 
for qualitative and quantitative analysis.  The details of these studies are presented in Table 4.1.  
Meropenem pharmacokinetics was reported in 15 articles, using differing modes of CRRT and 
hybrid techniques (EDD and SLED) [39-46, 79, 81, 102, 163, 164, 202, 203].  Piperacillin 
pharmacokinetics during CRRT was investigated in 8 studies [79, 155-159, 204, 205], while 
vancomycin data was reported in 9 studies, using both CRRT and hybrid techniques (EDD and 
SLED) [84, 102, 178-181, 206-208]. The mean age of included patient data was 55.3, 60.3, and 
56.8 years, while the median (IQR) sample size was 9 (7-10), 8.5 (8-11) and 10 (7-12) in studies of 
meropenem, piperacillin and vancomycin respectively. The majority of studies examined changes in 
pharmacokinetics during CRRT (n=26, 86.7%). The mean of the blood flow and effluent flow rates 
reported by the studies examining meropenem was 151.3 and 33.8 mL/min.  In studies investigating 
piperacillin and vancomycin, these were 131.8 and 27.0 mL/min, and 189.3 and 35.6 mL/min 
respectively.	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Table 4.1: Characteristics of the selected pharmacokinetic studies  
Drug/ 
Reference (s) 
Patient characteristicsa 
RRT type 
(Duration) 
RRT settings 
Population 
No. of 
patients 
(M/F) 
Age Weight APACHE SOFA Filter material Surface area (m2) 
Pre- or 
Postdilution 
Meropenem           
Thalhammer et al  
[39] 
Acute kidney 
injury, anuric 
9  
(6/3) 
57.9 ± 5.7 86.7 ± 23.1 NA NA CVVH Polysulfone 0.4 Post-
dilution 
Krueger et al  
[40]  
Acute kidney 
injury, anuric 
9  
(5/4) 
54.2 ±19.7 69.4 ± 9.7 22.3 ± 5.3 NA CVVHDF Polyacrylonitrile 0.9 NA 
Meyer et al  
[202] 
Acute kidney 
injury, anuric 
1  
(1/0) 
19.0 NA NA NA CVVHDF Polyacrylonitrile NA NA 
Tegeder et al  
[41] 
Acute kidney 
injury, anuric 
9  
(4/5) 
65.7 ± 13.2b NA NA NA CVVH Polyacrylonitrile NA NA 
Valtonen et al  
[203] 
Acute kidney 
injury 
6  
(3/3) 
45.0 ± 21.0 79.0 ± 11.0 NA NA CVVH/ 
CVVHDF 
Polysulfone 0.7 NA 
Ververs et al  
[42]  
Acute kidney 
injury 
5  
(1/4) 
46.6 ± 13.0b 85.8 ± 11.8 NA NA CVVH Polyacrylonitrile 0.6 Post-
dilution 
Giles et al  
[43] 
Acute kidney 
injury 
10  
(7/3) 
64.9 ± 8.0b 79.8 ± 18.5b 26.7 ± 6.3b NA CVVH/ 
CVVHDF 
Polyacrylonitrile 0.9 Post-
dilution 
Robatel et al  
[45] 
Renal failure 13  
(8/5) 
60.5 ± 8.3b 71.0 ± 16.3b NA NA CVVHDF Polyacrylonitrile 0.9 NA 
Krueger et al  
[44] 
Acute kidney 
injury 
8  
(5/3) 
66.5 ± 9.4b 79.6 ± 14.5b 22.3 ± 3.2b NA CVVH Polyacrylonitrile 0.9 Pre-/ Post-
dilution 
Isla et al  
[163] 
Renal failure 20  
(15/5) 
56.2 ± 20.5b 73.1 ± 6.9b 19.4 ± 6.8b 13.1 ± 4.0b CVVH 
CVVHDF 
Polyacrylonitrile/ 
Polysulfone 
0.9,1.4 Pre-dilution 
Langgartner et al  
[46] 
Renal failure 6  
(5/1) 
53.7 ± 7.9b 76.0 ± 16.7b NA NA CVVHDF Polysulfone 1.4 NA 
Bilgrami et al  
[81] 
Renal failure 10  
(6/4) 
57.0c 70.0c 25.0c NA CVVH Polyacrylonitrile 2.15 NA 
Seyler et al  
[79] 
Acute kidney 
injury 
17  
(NA) 
62.0±16.0 NA NA NA CVVH/ 
CVVHDF 
Polyacrylonitrile NA NA 
Kielstein et al  
[102] 
Acute kidney 
injury, anuric 
10  
(6/4) 
54.3 ± 9.4b 76.7 ± 15.0b NA NA EDD  
(8.0H) 
Polysulfone 1.3 NA 
Deshpande et al Renal failure 10  63.7 ± 11.7 88.9 ± 21.5 NA NA SLED  Polysulfone 0.7 NA 
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Drug/ 
Reference (s) 
Patient characteristicsa 
RRT type 
(Duration) 
RRT settings 
Population 
No. of 
patients 
(M/F) 
Age Weight APACHE SOFA Filter material Surface area (m2) 
Pre- or 
Postdilution 
[164] (8/2) (8.0H) 
Piperacillin           
Joos et al  
[204] 
Acute kidney 
injury, anuric 
8  
(NA) 
NA NA NA NA CVVH Polyamide NA NA 
van der Werf et 
al [159] 
Acute kidney 
injury, anuric 
9  
(5/4) 
56.4 ± 15.2b 86.6 ± 22.6b 30.1 ± 4.2b NA CVVH NA NA Pre-dilution 
Capellier et al  
[158]  
Acute kidney 
injury 
10  
(NA) 
70.0 ± 12.0 72.0 ± 20.0 74.0 ± 6.0 NA CVVH Polysulfone 0.5 NA 
Valtonen et al  
[205] 
Acute kidney 
injury 
6  
(5/1) 
54.0 ± 13.0 90.0 ± 12.0 NA NA CVVH/ 
CVVHDF 
Polysulfone 0.7 Post-
dilution 
Mueller et al  
[155] 
Acute kidney 
injury, anuric 
8  
(6/2) 
66.0 ± 9.0 67.0 ± 21.0 NA NA CVVHD Polyacrylonitrile NA NA 
Arzuaga et al  
[156] 
Acute kidney 
injury 
14  
(11/3) 
56.6 ± 6.9 75.6 ± 3.5 22.0 ± 2.8 11.0 ± 0.1 CVVH Polyacrylonitrile 0.9 Pre-dilution 
Seyler et al  
[79] 
Acute kidney 
injury 
8  
(NA) 
62.0 ± 16.0 NA NA NA CVVH/ 
CVVHDF 
Polyacrylonitrile NA NA 
Bauer et al  
[157]  
Renal failure 42  
(25/17) 
56. 8 ± 15.5 95.1 ± 26.8 NA NA CVVHD/ 
CVVHDF 
Polyacrylonitrile/ 
Polyether-
sulfone 
0.6,0.9,1.5 NA 
Vancomycin           
Santre et al  
[206] 
Acute kidney 
injury 
3  
(3/0) 
58.7 ± 19.1b NA NA NA CVVHDF Polyacrylonitrile NA NA 
Boereboom et al 
[207] 
Acute kidney 
injury, anuric 
2  
(1/1) 
46.0 ± 10.0b 82.5 ± 3.5b NA NA CVVH Polyacrylonitrile 0.6 Post-
dilution 
DelDot et al  
[178] 
Acute kidney 
injury 
10  
(6/4) 
60.3 ± 8.7b 79.1 ± 17.1b 31.4 ± 11.1b 16.2 ± 4.8b CVVHDF Polyacrylonitrile NA NA 
Chaijamorn et al  
[84] 
Acute kidney 
injury 
7  
(7/0) 
60.7 ±16.9b 66.4 ± 12.1b 33.0 ± 6.9b 15.7 ± 2.6b CVVH Triacetate NA Pre-dilution 
Petejova et al  
[179] 
Acute kidney 
injury 
17  
(11/6) 
58.0c 90.0c 32.0c 17.0c CVVH Polysulfone 1.4,1.8 Both 
Beumier et al  
[181] 
Septic,  
critically ill 
32  
(17/15) 
55.0c 80.0c 21.0c 14.0c CVVH/ 
CVVHDF 
Polyacrylonitrile/ 
Polysulfone 
NA NA 
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Drug/ 
Reference (s) 
Patient characteristicsa 
RRT type 
(Duration) 
RRT settings 
Population 
No. of 
patients 
(M/F) 
Age Weight APACHE SOFA Filter material Surface area (m2) 
Pre- or 
Postdilution 
Ahern et al  
[208] 
Acute kidney 
injury 
11  
(7/4) 
54.5 ± 14.6 89.6 ± 23.4 25.9 ± 7.7 NA SLED  
(24.0H) 
Polysulfone NA NA 
Kielstein et al  
[102] 
Acute kidney 
injury, anuric 
10  
(6/4) 
55.0 ± 12.6b 84.5 ± 24.0b NA NA EDD  
(8.0H) 
Polysulfone 1.3 NA 
Petejova et al  
[180] 
Acute kidney 
injury 
9  
(9/0) 
63.8 ± 11.0b 82.1 ± 11.4b NA 15.0c EDD  
(6.0H) 
Polysulfone 1.3,1.5 NA 
APACHE = Acute physiologic and chronic health evaluation; SOFA = Sequential organ failure assessment; RRT = renal replacement therapy; CVVH = continuous 
venovenous haemofiltration; CVVHDF = continuous venovenous haemodiafiltration; CVVHD = continuous venovenous haemodialysis; EDD = extended daily 
dialysis; SLED = sustained low efficiency dialysis; NA = data not available or not applicable; H = hour; M = male and F = female 
aData reported as mean ± SD (unless otherwise stated) 
bCalculated mean/median from reported data 
cData reported as median	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Reported and calculated pharmacokinetic parameters for meropenem, piperacillin and vancomycin 
during RRT are summarized as in Table 4.2. The median Vd was 31.6, 33.2, and 43.7 L 
respectively. The median Vd was 31.6, 33.2, and 43.7 L respectively.  Meropenem had a Sc of 
around 0.9, while for piperacillin and vancomycin, this was approximately 0.5 and 0.8 respectively. 
Mean/median elimination via the extracorporeal circuit from the included studies varied for 
meropenem (15-58% of CLtotal) and piperacillin (13-47% of CLtotal), and was insignificant (<2% of 
CLtotal) in patients with residual renal function [156, 163]. In contrast, CLRRT for vancomycin was 
significantly higher (> 60% of CLtotal) in some studies [178, 179].   
 
Based on mean or median CLtotal, CLRRT, blood flow and effluent flow rates, relationships between 
variables were examined using linear regression to determine the influence of CRRT intensity on 
antibiotic pharmacokinetics (Figure 4.2 and 4.3).  A statistically significant correlation was only 
observed between effluent flow rate and CLtotal with piperacillin (rs = 0.69, P = 0.02). However 
visual correlations were noted between effluent flow rate and CLRRT for all three antibiotics (Figure 
4.2). The relationship between blood flow rate and both CLtotal and CLRRT was non-significant for 
all three agents, possibly explained by limited available data (Figure 4.3).  However, positive trends 
were observed between blood flow rate and meropenem CLtotal and CLRRT (rs = 0.41 and rs = 0.10 
respectively) and blood flow rate with vancomycin CLRRT, rs = 0.66 (P = 0.33). 
 
PK/PD target attainment of meropenem and piperacillin were calculated based on the reported 
dosing regimens and pharmacokinetic parameters against selected susceptibility breakpoints (Table 
4.3). Of these, 89% and 83% of the doses successfully achieved more than 100%T>MIC, for 
meropenem and piperacillin respectively, against a MIC of 2 mg/L and 16 mg/L.  In the case of 
vancomycin, 60% of the evaluated doses achieved the desired AUC0-24/MIC ratio of at least 400 
against a MIC value of 1 mg/L, while only 20% achieved the target at a MIC of 1.5 mg/L.  All of 
the reported dosing regimens for vancomycin (ranging from 1-2 g/day) were insufficient to achieve 
the desired AUC0-24/MIC ratio at a MIC of 2 mg/L (Table 4.4).	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Table 4.2: Pharmacokinetic parameters of meropenem, piperacillin and vancomycin in critically ill patients receiving renal replacement therapy 
Reference (s) 
Dose/ 
No. of 
patients 
(n) 
Pharmacokinetic parametersa 
RRT 
Type 
RRT settings 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) AUC0-τ 
CLtotal 
(mL/min) 
CLRRT 
(mL/min) 
Vd 
(L) Sc 
Qb 
(mL/min) 
Qe 
(mL/min) 
Meropenem            
Thalhammer et al  
[39] 
1g  
(single dose) 
(n=9) 
28.1 ± 2.7 6.6 ± 1.5 118.0 ± 15.8b 143.7 ± 18.6 49.7 ± 8.3 29.5 ± 2.7 1.1 ± 0.1 CVVH 150.0 45.8 ± 6.2 
Krueger et al  
[40]  
1g 12H 
(n=9) 
103.2 ± 45.9 9.6 ± 3.8 344.0 ± 114.4 53.1 ± 16.8 30.4 ± 2.0 18.0 ± 6.2 1.1 CVVHDF 100.0 29.0 ± 1.8 
Meyer et al  
[202] 
1g 8H 
(n=1) 
19.6 5.8 128.8 129.4 19.8 ± 5.3 37.8 1.0 ± 0.3 CVVHDF 200.0 33.3 
Meyer et al  
[202] 
1g 12H 
(n=1) 
17.9 4.5 118.0 141.3 20.0 ± 7.6 44.1 1.1 ± 0.2 CVVHDF 200.0 33.3 
Tegeder et al  
[41] 
0.5g 8-12H 
(n=9) 
38.9 ± 9.7 7.3 ± 1.3 NA 52.0 ± 8.4 22.0 ± 4.7 12.4 ± 1.8 1.2 ± 0.1 CVVH 150.0-170.0 18.3-19.2 
Valtonen et al  
[203]  
1g 12H 
(n=6) 
NA NA NA 54.5 ± 38.3 NA NA NA CVVH 100.0 6.7 
Valtonen et al  
[203]  
1g 12H 
(n=6) 
NA NA NA 78.7 ± 44.8 NA NA NA CVVHDF 100.0 23.3 
Valtonen et al 
 [203]  
1g 12H 
(n=6) 
NA NA NA 95.2 ± 59.7 NA NA NA CVVHDF 100.0 40.0 
Ververs et al  
[42]  
0.5g 12H 
(n=5) 
24.5 ± 7.2 3.0 ± 0.9 129.5 ± 26.4 76.2 ± 14.8 17.2 ± 7.0 31.7 ± 
12.9 
0.6 ± 0.3 CVVH 200.0 25.0-30.0 
Giles et al [43]  1g 12H 
(n=10) 
55-128e 15.0 246.0 ± 97.1 70.6 ± 24.2 32.7 ± 11.2 27.3 ± 9.8 0.9 ± 0.1 CVVH/ 
CVVHDF 
150.0 
 
33.3 
Robatel et al  
[45]  
0.5-1g 8-12H 
(n=13) 
34.7(0.5g), 
59.4(1g) 
4.1(0.5g), 
7.6(1g) 
NA 74.7 27.0 33.2 0.7 CVVHDF 119.0 ± 15.0 
 
28.3 
Krueger et al  
[44] 
0.5g 12H 
(n=8) 
39.5 ± 10.5 2.4 ± 1.5 105.3 ± 21.7 82.9 ± 21.6 24.4 ± 8.0 22.3 ± 5.6 0.9 ± 0.1 CVVH 100.0 26.7 
Isla et al  
[163] 
0.5-1g 6-8H 
(n=7) 
30.4 ± 10.3 7.7 ± 5.4 NA 150.3 ± 75.8 27.0 ± 6.9 42.8 ± 
21.8 
0.8 ± 0.1 CVVHDF 100.0-180.0 25.0 
Isla et al  
[163] 
0.5-1g 6-8H 
(n=7) 
43.3 ± 20.1 4.4 ± 2.3 NA 134.4 ± 57.2 32.2 ± 7.2 25.9 ± 7.0 0.9 ± 0.1 CVVH/ 
CVVHDF 
150.0-220.0 
 
36.0 
	   69 
Reference (s) 
Dose/ 
No. of 
patients 
(n) 
Pharmacokinetic parametersa 
RRT 
Type 
RRT settings 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) AUC0-τ 
CLtotal 
(mL/min) 
CLRRT 
(mL/min) 
Vd 
(L) Sc 
Qb 
(mL/min) 
Qe 
(mL/min) 
Isla et al  
[163] 
1-2g 6-8H 
(n=6) 
34.5 ± 18.6 1.0 ± 1.6 NA 1064.8 ± 
662.3 
16.4 ± 6.7 91.7 ± 
63.0 
NA CVVH 120.0-180.0 16.7 
Langgartner et al  
[46]  
LD 0.5g, 1g 
12H (IB) 
(n=6) 
62.8d 8.2d NA 72.0d 31.3c,d 32.2d 1.0d CVVHDF 150.0 31.3 
Langgartner et al  
[46] 
LD 0.5g, 2g 
24H (CI) 
(n=6) 
20.0d 15.7d NA 73.3d 28.2c,d NA 0.9d CVVHDF 150.0 31.3 
Bilgrami et al  
[81] 
1g 8H 
(n=10) 
56.6d 7.6d 166.5d 100.0d 58.3d 25.9e 0.9d CVVH 275.0 73.3 
Seyler et al  
[79]  
1g 12H 
(n=17) 
26.0 6.0 134.0 80.5b NA 31.5e NA CVVH/ 
CVVHDF 
150.0 ± 24.0 52.5e 
Kielstein et al  
[102] 
1g  
(single dose) 
(n=10) 
NA NA NA NA 38.3 57.6 NA EDD  
(8.0H) 
160.0 ± 3.0 160.0 ± 3.0 
Deshpande et al 
[164] 
1g 12H 
(n=10) 
20.7 ± 8.2 4.0 ± 1.6f NA NA NA NA NA SLED 
(8.0H) 
160.0 ± 45.9 229.5 
Piperacilling            
Joos et al [204] 1-4g 4-12H 
(n=8) 
NA NA NA 56.0d 10.0d NA NA CVVH 100.0 13.2 ± 4.6 
van der Werf et al 
[159] 
4g 8H 
(n=9) 
NA NA NA 42.0 ± 23.0 NA 25.9 ± 
17.8 
NA CVVH NA 25.9 ± 9.8 
Capellier et al  
[158]  
4g  
(first dose) 
(n=6) 
125.0 ± 21.0 48.0 ± 8.0 964.0 ± 342.0 79.2 ± 23.7 NA 35.5 ± 
17.8 
NA CVVH 150.0 14.0 ± 1.0 
Capellier et al  
[158] 
4g 8H 
(n=4) 
470.0 ± 127.0 188.0 ± 71.0 3352.0 ± 
1750.0 
24.8 ± 13.1 NA 9.7 ± 4.8 NA CVVH 150.0 10.8 ± 0.8 
Valtonen et al  
[205]  
4g 12H 
(n=6) 
NA NA NA 64.8 ± 20.5 NA NA NA CVVH 100.0 13.3 
Valtonen et al  
[205]  
4g 12H 
(n=6) 
NA NA NA 84.3 ± 28.0 NA NA NA CVVHDF 100.0 30.0 
Valtonen et al  4g 12H NA NA NA 91.3 ± 35.2 NA NA NA CVVHDF 100.0 46.6 
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Reference (s) 
Dose/ 
No. of 
patients 
(n) 
Pharmacokinetic parametersa 
RRT 
Type 
RRT settings 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) AUC0-τ 
CLtotal 
(mL/min) 
CLRRT 
(mL/min) 
Vd 
(L) Sc 
Qb 
(mL/min) 
Qe 
(mL/min) 
[205]  (n=6) 
Mueller et al  
[155]  
2-4g 8-24H 
(n=8) 
NA NA NA 47.0d 22.0 ± 5.0 20.8 ± 4.7 0.8 ± 0.2 CVVHD 150.0 25.3 
Arzuaga et al  
[156]  
4g 6-8H 
(n=4) 
365.6 ± 232.3 NA 76143 ± 
49748 
50.0 ± 53.0 11.5 ± 6.5 21.0 ± 
11.7 
0.4 ± 0.3 CVVH 150.0-220.0 27.1 ± 7.8 
Arzuaga et al  
[156]  
4g 6-8H 
(n=5) 
244.5 ± 122.1 NA 45445 ± 
25525 
90.6 ± 29.9 12.2 ± 13.2 26.8 ± 
19.8 
0.4 ± 0.4 CVVH 150.0-220.0 30.3 ± 4.3 
Arzuaga et al  
[156]  
4g 6-8H 
(n=5) 
160.6 ± 93.2 NA 17328 ± 
11134 
265.2 ± 152.2 4.8 ± 3.3 44.9 ± 
20.4 
0.2 ± 0.1 CVVH 150.0-220.0 20.0 ± 7.5 
Seyler et al  
[79]  
4g 6H 
(n=8) 
138.0d 60.0d 527.0d 80.5e NA 30.8e NA CVVH/ 
CVVHDF 
150.0 ± 24.0 52.5e 
Bauer et al  
[157]  
2-3g 6-12H 
(n=42) 
115.0d 54.8d NA 78.6d 33.2d 38.2d NA CVVHD/ 
CVVHDF 
NA 40.7 ± 25.0 
Vancomycin            
Santre et al  
[206] 
7.5mg/kg 
(n=3) 
27.3 3.6 216.7 ± 23.3b 38.9 ± 4.3 4.2 ± 1.3 47.4 ± 6.4 NA CVVHDF 100.0-150.0 16.7 
Boereboom et al  
[207]  
1g  
(single dose) 
(n=1) 
NA NA 398.0 41.7 23.3 55.8 0.9 ± 0.0 CVVH 200.0 26.7 
Boereboom et al  
[207]  
0.5g 12H 
(n=1) 
NA NA 175.0b 23.3 23.3 41.7 0.9 ± 0.0 CVVH 200.0 26.7 
DelDot et al  
[178]  
0.75g 12H 
(n=10) 
45.4 ± 10.1 19.2 ± 5.2 262.5 ± 79.5 41.7 ± 11.7 30.0 ± 6.7 49.7 ± 
29.1 
0.7 ± 0.1 CVVHDF 200.0 50.0 
Chaijamorn et al  
[84]  
1g  
(single dose) 
(n=7) 
NA NA 671.1 ± 
181.1b 
26.5 ± 7.8 12.1 ± 3.5 24.7 ± 
11.0 
0.7 ± 0.1 CVVH 200.0-250.0 13.3-20.0 
Petejova et al  
[179]  
1g  
(1st dose),  
1g 12H 
(n=17) 
21.3d 10.0d 173.7d 49.5d 45.0d 36.9d 0.7d CVVH 200.0 67.5 
Beumier et al  
[181] 
35 mg/kg 
(loading), then 
44.0d 23.0d 652.0d 33.2d NA NA NA CVVH/ 
CVVHDF 
150 45.3 
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Reference (s) 
Dose/ 
No. of 
patients 
(n) 
Pharmacokinetic parametersa 
RRT 
Type 
RRT settings 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) AUC0-τ 
CLtotal 
(mL/min) 
CLRRT 
(mL/min) 
Vd 
(L) Sc 
Qb 
(mL/min) 
Qe 
(mL/min) 
14 mg/kg 24H 
(n=41) 
Ahern et al  
[208] 
15 mg/kg 
(n=11) 
NA 16.5 ± 6.7 NA 24.3 ± 8.4 NA 75.3 ± 
15.2 
NA SLED  
(24 hours) 
200.0 100.0 
Kielstein et al  
[102]  
1g  
(single dose) 
(n=10) 
NA NA NA NA 35.0d 45.6d NA EDD  
(8.0 hours) 
160.0 160.0 
Petejova et al  
[180] 
~11mg/kg 
(n=5) 
NA 11.7d 324.0d NA 29.0d 28.0d NA EDD  
(6.0 hours) 
200.0 500.0 
Petejova et al  
[180] 
~11mg/kg 
(n=4) 
NA 21.6d 555.5d NA 60.3d 40.0d NA EDD  
(6.0 hours) 
200.0 500.0 
H = hourly; IB = intermittent bolus; CI = continuous infusion; CVVH = continuous venovenous haemofiltration; CVVHDF = continuous venovenous 
haemodiafiltration; CVVHD = continuous venovenous haemodialysis; EDD = extended daily dialysis; SLED = sustained low efficiency dialysis; Qb = blood flow 
rate; Qe = effluent flow rate; Cmax = maximum concentration; Cmin = minimum concentration; Css, = concentration at steady state; AUC0-τ = area under the curve of 
concentration versus time profile in one dosing interval; CLtotal = total clearance; CLRRT = clearance by RRT; Vd = volume of distribution; Sc = sieving coefficient 
and NA = not available  
aData reported as mean ± SD (unless otherwise stated) 
bData reported as AUC0-∞  
cCalculated CLRRT based on alternative calculation 
dData reported as median 
eData calculated using estimated body weight = 70kg 
fConcentration at the end of RRT therapy 
gBased on piperacillin component	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Figure 4.2: The relationship between effluent flow intensity during continuous renal replacement 
therapy and clearance of meropenem (A), piperacillin (B) and vancomycin (C). A, correlation 
between effluent flow rate and meropenem CLtotal (left) and CLRRT (right). B, correlation between 
effluent flow rate and piperacillin CLtotal (left) and CLRRT (right). C, correlation between effluent 
flow rate and vancomycin CLtotal (left) and CLRRT (right) 
 
 
CLtotal = total drug clearance and CLRRT = clearance by renal replacement therapy 
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Figure 4.3: The relationship between blood flow intensity during CRRT and clearance of 
meropenem (A), piperacillin (B) and vancomycin (C). A, correlation between blood flow rate and 
meropenem CLtotal (left) and CLRRT (right). B, correlation between blood flow rate and piperacillin 
CLtotal (left) and CLRRT (right). C, correlation between blood flow rate and vancomycin CLtotal (left) 
and CLRRT (right) 
 
 
CLtotal = total drug clearance 
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Table 4.3: The pharmacokinetic/pharmacodynamic target attainments for meropenem and 
piperacillin 
Reference(s) RRT type Dose %T>MIC 
Meropenem   MIC 2 MIC 4 
Thalhammer et al [39] CVVH 1g (single dose) 39.6 29.9 
Krueger et al [40] CVVHDF 1g 12 hourly 181.0 143.3 
Meyer et al	  [202] CVVHDF 1g 8 hourly 190.9 139.7 
Meyer et al [202] CVVHDF 1g 12 hourly 125.5 89.7 
Tegeder et al	  [41] CVVH 0.5g 8 hourly 476.7 366.7 
Valtonen et al	  [203] CVVH 1g 12 hourly 238.8 176.3 
Valtonen et al	  [203] CVVHDF 1g 12 hourly 173.3 126.6 
Valtonen et al	  [203] CVVHDF 1g 12 hourly 146.4 106.4 
Ververs et al	  [42] CVVH 0.5g 12 hourly 158.2 105.1 
Giles et al [43] CVVH/CVVHDF 1g 12 hourly 180.4 137.4 
Robatel et al [45] CVVHDF 1g 12 hourly 167.3 124.5 
Krueger et al [44] CVVH 0.5g 12 hourly 105.5 75.2 
Isla et al [163] CVVHDF 0.5g 6 hourly 157.9 95.9 
Isla et al [163] CVVH/CVVHDF 0.5g 6 hourly 148.8 103.3 
Isla et al [163] CVVH 2g 8 hourly 65.1 46.2 
Langgartner et al [46] CVVHDF 0.5g (LD), 
2g 24 hourly 
116.6 94.5 
Bilgrami et al [81] CVVH 1g 8 hourly 230.6 176.6 
Seyler et al [79] CVVH/CVVHDF 1g 12 hourly 145.9 109.3 
Kielstein et al [102] EDD 1g (single dose) 192.3 130.6 
Piperacillin   MIC 8 MIC 16 
van der Werf et al [159] CVVH 4g 8 hourly 315.0 241.2 
Capellier et al [158] CVVH 4g (first dose) 81.1 59.8 
Capellier et al [158] CVVH 4g 8 hourly 341.3 281.3 
Valtonen et al [205] CVVH 4g 12 hourly 226.6 162.5 
Valtonen et al [205] CVVHDF 4g 12 hourly 184.5 128.7 
Valtonen et al [205] CVVHDF 4g 12 hourly 171.1 120.3 
Mueller et al [155] CVVHD 4g 12 hourly 164.4 128.5 
Arzuaga et al [156] CVVH 4g 8 hourly 445.9 348.4 
Arzuaga et al [156] CVVH 4g 8 hourly 221.6 169.1 
Arzuaga et al [156] CVVH 4g 8 hourly 113.0 80.5 
Seyler et al [79] CVVH/CVVHDF 4g 6 hourly 278.8 209.5 
Bauer et al [157] CVVHD/CVVHDF 3g 8 hourly 395.4 275.4 
*Dose based on piperacillin component 
LD = loading dose; RRT = renal replacement therapy; CVVH = continuous venovenous haemofiltration; 
CVVHDF = continuous venovenous haemodiafiltration; CVVHD = continuous venovenous haemodialysis; 
EDD = extended daily dialysis; MIC = minimum inhibitory concentration (mg/L) and %T>MIC = percentage 
of time during dosing interval that the concentration is above the MIC of targeted pathogen 
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Table 4.4: The pharmacokinetic/pharmacodynamic target attainment for vancomycin 
References Renal Replacement Therapy Type Dose 
AUC0-24/MIC 
MIC 1 MIC 1.5 MIC 2 
DelDot et al [178] Continuous 
venovenous 
haemodiafiltration 
0.75g 12 hourly 525.0 350.0 262.5 
Petejova et al [179] CVVH 1g (1st dose), 1g 12 
hourly 
347.4 231.6 173.7 
Beumier et al [181] CVVH 35 mg/kg (loading), 
then 14 mg/kg 24 
hourly 
652.0 434.7 326.0 
Petejova et al [180] EDD ~11mg/kg 324.0 216.0 162.0 
Petejova et al [180] EDD ~11mg/kg 555.5 370.3 277.8 
AUC0-24 = area under the concentration-time curve from 0 to 24 hours; MIC = minimum inhibitory 
concentration (mg/L); CVVH = continuous venovenous haemofiltration and EDD = extended daily dialysis. 
 
4.2.5 Discussion 
 
Based on published data, this analysis has demonstrated that RRT intensity (as determined by 
effluent flow rate) increases the extracorporeal elimination of meropenem, piperacillin and 
vancomycin.  Whilst such a concept maybe taken for granted, this relationship has not been 
demonstrated across a wide range of studies for these commonly used antibiotics. As such, effluent 
flow rate could potentially be used to estimate the filter clearance of these agents during varying 
modes of RRT and in particular CRRT. Conversely, blood flow rate was largely unhelpful in 
predicting drug clearance.  Our data are particularly interesting, as these strong correlations are 
present in spite of use of the different modalities (CVVHF and CVVHD etc.) grouped together in 
this analysis.  Our other major finding is the lack of efficacy of reported dosing regimens for 
vancomycin during RRT to achieve the target PK/PD index [21]. These regimens often failed to 
provide an AUC0-24/MIC ratio of at least 400 using a susceptibility breakpoint of >1 mg/L. 
Meropenem dosing achieved the desired PK/PD index in 89% of studies, while piperacillin dosing 
regimens were sufficient in 83% of cases for the targeted MICs. Of note however is the exposure to 
high piperacillin and tazobactam trough concentrations, when the fixed combination preparation 
was used.  This represents a concern given the potential accumulation of both compounds when 
using higher doses. 
 
The role of effluent flow rate in differing modes of CRRT as a potential modifier of antibiotic 
prescription in future clinical practice requires substantial future validation. In this current work, a 
positive correlation was observed between effluent flow rate and CLRRT for all three antibiotics, (rs 
= 0.44, rs = 0.77 and rs = 0.90), while similar relationships have been highlighted in previous studies 
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[43, 81]. In a prospective investigation of meropenem pharmacokinetics in ten critically ill patients 
receiving CRRT (blood flow rate – 150 mL/min, ultrafiltration rate - 16.7-33.3 mL/min), filter 
clearance was noted to be linearly correlated with effluent flow rate in CVVH and CVVHDF (r = 
1.00 and 0.85 respectively) [43]. In another study evaluating the influence of flow rate during 
CVVH on meropenem clearance, CLRRT was found to be associated with ultrafiltration rate (r = 
0.89), when the data were compared with previous studies [81].  
 
This relationship was also noted in a pharmacokinetic study of piperacillin in nine anuric critically 
ill patients receiving CVVH (ultrafiltration rate - 25.9 ± 9.8 mL/min) [159].  Here ultrafiltration rate 
was significantly associated with piperacillin CLtot, r = 0.83 (p <0.001) [159]. Similar data were also 
reported in recent vancomycin pharmacokinetic studies during CRRT [181, 209]. Of note, these 
findings are in contrast to those reported in a multicenter study of CRRT intensity in critically ill 
patients [80], whereby the variability in antibiotic concentrations were not influenced by the 
effluent flow rates.  This disparity is likely related to the small sample size and heterogeneity in 
patient characteristics, particularly the degree of residual native renal function, and filter lifespan.  
In this respect, while effluent flow intensity appears to predict extracorporeal drug elimination, 
modification of antibiotic doses will need to consider a variety of factors.  
 
Blood flow rate was demonstrated to be non-significant in predicting CLRRT and CLtotal overall. 
However, based on consistent positive correlations between blood flow rate and CLtotal (rs = 0.41) 
and CLRRT (rs = 0.10) with meropenem, this variable may have some impact on the clearance of 
antibiotics that have limited plasma protein binding. Specifically, meropenem has low plasma 
protein binding (<2%), as compared to piperacillin (30%) and vancomycin (50-60%), suggesting 
that blood flow intensity may more readily affect clearance of low protein bound drugs during 
CRRT. Furthermore, the influence of blood flow rate on CLRRT and CLtotal could be more relevant 
in different forms of RRT, particularly when a different principle of solute removal is apply (e.g 
haemodialysis). Further data is required to describe the influence of blood flow rate on clearance in 
such different forms of RRT.  
 
Substantial amounts of meropenem and vancomycin are also eliminated with hybrid techniques 
(EDD and SLED), requiring additional consideration when prescribing these antibiotics [102, 164, 
180].  To date, limited data are available describing piperacillin pharmacokinetics during such 
therapy.  Hybrid techniques combine the advantages of more efficient solute removal (as seen with 
traditional intermittent haemodialysis), with longer treatment duration (over a period of 8-12 hours), 
which is generally more tolerable in the unstable critically ill patient. This has significant potential 
	   77 
ramifications for antibiotic elimination. Specifically, in a study of critically ill patients treated with 
SLED over 8 hours, the median meropenem peak concentration was lower (21 mg/L versus 55 
mg/L) compared to those receiving CRRT, when similar doses were employed, [43, 164]. An 
additional factor when applying these therapies is the type of filter membrane, particularly with 
vancomycin extracorporeal elimination. In this respect, vancomycin clearance was higher when a 
high flux filter membrane was used (60.3 mL/min versus 29.0 mL/min) compared to a low flux 
device [180]. Additional studies are clearly required to better understand the pharmacokinetics of 
antibiotics when using such modalities.  
 
Achieving sufficient antibiotic concentrations at the site of infection is essential to maximize 
antibiotic efficacy. The associated PK/PD index is that parameter defining optimal antibiotic 
exposure in terms of maximal bacterial killing. For beta-lactams, it has been suggested that 
achieving 90-100%T>MIC represents an appropriate PK/PD target for maximal efficacy [61, 200]. 
Based on this, we determined the frequency with which current reported dosing regimes achieved 
100%T>MIC for meropenem and piperacillin against common ICU gram-negative pathogens. These 
doses were found to sufficiently achieve the target for meropenem against susceptible pathogens 
(MIC ≤2 mg/L), however were only moderately successful when a higher susceptibility breakpoint 
was used (e.g 4 mg/L).  This was particularly the case when doses less than 2g/day were employed 
[39, 44, 202], and in patients with a large Vd (e.g >80 L) [163].  As such, larger or more frequent 
doses may be mandated. Of concern, in patients with residual native renal function, higher doses 
(e.g 6 g per day) were insufficient to achieve this target [163].  Alternative dosing strategies require 
consideration of meropenem as an extended or continuous infusion to improve meropenem PK/PD 
target attainment in this population [46].   
 
Similarly, piperacillin doses between 8-24 g per day sufficiently achieved the target PK/PD index 
for susceptible pathogens (MIC <16 mg/L) [79, 155-159, 205]. However, such doses do predispose 
to accumulation of tazobactam, as has been highlighted in previous studies using the fixed 
combination preparation [155, 159].  The degree of residual native renal function is clearly 
important in this scenario, where previous research has shown significantly higher tazobactam 
concentrations in those with a creatinine clearance less than 50 mL/min [156]. Adding to this 
complexity is the impact of protein binding.  In one recent pharmacokinetic study it was highlighted 
that the probability of pharmacodynamic target attainment was higher when total drug 
concentration were employed, as compared to the unbound fraction (83% versus 77%) [157].  This 
reinforces the importance of measuring the unbound fraction of piperacillin, as this will more 
closely represent the amount of pharmacologically active drug at the site of infection.   
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As previously noted, 80% of the reported vancomycin dosing regimens failed to achieve the 
required PK/PD index when using a susceptibility breakpoint of ≥1.5 mg/L [178-181].  This raises 
major concerns about the validity of current dosing strategies, particularly as mortality associated 
with methicillin-resistant Staphylococcus aureus (MRSA) infection among critically ill patients is 
increasing [210].  Of note, higher mortality rates and a greater risk of treatment failure have also 
been demonstrated with MRSA infection where the vancomycin MIC is ≥1.5 mg/L [211]. 
Achieving an AUC/MIC ratio of at least 400 is considered essential to improve the possible 
outcome of vancomycin therapy [212].  In the case of a vancomycin MIC ≥1.5 mg/L, although 
vancomycin trough concentrations were ~22 mg/L [180], the observed AUC0-24 would be 
insufficient to achieve the target PK/PD index. Administration of higher loading doses followed by 
continuous infusion represents an evolving approach to improve drug dosing [181].  TDM remains 
essential in this setting, although consideration of alternative therapy may be required when 
impractically large doses are required.  
 
We wish to acknowledge the following limitations of this study; a) this is a secondary analysis of 
group data as individual patient data was unavailable; b) data were extracted from studies utilizing 
variable RRT techniques; c) the total number of patients included is small; d) there was 
heterogeneity between the included ICU populations (anuric and non-anuric patients); e) the 
approach to ICU management was not standardized; f) variable dosing regimens were employed; g) 
pharmacoknietic analyses varied between studies (e.g non-compartmental and compartmental); and 
h) alternative calculations were used to estimate pharmacokinetic parameters in the absence of 
reported pharmacokinetic data.  
 
4.2.6 Conclusion 
 
In conclusion, based on our analyses of published data, effluent flow rate predicts extracorporeal 
drug clearance of meropenem, piperacillin and vancomcyin during CRRT. Additional data from a 
well-designed large multicentre trial are now warranted to further evaluate this finding. We 
observed that antibiotic pharmacokinetic data from hybrid forms of RRT (e.g SLED or EDD) are 
scarce and further studies are urgently needed as solute removal is expected to be greatly different 
from CRRT [98]. Pharmacokinetic studies during different forms of RRT are recommended during 
drug development clinical trials in future to overcome this problem [98, 197]. As such, current data 
are not readily translatable to hybrid forms of RRT.  Given the absence of any standard globally 
applicable guidelines on antibiotic dosing during RRT, TDM will remain the most accurate means 
of optimizing antibiotic therapy, where available. Additional studies exploring other RRT settings, 
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such as the use of anticoagulation, filter material and size, replacement fluid type and placement, 
are also paramount in order to identify RRT factors that could also deleteriously affect antibiotic 
pharmacokinetics. 
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4.3 Conclusion 
 
The effluent flow rate in CRRT setting can be used as a predictor to estimate extracorporeal drug 
clearance of meropenem, piperacillin and vancomcyin. Additional data from a well-designed large 
multicentre trial are warranted to further evaluate this finding. Antibiotic pharmacokinetic data from 
other forms of RRT (e.g SLED or EDD) are scarce and further studies are urgently needed as solute 
removal is expected to be greatly different from CRRT and as such, current data are not readily 
translatable to these hybrid forms of RRT.  Given the moderate attainment of therapeutic targets, 
particularly for vancomycin, higher dosing regimens maybe required in the presence of high 
effluent flow rates and/or the presence of poorly susceptible pathogens. In the absence of any 
standard globally applicable guidelines on antibiotic dosing during RRT, TDM will remain the most 
accurate means of optimizing antibiotic therapy, where available. Additional studies exploring other 
RRT settings, such as the use of anticoagulation, filter material and size, replacement fluid type and 
placement, are also paramount in order to identify RRT factors that could also deleteriously affect 
antibiotic pharmacokinetics. 
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Chapter 5 
 
Renal replacement therapy prescribing practices in Malaysian intensive care units 
 
5.1 Sypnosis 
 
The aim of this chapter is to describe the RRT prescribing practice in Malaysian ICUs and to 
compare the findings to published literature on renal replacement prescribing practice in ICUs from 
other regions. Whilst numerous data exists from Western countries, limited data are currently 
available describing the RRT prescribing practices in other regions. This is the first study to provide 
baseline data on RRT modalities and settings from Malaysian ICUs. 
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5.2 Manuscript entitled, “A national survey of renal replacement therapy prescribing 
practice for acute kidney injury in Malaysian intensive care units” 
 
The manuscript entitled, “A national survey of renal replacement therapy prescribing practice for 
acute kidney injury in Malaysian intensive care units” has been accepted for publication by 
Nephrology (2014; 19(8): 507-512). 
 
The co-authors contributed to the manuscript as follows: All study design was performed by the 
PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. Roberts, Dr. Andrew A. 
Udy and Prof. Jeffrey Lipman. All data collection was performed by the PhD candidate, Janattul-
Ain Jamal, Dr. Mohd-Basri Mat-Nor and Dr. Fariz-Safhan Mohamad-Nor. All data analysis was 
undertaken by the PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. 
Roberts, Dr. Andrew A. Udy and Prof. Jeffrey Lipman. The PhD candidate, Janattul-Ain Jamal, 
took the leading role in manuscript preparation and writing. 
 
The manuscript is presented as published; except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted to 
fit the overall style of the Thesis. The references are found alongside the other references of the 
Thesis, in the section ‘References’. 
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5.2.1 Abstract 
 
Objectives: To describe RRT prescribing practices in Malaysian ICUs, and compare this with 
previously published data from other regions. 
 
Method: A survey was sent to physicians responsible for prescribing RRT in major ICUs 
throughout Malaysia. The questionnaire sought information on the physicians’ background, and 
detailed information regarding RRT settings. 
 
Results: Nineteen physicians from 24 sites throughout Malaysia responded to the survey (response 
rate 79.2%). Sixteen respondents were intensivists (84%), 2 were anaesthetists (11%) and one was a 
nephrologist (5%). The majority (58%) employed CVVH as the treatment of choice for AKI in 
critically ill patients. RRT prescription was predominantly practitioner-dependent (63%), while 
37% reported use of a dedicated protocol. The mean blood flow rate and effluent flow rate used for 
CRRT were 188.9 ± 28.9 mL/min and 30.6 ± 4.7 mL/kg/hour respectively. Replacement fluid 
solutions containing both lactate and bicarbonate were commonly used during CRRT, applied both 
pre- and post-dilution. 
 
Conclusion: CRRT was the first choice modality used to treat AKI in critically ill patients. CVVH 
was the most common CRRT technique utilised, while other RRT modalities were used less 
frequently.  Overall, RRT practices were similar to those observed in other regions, although the 
modality and settings utilised were slightly different, likely due to local availability. 
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5.2.2 Introduction 
 
AKI is a significant problem in critically ill patients. The reported incidence varies, but can be as 
high as 65% in some ICU populations, depending on the definition used [30, 114]. AKI is 
associated with mortality rates of approximately 50% [114], and early management with RRT is 
considered an essential intervention.  RRT modalities have evolved over time, in parallel with 
technological advances, to offer better patient tolerability and solute removal. However, ‘ideal’ 
RRT settings remain controversial, and delivery of a standard RRT prescription globally is unlikely. 
This is due, in part, to the high costs and need for specialised staff, which are unlikely to be 
sustainable in resource-limited settings.  
 
RRT can be given intermittently, lasting approximately 4 hours per session, such as occurs with 
conventional IHD. PIRRT adapted from both intermittent and continuous modalities, has a longer 
duration of treatment, lasting up to 18 hours [127]. CRRT is perhaps most common in the ICU, and 
is given over 24 hours. Generally, the aims of treatment are to control fluid volume, correct acid-
base abnormalities, improve uraemia, promote renal recovery and improve mortality without 
causing complications [126]. Solute removal during RRT occurs by convection and/or diffusion. 
Conventional dialysis uses diffusion for solute removal, whereas haemofiltration techniques employ 
convection. In some instances, both diffusion and convection are combined, as in 
haemodiafiltration. 
 
Describing RRT practice in the ICU is important, as significant heterogeneity has been reported 
globally [38, 119-124, 213, 214]. A survey conducted among nephrologists in the United States in 
1995, demonstrated that IHD and CRRT were both widely used in ICU, while PIRRT was utilised 
infrequently [119]. In contrast, a more recent survey of ICU practitioners revealed increasing use of 
CRRT and PIRRT in the critically ill, in preference to IHD [122]. In some countries, IHD is still 
used in the ICU although only for select critically ill patients who are haemodynamically stable, and 
approaching discharge to the ward [38]. Variability in training and availability of resources between 
different ICUs may help to explain some of these inconsistencies in RRT prescription. 
 
Whilst some data exists from Western countries, limited data are currently available describing 
RRT prescribing in other regions.  Advances in RRT technology are also likely to have influenced 
RRT practice among ICU clinicians in Malaysia, where the healthcare system is primarily 
government funded.  In a small number of University facilities a co-payment is required from 
patients, although this is thought not to influence RRT decisions.  In this respect it is important to 
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provide baseline data on local practice, which can then serve as a starting point to assess the impact 
of alternative RRT methods in this setting.  
 
The aims of this study were to describe RRT prescribing practices in Malaysian ICUs, and compare 
this with previously published data from other regions. 
 
5.2.3 Methods 
 
This study used a survey design and identified physicians who were responsible for RRT 
prescribing in major ICUs throughout Malaysia. Based on local ICU registry data [215], from a 
total of 51 facilities, 24 were classified as major ICUs.  These were all tertiary centers, with at least 
one ICU specialist, as well as an active in-house RRT service. The reported number of admissions 
to these ICUs was more than 500 per year [215]. Therefore, we expected that responses from 
physicians at these institutions would closely represent current RRT practices in ICU across 
Malaysia. 
 
Expressions of interest for involvement in the study were initially sought from specialists attending 
a local ICU meeting in Malaysia. They were typically the director, or a senior ICU specialist from 
one of these centers.  Subsequently a study questionnaire was developed based on previous 
literature [38, 122], and was sent or emailed in August 2013 to those willing to participate. These 
were distributed to the physician responsible for RRT prescribing at each unit/institution. The 
questionnaire sought detailed information on institutional RRT prescribing and practice. In order to 
obtain sufficient responses, contact was made with non-responders by email and/or phone. 
Respondents could return the questionnaire to the investigators via email or post.  
 
5.2.3.1 Statistical analysis 
Results were analysed using Microsoft Excel (Microsoft Office 2011; Redmond, WA) and Prism 
(GraphPad version 6.0; San Diego, CA), and are presented as the percentage of respondents, mean 
(± SD), or median (IQR), as appropriate. A Fisher’s exact test was used to compare categorical 
data.  A P values <0.05 were considered as statistically significant. 
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5.2.4 Results 
 
5.2.4.1 Respondents’ characteristics 
Of the 24 ICUs invited to participate, 19 physicians responded to the questionnaire (79.2% response 
rate). The characteristics of those facilities providing data are presented in Table 5.1. The 
respondents were intensivists (84%), anaesthetists (11%) and nephrologists (5%). Seventeen (90%) 
of the respondents were physicians practicing in public hospitals while the remaining were from 
university hospitals (10%). The mean reported capacity of ICU and/or high dependency unit (HDU) 
beds available at the respondent’s institutions was 24.0 ± 8.7. The majority of respondents (89.5%) 
practiced adult general critical care medicine. The mean estimated number of AKI patients in ICU 
requiring RRT was 16.3 ± 10.3 per month. Eight (42%) respondents reported that only an 
intensivist was able to commence RRT in ICU, 32% reported that this responsibility was with the 
nephrologists, while 26% reported that either an intensivist or nephrologist could prescribe RRT at 
their institution. RRT prescription was mostly practitioner-dependent without a unit protocol (63%). 
The majority of the respondents (58%) reported CVVH as the treatment of choice for AKI in 
critically ill patients.  
 
Table 5.1: Intensive care unit characteristics 
Characteristics Respondents (n=19) Non-respondents (n=5) 
Public/university hospitals 17/2 4/1 
ICU admissions (/year)a 1288.0 (1015.8-1611.3) 888.5 (573.5-1298.0) 
ICU beds (/facility)a 20.5 (19.3-23.5) 16.0 (11.8-23.0) 
Length of ICU stay (days)a 4.9 (4.2-5.4) 5.1 (4.6-5.3) 
SAPS IIa 39.1 (36.6-40.6) 39.8 (36.3-42.5) 
SOFAa 6.9 (6.6-7.2) 7.2 (6.4-7.7) 
ICU = intensive care unit; SAPS II = Simplified Acute Physiology Score II and SOFA = Sequential Organ 
Failure Assessment. 
aData are presented as the median (IQR) from 2012 [215] 
 
5.2.4.2 Continuous renal replacement therapy 
Eighteen respondents (95%) reported that they prescribed CRRT for AKI in the ICU (Table 5.2). 
Two types of appliances were commonly employed; the Aquarius (Edwards Lifesciences, Saint-
Prex, Switzerland) and Prismaflex (Gambro, Lund, Sweden) machines.  Most (67%) reported solely 
using Prismaflex machines, while 17% reported both were available for CRRT at their institution.  
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Table 5.2: Renal replacement therapy practices in Malaysia  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRRT = continuous renal replacement therapy; IHD = intermittent haemodialysis; PIRRT = 
prolonged intermittent renal replacement therapy and RRT = renal replacement therapy 
aData presented as mean (± SD).  
 
 
 
Criteria Response 
No. of respondents 19/24 
Response rate (%) 79.2 
Speciality  
 Intensivist (%) 84.0 
 Nephrologist (%) 5.0 
 Other (%) 11.0 
First-choice modality  
  CRRT (%) 79.0 
  IHD (%) 15.7 
  PIRRT (%) 5.3 
CRRT settings  
  Haemofiltration (%) 72 
  Haemodiafiltration (%) 56 
  Haemodialysis (%) 27.8 
  Prescribed dose (mL/kg/hour)a 30.6 (± 4.6) 
  Blood flow rate (mL/min)a 188.9 (± 24.9) 
Replacement fluid placement  
  Pre-dilution (%) 33.3 
  Post-dilution (%) 11.1 
  Both (%) 55.6 
IHD settings  
  Blood flow rate (mL/min)a 263.6 (± 67.4) 
  Duration (hours)a 4.2 (± 0.6) 
PIRRT settings  
  Blood flow rate (mL/min)a 183.3 (± 25.0) 
  Dialysate flow rate (mL/min)a 294.4 (± 80.8) 
  Duration (hours)a 6.2 (± 1.8) 
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In practice, 61% of respondents reported that they had utilised CRRT in more than 40% of AKI 
cases in the ICU. CRRT was prescribed on the basis of body weight by most physicians (78%), with 
the mean blood flow rate and targeted effluent flow rate being 188.9 ± 24.9 mL/min and 30.6 ± 4.7 
mL/kg/hour, respectively. Solutions containing both lactate and bicarbonate were commonly used 
for replacement and dialysate fluid (Figure 5.1). Polyacrylonitrile and polysulfone filter membrane 
types were the most commonly used (94%). The haemofilter membrane surface area was reported 
as 0.9 m2. 
 
Figure 5.1: Dialysate and replacement fluid solutions and site of delivery in continuous renal 
replacement therapy 
	  
 
5.2.4.3 Prolonged intermittent renal replacement therapy 
Nine respondents (50%) used a PIRRT modality; with SLED used exclusively by 78%, compared to 
the remainder of ICUs which used either SLED or extended daily diafiltration (EDD-f). The mean 
reported percentage of AKI patients receiving this form of RRT was 29.4 ± 13.6%. Mean blood 
flow rate and dialysate flow rate used were 183.3 ± 25.0 mL/min and 294.4 ± 80.8 mL/min, 
respectively. A polysulfone haemofilter with a membrane surface area of 1.8 m2 was most 
commonly used. The mean duration of treatment was 6.2 ± 1.8 hours, although this was largely 
determined by prescriber preference, as the treatment schedule varied (Figure 5.2). The most 
utilised treatment schedules were 3 times per week and every other day, with the mean reported 
percentage of patients treated with these schedules being 42.5 ± 32.2%, and 56.3 ± 33.5% 
respectively.  
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Figure 5.2: Treatment schedule for (n) intermittent haemodialysis (n=9) and (n) prolonged 
intermittent renal replacement therapy (n=9) among respondents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.4.4 Intermittent haemodialysis 
Nine respondents (50%) prescribed IHD to treat AKI in the ICU. These respondents included 
intensivists (78%), a nephrologist (11%) and an anaesthetist (11%). The mean reported percentage 
of AKI cases in ICU treated with IHD was 42.0 ± 20.4%. A blood flow rate between 100-300 
mL/min (mean 263.6 ± 67.4) was commonly used. Polysulfone haemofilters with a membrane 
surface area of 1.8 m2 were commonly used for IHD. The mean treatment duration for IHD was 4.2 
± 0.6 hours with a treatment schedule that varied between the prescribers (Figure 5.2). The most 
utilised treatment schedule was 3 times per week and the mean reported percentage of patients 
treated with this schedule was 44.3 ± 23.0%.  
 
Overall, there was no statistically significant association between use of any RRT modality, 
including CRRT, IHD, PIRRT, or at least 2 of these modalities, and the capacity of the ICU (more 
than 20 beds or less than 20 beds) (Table 5.3). 
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Table 5.3: Availability of varying renal replacement therapy modalities in comparison to intensive 
care unit bed capacity 
ICU capacity / 
RRT modality 
Less than 20 ICU beds 
(no. of respondents) 
More than 20 ICU beds 
(no. of respondents) P-value
a 
CRRT 8 10 0.47 
IHD 4 6 1.00 
PIRRT 5 6 0.67 
At least 2 modalities 5 6 0.85 
CRRT = continuous renal replacement therapy; ICU = intensive care unit; IHD = intermittent haemodialysis; 
PIRRT = prolonged intermittent renal replacement therapy and RRT = renal replacement therapy 
aP value calculated using Fisher’s exact test.  
 
5.2.5 Discussion 
 
This survey is the first report of RRT practices for AKI in Malaysian ICUs. The respondents that 
completed this survey are clinicians who routinely care for critically ill patients with AKI in 
Malaysia, and thus our findings are highly likely to reflect current RRT practices in this setting. We 
found that CRRT was the most frequently employed RRT modality, with CVVH being the most 
common technique (Table 6.3). Other forms of RRT, such as IHD and PIRRT were also practiced 
in some institutions, although this was less frequent.  
 
The reported incidence of AKI within 24 hours of ICU admission is approximately 14%, with 15% 
of all critically ill patients receiving RRT at some point [215]. Approximately half of the patients 
that develop AKI (49.3%) receive RRT [215]. The commencement of RRT for AKI in critically ill 
patients is varied, and is used more frequently (more than 60% of AKI cases) in some region [116]. 
In this population, AKI was associated with an in-hospital mortality rate of 41.4%, and is 
encountered in up to 80% of patients presenting with severe sepsis and multi-organ failure [215]. 
As such, RRT is commonly applied in ICUs across Malaysia, particularly in high-acuity patients.  
Of interest, our data suggest that RRT prescription in Malaysian ICUs is commonly based on 
practitioner preference (more than 60%), while in less than 40%, a local unit/institutional protocol 
is employed. This suggests significant heterogeneity is likely in this population, which may greatly 
influence further research in this area. 
 
CRRT appears to be the most commonly used RRT modality in critically ill patients with AKI in 
Malaysia, a finding also identified in other countries [38, 120, 121, 124]. Similarly, CVVH was 
reported as the most common technique among respondents, a finding consistent with ICU practice 
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in other regions [123, 124, 214]. In separate studies, continuous haemodiafiltration has been 
reported as the main approach to treating AKI in the critically ill [38, 124]. The blood flow rate and 
effluent flow rate listed here are similar to those reported by other ICU practitioners [122-124, 214]. 
Limited data are available to compare haemofilter material and size, however it is expected to be 
variable between different regions, as this is influenced mainly by product range and availability. 
 
The majority of respondents used a lactate-bicarbonate containing solution as the replacement or 
dialysate fluid for CRRT, where as using a lactate-based containing solution alone may not be 
preferable in certain situations, particularly critical illness [216]. However, other types of solutions, 
such as containing citrate or acetate, have been reported with CRRT in other areas [38, 122]. 
Combining predilution and postdilution replacement fluid during CVVH appears to be an 
increasingly common practice in many ICUs over recent years [124, 214]. Interestingly, previous 
study has suggested that applying predilution is advantageous in increasing filter life span [217]. 
 
PIRRT such as SLED and EDD-f techniques are alternative forms of RRT that appear to be 
increasingly being utilised in the critical care setting. In this manner, these techniques combine the 
benefits of both traditional RRT modalities [218]. Clear advantages include less haemodynamic 
instability, more efficient solute removal, better resource allocation, improved patient mobility (off-
treatment), and greater cost-benefit.  As such, recent data support a growing trend amongst ICU 
practitioners to use these modalities in treating AKI in critically ill patients [121, 122, 213]. Of 
note, the blood flow and dialysate flow rate employed by respondents in this survey, are similar to 
those reported in a previous survey [122].  
 
IHD is a more conventional form of RRT that is commonly utilised for hospitalized and ambulatory 
patients. The use of IHD in the ICU setting is therefore somewhat variable.  Specifically, although 
previous data suggests that some clinicians employ IHD regularly in the ICU [121, 122, 124, 213], 
many practitioners in fact have minimal experience with this modality in the critically ill [123, 214]. 
Of interest, the IHD settings reported in this survey are similar to those used in routine practice 
elsewhere [122, 124]. 
 
We acknowledge that this survey has several limitations. The number of respondents was low. 
However, all of them are ICU physicians who currently manage RRT for AKI in critically patients 
admitted to major ICUs across Malaysia. Thus their responses are likely to represent current 
practices in this population. There is also potential survey bias, in that the majority of respondents 
were critical care physicians (e.g intensivist and anaesthetist), as distinct from nephrologists. 
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Despite this, we believe that the respondents are suitably qualified to report on RRT prescribing at 
their institution. We acknowledge that these data are only applicable to Malaysian critical care 
practice, and may not be representative of current practice in other regions.  
 
We believe these data are crucial in establishing baseline critical care RRT practice in Malaysia.  
Benchmarking and acquisition of quality metrics around such interventions are essential to improve 
the quality of care delivered to critically ill patients nationally. Issues of access to varying RRT 
modalities, standards of practice, and any influence on clinical outcomes are key future quality 
assurance activities linked to these data.  In addition, our results can be used to inform future 
clinical research design, particularly in the development of protocols applicable to the Malaysian 
context. 
   
In conclusion, significant variability exists in RRT prescribing among ICU practitioners in 
Malaysia, however CRRT appears to be the first choice for most survey respondents.  These data 
are similar to reports from other regions. CVVH is the CRRT technique most commonly utilised, 
while other types of RRT (such as IHD and PIRRT) are applied only in select situations. 
Intensivists and nephrologists were mainly responsible on RRT prescription. Further studies 
utilising these data should now be considered. 
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5.3 Conclusion 
 
This chapter has described in detail the RRT prescribing practice in Malaysian ICUs. CRRT is the 
preferred modailty to treat AKI, which is a similar finding to that from other regions. CVVH is the 
CRRT setting that is most commonly utilized, while other types of RRT, such as IHD and SLED 
techniques, were also used by some institutions. The findings from this survey have established a 
preliminary insight into RRT prescribing in Malaysian ICUs, which is important as a template for 
designing potential multinational clinical research in this area. 
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Chapter 6 
 
The pharmacokinetics of meropenem by continuous infusion and intermittent bolus dosing 
during continuous venovenous haemofiltration 
 
6.1 Synopsis 
 
The primary aim of this chapter is to describe the pharmacokinetics of meropenem when 
administered by CI and IB dosing, in critically ill patients receiving CVVH. A prospective 
randomized controlled trial in critically ill patients receiving CVVH concurrently treated with 
meropenem for severe sepsis or septic shock was undertaken. This chapter also evaluated the 
frequency of PK/PD target attainment after administration of each dosing strategy. 
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6.2 Manuscript entitled, “Pharmacokinetics of meropenem in critically ill patients 
receiving continuous venovenous haemofiltration: A randomized controlled trial of 
continuous infusion versus intermittent bolus administration” 
 
The manuscript entitled, “Pharmacokinetics of meropenem in critically ill patients receiving 
continuous venovenous haemofiltration: A randomized controlled trial of continuous infusion 
versus intermittent bolus administration” has been accepted for publication by International Journal 
of Antimicrobial Agents (2015; 45(1): 41-45). 
 
The co-authors contributed to the manuscript as follows: All study design was performed by the 
PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. Roberts and Prof. 
Jeffrey Lipman. All data collection was performed by the PhD candidate, Janattul-Ain Jamal, Dr. 
Mohd-Basri Mat-Nor and Dr. Fariz-Safhan Mohamad-Nor. All data analysis was undertaken by the 
PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. Roberts, Dr. Andrew A. 
Udy, Prof. Jeffrey Lipman and Dr. Steven C. Wallis. The PhD candidate, Janattul-Ain Jamal, took 
the leading role in manuscript preparation and writing. 
 
The manuscript is presented as published; except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted to 
fit the overall style of the Thesis. The references are found alongside the other references of the 
Thesis, in the section ‘References’. 
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6.2.1 Abstract 
 
The objective of this study was to describe the pharmacokinetic parameters of meropenem, when 
administered by CI and IB, in critically ill patients receiving CVVH and to evaluate the frequency 
of attainment of PK/PD target atttainment with each dosing strategy. This was a prospective, 
randomised controlled trial in critically ill patients receiving CVVH and administered meropenem 
by CI or IB. Serial meropenem concentrations in plasma and ultrafiltrate were measured after 
administration of a standard total daily dose (4 g/day on day 1, followed by 3 g/day thereafter) on 
two occasions during antibiotic therapy. Meropenem pharmacokinetic parameters were calculated 
using a non-compartmental approach. Sixteen critically ill patients receiving CVVH concurrently 
treated with meropenem for severe sepsis or septic shock, were randomized to CI (n=8) or IB 
dosing (n=8). IB administration resulted in higher Cmax [64.7 (58.9-80.3) and 64.8 (48.5-81.8) mg/L, 
respectively] on both samplings compared with CI (P<0.01 and P=0.04, respectively).  CI resulted 
in a higher meropenem steady-state concentration (Css) on occasion 1 [26.0 (24.5-41.6) mg/L] 
compared with the Cmin observed for IB patients [17.0 (15.7-19.4) mg/L; P<0.01]. CVVH 
contributed to ca. 50% of meropenem total clearance in these patients. The administered 
meropenem doses resulted in plasma drug concentrations that were >4x the targeted susceptibility 
breakpoint (2 mg/L) for 100% of the dosing interval, for both groups, on both occasions. CI could 
be an alternative to IB for meropenem administration in critically ill patients receiving CVVH.  
 
 
 
 
 
 
  
	   99 
6.2.2 Introduction 
 
Effective antibiotic dosing is considered one of the key interventions to reduce mortality in 
critically ill patients with severe sepsis or septic shock [117]. Administration by CI is one of the 
approaches advocated to improve beta-lactam drug exposure in critical illness [25, 161, 219-223], 
particularly in an era of emerging bacterial resistance and limited availability of new antibiotics. 
Multiple studies have evaluated this method of beta-lactam administration in various critically ill 
sub-groups, demonstrating that CI achieves the required drug concentrations more consistently than 
conventional IB dosing [25, 160, 161, 223, 224].  
 
Existing literature on beta-lactam CI generally excludes critically ill patients treated with RRT, a 
group for which additional data are urgently required, as substantial amounts of drug may be 
cleared by this extracorporeal technique [51].  Indeed, previous data has shown that standard 
carbapenem dosing regimens were insufficient for critically ill patients receiving RRT [79]. As 
such, CI may offer a more effective dosing option, increasing the likelihood of achieving 
therapeutic concentrations in this patient group.  
 
The objectives of this study were therefore to describe the pharmacokinetics of meropenem 
administered by CI or IB to critically ill patients receiving CVVH. We also aimed to describe the 
frequency of PK/PD target attainment of meropenem with each method of administration. 
 
6.2.3 Patients and methods 
 
This was a prospective, randomised controlled pharmacokinetic study performed in a 12-bed ICU 
of a major tertiary hospital in Malaysia (Kuantan, Pahang, Malaysia). The study was approved by 
the local ethics committee, and consent to participate was obtained from the patient’s legally 
authorised representative. 
 
6.2.3.1 Patient selection and data collection  
All adult patients (age ≥18 years) admitted to the ICU with severe sepsis or septic shock and 
receiving CVVH for oligouric or anuric renal impairment were eligible for enrolment. Meropenem 
was prescribed at the discretion of the treating physician. Patients were randomised to receive the 
same dose of meropenem, administered by either CI or IB, using random allocations selected from 
sequentially numbered opaque sealed envelopes. 
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6.2.3.2 Meropenem administration 
All patients received meropenem (DBLTM Meropenem for Injection; Hospira Healthcare, Chennai, 
India). Patients in the CI group (n = 8) were administered a loading dose of 1 g of meropenem in 20 
mL of 0.9% sodium chloride over 30 min via a central line, followed immediately by CI over 24 h 
(125 mg/h). Owing to stability issues, meropenem was prepared every 8 h by diluting 1 g of 
meropenem in 100 mL of 0.9% sodium chloride. Patients in the IB group (n = 8) received 2 g of 
meropenem as a 30-min infusion via a central line for the first dose, followed by 1 g every 8 h 
thereafter. In both groups, meropenem was administered using a volumetric infusion pump 
controller, and all patients received a total dose of meropenem of 4 g/day on Day 1 and 3 g/day 
thereafter. 
 
6.2.3.3 Continuous renal replacement therapy 
CVVH was performed in all patients using an AquariusTM system (Edwards Lifesciences, Saint-
Prex, Switzerland). Polysulfone®-type haemofilters with a surface area of 1.2 m2 (Aquamax12TM; 
Baxter Healthcare, Zurich, Switzerland) were used. In all patients, CVVH was started at least 4 h 
prior to the sampling period. Vascular access was obtained via the internal jugular or femoral vein 
using a 14-French double-lumen catheter. The ultrafiltrate rate was set at 2000 mL/h (median [IQR] 
effluent flow rate, 30.09 mL/kg/h, [25.00–33.33 mL/kg/h]), combining pre- and post-dilution fluid 
replacement at a 1:1 ratio. The targeted blood flow rate was 200 mL/min. Net fluid removal was 
between 50 mL/h and 100 mL/h depending on the clinical circumstance. Lactate-containing 
(PrismaSol®; Gambro, Sondalo, Italy) or lactate-free (DuosolTM; B.Braun, Glandorf, Germany) 
solutions were used as the replacement solution, and the circuit was anticoagulated with heparin 
(100 U/mL) at the discretion of the attending physician. 
 
6.2.3.4 Sample collection 
Pharmacokinetic sampling occurred during one 8-h or 24-h dosing interval between Days 1–3 of 
treatment (occasion 1), and during an 8-h dosing interval between Days 4–6 of treatment (occasion 
2). For each sample, 3 mL of blood was collected in a lithium heparin tube, pre-filter, at 0, 15, 30, 
45, 60, 120, 240, 480 and 1440 min (CI only) and post-filter at 30, 120 and 480 min on occasion 1. 
For occasion 2, 3 mL of blood was collected in a lithium heparin tube, pre-filter or at arterial line, at 
0, 15, 30, 45, 60, 120, 240, 480 and post-filter at 480 min. Ultrafiltrate samples were collected and 
measured at 120, 240, 360 and 480 min, and 3 mL aliquots were kept for analysis. All samples were 
immediately centrifuged at 3000 rpm for 10 min and plasma was separated and frozen at –80 °C. 
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6.2.3.5 Meropenem assay 
Meropenem concentrations in plasma and ultrafiltrate were determined by validated assay methods 
on a Shimadzu Prominence (Shimadzu Corp., Kyoto, Japan) high-pressure liquid chromatography 
(HPLC) system at the Burns, Trauma and Critical Care Research Centre of The University of 
Queensland (Brisbane, Australia). The assay was conducted alongside a standard curve and quality 
control replicates at high, medium and low concentrations. The limit of quantification for 
meropenem was 0.2 mg/L and linearity was validated from 0.2 to 100 mg/L (plasma) and from 1 
mg/L to 200 mg/L (ultrafiltrate). All results were within 5% for all matrices at all levels, and the 
assay was validated and conducted according to criteria specified by the US Food and Drug 
Administration (FDA) guidance on bioanalysis [225].  
 
6.2.3.6 Pharmacokinetic analysis 
Pharmacokinetic parameter values were estimated using non-compartmental methods. The area 
under the concentration–time curve from 0 to 8 h in plasma (AUC0–8 plasma) or ultrafiltrate (AUC0–8 
ultrafiltrate) was calculated using the linear trapezoidal rule. Total body clearance (CLtotal) was 
calculated as dose/AUC0–8 plasma. The maximum concentration for the dosing period (Cmax) and the 
minimum concentration for the dosing period (Cmin) were the observed values. The apparent 
terminal elimination rate constant (ke) was determined from log-linear least-squares regression 
analysis of concentrations from 2–8 h (bolus dosing). The apparent volume of distribution during 
the terminal phase (Vd) was calculated as CLtotal/ke, and the half-life (t1/2) was calculated as ln(2)/ke 
(bolus dosing). The extraction ratio (ER) across the filter was calculated as the ratio of the 
meropenem post-filter blood sample concentration to the pre-filter blood sample concentration. The 
sieving coefficient (Sc) was calculated as the ratio of the concentration of meropenem in the 
ultrafiltrate to the concentration in the pre-filter blood. Clearance by CVVH (CLCVVH) was 
calculated using the equation CLCVVH = ACVVH/AUC0–8 ultrafiltrate (where ACVVH is the total amount of 
meropenem recovered in the ultrafiltrate in one dosing interval). Clearance not mediated by CVVH 
(CLnon-CVVH) was calculated using the equation CLnon-CVVH = CLtotal–CLCVVH. 
 
6.2.3.7 Pharmacodynamic analysis 
A susceptibility breakpoint of 2 mg/L for meropenem against common pathogens, based on the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2013 database [201], was 
used to determine the frequency of PK/PD target attainment. Based on previous publications [60, 
226], for IB administration we considered a plasma drug concentration ≥4x the MIC for more than 
40% of the dosing interval (40% T>4xMIC) was considered as a suitable PK/PD target, whereas for CI 
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administration, a plasma concentration 5x the MIC breakpoint over the entire dosing interval (100% 
T>5xMIC) was required. 
 
6.2.3.8 Statistical analysis 
Data were analysed using Microsoft Excel (Microsoft Corp., Redmond, WA) and GraphPad Prism® 
v.6.0 (GraphPad Software Inc., San Diego, CA). Continuous data are presented as the median 
(IQR). A Fisher’s exact test was used to compare categorical data, and a Mann-Whitney test was 
used for continuous data. A Wilcoxon Signed-rank test for was used for paired data. A P-value of 
<0.05 was considered statistically significant.  
 
6.2.4 Results 
 
6.2.4.1 Patient demographics 
In total, 16 patients were enrolled, with 8 randomized to CI and 8 to IB. Study participants’ 
demographic, illness severity and anthropometric data are presented in Table 6.1.  There were no 
significant differences between the groups in terms of age, gender, severity of illness, and organ 
dysfunction, although those receiving CI has greater weight and height (see Table 6.1). Seven 
patients in the CI group and six in the IB group were still in the ICU on the second occasion of 
sampling.  However, of these, only three patients in the CI group, and five in the IB group were 
receiving ongoing CVVH.  
 
6.2.4.2 Meropenem concentration 
The observed plasma concentration-time profiles for meropenem on occasion 1 of sampling (Days 
1-3 of treatment) and occasion 2 (Days 4-6 of treatment) in patients receiving CI and IB are shown 
in Figure 6.1. IB administration resulted in a significantly higher Cmax on both occasions.  
Conversely, CI resulted in significantly higher Css compared with the Cmin observed in IB patients 
on occasion 1 only (Table 6.2). 
 
 
 
 
 
 
 
 
	   103 
Table 6.1: Demographic and clinical data of patients receiving meropenem by continuous infusion 
or intermittent bolus dosing 
 Continuous infusion
a 
(n=8) 
Intermittent bolusa 
(n=8) P value 
Gender (Male/Female) (n) 7/1 4/4 0.28 
Age (years) 47.5 (32.0-63.3) 44.5 (29.0-60.8) 0.90 
Height (cm) 166.0 (161.5-170.8) 151.0 (150.0-158.3) 0.006* 
Weight (kg) 80.0 (68.5-80.0) 60.0 (50.0-63.8) 0.003* 
APACHE II score  30.0 (26.5-32.5) 32.5 (29.8-37.8) 0.13 
SOFA score (upon ICU admission) 15.5 (13.3-18.5) 14.5 (14.0-17.8) 0.90 
SOFA score (upon study inclusion) 16.0 (13.0-16.8) 17.5 (14.8-18.8) 0.11 
APACHE II = Acute physiologic and chronic health evaluation II; SOFA = Sequential organ failure 
assessment and ICU = Intensive care unit 
aData presented as median (interquartile range) (except for gender) 
bAll P-values were calculated using Mann-Whitney test, except for gender which used the Fisher’s Exact test 
*Indicates statistically significant (P<0.05) 
 
Figure 6.1: Concentration-time profiles of meropenem in plasma (median, IQR) at an 8-hour dosing 
interval, during occasion 1 (Days 1-3, cumulative meropenem doses received = 3-4 g) and occasion 
2 (Days 4-6, cumulative meropenem doses received = 9-10 g), by (a) continuous infusion and (b) 
intermittent bolus administration. 	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Table 6.2: Meropenem pharmacokinetic parameters between continuous infusion and intermittent 
bolus dosing. 
Parameters Continuous infusion  Intermittent bolus  P valueb 
Occasion 1 (Day 1-3)a (n=8) (n=8)  
Cmax (mg/L) 34.51 (28.97-47.10) 64.66 (58.89-80.33) 0.0006* 
Cmin/Css (mg/L) 25.96 (24.51-41.64) 16.99 (15.67-19.83) 0.003* 
AUC0-8 plasma (mg.h/L) 215.28 (195.95-250.35) 250.82 (215.48-294.79) 0.27 
CLtotal (mL/kg/min) 0.96 (0.86-1.01) 1.13 (0.88-1.60) 0.19 
Sieving coefficient 1.02 (0.93-1.14) 1.10 (1.04-1.31) 0.15 
Extraction ratio 0.89 (0.85-1.01) 0.95 (0.86-1.02) 0.70 
AUC0-8 ultrafiltrate (mg.h/L) 188.44 (182.93-208.80) 226.70 (192.08-342.25) 0.16 
ACVVH (mg) 442.44 (410.92-481.34) 482.00 (422.06-540.08) 0.49 
CLCVVH (mL/kg/min) 0.49 (0.43-0.58) 0.58 (0.52-0.67) 0.06 
CLnon-CVVH (mL/kg/min) 0.45 (0.38-0.56) 0.55 (0.32-1.03) 0.56 
Occasion 2 (Day 4-6)a (n=3) (n=5)  
Cmax (mg/L) 24.80 (22.69-33.36) 64.80 (48.45-81.80) 0.04* 
Cmin/Css (mg/L) 21.91 (17.18-32.64) 16.86 (9.73-19.72) 0.14 
AUC0-8 plasma (mg.h/L) 186.30 (144.71-241.03) 234.79 (174.53-288.36) 0.36 
CLtotal (mL/kg/min) 1.12 (0.86-1.69) 1.29 (1.07-1.49) 0.86 
Sieving coefficient 0.92 (0.81-1.07) 1.21 (1.02-1.40) 0.14 
Extraction ratio 0.93 (0.86-0.96) 0.97 (0.88-1.09) 0.45 
AUC0-8 ultrafiltrate (mg.h/L) 147.60 (122.64-218.28) 179.29 (167.39-288.55) 0.25 
ACVVH (mg) 346.71 (335.51-482.43) 429.98 (378.85-576.02) 0.25 
CLCVVH (mL/kg/min) 0.49 (0.46-0.67) 0.66 (0.56-0.67) 0.50 
CLnon-CVVH (mL/kg/min) 0.63 (0.40-1.02) 0.63 (0.40-0.92) 0.85 
Cmax = maximum concentration; Cmin = minimum concentration; Css  = Concentration at steady state; AUC0-8 
plasma = area under the concentration-time curve from 0 to 8 hours in plasma; CLtotal = total clearance; AUC0-8 
ultrafiltrate  = area under the concentration-time curve from 0 to 8 hours in ultrafiltrate; ACVVH = total amount of 
meropenem recovered in ultrafiltrate in one dosing interval; CLCVVH = clearance by continuous venovenous 
haemofiltration and CLnon-CVVH = clearance not mediated by continuous venovenous haemofiltration 
aData presented as median (IQR) 
bP-values were calculated using Mann-Whitney test 
*Indicates statistically significant (P<0.05) 
 
Table 6.3 summarises the pharmacokinetic parameters for patients receiving CVVH on two 
sampling occasions.  Overall, the parameter estimates were numerically higher on occasion 1 for 
both CI and IB, except for CLtotal, ER and CLnon-CVVH, as well as Sc in patients who received IB. 
However all differences were statistically insignificant (P>0.05) when comparing paired data. The 
	   105 
median (IQR) meropenem Vd and t1/2 in patients who received IB administration were 0.43 (0.40-
0.50) L/kg and 4.4 (4.1-5.1) h, respectively, however these data were unable to be calculated in 
patients who received CI. 
 
Table 6.3: Meropenem pharmacokinetics in patients continuing to receive continuous venovenous 
haemofiltration on both occasions 
Parameters Occasion 1 Occasion 2 P valueb 
Continuous infusion (n=3)a    
Cmax (mg/L) 37.34 (28.87-37.40) 24.80 (22.69-33.36) 0.25 
Cmin/Css (mg/L) 27.75 (26.41-32.39) 21.91 (17.18-32.64) 0.50 
AUC0-8 (pl) (mg.h/L) 231.38 (211.11-256.67) 186.30 (144.71-241.03) 0.25 
Total clearance (mL/kg/min) 0.98 (0.87-1.01) 1.12 (0.86-1.69) 0.50 
Sieving coefficient 0.94 (0.92-1.05) 0.92 (0.81-1.07) 0.75 
Extraction ratio 0.88 (0.84-0.88) 0.93 (0.86-0.96) 0.50 
AUC0-8 (uf) (mg.h/L) 199.00 (183.62-212.07) 147.60 (122.64-218.28) 0.50 
Amount0-8 (uf) (mg) 465.63 (448.47-486.57) 346.71 (335.51-482.43) 0.50 
CLCVVH (mL/kg/min) 0.51 (0.46-0.60) 0.49 (0.46-0.67) 0.75 
CLnon-CVVH (mL/kg/min) 0.42 (0.38-0.50) 0.63 (0.40-1.02) 0.50 
Intermittent bolus (n=5)a    
Cmax (mg/L) 64.97 (61.42-86.92) 64.80 (48.45-81.80) 0.31 
Cmin/Css (mg/L) 19.12 (16.78-24.42) 16.86 (9.73-19.72) 0.13 
AUC0-8 (pl) (mg.h/L) 282.35 (250.82-351.09) 234.79 (174.53-288.36) 0.13 
Total clearance (L/h) 0.98 (0.84-1.14) 1.29 (1.07-1.49) 0.13 
Sieving coefficient 1.08 (0.95-1.27) 1.21 (1.02-1.40) 0.31 
Extraction ratio 0.95 (0.78-1.06) 0.97 (0.88-1.09) 0.81 
AUC0-8 (uf) (mg.h/L) 247.00 (194.45-373.27) 179.29 (167.39-288.55) 0.06 
Amount0-8 (uf) (mg) 522.55 (482.01-666.66) 429.98 (378.85-576.02) 0.13 
CLCVVH (L/h) 0.65 (0.50-0.68) 0.66 (0.56-0.67) 0.63 
CLnon-CVVH (mL/kg/min) 0.34 (0.22-0.56) 0.63 (0.40-0.92) 0.19 
Cmax = maximum concentration; Cmin = minimum concentration; Css  = Concentration at steady state; AUC0-8 
plasma = area under the concentration-time curve from 0 to 8 hours in plasma; CLtotal = total clearance; AUC0-8 
ultrafiltrate  = area under the concentration-time curve from 0 to 8 hours in ultrafiltrate; ACVVH = total amount of 
meropenem recovered in ultrafiltrate in one dosing interval; CLCVVH = clearance by continuous venovenous 
haemofiltration and CLnon-CVVH = clearance not mediated by continuous venovenous haemofiltration 
aData presented as median (IQR) 
bP-values were calculated using Wilcoxon Signed Rank test (which compares paired data from patients 
sampled on both occasions). 	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6.2.4.3 Pharmacokinetic/pharmacodynamic target attainment 
Overall, the meropenem dosing regimen used in this study resulted in plasma concentrations that 
were >4x the targeted susceptibility breakpoint (2 mg/L) for 100% of the dosing interval in patients 
receiving IB administration on both occasions of sampling. In the CI group, the plasma 
concentrations were all >10x the susceptibility breakpoint throughout the entire dosing interval on 
both occasions of sampling.	  
 
6.2.5 Discussion. 
 
This prospective study of meropenem pharmacokinetics in critically ill patients receiving CVVH 
has demonstrated that CI produces a significantly higher Css compared with the Cmin observed with 
IB administration when samples were drawn between Days 1 – 3 of therapy. The dosing regimen 
chosen for this study is the same as that recommended by the product information for use in patients 
with ‘normal’ renal function. For both methods of administration, this dose resulted in meropenem 
plasma concentrations that easily met our chosen PK/PD targets and were in fact greater than 
4xMIC for the entire dosing interval when considering a susceptibility breakpoint of 2 mg/L. These 
results demonstrate that lower doses overall of meropenem could be used with the RRT settings 
[median (IQR) effluent flow rate, 30.09 [25.00-33.33] mL/kg/h) used in this study. 
 
In patients who continued to receive CVVH on Days 4 to 6, meropenem concentrations tended to be 
lower than those observed earlier during treatment (Days 1 to 3).  These changes were not 
statistically significant, although the fact many patients were not eligible for sampling on occasion 2 
(due to discontinuation of RRT) limits this analysis.  Temporal variability in pharmacokinetic 
parameters can also be related to a number of patient factors, including recovering native renal 
function.  Unfortunately, quantifying such changes remains problematic, as ongoing RRT will 
confound the interpretation of both plasma biochemistry, and of mathematical estimates of renal 
function. However, CLnon-CVVH improved during occasion 2 sampling both in CI and IB groups, 
which might indicate recovering of intrinsic renal function or upregulation of non-renal elimination 
pathways. For treatment of pathogens with higher MICs, this could represent an advantage for CI in 
terms of more consistent achievement of therapeutic concentrations, although this observation 
appears to be more dependent on dose rather than infusion duration. 
 
The observed median meropenem CLtotal was similar to that reported in previous studies [42, 43, 45, 
46, 203].  Of note, CVVH accounted for ca. 50% of  meropenem CLtotal, either administered by CI 
or IB, which is also in-agreement with previous work [41, 81].  In comparison with data derived 
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from studies using similar CRRT intensity [43, 163, 202], we found that the impact of 
extracorporeal clearance was slightly higher in this study. This could be explained by differing 
patient factors, including the presence of residual native renal function, as described in previous 
reports [156, 163]. This is highly likely given that in this study cohort, all patients were oligo-
anuric, such that significant intrinsic renal clearance would be very unlikely.  
 
Despite reported physiological differences in Asian patients compared with Western patients [227], 
the observed median Vd in patients who received IB dosing was comparable with previous findings 
in critically ill patients receiving variable CRRT settings (0.30-0.50 L/kg) [39, 42-46, 79, 81].  
 
The dosing regimen used in this study easily achieved the selected PK/PD targets for meropenem, 
administered by either CI or IB. The result suggests that in critically ill patients receiving CVVH, 
choice of dose rather than mode of administration may be the more important consideration for 
clinicians. Earlier studies of meropenem in CRRT demonstrated that lower meropenem doses (e.g 
1-2 g/day) rarely enabled concentrations to be maintained above higher MICs (e.g >2 mg/L) [41, 
42, 44, 45, 163], supporting the need for more aggressive meropenem dosing in this population 
[79]. Interestingly, despite higher meropenem dosing (e.g 3 g/day) in patients receiving higher-
intensity CRRT, this was still sub-optimal for the desired therapeutic target [81]. 
 
Importantly, the current study has highlighted that unselected application of meropenem CI in the 
ICU is unlikely to deliver additional benefits in some patient groups, such as those receiving 
CVVH. However, given the varying effects of different CRRT settings on meropenem clearance 
[81, 228], dose individualization based on individual patient circumstances should still be 
considered the best approach for optimal dosing. 
 
We wish to acknowledge the following limitations. Firstly, this was a single-center study from a 
patient population different to that encountered in other regions. Despite this, we believe these data 
provide useful insights into this area of practice. Second, local ICU management may be different to 
that used in other institutions, and therefore any recommendation from this work may not be 
directly transferrable to other ICU populations. Third, the EUCAST database was used to evaluate 
the achievement of the PK/PD index during meropenem treatment and this may underestimate the 
scenario in a clinical dataset. However, in the absence of these data locally, these susceptibility 
breakpoints are a useful guide for antibiotic dosing. Finally, we did not specifically measure 
intrinsic renal function, and therefore other than by examining CLnon-CVVH, we cannot reliably 
quantify changes in intrinsic renal function over time. 
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6.2.6 Conclusion 
 
CI administration resulted in more rapid and sustained meropenem concentrations compared with 
IB. The dosing regimen used in this study was associated with achievement of the desired 
meropenem PK/PD target for both CI and IB, suggesting that a lower dose could be considered in 
this CRRT setting if susceptible pathogens are present. If more resistant pathogens are being 
targeted then CI is likely to result in more consistent achievement of PK/PD targets. 
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6.3 Conclusion 
 
This chapter has described the pharmacokinetics of meropenem by CI and IB administration in 
critically ill patients receiving CVVH. Our findings showed that CI could be an advantageous 
alternative dosing strategy for this RRT setting as it resulted in more rapid and sustained 
meropenem concentrations than IB administration. The standard meropenem dosing regimens used 
in this study sufficiently achieved the desired therapeutic targets, thus suggesting the need for 
altered meropenem administration depends on the selected dose and the chosen target concentration 
for this population.	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Chapter 7 
 
The pharmacokinetics of piperacillin by continuous infusion and intermittent bolus dosing 
during continuous venovenous haemofiltration 
 
7.1 Sypnosis 
 
The main aim of this chapter is to describe the pharmacokinetics of piperacillin when administered 
by CI and IB dosing, in critically ill patients receiving CVVH. A prospective randomized controlled 
trial in critically ill patients receiving CVVH concurrently treated with piperacillin for severe sepsis 
or septic shock was undertaken. The frequency of achieving the selected therapeutic target for each 
dosing strategy was also evaluated.  
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7.2 Manuscript entitled, “Pharmacokinetics of piperacillin in critically ill patients 
receiving continuous venovenous haemofiltration: A randomized controlled trial of 
continuous infusion versus intermittent bolus administration” 
 
A manuscript entitled, “Pharmacokinetics of piperacillin in critically ill patients receiving 
continuous venovenous haemofiltration: A randomized controlled trial of continuous infusion 
versus intermittent bolus administration” has been accepted for publication by International Journal 
of Antimicrobial Agents (12th February 2015). 
 
The co-authors contributed to the manuscript as follows: All study design was performed by the 
PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. Roberts and Prof. 
Jeffrey Lipman. All data collection was performed by the PhD candidate, Janattul-Ain Jamal, Dr. 
Mohd-Basri Mat-Nor and Dr. Fariz-Safhan Mohamad-Nor. All data analysis was undertaken by the 
PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. Jason A. Roberts, Dr. Darren M. 
Roberts, Dr. Andrew A. Udy, Prof. Jeffrey Lipman and Dr. Steven C. Wallis. The PhD candidate, 
Janattul-Ain Jamal, took the leading role in manuscript preparation and writing. 
 
The manuscript is presented as published; except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted to 
fit the overall style of the Thesis. The references are found alongside the other references of the 
Thesis, in the section ‘References’. 
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7.2.1 Abstract 
 
Objective: To describe the pharmacokinetics of piperacillin administered by CI versus IB dosing in 
critically ill patients receiving CVVH, and to compare the frequency of PK/PD target attainment 
with each strategy.  
 
Method: This was a prospective pharmacokinetic trial in 16 critically ill patients with severe sepsis 
or septic shock undergoing CVVH, and randomized to receive either CI or IB administration of a 
standard total daily dose of piperacillin/tazobactam (11.25 g per day on day 1 followed by 9 g per 
day). Serial blood samples were measured on two occasions. Piperacillin pharmacokinetics were 
calculated using a non-compartmental approach. Blood concentrations were compared to 
established PK/PD targets. 
 
Results: On occasion 1 (days 1-3 of therapy), IB administration resulted in significantly higher 
piperacillin peak concentrations (Cmax; 169 vs 89 mg/L, P=0.002), whereas significantly higher Css 
were observed in CI patients (83 vs 57 mg/L, P=0.04 respectively). CLtotal and clearance not 
mediated by CVVH (CLnon-CVVH) were significantly higher with CI administration (median [IQR], 
1.0 [0.7-1.1] mL/kg/min and 0.8 [0.6-1.0] mL/kg/min), P=0.001 and P=0.001 respectively. The 
estimated unbound piperacillin concentrations were 4 times above the target susceptibility 
breakpoint (16 mg/L) for the entire dosing interval (100% fT>4xMIC), in 87.5% patients who received 
CI administration (occasion 1 of sampling), as compared to 62.5% IB patients achieved the desired 
target (50%fT>4xMIC). 
 
Conclusion: Compared to IB dosing, and despite similar CVVH settings, CI administration of 
piperacillin results in a pharmacokinetic profile that may optimize outcomes for less susceptible 
pathogens. 
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7.2.2 Introduction 
 
Optimization of antibiotic therapy is considered essential to reduce mortality in critically ill patients 
with severe sepsis or septic shock [117]. Rapid achievement of therapeutic concentrations is an 
important aim of antibiotic dosing. CI of piperacillin has been advocated to increase the likelihood 
of achieving PK/PD targets in critically ill patients not receiving RRT [25, 160, 161, 229]. 
Therefore, CI may be particularly advantageous in the treatment of less susceptible pathogens, or 
when limited antibiotic options are available. As such, many clinicians have adopted this approach 
in managing critically ill patients with severe sepsis or septic shock [222, 230, 231].  
 
The use of RRT in critically ill patients can affect antibiotic pharmacokinetics. Variability in RRT 
prescribing in the ICU adds to the complexity of antibiotic dosing. Previous experience suggests 
that despite attempts to dose-adjust the antibiotic regimen during RRT, PK/PD targets are rarely 
achieved [79]. Therefore, dosing strategies noted to be generally useful must be tested in critically 
ill patients receiving RRT.  
 
There are no data describing the extent to which prolonged infusions (such as CI of piperacillin) 
maximize PK/PD target attainment in critically ill patients receiving RRT. Although numerous 
piperacillin pharmacokinetic studies have been conducted in critically ill patients concurrently 
treated with variable modes and doses of CRRT [79, 155-159, 204, 205], none have evaluated CI 
administration. The only related paper was based on simulation, and it concluded that CI 
administration of piperacillin could be beneficial in this context [232]. Therefore, evaluating the use 
of CI piperacillin during CRRT will inform ICU clinicians regarding its application. 
 
This study aimed to compare the pharmacokinetics of piperacillin administered by CI to IB dosing, 
in critically ill patients receiving CVVH. We also aimed to describe the frequency of PK/PD target 
attainment of piperacillin with each method of administration. 
 
7.2.3 Patients and methods 
 
This prospective, randomized-controlled pharmacokinetic study was performed in a 12-bed ICU of 
a major tertiary hospital in Malaysia (Kuantan, Pahang, Malaysia). The study was approved by the 
local ethics committee (NMRR-12-573-12765), and consent to participate was obtained from the 
patient’s legally authorized representative. 
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7.2.3.1 Patient selection and data collection 
All adult patients (age ≥18 years old) admitted to the ICU with known or suspected sepsis [233], 
concurrently receiving CVVH for oligo- (<500 mL/day) or anuric renal impairment were eligible 
for enrollment. The decision to use piperacillin/tazobactam was at the discretion of the treating 
physician. Patients were randomized in a 1:1 ratio, using random numbers selected from 
sequentially numbered opaque sealed envelopes, to receive a standard dose of piperacillin 
administered by either CI or IB. 
 
7.2.3.2 Piperacillin administration  
All patients received standard doses of fixed-combination piperacillin/tazobactam (TazpenTM 
Piperacillin (4 g) and Tazobactam (0.5 g) for Injection; Agila Specialties Pvt. Ltd., Bangalore, 
India). Patients in the CI group (n=8) were administered a loading dose 2.25 g 
piperacillin/tazobactam in 20 mL of 0.9% sodium chloride over 30 min via a central line, followed 
immediately by a CI over 24 hours (37.5 mg/h). Patients in the IB group (n=8) received 4.5 g 
piperacillin/tazobactam as a 30 min infusion via a central line for the first dose, followed by 2.25 g 
every 6 hours thereafter. In both groups, the antibiotic was administered using a volumetric infusion 
pump controller, and all patients received a total dose of 11.25 g per day on day 1, and 9 g per day 
thereafter. 
 
7.2.3.3 Continuous renal replacement therapy 
CVVH was performed in all patients using the AquariusTM system (Edwards Lifesciences, Saint-
Prex, Switzerland) and polysulfone-type hemofilters with a surface area of 1.2 m2 (Aquamax12TM; 
Baxter Healthcare, Zurich, Switzerland). In all patients, CVVH was started at least 4 hours prior to 
the sampling period. Vascular access was obtained via the internal jugular or femoral vein, using a 
14-French double-lumen catheter. The ultrafiltrate rate was set at 2000 mL/h, combining pre- and 
post-filter fluid replacement at a ratio of 1:1. The targeted blood flow rate was 200 mL/min. Net 
fluid removal was 50-100 mL/hour depending on the clinical circumstance. Lactate containing 
(PrismasolTM; Gambro, Sondalo, Italy) or lactate free (DuosolTM; B.Braun, Glandorf, Germany) 
solutions were used as the replacement solution, and the circuit was anticoagulated with heparin 
(100 unit/mL) at the discretion of the attending physician. 
 
7.2.3.4 Sample collection  
Pharmacokinetic sampling occurred over either a 6-hour or 24-hour dosing interval, between days 
1-3 of treatment (occasion 1) and over a 6-hour interval between days 4-6 of treatment (occasion 2). 
For each sample, 3 mL of blood was collected in a lithium heparin tube, pre-filter (before the pre-
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filter replacement fluid infusion site), at 0, 15, 30, 45, 60, 120, 240, 360 and 1440 min (continuous 
infusion only) and post-filter (after the post-filter replacement fluid infusion site) at 30, 120 and 360 
minutes on occasion 1. On occasion 2, 3 mL of blood was collected at pre-filter, at 0, 15, 30, 45, 60, 
120, 240, 360 and post-filter at 360 min. All samples were immediately centrifuged at 3000 rpm for 
10 minutes and plasma was separated and immediately frozen at -80 oC. 
 
7.2.3.5 Piperacillin assay  
Piperacillin concentrations in plasma were determined by validated assay methods on a Shimadzu 
Prominence (Shimadzu Corp., Kyoto, Japan) HPLC system at the Burns, Trauma and Critical Care 
Research Centre, The University of Queensland, Australia. The assay was conducted alongside a 
standard curve and quality control replicates at high, medium and low concentrations. The limit of 
quantification for piperacillin in plasma was 0.5 mg/L and linearity was validated from 0.5 to 500 
mg/L. All results were within 5% at all levels, and the assay was validated and conducted according 
to criteria specified by the US FDA guidance on bioanalysis [225]. Unbound piperacillin 
concentrations in plasma were estimated from the measured total piperacillin multiplied by 0.7 (e.g 
30% protein binding in critically ill patients)[161]. 
 
7.2.3.6 Pharmacokinetic analysis  
The pharmacokinetic parameter values were estimated using non-compartmental methods. The area 
under the concentration-time curve for plasma from 0 to 6 hours (AUC0-6) and 0 to infinity (AUC0-
∞) were calculated using the linear trapezoidal rule. Total body clearance (CLtotal) was calculated as 
dose/AUC0-∞ for IB dosing, and MDrate/Css for CI dosing (MDrate is the maintenance dose 
administration rate and Css is the steady state concentration. The maximum concentration for the 
dosing period (Cmax), minimum concentration (Cmin) and Css for the dosing period were the 
observed values. The apparent terminal elimination rate constant (Ke) was determined from log-
linear least squares regression analysis of concentrations from 2 to 6 hours (bolus dosing). The 
apparent volume of distribution during the terminal phase (Vd) was calculated as CLtotal/Ke and the 
half-life (t1/2) was calculated as ln(2)/Ke (bolus dosing only). The extraction ratio (ER) was 
calculated using the equation ER = (Ca-Cv)/Ca, where Ca is the plasma concentration from pre-
filter, while Cv is the plasma concentration from post-filter at same time point. Clearance mediated 
by CVVH (CLCVVH) was calculated using the equation CLCVVH = Qb x (1-hematocrit) x [(Ca-
Cv)/Ca], where Qb is the blood flow rate. Clearance not mediated by CVVH (CLnon-CVVH) was 
calculated as CLtotal – CLCVVH. Net fluid removal (ultrafiltration) was not accounted for in the 
calculations because it accounted for <1% of blood flow.  
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7.2.3.7 Pharmacodynamic analysis  
A susceptibility breakpoint of 16 mg/L for piperacillin against Pseudomonas aeruginosa based on 
the EUCAST 2013 database [201], was used to determine the frequency of PK/PD target 
attainment. Based on previous data [200, 234], we considered a plasma drug concentration 
(unbound) of at least 4 times MIC for more than 50% of the dosing interval (50%T>4xMIC) as the 
optimal PK/PD target for IB administration, whereas for CI administration, a plasma concentration 
(unbound) 4 times the MIC breakpoint over the entire dosing interval (100% T>4xMIC) was required. 
 
7.2.3.8 Statistical analysis  
Data were analyzed using Microsoft Excel (Microsoft Office 2011; Redmond, WA) and Prism 
(GraphPad version 6.0; San Diego, CA), and are presented as median (IQR). A Fisher’s exact test 
was used to compare categorical data, and a Mann-Whitney test for continuous data. A P-value of 
<0.05 was considered as statistically significant. 
 
7.2.4 Results 
 
7.2.4.1 Patient demographics 
Sixteen eligible patients treated with piperacillin and receiving CVVH (median [IQR] effluent flow 
rate = 28.57 [26.67-33.33] mL/kg/hour) were enrolled, with eight randomized to CI and eight 
randomized to IB. All patients completed sampling on occasion 1 (days 1-3 of treatment). Five 
patients in the CI group, and six in the IB group were still in ICU on the second occasion of 
sampling (days 4-6 of treatment). However, of these, only two patients in each group were 
receiving ongoing CVVH, and hence could provide data on this occasion. The demographics, 
illness severity, and anthropometric data of the enrolled patients are depicted in Table 7.1. There 
were no statistically significant differences between the groups in terms of severity of illness and 
organ dysfunction. Although age was numerically lower in the CI group and the distribution of sex 
was not the same in both groups, the differences were not statistically significant. No adverse 
reactions were noted during the study. 
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Table 7.1: Demographic and clinical data for patients receiving piperacillin by continuous infusion 
or intermittent bolus dosing 
 Continuous infusiona 
(n=8) 
Intermittent bolusa 
(n=8) P value
b 
Gender (Male/Female) (n) 8/0 4/4 0.08 
Age (years) 44.0 (33.8-70.0) 62.5 (46.0-70.5) 0.34 
Height (cm) 162.5 (152.5-168.8) 155.0 (150.0-161.5) 0.14 
Weight (kg) 73.0 (62.5-78.8) 70.0 (60.0-73.8) 0.24 
APACHE II score  33.0 (29.8-34.8) 33.5 (28.3-40.5) 0.82 
SOFA score (upon ICU admission) 15.5 (14.0-17.5) 14.0 (13.0-17.8) 0.52 
SOFA score (upon study inclusion) 14.0 (13.0-17.8) 15.0 (14.0-16.8) 0.66 
APACHE II = Acute Physiologic and Chronic Health Evaluation II; SOFA = Sequential Organ Failure 
Assessment and ICU = intensive care unit. 
aData presented as median (IQR) (except for gender) 
bAll P-values were calculated using Mann-Whitney U test, except for gender which used the Fisher’s Exact 
test 
 
7.2.4.2 Piperacillin concentrations 
The observed piperacillin concentration-time profiles in plasma on the first occasion of sampling 
(days 1-3 of treatment) are illustrated in Figure 7.1. IB administration resulted in a significantly 
higher Cmax (P=0.002), while significantly higher piperacillin Css was observed with CI 
administration compared to the observed Cmin with IB administration (P=0.04) (Table 7.2). IB 
administration resulted in a numerically higher, but non-significant, piperacillin AUC0-6.  
 
Figure 7.1: The estimated unbound concentration-time profiles of piperacillin in plasma (median, 
interquartile range) for a 6-hour dosing interval, during occasion 1 (day 1-3, cumulative piperacillin 
doses received = 8 to 10 g) 	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Table 7.2: Piperacillin pharmacokinetics on occasion 1 (day 1-3) for continuous infusion and 
intermittent bolus administration 
Parameters Continuous infusion
a 
(n=8) 
Intermittent bolusa  
(n=8) P value
b 
Cmax (mg/L) 88.7 (82.9-120.4) 168.9 (129.2-219.4) 0.002 
Cmin or Css (mg/L) 83.1 (67.5-102.6) 57.2 (36.5-82.0) 0.04 
AUC0-6 plasma (mg.h/L) 449.8 (409.0-653.8) 559.7 (414.2-681.9) 0.70 
CLtotal (mL/min/kg) 1.0 (0.7-1.1) 0.4 (0.3-0.7) 0.001 
ER 0.09 (0.07-0.11) 0.11 (0.08-0.13) 0.16 
CLCVVH (mL/min/kg) 0.17 (0.13-0.18) 0.23 (0.15-0.26) 0.05 
CLnon-CVVH 
(mL/min/kg) 
0.8 (0.6-1.0) 0.2 (0.1-0.4) 0.001 
Cmax = maximum concentration; Cmin = minimum concentration; Css = concentration at steady state; AUC0-6 = 
area under the concentration-time curve from 0 to 6 hours in plasma; CLtotal = total clearance; ER = 
extraction ratio; CLCVVH  = clearance mediated by continuous venovenous haemofiltration and CLnon-CVVH = 
clearance not mediated by continuous venovenous haemofiltration.  
aData presented as median (IQR) 
bP-values were calculated using Mann-Whitney test 
 
Also, a significantly higher piperacillin CLtotal and CLnon-CVVH were observed in CI patients 
(P<0.01). While the observed median (IQR) CLCVVH was slightly higher in IB compared to CI 
patients, 0.23 (0.15-0.26) versus 0.17 (0.13-0.18), it was did not reach statistical significance 
(P=0.05). The median (IQR) piperacillin Vd and t1/2 in patients who received IB administration were 
0.22 (0.18-0.29) L/kg and 5.4 (4.6-8.3) h respectively. 
 
The piperacillin plasma concentration-time profiles in patients who continued to receive CVVH on 
occasion 2 is illustrated in Figure 7.2, where similar patterns were observed. The calculated 
individual pharmacokinetic parameters are presented in Table 7.3. A higher Cmax was again 
observed in patients who received IB administration, while higher CLtotal and CLnon-CVVH were 
observed in patients who received CI dosing. 
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Figure 7.2: The estimated unbound concentration-time profiles of piperacillin in plasma for a 6-
hour dosing interval, in patients continuing continuous venovenous haemofiltration on day 4-6 
(cumulative piperacillin doses received = 24-26 g) (continuous infusion, n=2 and intermittent bolus, 
n=2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2.4.3 Pharmacokinetic/pharmacodynamic target attainment 
The piperacillin dosing regimens used in this study resulted in estimated unbound piperacillin 
plasma concentrations that were 4 times above the targeted susceptibility breakpoint (16 mg/L) for 
the entire dosing interval, in 87.5% patients (n=7/8) who received CI administration on occasion 1 
of sampling. In the IB group, 62.5% (n=5/8) of patients had estimated unbound piperacillin plasma 
concentrations that were at least 4 times above the susceptibility breakpoint of 16 mg/L, for at least 
50% of the time in one 6-hour dosing interval. While in patients receiving ongoing CVVH (CI, n=2 
and IB, n=2), the desired targets were only achieved in one patient from both groups (Figure 7.2, 
Table 7.3). 
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Table 7.3: Piperacillin pharmacokinetics in patients receiving ongoing continuous venovenous 
haemofiltration on occasion 2 (day 4-6) for continuous infusion and intermittent bolus 
administration 
Parameters Occasion 1 (day 1-3) Occasion 2 (day 4-6) 
Continuous infusion (n=2) Patient no. 4 Patient no. 8 Patient no. 4 Patient no. 8 
Cmax (mg/L) 82.7 69.1 86.7 78.8 
Cmin or Css (mg/L) 70.7 50.9 74.2 61.0 
AUC0-6 plasma (mg.h/L) 409.6 399.4 429.5 409.2 
CLtotal (mL/min/kg) 0.8 1.1 1.1 1.4 
ER 0.1 0.1 0.1 0.1 
CLCVVH (mL/min/kg) 0.1 0.2 0.2 0.2 
CLnon-CVVH (mL/kg/min) 0.7 0.9 0.8 1.2 
     
Intermittent bolus (n=2) Patient no. 1 Patient no. 2 Patient no. 1 Patient no. 2 
Cmax (mg/L) 175.0 162.9 137.4 140.8 
Cmin or Css (mg/L) 82.5 80.5 79.2 59.3 
AUC0-6 plasma (mg.h/L) 692.2 650.8 609.5 521.3 
CLtotal (mL/min/kg) 0.3 0.2 0.3 0.4 
ER 0.1 0.1 0.1 0.1 
CLCVVH (mL/min/kg) 0.1 0.1 0.2 0.1 
CLnon-CVVH (mL/kg/min) 0.2 0.1 0.1 0.3 
Cmax = maximum concentration; Cmin = minimum concentration; Css = concentration at steady-state; AUC0-6 = 
area under the concentration-time curve from 0 to 6 hours in plasma; CLtotal = total clearance; ER = 
extraction ratio; CLCVVH = clearance mediated by continuous venovenous haemofiltration and CLnon-CVVH = 
clearance not mediated by continuous venovenous haemofiltration. 
 
7.2.5 Discussion 
 
This prospective randomized controlled study is the first to describe the difference in piperacillin 
pharmacokinetics between CI and IB administration in critically ill patients receiving CVVH. The 
results demonstrate a significantly higher Cmax with IB administration, while CI produces a 
significantly higher Css compared to the Cmin observed with IB administration on days 1 to 3 of 
antibiotic treatment. Piperacillin CLtotal and CLnon-CVVH were significantly higher in patients who 
received CI administration. CI administration universally achieved the required PK/PD target when 
considering a susceptibility breakpoint of 16 mg/L on occasion 1 of sampling, despite an observed 
higher piperacillin clearance.  
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The pharmacokinetics of piperacillin by CI and IB administration in the critically ill has been 
studied previously [25, 160, 161, 223]; however, none of these data included patients receiving 
RRT and are thus of limited use in describing the effects of CI administration in this subpopulation.  
We observed a higher piperacillin Cmax with IB administration, and higher piperacillin Css with CI 
administration, findings which are in agreement with previous literature concerning critically ill 
patients not receiving RRT [160]. In patients continuing to receive CVVH on day 4-6 of treatment, 
Cmax remained higher in those receiving IB versus CI administration. However, describing further 
pharmacokinetic changes was limited by the discontinuation of CVVH in the majority of the 
enrolled patients.  
 
Considering the present CVVH settings (median effluent flow rate = 28.57 [26.67-33.33] 
mL/kg/hour), no significant different was observed in piperacillin CLCVVH between CI and IB 
administration, although numerically higher values were observed with IB administration. 
However, our study has showed that the piperacillin CLtotal was significantly higher in CI patients, 
and interestingly CLnon-CVVH was also significantly greater in these patients. The higher CLtotal and 
CLnon-CVVH may in part be due to the CI group having a numerically lower age and more males 
than the IB group, although these demographic differences did not reach statistical significance. In a 
pharmacokinetic study conducted in 24 non-critically ill patients that were randomized to CI and IB 
piperacillin dosing, higher piperacillin clearance was observed in CI patients compared to IB (8.9 
L/h versus 5.7 L/h), although the CI patients received mean piperacillin dose that was 15% less than 
the IB [223]. This observation was also noted in other pharmacokinetic studies in critically ill 
patients without RRT [160, 161]. In a randomized crossover study in 7 critically ill patients treated 
with either CI or IB administration of piperacillin, the observed mean piperacillin clearance in CI 
patients was 37% higher than IB patients [160]. Roberts et al [161] has also reported on higher 
piperacillin clearance observed in patients who received CI dosing compared to IB, from a 
pharmacokinetic study in 13 critically ill patients with sepsis that were randomized to CI or IB 
piperacillin dosing. Our finding of higher piperacillin clearance with CI administration resulted in is 
in agreement with these previous studies. The observed higher CLnon-CVVH in our study suggests an 
up-regulation of an alternative piperacillin elimination pathway (e.g biliary excretion) may occur 
when CI is used [235-238]. It could also suggest the recovering of native renal function in the CI 
patients was greater than the IB patients. We are unable to confirm this finding in current study and 
further study would be required to confirm this mechanism of increase in CLnon-CVVH in patients 
receiving CI. 
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Despite the physiological differences between our Malaysian patients and previous data from 
Western critically ill patients receiving variable CRRT techniques, a comparable piperacillin Vd 
was observed (0.3-0.5 L/kg) [155-157].  Importantly, factors such as fluid resuscitation, and 
pathophysiological alterations related to critical illness, can significantly increase the Vd of 
hydrophilic antibiotics (such as piperacillin [12]) from that observed in non-critically ill cohorts.  
 
Previous data has demonstrated that piperacillin doses between 8-24 g per day do not consistently 
achieve the desired piperacillin PK/PD targets [79, 157] and as such more aggressive piperacillin 
dosing has been suggested for critically ill patients receiving CRRT [79]. Conversely, other data in 
critically ill patients receiving CRRT has suggested that standard piperacillin dosing (e.g 12 g 
piperacillin per day) with administration of an additional first dose can achieve target piperacillin 
concentrations [158]. Our study observed that administration of the selected dosing regimen of 
piperacillin by CI in patients receiving CVVH consistently achieves and maintains the selected 
piperacillin PK/PD target throughout therapy.  In contrast, it was difficult the IB administration 
PK/PD target was less consistently achieved, particularly after 3 days of treatment.  
 
In patients continuing to receive CVVH (CI, n=2 and IB n=2), the estimated unbound piperacillin 
plasma concentration in CI patients were more consistent, although only one patient achieve the 
desired PK/PD index, which might support the need for altered piperacillin dosing in these patients. 
Administration of a higher front loaded dose followed by the standard dosing regimen by either CI 
or IB dosing may result in better achievement of the desired PK/PD targets. 
 
Importantly, ours, and previous findings may not translate to different ICU settings, and thus dose 
optimization based on individual patient circumstances and RRT settings should be considered the 
best approach for accurate dosing in ICU patients receiving CRRT. Although the unbound 
piperacillin concentration in plasma can be estimated [161], measurement of the actual unbound 
piperacillin concentration should be considered, as this more closely reflects the therapeutic 
concentration at the target site of infection. Importantly, aggressive dosing should be rationalized 
with careful drug concentration monitoring, particularly to prevent unnecessary high drug exposure.  
 
We wish to acknowledge the following limitations. Firstly, this is a single center Malaysian study 
that has patient characteristics different to that observed in Western populations (e.g. lower body 
weight). Secondly, in the absence of local antibiogram data, we used susceptibility breakpoints 
from the EUCAST database to evaluate the achievement of PK/PD targets, although this should 
serve to improve the generalizability of the interpretations. Specific details regarding endogenous 
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renal function were not available so it is not possible to ascertain its influence on renal function on 
CLnon-CVVH. Anyway, despite CLtot being highest in the CI patients, these patietns were most likely 
to achieve the PK/PD targets. Finally, this is an exploratory study with a small number of patients. 
Although we attempted to minimize bias through randomization, we cannot exclude the potential 
for a type 1 error. However, an advantage of PK/PD endpoints is that they are reproducible and 
readily quantifiable data that are less subject to personal bias, compared to clinical data.   
  
7.2.6 Conclusion 
 
CI is useful in achieving rapid and consistent piperacillin concentrations above the desired PK/PD 
target in critically ill patients receiving CVVH. Such a strategy is likely to be clinically 
advantageous, particularly in the presence of more resistant pathogens.  
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7.3 Conclusion 
 
This chapter has described the pharmacokinetics of piperacillin when administered by CI and IB 
dosing in critically ill patients receiving CVVH. Our findings showed that CI could be an 
advantageous strategy in these patients as it allowed achievement of rapid and consistent 
piperacillin concentrations above the desired therapeutic target. Such a strategy is likely to be 
clinically advantageous when lower doses than that used here are prescribed, or in the presence of 
less susceptible pathogens. 
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Chapter 8 
 
Pharmacokinetics of meropenem and piperacillin using an ex vivo continuous haemofiltration 
circuit 
 
8.1 Sypnosis 
 
The first aim of this chapter is to determine whether meropenem or piperacillin adsorbs onto an 
extracorporeal circuit during a simulated CRRT modality. Secondly, this chapter aims to describe 
the elimination characteristics of each antibiotic during different continuous haemofiltration 
settings. The chapter also aimed to compare the accuracy of the pharmacokinetic findings from this 
ex vivo study with those obtained from prior clinical pharmacokinetic studies, as described in 
Chapter 6 and Chapter 7. 
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8.2 Manuscript entitled, “Can we use an ex vivo continuous haemofiltration model instead 
of a clinical pharmacokinetic study to describe the adsorption and elimination of meropenem 
and piperacillin during continuous venovenous haemofiltration?” 
 
A manuscript entitled, “Can we use an ex vivo continuous haemofiltration model instead of a 
clinical pharmacokinetic study to describe the adsorption and elimination of meropenem and 
piperacillin during continuous venovenous haemofiltration?” has been submitted to Artificial 
Organs (26th November 2014). 
 
The co-authors contributed to the manuscript as follows: All literature review, analysis and study 
design were performed by the PhD candidate, Janattul-Ain Jamal, under the supervision of Prof. 
Jason A. Roberts, Dr. Andrew A. Udy, Prof. Jeffrey Lipman, Dr. Steven C. Wallis, Dr. Jacobus 
Ungerer, Mr. Brett McWhinney and Dr. Dwarakanathan Ranganathan. The PhD candidate, Janattul-
Ain Jamal, took the leading role in manuscript preparation and writing. 
 
The manuscript is presented as published; except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted to 
fit the overall style of the Thesis. The references are found alongside the other references of the 
Thesis, in the section ‘References’. 
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8.2.1 Abstract 
 
Objectives: To determine the adsorption and elimination characteristics of meropenem and 
piperacillin during simulated CRRT, as well as to compare the observed data from this ex vivo study 
with previous data from clinical studies. 
 
Method: This was an experimental study utilizing a modified CRRT circuit and polysulfone 
membrane (1.2 m2), circulated with a blood-crystalloid mixture. Adsorption onto the CRRT circuit 
was tested over a 4-hour period, and clearance was assessed separately using variable continuous 
haemofiltration settings. 
 
Results: A rapid 9% reduction in circulating meropenem and piperacillin concentrations was 
observed at approximately 0.5 and 1.0 hour for each antibiotic respectively. The post-dilution 
setting was associated with a significantly higher Sc and filter clearance (CLfilter) (mean ± SD) (Sc 
1.14±0.10 versus 1.06±0.04; CLfilter 19.05±1.63 versus 17.59±0.62 mL/min, P values <0.05), while 
the pre-dilution setting was associated with a significantly higher extraction ratio (0.08±0.05 versus 
0.03±0.04, P<0.05), for meropenem. While no significant differences were observed for piperacillin 
pharmacokinetics. Overall, clinically comparable pharmacokinetic data were observed between data 
obtained from the ex vivo study and data from previous clinical studies, for both antibiotics.  
 
Conclusion: Meropenem and piperacillin appear to be rapidly adsorbed onto the CRRT circuit, and 
the site of delivery of fluid replacement significantly influenced meropenem pharmacokinetics. 
However, these findings are likely to be clinically insignificant and not affect dosing requirements. 
Comparable data were observed between this ex vivo study and previous clinical studies for both 
antibiotics. This ex vivo method could be a surrogate for future clinical pharmacokinetic studies of 
CRRT.  
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8.2.2 Introduction 
 
Commencement of RRT is common among critically ill patients [115], and CRRT is the most 
widely used RRT technique in this population [38, 120, 121, 124]. In clinical practice, CRRT can 
significantly affect antibiotic elimination [57], and standard dosing for commonly used antibiotics 
in the ICU has been shown to frequently be suboptimal among critically ill patients receiving RRT 
[79]. The clearance of antibiotics during RRT is not only caused by RRT-driven solute removal, but 
potentially also by adsorption onto the CRRT filter. This phenomenon has been shown to be 
clinically significant for some classes of antibiotics including aminoglycosides [47, 48, 239, 240], 
fluoroquinolones [50, 241], glycopeptides, and lipopeptides [49, 242]. Estimating any additional 
clearance by RRT is complex, as there is wide variability in RRT materials, modalities and settings. 
This variability may lead to differences in antibiotic dosing requirements between patients receiving 
different forms or settings of RRT, although more data are required to quantify any 
pharmacokinetic changes associated with these issues. 
 
Numerous clinical pharmacokinetic studies of meropenem and piperacillin in critically ill patients 
receiving different forms of RRT have been published [46, 81, 102, 155, 156, 164, 205]. However 
data describing potential drug adsorption onto the extracorporeal circuit remains elusive, and may 
in fact not be possible to accurately determine during such a study. In addition, conducting repeated 
clinical pharmacokinetic studies to define the mechanisms for antibiotic disposition in the presence 
of RRT is difficult, because of the high costs and ethical issues surrounding studies in these 
patients. Therefore, an experimental study design using a simulated RRT circuit may help provide 
the required data to inform dosing in a clinical setting. 
 
The purpose of this study was therefore to determine the adsorption and elimination characteristics 
of meropenem and piperacillin during a simulated continuous haemofiltration and to compare the 
results from this ex vivo study with those from a previous clinical pharmacokinetic study. 
 
8.2.3 Materials and methods 
 
This was an experimental study using the Aquarius RRT system (Baxter Healthcare; Australia) and 
a blood-crystalloid mixture. Whole blood supplies were provided by the Australian Red Cross 
Blood Service, Australia. The study consisted of repeated experiments (3 times) using new 
Aquamax filters (1.2 m2 polysulfone filter) (Baxter Healthcare; Australia) for each experiment. This 
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study received ethical clearance from the Medical Research Ethics Committee, The University of 
Queensland, Australia (No. 2013000096). 
 
8.2.3.1 Continuous haemofiltration study and sample handling 
The blood-crystalloid mixture was prepared by mixing one unit whole blood (400-600 mL) with 
Hartmanns Solution (sodium compound lactate) up to a total volume of 1000 mL. This mixture was 
heparinized with 5000 units sodium heparin and kept warm (~38°C) using a modified incubator. 
Meropenem (Meropenem trihydrate; AstraZeneca) (10 mg) or piperacillin (Tazopip; Aspen 
Pharmacare) (50 mg) was added into the mixing chamber containing the blood-crystalloid mixture.  
 
The blood-crystalloid mixture flow rate was set at 200 mL/min and the bicarbonate-containing 
replacement fluid (AHB7864, Baxter Healthcare; Australia) flow rate used was 1000 mL/h. Sodium 
heparin 1000 unit/mL was infused at 5 mL/h. The adsorption and elimination experiments were 
conducted according to a previously published approach [50]. In the adsorption study, a 
recirculating mode was used. Meropenem or piperacillin was spiked into the blood-crystalloid 
mixture.  Samples were taken immediately before the start of infusion and at 0, 30, 60, 120, 180 and 
240 min after administration. No replacement fluid or ultrafiltration was introduced in this phase. 
The elimination study consisted of six 15-minute cycles.  Meropenem or piperacillin was added 
after the CRRT system had been filled with the blood-crystalloid mixture. Similar CRRT settings 
were used throughout, with replacement fluid administered pre- or post-dilution in each cycle. 
Blood sampling occurred after the system reached equilibrium (9 min), and were taken pre- and 
post-filter. Ultrafiltrate volume was measured at the end of each equilibrium period in each cycle, 
and 2 mL was kept for further analysis.  All blood and ultrafiltrate samples were immediately 
centrifuged at 3,000 rpm for 10 min, and plasma was separated. All samples were kept frozen at -
80°C.  
 
8.2.3.2 Sample analysis 
Antibiotic concentrations in plasma and ultrafiltrate were determined by validated assay methods 
[243], using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) on a 
Shimadzu Prominence instrument (Shimadzu Corp., Kyoto, Japan). All samples were assayed 
alongside calibration standards and quality controls, and the assay was validated and conducted as 
per criteria specified by the US FDA guidance on bioanalysis [225].  
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8.2.3.3 Calculations 
Adsorption onto the circuit was calculated as follows: 
 
Adsorption = Dose added – (antibiotic concentration x total fluid volume)   Eq. 1 
 
The sieving coefficient (Sc) was calculated as follows: 
 
Sc  =  Total antibiotic concentration in ultrafiltrate      Eq. 2 
  Total antibiotic concentration in blood  
 
The extraction ratio (ER) across the filter was calculated as follows: 
 
ER  =  (Ca-Cv)/Ca          Eq. 3 
(where Ca is total antibiotic concentration at pre-filter and Cv is total antibiotic concentration at 
post-filter in blood, at same time point). 
 
Filter clearance (CLfilter) was calculated as follows: 
 
CLfilter  =  Sc.(Quf)          Eq. 4 
where Quf is the ultrafiltration flow rate.  
 
For comparison to clinical RRT pharmacokinetic data, similar calculations were used to determine 
clearance by continuous venovenous haemofiltration (CLCVVH). 
 
8.2.3.4 Clinical renal replacement therapy pharmacokinetic data 
Sc and ER were calculated using data from our previously conducted pharmacokinetic study in 
critically ill patients treated with meropenem [244] or piperacillin (data submitted) and receiving 
CVVH (see eq. 2 and eq.3). For CLCVVH, the above calculation (see eq. 4) was used and the Quf was 
fixed to 1000 mL/hour. These data were used to determine the clinical applicability of the ex vivo 
results. Briefly, 16 patients receiving either meropenem (n=8) or piperacillin (n=8) with serial blood 
samples taken over one dosing interval were analysed. Meropenem was administered as a 1 g IV 
30-minute infusion every 8 hours and piperacillin was administered as 2.25g IV 30-minute infusion 
every 6 hours.  
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8.2.3.5 Statistical analysis 
Statistical analyses were performed using Prism (GraphPad, version 6.0; San Diego, CA) and 
Microsoft Excel (Microsoft Office 2011; Redmond, WA). Data are presented as mean ± SD or 
median (IQR) as appropriate. Paired t test was used to analyze dependent data and the comparison 
of different experimental groups (e.g ex vivo versus clinical data) was determined by Mann-
Whitney test. A P value <0.05 was considered as significant. 
 
8.2.4 Results. 
 
The median (IQR) pre-infusion concentrations of haemoglobin and albumin from the blood 
mixtures were 27.0 (23.5-47.5) g/L and 10.0 (7.5-12.0) g/L respectively during the adsorption 
study, and 10.3 (10.2-12.2) g/L and 48.0 (45.5-57.0) g/L respectively in the elimination study.  
 
The mean ± SD of meropenem and piperacillin concentrations at different time points, throughout 
the 4-hour adsorption study, are shown in Figure 8.1. The mean meropenem and piperacillin loss at 
4 hours using the CRRT circuit were 0.7 ± 0.0 mg (8.5%) and 3.6 ± 1.4 mg (8.9%) respectively. 
Similar meropenem concentrations were achieved in the circulating blood mixture after 0.5 hours 
post antibiotic administration, and after 1 hour for piperacillin . 
 
Figure 8.1: The concentration (mg/L) (left y-axis) and amount loss (mg) (right y-axis) of (a) 
meropenem and (b) piperacillin during a 4-hour adsorption study (ex vivo) 
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Pre-dilution during continuous haemofiltration led to higher mean meropenem and piperacillin 
concentrations, in all pre-filter samples (Figure 8.2). Similar concentrations were observed from all 
samples obtained at both filter ports (pre- and post-filter), during post-dilution, for both antibiotics.  
 
Figure 8.2: The concentration-time profiles of meropenem and piperacillin at pre- and post-filter 
with different continuous haemofiltration settings (pre- and post-dilution) (P values were obtained 
by paired t test) 	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Sc, ER and CLfilter of meropenem and piperacillin, using pre-dilution and post-dilution are 
shown in Table 8.1. Post-dilution resulted in a statistically significantly higher observed 
meropenem Sc, and CLfilter, while pre-dilution has led to a significantly higher meropenem ER 
(P<0.05). No statistically significant differences were observed for piperacillin, although the pre-
dilution setting led to a numerically higher piperacillin ER (0.10±0.05 versus 0.04±0.06, P>0.05). 
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Table 8.1: Meropenem and piperacillin pharmacokinetics during different continuous 
haemofiltration settings 
Parameters Meropenem
a P valueb Piperacillin
a P valueb Pre-dilution Post-dilution Pre-dilution Post-dilution 
Sieving coefficient 
(n=18) 
1.06 ± 0.04 1.14 ± 0.06 0.006 0.87 ± 0.06 0.94 ± 0.09 0.12 
Extraction ratio  
(n=18) 
0.08 ± 0.05 0.03 ± 0.04 0.001 0.10 ± 0.05 0.04 ± 0.06 0.06 
Filter clearance 
(mL/min) (n=18) 
17.59 ± 0.62 19.05 ± 1.63 0.006 14.57 ± 0.97 15.69 ± 1.52 0.12 
aData presented as mean ± SD 
bP-values were calculated using paired Student t test 
 
Comparable values were observed in the Sc, ER and clearance data between the ex vivo study and 
clinical studies utilising similar CRRT settings, for both antibiotics. However, the observed 
differences in certain parameters were statistically significant (P<0.05) (Table 8.2). 
 
Table 8.2: Comparison between parameters observed during ex vivo and clinical studies 
Parameters Clinical data
a  
(n=8) 
Ex vivo dataa 
Pre-dilution  
(n=9) P value
d Post-dilution  (n=9) P value
d 
Meropenem      
Sc 1.10 (1.03-1.31)b 1.06 (1.04-1.08 0.17 1.17 (1.15-1.19) 0.41 
ER 0.12 (0.11-0.14)b 0.08 (0.05-0.10) 0.008 0.02 (0.01-0.04 0.001 
Clearance  
(mL/min) 
18.34 (17.20-21.80)b 17.70 (17.24-18.07) 0.17 19.48 (19.22-19.85) 0.41 
Piperacillin      
Sc 1.02 (0.98-1.09)c 0.90 (0.87-0.90) <0.001 0.97 (0.96-0.98) 0.02 
ER 0.11 (0.08-0.13)c 0.09 (0.07-0.10) 0.11 0.03 (0.01-0.04) 0.01 
Clearance 
(mL/min) 
17.01 (16.28-18.21)c 14.94 (14.47-15.03) 0.07 16.02 (15.92-16.41) 0.02 
Sc = sieving coefficient and ER = extraction ratio 
aData reported as median (interquartile range) 
bData were calculated using meropenem concentrations in plasma/ultrafiltrate (n = 8 patients) from previous 
study [244]  
cData were calculated using piperacillin concentrations in plasma/ultrafiltrate (n = 8 patients) from previous 
study (data submitted) 
dP values were calculated using Mann-Whitney test
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8.2.5 Discussion. 
 
This experiment was conducted using a RRT system that is used in clinical practice and 
demonstrated rapid loss of meropenem and piperacillin due to circuit adsorption; approximately 9% 
for both drugs. The post-dilution setting during continuous haemofiltration resulted in a higher 
meropenem Sc, CLfilter and ER, while the pre-dilution setting has led to a higher meropenem ER. 
Significantly higher drug concentrations at the pre-filter port were observed with pre-dilution 
settings for both drugs. Overall there were no clinically significant differences observed between 
the pharmacokinetic parameters obtained from the ex vivo model compared to those derived from 
clinical studies.  
 
Circulating meropenem and piperacillin concentrations were rapidly reduced during a 4-hour 
recirculation process of the blood-crystalloid mixture. However the 9% loss is not large for either 
antibiotic, suggesting that adsorption should be considered minimal with this RRT system. A 
previous experimental study evaluating different filter materials and CRRT settings demonstrated 
that meropenem did not bind to any of the different membranes [245], while limited data are 
available to describe piperacillin adsorption [246]. However, antibiotic adsorption onto haemofilter 
materials can be significant, as has been reported with aminoglycosides [47, 48, 239, 240], 
glycopeptides [49], lipopeptides [242] and fluroquinolones [50, 241]. Interestingly, some of these 
studies have suggested that adsorption onto the haemofilter is dependent on the type of material 
used, in addition to the specific antibiotic [47-50]. In addition, the degree of antibiotic adsorption 
onto different haemofilter materials can be irreversible [47-49, 242] and concentration-dependent 
[48, 239, 240], or reversible [241]. Therefore, to further inform this area for meropenem and 
piperacillin, extensive studies using different types of commercially available haemofilters, RRT 
settings and methods, maybe required. 
 
The site of delivery of replacement fluid before a solute enters a haemofilter (pre-dilution) is 
expected to reduce solute concentrations and potentially lead to decreased solute clearance [247]. In 
this ex vivo study, the delivery of replacement fluid by pre-dilution or post-dilution, appeared to 
significantly influence meropenem pharmacokinetics (e.g Sc, ER and CLfilter) but not piperacillin. A 
statistically significantly higher meropenem Sc, and CLfilter of were observed with post-dilution, 
while higher meropenem ER was observed with pre-dilution, although the observed differences 
were minimal and are likely to be clinically insignificant. Interestingly, pre-dilution led to higher 
pre-filter concentrations of meropenem and piperacillin than the post-filter concentrations, while no 
differences in concentrations were observed during post-dilution studies for both antibiotics. The 
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pre-filter sampling port is located before the point for pre-dilution delivery along the CRRT circuit, 
while the post-filter sampling port is located before the point for post-dilution delivery. This 
therefore explains the difference in pre- and post-filter piperacillin and meropenem concentrations 
during pre-dilution.  Importantly, these findings highlight that post-filter sampling should be 
considered for antibiotic measurement during a pharmacokinetic study with a similar RRT circuit, 
as this is more likely to reflect the actual circulating concentrations.  
 
The observed Sc in this experimental study was similar to those reported from previous clinical 
studies, for both antibiotics [39, 41, 155, 202]. Effluent flow rate and the filter material are not 
generally associated with changes in antibiotic permeability, as suggested by other in vitro studies 
of carbapenems [245, 248], cephalosporins [148, 249-251] and osetalmivir [252]. Inversely, RRT 
materials can influence the permeability of lipopeptide antibiotics [253, 254]. Interestingly, the 
mixture composition used as the drug reservoir during an experimental study can also influence 
antibiotic permeability [163, 242, 246]. This suggests that identifying drug characteristics and RRT 
materials can be used to estimate antibiotic permeability during any form of RRT where it may 
need some consideration, and this could be a limitation for certain classes of antibiotic.  
 
In this study we found that the observed parameters (Sc, ER and clearance) from the ex vivo 
experiments were comparable to those observed from clinical data for both antibiotics.  This 
suggests the ex vivo study design is useful to further characterize antibiotic pharmacokinetics in the 
absence of data provided by clinical studies. Even though a statistically significant differences were 
observed between the ex vivo data and clinical data, the differences may not be clinically 
significant. Furthermore, despite similar CRRT settings (e.g technique, blood flow rate, modality, 
haemofilter size and type), the actual effluent flow rate utilized in clinical studies was higher than 
the effluent flow rate used in this ex vivo study (2000 mL/h versus 1000 mL/h) and both of pre-
dilution and post-dilution settings were combined during CVVH in clinical study, that might 
slightly contributed to the differences in clinical antibiotic concentration data for both antibiotics. 
While plasma protein binding may explain on the significant differences observed in some of 
piperacillin parameters, as plasma albumin concentrations in patients from the clinical study and in 
the blood-crystalloid mixture were very different (24.15 (21.45-26.98) and 48.0 (45.5-57.0) g/L). 
As previously highlighted, the composition of the blood mixture used during experimental studies 
could influence findings for certain antibiotics [163, 242, 246].  
 
We wish to acknowledge that this study has several limitations. This is small experimental study, 
which can only model an actual clinical scenario. A blood-crystalloid mixture was used as matrices 
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for all antibiotics that may not exactly represent human physiology, however preparations of the 
mixture have followed previous established works in this area. All data interpretations have been 
made carefully and not directly translated to dosing recommendations. This study also evaluated a 
single RRT modality using one type of haemofilter material, and therefore findings from this study 
may not be applicable to other types of RRT. 
 
8.2.6 Conclusion 
 
Meropenem and piperacillin are rapidly adsorbed onto the extracorporeal circuit during continuous 
haemofiltration, however the adsorption was minimal. The pre-dilution and post-dilution settings 
during continuous haemofiltration may have a different impact on meropenem clearance but is 
likely to be clinically insignificant. While the site of delivery of replacement fluid during 
continuous haemofiltration has no significant impact on piperacillin pharmacokinetics. The overall 
clinically insignificant differences observed between parameters from ex vivo and clinical data 
suggest that the ex vivo study is useful to further explore meropenem or piperacillin 
pharmacokinetics during continuous haemofiltration, particularly in the absence of clinical data. 
 
8.2.7 Acknowledgements 
 
Prof Roberts is funded by a Career Development Fellowship from the National Health and Medical 
Research Council of Australia (APP1048652). Ms Jamal is funded by a scholarship from the 
Ministry of Health, Malaysia. We acknowledge research funding provided to the Burns Trauma and 
Critical Care Research Centre from an Australian National Health and Medical Research Council 
Project Grant (APP1044941). 
 
 
 
 
 
 
 
 
 
  
	   139 
8.3 Conclusion 
 
This chapter has characterized the adsorption and elimination of meropenem and piperacillin during 
an ex vivo continuous haemofiltration circuit. Our findings showed that both antibiotics are rapidly 
adsorbed onto the extracorporeal circuit, however the total adsorption was minimal. The site of 
delivery of the replacement fluid, either pre-dilution or post-dilution during continuous 
haemofiltration resulted in no significant impact on meropenem or piperacillin pharmacokinetics. 
There were no clinically significant between the pharmacokinetic parameters obtained from the ex 
vivo and clinical studies. The ex vivo model studied here, could be used to further explore antibiotic 
pharmacokinetics during RRT, particularly in the where there is limited data in the clinical setting. 
 
 	  
	   140 
Chapter 9 
 
Summary of findings, discussion, future directions and conclusion 
 
9.1 Summary of findings and discussion 
 
The overall aim of the Thesis was to describe the pharmacokinetics of commonly used anitbiotics in 
critically ill patients. The main findings of this Thesis are summarized below. 
 
9.1.1 The impact of renal replacement therapy settings on antibiotic clearance 
 
Based on the literature review of antibiotic pharmacokinetics in critically patients receiving RRT, as 
described in Chapter 2 and 3, it can be concluded that there is wide variability in pharmacokinetics 
for various classes of antibiotic during different RRT modalities. In Chapter 2, special populations 
of ICU patients, such as burn patients and those receiving extracorporeal treatment (e.g RRT and/or 
ECMO), have increased potential for changes in antibiotic pharmacokinetics in critically ill 
patients, particularly for Vd and clearance. Suboptimal antibiotic dosing remains a major concern in 
critically ill patients receiving RRT. Determining the optimal dosing from existing data is difficult, 
as it is not easily translatable to different ICU populations, RRT modalities and settings. 
 
A meta-review of the published literature on the pharmacokinetics and dosing of commonly used 
antibiotics in the ICU setting (meropenem, piperacillin and vancomycin) during different RRT 
modalities is described in Chapter 4. This analysis has highlighted the impact of RRT settings on 
antibiotic clearance that may be used as a predictor for the need for different doses during different 
RRT approaches. It was observed that correlations existed between the effluent flow rates of 
different CRRT settings and CLRRT for meropenem, piperacillin and vancomycin, rs = 0.43 (P = 
0.12), rs = 0.77 (P = 0.10) and rs = 0.90 (P = 0.08) respectively. Inconsistent relationships were 
observed between blood flow rates and CLtotal and CLRRT for the three antibiotics. In this context, 
the effluent flow rate could be used to predict extracorporeal clearance of meropenem, piperacillin 
and vancomycin during different CRRT techniques.  
 
Additionally, in the meta-review reported in Chapter 4, it was observed that 89% and 83% of 
meropenem and piperacillin doses respectively, successfully achieved the selected therapeutic target 
(more than 100% fT>MIC), against a MIC of 2 mg/L and 16 mg/L for both antibiotics respectively. 
However, only 60% of the evaluated vancomycin doses achieved the AUC0-24/MIC of at least 400, 
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against MIC value of 1 mg/L, while only 20% achieved the target at a MIC of 1.5 mg/L. Target 
attainment for a MIC of 2 mg/L was very low. These findings highlight the need for altered dosing 
strategies, in the presence of less susceptible pathogens and/or when higher RRT setting is used, 
particularly for vancomycin. 
 
9.1.2 Meropenem pharmacokinetics by continuous infusion and intermittent bolus dosing 
during continuous venovenous haemofiltration 
 
The settings studied in the studies in Chapters 6 and Chapter 7 are commonly used in Malaysian 
ICUs as described in the RRT prescribing practice survey reported in Chapter 5.  
 
Sixteen critically ill patients receiving CVVH concurrently treated with meropenem for severe 
sepsis or septic shock, were randomized to receive either CI or IB dosing of standard meropenem 
regimens in a prospective pharmacokinetic trial, as described in Chapter 6. Serial meropenem 
concentrations in plasma and ultrafiltrate were measured at selected time points in one dosing 
interval, after administration of standard dosing regimen (a total dose of 4 g per day on day 1 then 
followed by 3 g per day), on two occasions during antibiotic therapy, between day 1-3 and between 
day 4-6). The study was conducted in a Malaysian ICU population, which have significant 
arthropometric differences to Western patients. In the meropenem study comparing CI and IB 
dosing (Chapter 6), it was observed that IB administration resulted in higher median Cmax during 
occasion 1 and occasion 2 samplings. CI dosing resulted in higher median meropenem Css 
compared to the Cmin for IB dosing on occasion 1 only. CVVH contributed to approximately 50% of 
meropenem CLtotal in these patients. The selected meropenem doses in this study achieved plasma 
concentrations that were greater than 4 times the targeted susceptibility breakpoint (2 mg/L) for 
100% of the dosing interval, regardless of the mode of administration on both occasions. The 
findings from this study highlighted the applicability of CI administration as an alternative to IB for 
meropenem administration in patients receiving CVVH. In this ICU population and CVVH settings, 
the need for altered administration may be unnecessary for meropenem, but depends on the dose 
selected and target concentration. 
 
9.1.3 Piperacillin pharmacokinetics by continuous infusion and intermittent bolus dosing 
during continuous venovenous haemofiltration 
 
A prospective pharmacokinetic trial of piperacillin by CI and IB administration was conducted in 
Malaysian critically ill patients receiving CVVH, as described in Chapter 7. Sixteen critically ill 
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patients receiving CVVH treated with piperacillin for severe sepsis or septic shock, were 
randomized to receive either CI or IB administration of a standard total daily dose of a fixed 
combination of piperacillin/tazobactam. Serial piperacillin concentrations in plasma and ultrafiltrate 
were measured at selected time points during dosing intervals on two occasions during antibiotic 
therapy (day 1-3 and day 4-6). It was observed that IB administration resulted in significantly 
higher piperacillin Cmax, while significantly higher Css was observed in CI patients, on occasion 1. 
The median piperaciilin CLCVVH was significantly higher with IB administration compared to CI on 
occasion 1. The administered dose achieved PK/PD targets in 88% patients who received CI but 
only 63% for IB during occasion 1. CI could be an alternative strategy to optimize piperacillin 
therapy in critically ill patients receiving CVVH. Administration of a higher ‘loading dose’, in 
particular may enable achievement of PK/PD targets for less susceptible pathogens when using 
these CVVH settings.  
 
9.1.4 Meropenem and piperacillin pharmacokinetics in ex vivo continuous venovenous 
haemofiltration study 
 
The pharmacokinetics of meropenem and piperacillin were further characterized in an ex vivo study 
design utilizing a modified CRRT circuit (AquariusTM RRT system) and polysulfone haemofilter 
with membrane surface area of 1.2 m2, and circulated with a blood-crystalloid mixture, as described 
in Chapter 8. The RRT system was set up so that the settings were similar to those used in the 
meropenem and piperacillin pharmacokinetic clinical trials (in Chapter 6 and 7). Meropenem and 
piperacillin were spiked into a blood-crystalloid mixture, and adsorption onto the CRRT circuit was 
tested over a 4-hour period and clearance was assessed separately using a range of continuous 
haemofiltration settings.  
 
In the adsorption study, a rapid reduction (approximately 9%) of circulating meropenem and 
piperacillin concentrations was observed at approximately 0.5 and 1.0 hour for each antibiotic 
respectively. In this context, the adsorption for meropenem and piperacillin onto the CRRT circuit 
can be considered as minimal and clinically insignificant. 
 
In the clearance study, no significant difference was observed with the pre-dilution versus post-
dilution settings during continuous haemofiltration for both antibiotics. The post-dilution setting in 
this CRRT circuit has led to a significantly higher ER for both antibiotics. The pharmacokinetic 
parameters of meropenem and pipearcillin observed in this ex vivo study would not be considered to 
be clinically significantly different compared to those observed in clinical studies (Chapter 6 and 7). 
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The findings from this study has highlighted that the ex vivo study design could be useful to further 
explore antibiotic pharmacokinetics during RRT.  
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9.2 Future directions for research 
 
Based on the findings of this Thesis, there are number of areas for further research that should be 
considered for further research to address gaps in knowledge. These include: 
 
• Non-compartmental analyses were conducted in Chapter 6 and 7 in this Thesis to describe 
pharmacokinetic parameters. However, a population pharmacokinetic approach would be 
more robust to describe pharmacokinetic variability within and between individuals. Thus 
this approach should be applied in future pharmacokinetic studies involving variety RRT 
approaches and patients characteristics. Covariates such as age, weight, severity of illness 
and RRT settings can be tested and where appropriate incorporated into a pharmacokinetic 
model. Subsequently, a simulation approach of varying antibiotic dosing regimens during 
different RRT modalities and settings can be conducted, thus antibiotic dosing nomogram 
can be developed that can be widely used. 
 
• An ex vivo study design, as described in Chapter 8 of this Thesis could be used to describe 
the pharmacokinetics of antibiotics during RRT. It would allow a more extensive description 
of the effects of the operational characteristics of RRT as well as the use of different 
modalities (e.g CVVHD, CVVHDF, IHD, PIRRT) on antibiotic pharmacokinetics. Such a 
study would supplement any clinical pharmacokinetic studies. 
 
• A well-designed, large multi-centre trial comparing the clinical outcomes of CI and IB 
administration of beta-lactam antibiotics in critically ill patients receiving different RRT 
modalities is required. These studies should include patients administered intensive RRT 
settings (i.e. high effluent flow rates) and with a greater likelihood for the presence of less 
susceptible pathogens.  
 
• Besides RRT, the applicability of CI administration could also be considered in patients 
receiving other form of extracorporeal treatment such as ECMO. The materials of the circuit 
and settings used during ECMO are different to RRT, thus findings from this proposed 
research would provide more information on applicability to optimize antibiotic dosing 
using CI.   
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9.3 Conclusion 
 
CVVH contributes significantly to meropenem and piperacillin clearance in critically ill patients. CI 
should be considered as an alternative dosing strategy in these patients receiving CVVH, to 
optimize meropenem and pipercillin dosing, particularly for treatment of less susceptible pathogens 
and/or when utilizing higher RRT intensities. The ex vivo study design can be used to describe 
meropenem and piperacillin pharmacokinetics in the absence data from clinical pharmacokinetic 
studies. Extensive further research is required in this area, particularly when using other types of 
RRT modalities, such as PIRRT, in order to establish better antibiotic dosing guidelines. 
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CREVIEW CURRENTOPINION Improving antibiotic dosing in special situations in
the ICU: burns, renal replacement therapy and
extracorporeal membrane oxygenationopyright © Lippincott Willi
www.co-criticalcare.coma a a,bJanattul-Ain Jamal , Caleb J.P. Economou , Jeffrey Lipman , and
Jason A. Robertsa,b,cPurpose of review
Antibiotic dosing for critically ill patients that is derived from other patient groups is likely to be suboptimal
because of significant antibiotic pharmacokinetic changes, particularly in terms of drug volume of
distribution and clearance. Organ support techniques including renal replacement therapy (RRT) and
extracorporeal membrane oxygenation (ECMO) increase the pharmacokinetic variability. This article
reviews the recently published antibiotic pharmacokinetic data associated with burns patients, those
receiving continuous RRT (CRRT), sustained low-efficiency dialysis (SLED) and ECMO.
Recent findings
These groups develop increases in volume of distribution that necessitate the use of higher initial doses to
rapidly achieve therapeutic antibiotic concentrations. Burns patients have supranormal drug clearances
requiring more frequent administration of antibiotics. Patients receiving CRRT or SLED have variable drug
clearances related to different equipment and RRT settings at different institutions. ECMO presents a
different challenge because there is such a dearth of data with higher than standard doses potentially
required, even in the presence of end-organ failure.
Summary
In the context of such variable pharmacokinetics, a guideline approach to dosing remains elusive because
of insufficient available data and, therefore, use of therapeutic drug monitoring should be considered
advantageous where possible.
Keywords
critical care, extracorporeal membrane oxygenation, pharmacokinetics, renal replacement therapy,
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Curr Opin Crit Care 2012, 18:460–471
DOI:10.1097/MCC.0b013e32835685adINTRODUCTION
The healthcare system burden associated with infec-
tions in critical care units remains high. Given that
as many as 70% of patients may be receiving anti-
biotics at any one time and with 50% of patients
deemed infected, antibiotic prescription is a very
common part of care of the critically ill patient [1].
However, the types of patients, infections and anti-
biotics can vary significantly and an individualized
approach to patient care should be a focus of patient
care plans. Clinicians will initially identify the likely
source of the infection, then determine the likely
pathogen and commence an appropriate antibiotic
to treat the infection. To further optimize antibiotic
therapy, individualization of antibiotic dosing is
important – that is, to prescribe a dose which will
ensure a pharmacokinetic exposure of the drugams & Wilkins. Unautholikely to maximize bacterial killing and clinical out-
come [2].
A challenge for critical care clinicians, however,
is the variation in organ function of the critically
ill patient [3]. Although some patients may berized reproduction of this article is prohibited.
Volume 18  Number 5  October 2012
KEY POINTS
 Burns patients develop significant pharmacokinetic
changes which generally require higher antibiotic
dosing over the first 24–48h from an increased drug
volume of distribution and then higher than standard
doses throughout the course of therapy due to the
presence of augmented renal clearance.
 Antibiotic dosing guidelines for use across all renal
replacement therapies including continuous renal
replacement therapy or sustained low-efficiency dialysis
are not possible because of widely varied drug
clearances across the different modalities and settings.
 There is a dearth of data describing optimized dosing
approaches for antibiotics in the presence of
extracorporeal membrane oxygenation. Like some other
critically ill patient groups, use of therapeutic drug
monitoring to improve antibiotic dosing should be used
where available.
Antibiotic dosing challenges in ICU Jamal et al.hyperdynamic with elevated cardiac outputs and
renal and hepatic blood flows predisposing to supra-
normal drug clearances, other patients may develop
single or multiple organ dysfunction leading to very
low drug clearances and corresponding high drug
concentrations [4]. Patients with burns injuries and
those receiving extracorporeal therapies including
extracorporeal membrane oxygenation (ECMO) [5],
continuous renal replacement therapy (CRRT) [6]
and sustained low-efficiency dialysis (SLED) [7
&
] can
develop profoundly altered pharmacokinetics and
will have varying antibiotic dosing requirements for
which little data are presently available. Achieving
timely and appropriate antibiotic exposures in theseCopyright © Lippincott Williams & Wilkins. Unaut
Table 1. Antibiotic killing characteristics and pharmacokin
Antibiotic classification Definition of PK/PD target
Concentration-dependent Ratio of the peak antibiotic
concentration to the MIC o
the pathogen (Cmax/MIC)
Time-dependent Percentage of time during do
interval for which the free
concentration of the antibio
remains more than the MIC
the pathogen (%fT>MIC)
Concentration-dependent
with time-dependent
Ratio of the area under the
concentration–time curve (
during a 24-h period to the
of the pathogen (AUC0–24
AUC, area under the curve; Cmax, maximum concentration; fT>MIC, unbound plasma
MIC, minimum inhibitory concentration; PK/PD, pharmacokinetic/pharmacodynami
aCiprofloxacin.
bVancomycin.
1070-5295  2012 Wolters Kluwer Health | Lippincott Williams & Wilkpatients is essential, as has been shown to improve
patient outcomes in previous studies [8–10].
The aim of this review is to examine the recently
published data describing the altered pharmacoki-
netics and dosing requirements for critically ill
patients with burn injuries and those receiving
extracorporeal therapies including ECMO, CRRT
and SLED.METHODS
A PubMed search using relevant keywords was under-
taken to identify relevant recently published English
language articles. Journal articles referenced in the
primary article identified if appropriate were also
cited.PHARMACOKINETICS AND
PHARMACODYNAMICS IN CRITICAL
ILLNESS
Pharmacokinetic/pharmacodynamic (PK/PD) opti-
mization of antibiotics is being increasingly seen
as a tool to improve dosing regimens for critically
ill patients. PK/PD relates pharmacokinetic
parameters to pharmacodynamic indices which
describe antibiotic activity at different concen-
trations [11,12]. Different classes of antibiotics
exhibit different PK/PD indices which have been
defined through previous in-vitro and in-vivo
studies in animals and humans (Table 1) [13–21].
Critically ill patients may develop unique path-
ophysiological changes which can affect antibiotic
pharmacokinetics, thus necessitating different doses
so that the pharmacokinetic exposures associatedhorized reproduction of this article is prohibited.
etic/pharmacodynamic target
PK/PD target
f
Aminoglycoside: Cmax/MIC 8:10 [13],
daptomycin: Cmax/MIC 8:10,
AUC0–24/MIC 100 [14,15]
sing
plasma
tic
of
b-Lactams: 50–70% fT>MIC [14];
carbapenems: 40% fT>MIC [14];
linezolid: 40–80% fT>MIC [16,17]
AUC)
MIC
/MIC)
Fluoroquinolones: Cmax/MIC 10,
AUC0–24/MIC 125
a (Gram negatives)
[18,19]; Glycopeptides: AUC0–24/MIC
400b (Staphylococcus aureus) [20];
colistin: AUC0–24/MIC 53–141
(Pseudomonas aeruginosa) [21]
concentration above the minimum inhibitory concentration of the pathogen;
c.
ins www.co-criticalcare.com 461
Co
Infectious diseaseswith optimal activity can be achieved. The inter-
relationship between pathophysiological changes in
critically ill patients and how these affect antibiotic
pharmacokinetic parameters has been reviewed else-
where [3]. Two main pharmacokinetic parameters
that are commonly affected due to these changes are
the volume of distribution (Vd) and clearance. An
increase in the Vd typically affects hydrophilic anti-
biotics and may warrant an increase in the initial
dosing requirements (i.e. loading doses or front-
loaded doses) to produce target drug concen-
trations. In contrast, clearance will affect the day-
to-day dosing requirements for patients with those
patients developing very high clearance requiring
more frequent dosing than those that develop low
clearance from organ dysfunction. Alterations in
protein binding can affect both Vd and clearance.
In critical illness, albumin is redistributed dispro-
portionately from intravascular to extravascular
compartments, resulting in lowplasma albumin con-
centrations [22]. This causes decreases in drug–albu-
min binding resulting in an increased proportion of
unbound drug which will distribute extravascularly
or be eliminated from the body causing low plasma
drug concentrations toward the end of a dosing
interval. Predicting such pharmacokinetic changes
is essential for developing appropriate antibiotic
dosages and may be undertaken with knowledge ofpyright © Lippincott Williams & Wilkins. Unautho
Examples:
• Aminoglycoside
• β-lactams
• Carbapenems
• Linezolid
• Glycopeptides
• Colistin
• Daptomycin
Hydrophilic antibiotics
PK
changes
critically
•  ↑Vd,
• ↑ or ↓ in CL (dependent on
   renal function),
• ↓ in interstitial penetration  
• Low Vd
• Predominant renal CL
• Low intracellular penetration
General PK parameters
FIGURE 1. The association between antibiotic physicochemic
alterations during critical illness.
462 www.co-criticalcare.comthe physicochemical characteristics of the antibiotic
as described in Fig. 1.
Significant pharmacokinetic changes are com-
mon to many critically ill patients, although there
have been increasing data published for special
critical care populations which have extreme phar-
macokinetic changes, burns patients and patients
receiving ECMO, CRRT and SLED. Below, we
describe the latest data describing the altered phar-
macokinetics in these patient groups and we inter-
pret the clinical relevance to antibiotic dosing.
BURNS PATIENTS
Critically ill burns patients develop complex hemo-
dynamic changes such as hypovolemia, hypoalbu-
minemia and low (or high) [23] glomerular filtration
rates during the early phase postburn injury [24]. In
later phase postburn injury (>48–72h), the patients
can exhibit hyperdynamic states that can cause
increased cardiac output, increases in renal and
nonrenal clearance, significant decreases in plasma
albumin concentrations and liver dysfunction [24].
Protein binding may be affected in these patients
partly contributing to increases in Vd and clearance.
The efficacy of highly protein-bound antibiotics
(ertapenem, daptomycin, ceftriaxone, the ‘oxacil-
lins’) in light of hypoalbuminemia is particularly
important as small changes in protein binding resultrized reproduction of this article is prohibited.
• High Vd
• Predominant hepatic CL
• Good intracellular penetration
Lipophilic antibiotics
Examples:
• Fluoroquinolones
• Macrolides
• Lincosamides
• Tigecycline
• Clindamycin
 in
 ill
• ↔ Vd
• ↑ or ↓ in CL (dependent on
   hepatic function)
• ↔interstitial penetration 
General PK parameters
al characteristics and possible pharmacokinetic parameter
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Antibiotic dosing challenges in ICU Jamal et al.in a disproportionately greater amount of unbound
drug available for activity; however, the consequen-
tial increase in clearance decreases the time that
the unbound concentration of antibiotic remains
above theminimum inhibitory concentration of the
pathogen (MIC, fT>MIC) leading to potential thera-
peutic failure if dosing is not adjusted in line with
the altered pharmacokinetics. The recent studies
published on antibiotic PK/PD in burns patients
are summarized in Table 2 [25–32].
Aminoglycosides
Recent studies have confirmed that amikacin phar-
macokinetic parameters are significantly different in
burns patients compared with nonburns patients
[25,26]. Amikacin penetrates into eschar tissue
during early burn injury [25]; however, concen-
trations in one study did not reach the desired
maximum concentration in a dosing interval (Cmax)
to MIC (Cmax/MIC) ratio of 8–10. However, a very
low amikacin dose (400mg; <10mg/kg) was used in
this study, suggesting that higher doses of 20–
30mg/kg may enable achievement of PK/PD targets
in eschar tissue. In order to achieve PK/PD targets,
that is, high Cmax, a dose that is significantly
higher than usual is required in burns patients
particularly when the isolated pathogens have high
MICs (e.g. gentamicin and tobramycin 7mg/kg or
amikacin 30mg/kg). In renally impaired patients,
less frequent aminoglycoside dosing is suggested
(24–48-h dosing). Where clearance is excessively
high, as seen in some patients such as in those with
augmented renal clearance, more frequent dosing
may be appropriate (e.g. 18h).
b-Lactams
Changes in b-lactam pharmacokinetic parameters
in burns patients have been well described in recent
studies [27,28,33]. The magnitude of burn injury as
well as early treatment in burn patients could
alter the pharmacokinetic parameters [27]. Usual
b-lactam doses are unlikely to achieve target plasma
concentrations above the MIC [14] of causative
pathogens [28,33,34]. Increasing the dose, infusion
time or frequency of administration would be
required in this population to optimize drug
therapy, that is, to increase the fT>MIC [33]. Thera-
peutic drug monitoring (TDM) may also be useful
for these patients [35
&&
].
Glycopeptide
Recent studies have described increases in clearance
and Vd of vancomycin in burns patients [29,30].
Vancomycin appears to extensively penetrate burnt
tissue during the early phase of burn injuries with
concentrations sustained in tissue for longer periodsCopyright © Lippincott Williams & Wilkins. Unaut
1070-5295  2012 Wolters Kluwer Health | Lippincott Williams & Wilkthan that observed in plasma [25]. Standard doses of
1 g intravenous every 12h rarely achieve PK/PD
targets [20] in these patients [29,30]. A larger loading
dose subsequently followed by a large total main-
tenance dose such as that previously shown necess-
ary for critically ill patients with conserved organ
function is required [36]. Routine TDM is recom-
mended to maintain adequate concentrations in
light of potential supranormal clearance or alterna-
tively acute kidney injury both known to occur in
burns patients.Other drugs
Standard linezolid doses were found to be
inadequate to achieve PK/PD targets [16,17] in burn
patients [31]. Similarly, a higher than standard dose
of colistin [32] is required to optimize PK/PD targets
[21] in burns patients, although the clinical con-
sequences of this altered approach are yet to be
clarified.CONTINUOUS RENAL REPLACEMENT
THERAPY
Commencement of RRT in critically ill patients is
common [3]. There are different types of RRT used in
critically ill patients, including continuous, inter-
mittent and hybridmodalities (e.g. SLED). CRRT can
be performed in different modes, continuous
venovenous hemofiltration (CVVH), continuous
venovenous hemodialysis (CVVHD) and continu-
ous venovenous hemodiafiltration (CVVHDF). Pres-
ently, there are no clinical data supporting one
mode over another, meaning that hospitals use
different modes and settings according to local
needs causing the extreme variability of RRT prac-
tices worldwide. Advancing technology has meant
that these techniques are very efficient at removing
not only metabolic waste products such as creati-
nine and urea, but also hydrophilic antibiotics,
especially those with low plasma protein binding
[37]. However, the amount of antibiotic eliminated
will depend on the mode of RRT, dose of RRT
delivered, blood flow rate, filter material and
surface area, each of which should be considered
when dosing during RRT [38]. The following are the
recent antibiotic pharmacokinetic studies in
critically ill patients receiving CRRT with their
pharmacokinetic parameters summarized in
Table 3 [26,39,40
&&
,41
&&
,42–51,52
&
,53].Aminoglycosides
The pharmacokinetics of aminoglycosides in CRRT
have been well described recently [26,39]. Thesehorized reproduction of this article is prohibited.
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Antibiotic dosing challenges in ICU Jamal et al.studies suggest that standard approaches to dosing
do not achieve PK/PD targets due to an increased
clearance and Vd. Given that high Cmax/MIC ratios
of 8–10 are associated with better clinical outcome
[13], higher doses to account for the higher Vd and
less frequent dosing to account for the decreased
clearance in this patient population may provide
better aminoglycoside exposures [13]. Subsequent
dose adjustment using TDM remains appropriate.
b-Lactam
Seyler et al. [40
&&
] recently suggested that b-lactam
doses of piperacillin–tazobactam, cefepime and cef-
tazidime administered during CRRT inadequately
achieved PK/PD targets for Pseudomonas aeruginosa
during early phase (first 24–48h) of severe sepsis or
septic shock. The conclusions of this study support
the use of higher doses or extended infusions of
b-lactams to maintain adequate serum concen-
trations during the dosing interval [37]. Further
studies have described how different CRRT modes
result in variable b-lactam clearance [42–44] and
that variable antibiotic doses are required to achieve
PK/PD targets during different forms of CRRT [41
&&
],
thus demonstrating that dose standardization for
b-lactams in CRRT is not possible with current data.
Glycopeptides
In recent studies, CRRT has been reported respon-
sible for up to 50% of total glycopeptide clearance
[45,46]. Similar to other hydrophilic antibiotics,
dose standardization across different CRRT modes
and settings for glycopeptides is difficult. Standard
dosing regimens do not achieve PK/PD targets
[41
&&
,45,46]. Administration of a loading dose (e.g.
20mg/kg) would enable faster attainment of target
vancomycin exposures with subsequent dosing
based on local vancomycin pharmacokinetic data
or TDM. The high protein binding of teicoplanin
makes dosing in CRRT challenging, particularly in
patients with hypoalbuminemia [54], in which
higher clearance of the unbound fraction can be
expected. In these patients, supplemental dosing or
higher doses should be considered given the good
safety profile.
Fluoroquinolones
Recent pharmacokinetic studies have reported that
varied doses are required for different CRRT settings
[41
&&
,47–49]. Ciprofloxacin dose requirements
remain moderate in the presence of renal dysfunc-
tion and/or CRRT because of hepatic metabolism
(contributes approximately one-third of ciproflox-
acin elimination [55]). It follows that hepatic dys-
function will be associated with decreased
ciprofloxacin elimination and, thus, in patientsCopyright © Lippincott Williams & Wilkins. Unaut
1070-5295  2012 Wolters Kluwer Health | Lippincott Williams & Wilkwith concurrent renal and hepatic dysfunction,
significantly decreased ciprofloxacin dosing and
perhaps TDM should be considered to optimize
antibiotic exposure [56] and achieve PK/PD targets
[18,19].
Other drugs
Recent studies have recommended varied dosing
regimens for daptomycin in CRRT [50,51,52
&
]. Even
though similar CRRT characteristics are reported
[50,51], none of these are superior from the other
because of differences in study design, and most
importantly the intervariability of critically ill
patients. The hydrophilicity, high protein binding
and predominant renal excretion can lead to differ-
ent rates of daptomycin clearance through extrac-
orporeal circuits. The association between Cmax/
MIC and the ratio between the area under the
concentration–time curve from 0–24h (AUC0–24)
to MIC (AUC0–24/MIC) for optimal bactericidal
effect for daptomycin [15] suggest that initial high
dosing (6–8mg/kg IV daily) is required to achieve
the targeted Cmax. Maintenance dosing based on
likely CRRT clearance should then be used. A higher
than usual dose is also recommended for other
drugs, such as fluconazole, during CRRT [53].SUSTAINED LOW-EFFICIENCY DIALYSIS
Although SLEDwas first successfully utilized in 1945
by Willem J. Kolff [57], there are surprisingly few
antibiotic pharmacokinetic data [58,59]. Available
studies have shown that the removal of antibiotics
occurs more efficiently during SLED in comparison
to standard CRRT and intermittent hemodialysis
modalities [7
&
,60–71]. SLED is called a ‘hybrid
modality’ because each treatment typically only
lasts 8–12h. Recently, Bogard et al. [7
&
] reviewed
the studies describing antibiotic pharmacokinetics
in SLED. The authors found higher antibiotic clear-
ance during SLED for hydrophilic drugs without
high protein binding (<90%) or weak protein bind-
ing (as with daptomycin), those of small molecular
size and those with significant renal clearance in the
presence of normal renal function [7
&
]. Like CRRT,
antibiotic pharmacokinetics in SLED should be
interpreted with knowledge of blood and dialysate
flow rates, treatment duration and filter surface area
[7
&
]. The frequency and duration of SLED adminis-
tration must also be borne in mind when consider-
ing dosing adjustments. As SLED has been shown to
more effectively remove time-dependent antibiotics
such as the b-lactams, it may be necessary to provide
supplemental doses of antibiotics during or follow-
ing SLED treatments or prolong infusion times to
maintain the desired fT>MIC. In a recent study ofhorized reproduction of this article is prohibited.
ins www.co-criticalcare.com 467
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suggested that because of the altered pharmacoki-
netics resulting from sepsis and the effects of SLED,
TDM should be considered useful for dose optimiz-
ation [68]. More recently, Lorenzen et al. [62] inves-
tigated the pharmacokinetics of ampicillin/
sulbactam in critically ill patients on SLED in which
they found patients would be significantly under-
dosed if dosing for regular haemodialysis were to be
implemented. The authors found more than 75%
removal of both ampicillin and sulbactam during an
8-h SLED session, and recommended 3g IV 12-h
dosing of ampicillin/sulbactam for patients on com-
parable SLED specifications [62]. Burkhardt et al. [71]
reported that SLED does not affect the pharmacoki-
netics of voriconazole; however, accumulation of
the toxic solubilizing agent was observed. Therefore,
the use of voriconazole in this setting cannot be
supported at this time. Variability in SLED
parameters as noted by Bogard et al. [7
&
] and residual
renal function make recommendations regarding
antibiotic prescribing during SLED problematic.
Table 4 [60–71] displays the pharmacokinetic data
described for various antibiotics in patients
undergoing SLED.EXTRACORPOREAL MEMBRANE
OXYGENATION
ECMO is a highly invasive intervention that
assists critically ill patients with severe lung
and/or heart dysfunction. Generally, ECMO may
cause increases in Vd for certain drugs as well
as the possible binding of drugs in the ECMO circuit
[72]. However, the variable characteristics of ECMO
technologies and settings (e.g. composition of
tubing, flow rates and machine specifications)
make comparisons between different pharmacoki-
netic studies challenging. The pharmacokinetics of
antibiotics in ECMO has recently been reviewed in
detail [5]. Adsorption of lipophilic drugs to ECMO
membranes and tubing appears common and likely
to rapidly reduce plasma concentrations [5].
Problematic to this issue is that not all drugs are
affected and the extent of sequestration is not
consistent [73]. The final challenge in providing
adequate antibiotic doses for critically ill patients
receiving ECMO is the presence of RRT which also
needs to be considered as a source of potentially
significant drug clearance in the presence of renal
dysfunction. From the available data, we agree with
the findings of a systematic review from Mousavi
et al. [74] and suggest that individualizing drug
regimens in patients receiving ECMO using TDM
is necessary until further data become available to
guide dosing.horized reproduction of this article is prohibited.
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In conclusion, antibiotic dosing in critically ill
patients is challenging especially in the era of emerg-
ing antibiotic resistance. The best approach for
optimal dosing of antibiotics in critically ill patients
is through an understanding of the relationship
between the pharmacodynamics and the extent to
which pharmacokinetics are altered by illness. Var-
iability of patient characteristics, disease state man-
agement by individual units and variable pathogen
susceptibility favour individualized dosing regimens
in this population. To this end, the increase in Vd
common to aminoglycosides, b-lactams and glyco-
peptides supports the use of higher doses in the first
24–48h of therapy. In patients such as burns
patients with apparently higher clearance for most
antibiotics, more frequent administration appears
necessary to ensure the equivalent exposure in crit-
ically ill patients to that observed in noncritically
ill patients. In patients receiving extracorporeal
circuits (CRRT, SLED and ECMO), significant phar-
macokinetic variability makes a guideline approach
to dosing not possible with the available data. All of
the above lead us to believe that TDM should be used
wherever available.
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Defining Antibiotic Dosing in Lung Infections
Janattul-Ain Jamal, BPharm(Hons),* Mohd-Hafiz Abdul-Aziz, BPharm(Hons),*
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Abstract: Defining optimal antibiotic dosing for treatment of lung
infections is challenging because of the interrelationship between
patient characteristics (eg, pathophysiological changes of lung during
an infection, albumin level, renal function), antibiotic characteristics
(eg, physicochemical properties, protein binding), and bacterial
pathogen susceptibility. Measurement of antibiotic concentration in the
lung compartments, such as epithelial lining fluid (ELF), is important
to describe the drug exposure at site of infection. This article reviews
published data on antibiotic penetration described by the ELF to
plasma (ELF:plasma) ratios and the probability of pharmacokinetic/
pharmacodynamics (PK/PD) attainment at the target site with current
dosing regimens to outline dosing strategies that could optimize the
PK/PD indices. Antibiotic physicochemical properties could be used to
predict the extent of penetration into the lung tissues. Lipophilic
antibiotics penetrate well into the lung compartments; however,
standard dosing regimens generally seem to be insufficient to achieve
optimal PK/PD indices in the ELF, particularly during severe infec-
tions. Aggressive dosing regimens are required for antibiotics that
poorly or moderately penetrate the lung tissues, whereas nebulization
could be the alternative method to enhance antibiotic concentration at
the target site. Special populations such as the critically ill, patients on
renal replacement therapy, and those with renal impairment need
dosing to be individualized, as these populations have high PK vari-
ability. Dosing based on free drug concentrations should be considered
preferred, as these concentrations frequently reflect the antibiotic
concentration at the target site. Therefore, the use of therapeutic drug
monitoring should be considered necessary, whenever possible, to
guide dosing in lung infection.
Key Words: pharmacodynamics, pharmacokinetics, PK/PD, pulmo-
nary, therapeutic drug monitoring
(Clin Pulm Med 2013;20:121–128)
Lung infection is common in hospitalized patients and isassociated with considerable morbidity and mortality. This
was comprehensively shown in a prevalence study of infection
in the intensive care unit (ICU), where 64% of infections were
respiratory infections in which these patients had higher ICU
and hospital mortality rates.1 Inadequate empirical antibiotic
therapy is associated with reduced survival in patients with
severe lung infection2 and, thus early and appropriate
antibiotic therapy is an essential intervention.3 Optimizing
antibiotic exposure for lung infections is challenging, espe-
cially when considering drug penetration into the lung tissue.
Although infection can occur throughout most of the lung,
alveolar compartments such as epithelial lining fluid (ELF) or
the cells (alveolar macrophage, AM) are considered as the area
where pathogens commonly accumulate during lung infections
and thus antibiotic penetration into such compartments is of
high importance.4 Sufficient antibiotic concentrations in the
ELF or AM are likely to enable optimal antibiotic activity at
the site of infection in the lung. However, changes in the lung
pathology in infected patients may reduce the likelihood of
achieving target concentrations at the site of infection.
The decreasing susceptibility of respiratory pathogens
further complicates this situation. On the basis of the European
Committee on Antimicrobial Testing (EUCAST),5 the mini-
mum inhibitory concentration (MIC) breakpoint for the clas-
sical respiratory pathogen, Streptococcus pneumoniae reached
2mg/L for the commonly used antibiotic, levofloxacin.
Although in cases of nosocomial infection, MIC breakpoints
for gram-negative pathogens, for example, Pseudomonas
aeruginosa (16mg/L for piperacillin/tazobactam), can be high
and difficult to achieve in some patients.
The objective of this paper is to review and interpret the
data describing antibiotic pharmacokinetics/pharmacody-
namics (PK/PD) in critically ill patients with lung infections
and to discuss target site penetration and the potential need for
altered dosing strategies to increase the likelihood of suc-
cessful treatment.
SEARCH STRATEGY AND SELECTION CRITERIA
A PubMed search using relevant keywords was undertaken
to identify relevant recently published the English language arti-
cles. Journal articles referenced in the primary article identified,
if appropriate, were also cited. Search terms included:
“carbapenem,” “cephalosporin,” “penicillin,” “fluoroquinolone,”
“aminoglycoside,” “oxazolidinone,” “macrolide,” “ketolide,”
“colistin,” “lung infection,” “respiratory infection,” “pneumonia,”
“epithelial lining fluid,” “alveolar concentration,” “intrapulmonary
concentration,” “pharmacokinetic,” and “pharmacodynamic.” To
emphasize the antibiotic PK/PD data in the lung tissue, only
articles with data on antibiotic concentrations in blood and ELF
were included.
PK/PD INDICES RELATED TO ANTIBIOTIC
EFFICACY AND RESISTANCE
Achieving PK/PD indices associated with maximal bac-
terial killing will increase the likelihood of treatment efficacy.
PK/PD relates PK parameters to PD, which describe antibiotic
activity at different concentrations.6 Different PK/PD indices
have been defined for different classes of antibiotics (Table 1).
These relationships have been defined through in vitro and
in vivo studies in animals and humans.7–9 For optimal bac-
tericidal activity in the lung, high penetration into the ELF,
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which is defined by the ELF concentrations relative to plasma,
is likely to be advantageous.
PATHOPHYSIOLOGY CHANGES IN LUNG
INFECTIONS AND FACTORS INFLUENCING
ANTIBIOTIC PENETRATION INTO ELF
Many factors could contribute to the pathogenesis of lung
infections such as nasal colonization, oropharyngeal or gastric
colonization, aspiration or colonization of the artificial airway.
The invasion of pathogens into the lung parenchyma stimulates
immune mechanisms of defense. As the process progresses,
pathogens can reach the alveoli with host defenses quickly
overwhelmed by the virulence of the microorganism and/or the
inoculum size. The ELF is the fluid that fills the alveolar space.
To reach the ELF, the antibiotic must be able to diffuse across
the blood-alveolar barrier, in which it depends on its phys-
icochemical characteristics (eg, lipophilicity, molecular
weight, protein binding) and patient-specific characteristics
(eg, tissue permeability, renal function).
Physicochemical Properties
Excellent penetration into the alveolar compartments is
more common with lipophilic antibiotics (eg, fluo-
roquinolones, macrolides, oxazolidinones).10 The ELF to
plasma ratio (ratio of the area under the concentration time
curve (AUC) of antibiotic for 1 dosing interval in ELF:plasma)
of fluoroquinolones is reported to be >100% when adminis-
tered by either the oral or intravenous (IV) route.11–13
Numerous studies have reported the extensive penetration of
fluoroquinolones into the lung tissue (eg, AM)13,14 with con-
centrations that were higher than those in plasma and ELF.
Similarly with tigecycline and oxazolidinones, the ELF to
plasma penetration is also high.15,16 Inversely for hydrophilic
antibiotics (eg, aminoglycosides, glycopeptides), poorer pen-
etration into the lung compartments has been reported in many
studies. The aminoglycosides’ ELF:plasma penetration ratio
has been reported between 12% and 32% in critically ill
patients with severe lung infection.17,18 The ELF:plasma
penetration ratio for vancomycin is reported to be approx-
imately B15% in a similar population.19 These data support
the importance of drug physicochemistry as 1 important
determinant of drug penetration.
Protein Binding
The importance of the free, or unbound, drug exposure at
the site of lung infection (ELF) has been advocated by many
studies.12,20–22 Measurement of unbound concentrations in the
ELF is likely to best describe antibiotic activity, particularly
for highly protein bound antibiotics. In a prospective PK study
of 13 critically ill patients with ventilator-associated pneu-
monia (VAP) treated with teicoplanin (> 85% protein binding),
the median unbound teicoplanin concentrations in blood and
ELF were similar,21 which suggested that the unbound fraction
of drug penetrated well into the lung tissue. Dose adjustment
should be made in patients with low albumin concentrations,
such as critically ill patients, and the unbound fraction in blood
could guide dosing.
Tissue Permeability
Another important factor that might influence the pene-
tration of antibiotic into the alveolar compartments is tissue
permeability, although predicting permeability may be diffi-
cult. Lamer et al19 reported that in critically ill patients treated
with IV vancomycin, that significantly higher vancomycin
penetration was seen in patients with higher albumin concen-
trations in the ELF, 25% versus 14% (P < 0.02). In this context,
albumin movement from plasma into ELF was seen as an
indicator of lung inflammation and that inflammation was
associated with higher antibiotic concentrations in ELF.
RECENT PK STUDIES OF VARIOUS ANTIBIOTICS:
ELF PENETRATION WITH PK/PD TARGET
ATTAINMENT
Recent PK studies have showed variable antibiotic pen-
etration into the lung tissue based on ELF:plasma ratios. Of
interest is the question whether current antibiotic dosing reg-
imens optimize PK/PD target attainment at the site of lung
infection. Studies comparing the ELF concentrations and
plasma concentrations have generally shown that lipophilic
antibiotics have superior penetration into the lung
tissue. Table 2 summarizes the recently published PK studies
and data on ELF:plasma ratios and the probability of PK/PD
target attainment in the ELF for different current dosing reg-
imens of different antibiotic classes.
b-lactam
b-lactam penetration into the lung tissue is variable.
Penicillins penetrate the lung tissue approximately 40% to
50%,23,24 cephalosporins range from 30% to 100%,26,37,38 and
carbapenems about 30% to 40%.27,28,39 Standard doses that
achieve PK/PD targets in blood are unlikely to achieve the
same targets in the presence of severe nosocomial
TABLE 1. The PK/PD Indices of Different Class of Antibiotics
Antibiotic-Killing
Characteristics Definition of PK/PD Indices PK/PD Indices
Concentration
dependent
Ratio of the peak antibiotic concentration (Cmax)
to the MIC of the pathogen (Cmax/MIC)
Cmax/MIC= 8-10
(aminoglycoside)
Time dependent Percentage of time during dosing interval for
which the free concentration remain above the
MIC of the pathogen (%f T>MIC)
40%-70% f T>MIC
(b-lactams)
40%-80% f T>MIC (linezolid)
Concentration
dependent with
time dependent
Ratio of the area under the concentration-time
curve during a 24 h period (AUC0-24) to the
MIC of the pathogen (AUC0-24/MIC)
AUC0-24/MIC> 125
(fluoroquinolone)
AUC0-24/MICZ400
(vancomycin)
AUC0-24/MIC> 50 (colistin)
%f T>MIC indicates percentage of time in which the free drug concentration is above the MIC of the pathogen; AUC0-24,
area under the concentration-time curve during a 24-hour period; Cmax, maximum concentration; MIC, minimum inhibitory
concentration; PK/PD, pharmacokinetic/pharmacodynamics.
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TABLE 2. Plasma and ELF Concentrations of Different Class of Antibiotics (Oral and IV)
Antibiotics
Dosage
Regimen
Population [No.
Patients (n)]
Sampling
Time (h)w
Plasma
Concentration
(mg/L)z
ELF
Concentration
(mg/L)z
ELF:Plasma
Ratioz
Probability PD
Target
Attainment in
ELF*
b-lactams
Piperacillin
(Boselli
et al23)
4.5 g 8 h Critically ill patients,
severe bacterial
pneumonia (n = 10)
Steady
state
24.0 ± 13.8 13.6 ± 9.40 0.578 Low
Piperacillin
(Boselli
et al24)
4.5 g (LD),
13.5 g/d (CI)
Critically ill patients
with VAP (n = 20)
Steady
state
25.3 (23.1-
32.6)y#
102.4 (97.4-
112.6)y**
12.7 (6.7-18.0)y#
44.1 (33.4-48.3)y**
0.46 Medium
(MIC< 8mg/L)
Piperacillin
(Boselli
et al24)
4.5 g (LD),
18 g/d (CI)
Critically ill patients
with VAP (n = 20)
Steady
state
38.9 (32.9-
59.6)y#
135.3 (119.5-
146.2)y**
19.1 (14.0-
21.5)y#
54.9 (45.2-
110.3)y**
0.43 Medium
(MIC< 16mg/L)
Ceftazidime
(Boselli
et al25)
2 g (LD),
4 g/d (CI)
Critically ill patients
(n = 15)
Steady
state
39.6 ± 15.2 8.2 ± 4.8 0.218 Low
(MIC> 2mg/L)
Cefepime
(Boselli
et al26)
2 g (LD),
4 g/d (CI)
Critically ill patients
with severe
nosocomial
pneumonia (n = 20)
Steady
state
13.5 ± 3.3 13.7 ± 3.0 1.048 Low
(MIC> 4mg/L)
Meropenem
(Conte
et al27)
0.5 g 8 h4 doses Healthy volunteers
(n = 20)
1
2
3
5
8
10.9 ± 1.3
5.2 ± 1.6
2.4 ± 0.9
0.3 ± 0.4
0.0 ± 0.0
5.3 ± 2.5
2.7 ± 1.8
1.9 ± 0.9
0.7 ± 0.4
0.2 ± 0.1
0.49-0.80 Low
Meropenem
(Conte
et al27)
1 g 8 h4 doses Healthy volunteers
(n = 20)
1
2
3
5
8
19.0 ± 7.6
7.5 ± 1.3
5.3 ± 1.5
2.0 ± 1.3
0.0 ± 0.0
7.7 ± 3.1
4.0 ± 1.1
1.7 ± 1.4
0.8 ± 0.4
0.0 ± 0.0
0.32-0.53 Low
Meropenem
(Conte
et al27)
2 g 8 h4 doses Healthy volunteers
(n = 8)
1
3
60.9 ± 8.0
12.8 ± 2.7
2.9 ± 1.0
2.8 ± 1.5
0.18
0.28
Low
Ertapenem
(Boselli
et al28)
1 g 24 h Critically ill patients
with early-onset VAP
(n = 15)
1
12
24
30.3 (27.1-37.8)y
4.8 (3.9-6.4)y
0.8 (0.5-1.2)y
9.4 (8.0-10.7)y
2.0 (1.1-2.5)y
0.3 (0.2-0.4)y
0.32 (0.28-
0.46)y
Medium
(MICr4mg/L)
Macrolides
Azithromycin
(Capitano
et al13)
500mg first dose
then 250mg
daily4 doses
(oral)
Patients undergoing
diagnostic
bronchoscopy (n = 16)
4
8
12
24
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.9
0.0 ± 0.0
0.6 ± 0.4
0.7 ± 0.4
0.9 ± 0.5
0.9 ± 0.7
6.4
13.2
12.6
31.3
Medium
(MIC< 1mg/L)
Azithromycin
(Rodvold
et al29)
500mg daily5
doses (IV)
Healthy volunteers
(n = 12)
4
12
24
0.4 ± 0.1
0.3 ± 0.0
0.1 ± 0.0
1.7 ± 0.7
1.3 ± 0.5
2.9 ± 1.8
4.6
5.1
20.4
High
Fluoroquinolones
Levofloxacin
(Nicolau
et al14)
750mg daily5 d
(oral)
Acute exacerbation of
chronic bronchitis
(n = 18)
4
12
24
8.0 ± 2.5
5.8 ± 1.2
2.2 ± 1.2
7.5 ± 3.1
8.4 ± 6.0
1.2 ± 0.9
0.98
0.58
Medium
(MICr1mg/L)
Levofloxacin
(Zhang
et al30)
500mg single
dose (oral)
Patients with lower
respiratory tract
infections (n = 40)
1.2 ± 0.1
4.1 ± 0.2
8.1 ± 0.1
12.1 ± 0.1
24.2 ± 0.1
3.3 ± 3.0
4.1 ± 1.9
2.1 ± 1.1
1.9 ± 0.6
0.9 ± 0.6
3.4 ± 3.7
2.4 ± 2.0
1.6 ± 1.5
1.0 ± 0.9
0.9 ± 0.7
0.8 ± 0.4
0.6 ± 0.5
0.7 ± 0.3
0.5 ± 0.6
1.0 ± 0.9
Low
Levofloxacin
(Boselli
et al31)
500mg daily2 d
(IV)
Critically ill patients,
severe CAP (n = 12)
1
24
12.6 (12.0-14.1)y
3.0 (2.1-3.3)y
11.9 (8.7-13.7)y
3.9 (2.1-5.7)y
1.3 ± 3.1
1.2 ± 3.6
Medium
(MICr1mg/L)
Levofloxacin
(Boselli
et al31)
500mg 12 h2 d
(IV)
Critically ill patients,
severe CAP (n = 12)
1
12
19.7 (19.0-22.0)y
7.7 (7.4-11.9)y
17.8 (16.2-23.5)y
11.8 (10.3-16.7)y
1.3 ± 4.6
1.1 ± 4.0
High
(MIC> 1mg/L)
Glycopeptides
Vancomycin
(Lamer
et al19)
15mg/kg (at least
5 d) (IV)
Critically ill,
ventilated (n = 14)
24 24.0 ± 10.0 4.5 ± 2.3 0.28 Low
Vancomycin
(Georges
et al32)
30mg/kg daily
(IV)
Critically ill,
ventilated, MRSA
pneumonia (n = 10)
24 16.3 ± 5.8 0.8 ± 1.18 0.08 Low
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infection.23–26 It follows that more aggressive dosing regimens
may be required, especially in severe infections with more
resistant pathogens. Continuous infusion (CI) could also be
used as alternative administration for b-lactams in lung
infections.24–26,40,41 In patients with moderate to severe renal
failure, a reduction in drug clearance may help in the ach-
ievement of PK/PD targets with usual dosing regimens.24
Macrolides
The macrolides penetrate well into the lung tissue
(> 100% ELF:plasma ratio).13,29,42 Previous studies have
consistently reported significantly higher concentrations in
ELF and AM than in plasma throughout the therapy course,
with concentrations in AM always far higher than ELF. Rapid
distribution of macrolides into the lung compartments had
resulted in lower plasma concentrations throughout dosing
interval,13,29,42 thus leading to theoretical concerns of its use in
primary bacteremia. In healthy adults administered standard
doses of azithromycin, at the end of 24-hour dosing interval,
100% ELF concentrations (n = 4) were above the susceptibility
breakpoint of 1mg/L.29 Although standard doses achieve
desired concentrations in the lung tissue of healthy volun-
teers,29,42 there are limited data available to evaluate the ade-
quacy of these dosing regimens in infected patients.
Fluoroquinolones
Fluoroquinolones such as levofloxacin generally show
excellent penetration into intrapulmonary sites.14,30,31 Some
studies have shown parallel relationships between plasma and
ELF concentrations of levofloxacin after oral and IV
administration.30,31 Figure 1 is a PK model describing this
relationship and suggests that at steady state, plasma PK could
be used to guide dosing when the lung is the source of infec-
tion. Peak concentrations will be achieved in the ELF
TABLE 2. (continued)
Antibiotics
Dosage
Regimen
Population [No.
Patients (n)]
Sampling
Time (h)w
Plasma
Concentration
(mg/L)z
ELF
Concentration
(mg/L)z
ELF:Plasma
Ratioz
Probability PD
Target
Attainment in
ELF*
Vancomycin
(Lodise
et al33)
1000mg 12 h9
doses (IV)
Healthy subjects
(n = 10)
4 and 12 NA NA 0.7 ± 0.7z Low
(MIC> 1mg/L)
Teicoplanin
(Mimoz
et al21)
12mg/kg
12 h2 d, then
12mg/kg daily
Critically ill patient
with VAP (n = 13)
18-24 3.7 (2.0-5.4)y 4.9 (2.0-11.8)y 1.3 (0.5-3.3)y Low
Aminoglycosides
Tobramycin
(Boselli
et al17)
7-10mg/kg
daily2 doses
Critically ill patients
with VAP (n = 12)
0.5 22.4 ± 5.9 2.7 ± 0.7 0.1 ± 0.0 Low
Gentamicin
(Panidis
et al18)
240mg daily1
dose
Critically ill patients
with VAP (n = 24)
0.5
1
2
4
6
13.4 ± 0.9
8.8 ± 0.6
6.4 ± 0.5
4.7 ± 0.5
3.8 ± 0.6
NA
3.0 ± 0.4
4.2 ± 0.4
3.1 ± 0.4
2.7 ± 0.4
NA
0.3 ± 0.1
0.9 ± 0.1
1.1 ± 0.3
0.7 ± 0.2
Low
Oxazolidinones
Linezolid
(Boselli
et al16)
600mg 12 h2 d
(IV)
Critically ill patients
with VAP (n = 16)
1
12
17.7 ± 4.0
2.4 ± 1.2
14.4 ± 5.6
2.6 ± 1.7
1.1 ± 0.3
1.0 ± 0.3
Medium
(MIC< 4mg/L)
Linezolid
(Boselli
et al34)
600mg (LD),
then 1200mg/d
(CI)2 d
Critically ill patients
with VAP (n = 12)
48 7.1 (6.1-9.8)y 6.9 (5.8-8.6)y 1.0 (0.8-1.1)y Medium
(MIC< 4mg/L)
Others
Colistin
(Imberti
et al35)
2mU 8h (at least
2 d)
Critically ill patients
with VAP (n = 13)
1
8
2.2 ± 1.1
1.0 ± 0.7
0.0 0.0 Low
Colistin
(Markou
et al36)
225mg 8 h
(4-12 d)
Critically ill patients
(n = 2)
1.5-4.0 3.3 ± 0.48 15.3 ± 14.88 4.6 ± 4.08 NA
*Susceptibility breakpoint based on EUCAST 5 and targeted PD indices 7–9 of at least 50% fT>4xMIC for b-lactam, AUC0-24/MIC> 25 for macrolide, AUC0-24/
MIC > 125 for levofloxacin, AUC0-24/MICZ400 for glycopeptide, Cmax/MICZ10 for aminoglycoside, AUC0-24/MIC > 50 for linezolid, and AUC0-24/MICZ50 for
colistin, unless otherwise stated.
wSampling time after the last dose.
zValue expressed as mean ± SD unless specified otherwise.
yValue expressed as median (range).
8Calculated value based on reported data.
zValue based on AUC0-24 (mg h/L).
#Patients with no to mild renal impairment.
**Patients with moderate to advanced renal impairment.
CI indicates continuous infusion; ELF, epithelial lining fluid; H, hourly; IV, intravenous; LD, loading dose; MRSA, methicillin-resistant Staphylococcus aureus;
NA, data not available; VAP, ventilator-associated pneumonia.
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approximately an hour after administration.30,31 Standard
doses of levofloxacin rarely achieved the desired PK/PD tar-
gets in infected younger patients and those without renal
impairment.12 In critically ill patients, the administration of a
higher doses (eg, 1000mg/d) achieve the targeted PK/PD
index, AUC0-24/MIC> 125 for levofloxacin in ELF.
31 Ach-
ieving these PK/PD targets is important with 1 study finding
that when the PK/PD targets were achieved, >85% had
microbiological and clinical cure. Importantly, dose adjust-
ment should be considered necessary in renal dysfunction or in
the elderly, as these patients will have a reduced clearance of
levofloxacin.12,13 With the excellent penetration into the lung
tissue, use of fluoroquinolones in lung infections is usually
reliable as long as pathogen susceptibility remains acceptable.
Higher dosing regimens will be of course necessary when
aiming for a more aggressive PK/PD targets.
Glycopeptides
Vancomycin was shown to penetrate well (B70%) in
noninfected lung tissue33 as compared with critically ill
patients with pneumonia (< 20%).19,32 However, in healthy
volunteers, standard dosing (1 g IV 12 h) rarely achieved the
desired PK/PD target, AUC0-24/MIC ratio of Z400 in the ELF
(assuming an MIC 1mg/L).33 Thus with the poor lung pene-
tration in infected patients, standard dosing would rarely ach-
ieve sufficient drug exposures in the ELF. Maintaining a
constant plasma concentration (eg, 20mg/L) to enhance drug
concentrations in the lung compartment,19,32 supports the use
of therapeutic drug monitoring (TDM) to guide dosing with
vancomycin.43 The use of vancomycin to treat less susceptible
pathogens in lung infection could be considered unreliable due
to this low penetration and the need for higher doses to achieve
the PK/PD target in the lung compartments, although clinical
studies do not strongly reflect this at this time.44
Aminoglycosides
Similar to other hydrophilic antibiotics, aminoglycosides
(eg, tobramycin, gentamicin, amikacin) are not considered to
penetrate well into the pulmonary compartments. In critically
ill patients with VAP,17,18 standard dosing regimens failed to
achieve the target PK/PD index, Cmax/MIC> 10. As amino-
glycosides poorly penetrate the lung tissue, higher doses may
be required to treat severe lung infections. However, aiming
for aggressive dosing with aminoglycosides may be imprac-
tical due to the potential toxicity associated with high doses.
Oxazolidinones
Linezolid had shown excellent penetration (> 100%) into
the pulmonary compartments in critically ill patients with
VAP.16,34 The administration of standard doses (eg, 1200mg/
d) commonly achieved PK/PD targets for pathogens with a
susceptibility breakpoint of <4mg/L in the ELF.16 Fur-
thermore, CI has been shown to be advantageous for achieving
even higher PK/PD target attainment.34 The measurement of
unbound concentrations in the ELF for oxazolidinones may be
necessary to guide for optimal dosing.
Others
Limited data are available to provide robust dosing for
colistin during lung infections. Variable reports of colistin
penetration into the lung tissue have been published. Imberti
et al35 reported an undetectable colistin concentration in BAL
at steady state, after at least 2 days therapy of a lower dose
(174mg IV 8 h). However, in another study, the administration
of a 30% higher dose of colistin (225mg IV 8 h) in 2
mechanically ventilated trauma patients showed better ELF
penetration, with a high ELF:plasma ratio of 5.36 Despite the
conflicting results, both of these reports agree that a higher
dosing regimen is required to treat severe lung infections,
particularly in critically ill patients.35,36 The variation of pen-
etration above is likely to be related to the nature of the lung
injury, rather than other drug-related factors. It follows that
consideration of inhaled colistin is warranted in these clinical
scenarios.
ALTERNATIVE DOSING STRATEGIES:
NEBULIZATION
Nebulization has been used for many years to deliver
drugs into the lung compartments. In recent years, this method
has also been extended for antibiotic treatment of lung infec-
tions. Nebulization aims to enhance the amount of antibiotic at
the site of lung infection by delivering the drug at an ana-
tomically closer location, which can also lead to reduced
systemic exposure of drug. This mode of administration has
been applied for hydrophilic antibiotics that have traditionally
been considered to poorly penetrate the lung tissue. PK studies
reporting antibiotic concentrations in the lung compartments
using nebulization are becoming increasingly reported.45,46
Athanassa et al45 evaluated 20 critically ill patients with ven-
tilator-associated tracheobronchitis treated with nebulized
colistin. After the first nebulization, the median ELF concen-
trations were 6.7 and 2.0mg/L at 1 and 8 hours, respectively.
At these times, the median concentration in serum were 1.2
and 0.31mg/L, respectively, indicating higher colistin
FIGURE 1. A pharmacokinetic description of drug distribution
between blood and alveolar compartments. After drug admin-
istration (IV/PO), drug distributes from the blood compartment
to the peripheral compartment (alveolar) (distribution phase). At
steady state, the concentration of drug in blood (C1) and alveolar
(C2) are equivalent. Drug is removed from the body through the
elimination rate constant (Ke). Clearance (CL) = KeVd, where Vd
is the apparent volume of distribution which is the sum of V1 +V2
(V1 is volume of distribution in blood and V2 is volume of dis-
tribution in alveolar compartments). AM indicates alveolar mac-
rophage; ELF, epithelial lining fluid; IV, intravenous; Ko, rate
constant after IV administration; Ka, absorption rate constant after
oral administration; K12, transfer rate constant from blood to
alveolar compartments; K21, transfer rate constant from alveolar
compartments to blood; PO, by mouth.
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concentrations can be achieved in the ELF with nebulization,45
which suggests improved target site concentrations with neb-
ulization. Luyt et al46 similarly showed favorable amikacin
concentrations in ELF in a study of 28 mechanically ventilated
patients with gram-negative VAP. In this study, patients
received nebulized amikacin through an advanced nebulizer
system as an adjunct to IV therapy. The median peak amikacin
concentration in the ELF (976mg/L) was far higher than that
observed in serum (0.85mg/L).46
With the advancement of this antibiotic delivery system,
nebulization may prove to be an effective alternative method
of administration to improve antibiotic concentrations in the
lung tissue. However, issues relating to appropriate dose
selection in the context of pathogen susceptibility need to be
considered.45 Further, TDM to prevent any local or systemic
unwanted effects46 as well as use of a specially formulated
antibiotic solutions for inhalation and delivery devices should
be considered.46
RECOMMENDED DOSING APPROACH DURING
LUNG INFECTION
The published data on the ELF:plasma ratios provide only a
moderate level of understanding of antibiotic disposition in the
lung. Evaluation of PK/PD target attainment in the ELF with
current dosing regimens is required to define the optimal anti-
biotic dosing strategies for treatment of lung infections (Fig. 2).
Lipophilic antibiotics generally penetrate well into the
lung tissue, and thus standard dosing will achieve the PK/PD
targets for susceptible pathogens. Aggressive dosing may be
necessary for treatment of less susceptible pathogens. Dosing
for hydrophilic antibiotics is more challenging, particularly in
critically ill patients. Standard dosing regimens rarely achieve
the PK/PD targets in the lung tissue. The problem is likely to
be heightened in patients with altered antibiotic clearance (CL)
(eg, augmented renal clearance, renal replacement ther-
apy)47,48 and/or an increased volume of distribution (eg, crit-
ically ill patients, burns),49,50 and therefore higher doses may
be necessary in these populations. Use of nebulization to
enhance drug delivery into the lung compartments is likely to
be advantageous as well.
The bacterial kill characteristics of the different classes of
antibiotics should be used to guide dosing. Aiming for a high
Cmax:MIC ratio using larger doses is especially important for
antibiotic classes like the aminoglycosides. More frequent
administration to maximize the percentage of time in which the
free antibiotic concentration is above the MIC (%f T>MIC)
should be considered for time-dependent antibiotics like the
b-lactams. Alternatively, use of extended infusion or CI should
be considered as other approaches to increase f T>MIC.
Administration of intermittent doses can enable achievement
of target AUC0-24/MIC ratios for antibiotic classes such as the
fluoroquinolones.
CONCLUSIONS
Antibiotic dosing for lung infections is challenging and
understanding the relationship between the antibiotic and the
pathophysiology changes in the lung during an infection is
required. The alveolar compartments (ELF, AM) best represent
the site of infection in the lung, and as such dose adjustment
based on the antibiotic penetration into the ELF or AM may
lead to the development of better antibiotic dosing regimens to
treat lung infections. TDM should be utilized whenever pos-
sible as a mechanism to optimize dosing.
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Objectives:	To	describe	the	effect	of	different	renal	replacement	
therapy	modalities	and	settings	on	the	clearance	of	meropenem,	
piperacillin,	and	vancomycin	in	critically	ill	patients	and	to	evaluate	
the	frequency	with	which	current	dosing	regimens	achieve	thera-
peutic	concentrations.
Design:	Regression	analyses	of	published	pharmacokinetic	data.
Setting:	 Pubmed	 was	 searched	 for	 relevant	 articles	 published	
between	1952	and	2013.
Subjects:	Original	 research	 articles	 describing	 the	 pharmacoki-
netics	of	meropenem,	piperacillin,	and	vancomycin	in	critically	 ill	
patients	receiving	renal	replacement	therapy.
Interventions:	None.
Measurements and Main Results:	Data	from	30	studies	were	ana-
lyzed.	The	mean	age	of	the	patient	groups	involved	in	studies	of	
meropenem,	piperacillin,	 and	 vancomycin	were	55.3,	 60.3,	 and	
56.9	years,	respectively.	The	mean	blood	and	effluent	flow	rates	
used	for	each	antibiotic	were	151.3	and	33.8	mL/min,	131.8	and	
27.3	mL/min,	 and	 189.3	 and	 35.6	mL/min,	 respectively,	 in	 con-
tinuous	 renal	 replacement	 therapy	 studies.	Correlations	 existed	
between	 effluent	 flow	 rate	 in	 continuous	 renal	 replacement	
therapy	and	extracorporeal	clearance	for	meropenem	(rs	=	0.43;	
p	 =	 0.12),	 piperacillin	 (rs	 =	 0.77;	 p	 =	 0.10),	 and	 vancomycin	
(rs	=	0.90;	p	=	0.08).	Current	dosing	regimens	achieved	target	
concentrations	 for	 meropenem	 (89%),	 piperacillin	 (83%),	 and	
vancomycin	(60%)	against	susceptible	pathogens.
Conclusions:	 Effluent	 flow	 rate	 appears	 to	 be	 a	 reliable	 predic-
tor	of	 antibiotic	clearance	 in	critically	 ill	 patients	despite	 signifi-
cantly	altered	pharmacokinetics	in	these	patients.	Higher	dosing	
regimens	maybe	 required	 in	 critically	 ill	 patients	 receiving	 renal	
replacement	 therapy,	 in	 the	presence	of	high	effluent	flow	rates	
and/or	the	presence	of	poorly	susceptible	pathogens,	particularly	
for	vancomycin.	(Crit Care Med	2014;	42:1640–1650)
Key Words: β-lactam;	carbapenem;	continuous	renal	replacement	
therapy;	 intensive	 care;	 pharmacodynamics;	 pharmacokinetics;	
sepsis
Acute kidney injury (AKI) in the ICU is encountered in 16–65% of patients (1, 2), often in association with severe sepsis or septic shock. Initiation of renal replace-
ment therapy (RRT) is common in this population, with up 
to 70% of these patients requiring this intervention (2). Not 
only is AKI common, the associated mortality rate is high, at 
around 50% (1). In those needing RRT, mortality increases to 
60% (3). Further complicating ICU management is the high 
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prevalence of Gram-negative and Gram-positive infections 
(62% and 47%, respectively) (4). Of these, Pseudomonas spe-
cies (20%) and Staphylococcus aureus (20%) are among the 
most commonly isolated pathogens in the ICU (4). As such, 
antipseudomonal β-lactam antibiotics (such as meropenem 
and piperacillin) and vancomycin for resistant Gram-positive 
infections are commonly used for both empirical and directed 
therapies (5). Importantly, adequate antibiotic treatment in 
this population is considered a key intervention to reduce 
mortality (6) although the delivery of RRT will alter the con-
centrations of many agents.
Designing drug-dosing regimens that produce therapeutic 
antibiotic concentrations at the site of infection is challeng-
ing in critically ill patients. This process should aim to ensure 
that the pharmacokinetic/pharmacodynamic (PK/PD) indi-
ces correlated with maximal antibiotic activity are achieved. 
However, many factors can influence drug exposure, least of 
which is the potential impact of extracorporeal modalities. 
In this respect, the global heterogeneity of RRT prescription 
within ICU is likely to significantly impact antibiotic PK. Of 
concern, most data on antibiotic concentrations during RRT 
are from single-center studies, where consistent RRT settings 
are applied to all study participants. Despite this, many of these 
studies show that dosing is presently insufficient (7, 8). Clearly, 
recommending a single antibiotic dose for all forms of RRT is 
therefore flawed, while currently there is little data quantify-
ing how varying modes and settings influence antibiotic PK. 
As such, an improved understanding of the influence of differ-
ing modalities and settings (e.g., modes, blood flow rate, efflu-
ent flow rate, and filter material and size) would likely greatly 
improve the prescription of antibiotics in critically ill patients 
concurrently receiving RRT (9–11).
The primary aim of this article was to describe the effect of 
different RRT modalities and settings on the clearance of the 
antibiotics most commonly used in ICU setting, meropenem, 
piperacillin, and vancomycin (5). We also aimed to evaluate 
if the dosing regimens used were likely to achieve the neces-
sary PK/PD targets associated with maximal antibiotic efficacy 
against commonly encountered pathogens in the ICU.
METHODS
Search Strategy
We searched the Pubmed database (1951–2013) for relevant 
articles using the following terms: “meropenem,” “piperacillin,” 
“vancomycin,” “h(a)emofiltration,” “h(a)emodiafiltration,” 
“h(a)emodialysis,” “renal replacement therapy,” “continuous 
renal replacement therapy,” “extended daily dialysis,” “sustained 
low efficiency dialysis,” “pharmacokinetic,” “critically ill,” and 
“intensive care” (Fig. 1). The reference lists of articles selected 
were also searched. Original prospective studies reporting on 
the PK of meropenem, piperacillin, and vancomycin in criti-
cally ill patients receiving RRT were included. Articles that did 
not provide qualitative or quantitative data on RRT settings 
used and/or associated PK variables, were from noncritically 
ill populations, or were retrospective, were excluded. A waiver 
for ethical review was provided by the local ethics committee 
for this analysis.
Data Extraction
For all included studies, the following data were extracted: 
first author’s name, year of publication, sample size, baseline 
patient characteristics (age, weight, Acute Physiology and 
Chronic Health Evaluation II score [12], Sequential Organ 
Failure Assessment score [13], and creatinine clearance), anti-
biotic dosing, RRT settings (mode, blood flow rate, ultrafiltra-
tion rate, dialysate flow rate, hemofilter material, and surface 
area), PK variables (peak concentration, C
max
; trough concen-
tration, C
min
; area under the concentration-time curve, AUC; 
total body clearance, CL
total
; extracorporeal clearance, CL
RRT
; 
volume of distribution, Vd; and sieving coefficient, Sc), and 
dosing regimens. The effluent flow rate was determined from 
the reported ultrafiltration rate in continuous venovenous 
hemofiltration (CVVH) or dialysate flow rate in continu-
ous venovenous hemodialysis (CVVHD). Data from hybrid 
RRT techniques (extended daily dialysis, EDD or sustained 
low-efficiency dialysis, SLED) were also included. The sum 
of ultrafiltration and dialysate flow rates was used for defin-
ing the RRT dose in continuous venovenous hemodiafiltration 
(CVVHDF). For quantitative analysis, only mean or median 
data of the patient cohorts were extracted.
PK Calculations
PK variables were calculated using the following equations 
where reported data were not available. The elimination 
 half-life was calculated as t
1/2
 = ln2/ke, where ke is the elimina-
tion rate constant. Vd was calculated as Vd = CL
total
/ke, where 
Figure 1. Study selection process. RRT = renal replacement therapy.
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TablE 1. Characteristics of the Selected Pharmacokinetic Studies
Drug/Reference (s)
Patient Characteristicsa
RRT Type  
(Duration)
RRT Settings
Population
No. of Patients 
(Male/Female) age Weight
acute Physiology  
and Chronic Health 
Evaluation
Sequential 
Organ Failure 
 assessment Filter Material
Surface  
area (m2)
Pre- or  
 Postdilution
Meropenem
  Thalhammer et al (17) Acute kidney injury, anuric 9 (6/3) 57.9 ± 5.7 86.7 ± 23.1 NA NA CVVH Polysulfone 0.4 Postdilution
  Krueger et al (18) Acute kidney injury, anuric 9 (5/4) 54.2 ± 19.7 69.4 ± 9.7 22.3 ± 5.3 NA CVVHDF Polyacrylonitrile 0.9 NA
  Meyer et al (19) Acute kidney injury, anuric 1 (1/0) 19.0 NA NA NA CVVHDF Polyacrylonitrile NA NA
  Tegeder et al (20) Acute kidney injury, anuric 9 (4/5) 65.7 ± 13.2b NA NA NA CVVH Polyacrylonitrile NA NA
  Valtonen et al (21) Acute kidney injury 6 (3/3) 45.0 ± 21.0 79.0 ± 11.0 NA NA CVVH/CVVHDF Polysulfone 0.7 NA
  Ververs et al (22) Acute kidney injury 5 (1/4) 46.6 ± 13.0b 85.8 ± 11.8 NA NA CVVH Polyacrylonitrile 0.6 Postdilution
  Giles et al (23) Acute kidney injury 10 (7/3) 64.9 ± 8.0b 79.8 ± 18.5b 26.7 ± 6.3b NA CVVH/CVVHDF Polyacrylonitrile 0.9 Postdilution
  Robatel et al (24) Renal failure 13 (8/5) 60.5 ± 8.3b 71.0 ± 16.3b NA NA CVVHDF Polyacrylonitrile 0.9 NA
  Krueger et al (25) Acute kidney injury 8 (5/3) 66.5 ± 9.4b 79.6 ± 14.5b 22.3 ± 3.2b NA CVVH Polyacrylonitrile 0.9 Pre/postdilution
  Isla et al (26) Renal failure 20 (15/5) 56.2 ± 20.5b 73.1 ± 6.9b 19.4 ± 6.8b 13.1 ± 4.0b CVVH/CVVHDF Polyacrylonitrile/polysulfone 0.9, 1.4 Predilution
  Langgartner et al (27) Renal failure 6 (5/1) 53.7 ± 7.9b 76.0 ± 16.7b NA NA CVVHDF Polysulfone 1.4 NA
  Bilgrami et al (28) Renal failure 10 (6/4) 57.0c 70.0c 25.0c NA CVVH Polyacrylonitrile 2.15 NA
  Seyler et al (8) Acute kidney injury 17 (NA) 62.0 ± 16.0 NA NA NA CVVH/CVVHDF Polyacrylonitrile NA NA
  Kielstein et al (29) Acute kidney injury, anuric 10 (6/4) 54.3 ± 9.4b 76.7 ± 15.0b NA NA EDD (8.0 hourly) Polysulfone 1.3 NA
  Deshpande et al (30) Renal failure 10 (8/2) 63.7 ± 11.7 88.9 ± 21.5 NA NA SLED (8.0 hourly) Polysulfone 0.7 NA
Piperacillin
  Joos et al (31) Acute kidney injury, anuric 8 (NA) NA NA NA NA CVVH Polyamide NA NA
  van der Werf et al (32) Acute kidney injury, anuric 9 (5/4) 56.4 ± 15.2b 86.6 ± 22.6b 30.1 ± 4.2b NA CVVH NA NA Predilution
  Capellier et al (33) Acute kidney injury 10 (NA) 70.0 ± 12.0 72.0 ± 20.0 74.0 ± 6.0 NA CVVH Polysulfone 0.5 NA
  Valtonen et al (34) Acute kidney injury 6 (5/1) 54.0 ± 13.0 90.0 ± 12.0 NA NA CVVH/CVVHDF Polysulfone 0.7 Postdilution
  Mueller et al (35) Acute kidney injury, anuric 8 (6/2) 66.0 ± 9.0 67.0 ± 21.0 NA NA CVVHD Polyacrylonitrile NA NA
  Arzuaga et al (36) Acute kidney injury 14 (11/3) 56.6 ± 6.9 75.6 ± 3.5 22.0 ± 2.8 11.0 ± 0.1 CVVH Polyacrylonitrile 0.9 Predilution
  Seyler et al (8) Acute kidney injury 8 (NA) 62.0 ± 16.0 NA NA NA CVVH/CVVHDF Polyacrylonitrile NA NA
  Bauer et al (37) Renal failure 42 (25/17) 56. 8 ± 15.5 95.1 ± 26.8 NA NA CVVHD/CVVHDF Polyacrylonitrile/polyethersulfone 0.6, 0.9, 1.5 NA
Vancomycin
  Santre et al (38) Acute kidney injury 3 (3/0) 58.7 ± 19.1b NA NA NA CVVHDF Polyacrylonitrile NA NA
  Boereboom et al (39) Acute kidney injury, anuric 2 (1/1) 46.0 ± 10.0b 82.5 ± 3.5b NA NA CVVH Polyacrylonitrile 0.6 Postdilution
  DelDot et al (40) Acute kidney injury 10 (6/4) 60.3 ± 8.7b 79.1 ± 17.1b 31.4 ± 11.1b 16.2 ± 4.8b CVVHDF Polyacrylonitrile NA NA
  Chaijamorn et al (41) Acute kidney injury 7 (7/0) 60.7 ± 16.9b 66.4 ± 12.1b 33.0 ± 6.9b 15.7 ± 2.6b CVVH Triacetate NA Predilution
  Petejova et al (42) Acute kidney injury 17 (11/6) 58.0c 90.0c 32.0c 17.0c CVVH Polysulfone 1.4, 1.8 Both
  Beumier et al (43) Septic, critically ill 32 (17/15) 55.0c 80.0c 21.0c 14.0c CVVH/CVVHDF Polyacrylonitrile/ Polysulfone NA NA
  Ahern et al (44) Acute kidney injury 11 (7/4) 54.5 ± 14.6 89.6 ± 23.4 25.9 ± 7.7 NA SLED (24.0 hourly) Polysulfone NA NA
  Kielstein et al (29) Acute kidney injury, anuric 10 (6/4) 55.0 ± 12.6b 84.5 ± 24.0b NA NA EDD (8.0 hourly) Polysulfone 1.3 NA
  Petejova et al (45) Acute kidney injury 9 (9/0) 63.8 ± 11.0b 82.1 ± 11.4b NA 15.0c EDD (6.0 hourly) Polysulfone 1.3, 1.5 NA
RRT	=	renal	replacement	therapy,	NA	=	data	not	available	or	not	applicable,	CVVH	=	continuous	venovenous	hemofiltration,	CVVHDF	=	continuous	venovenous	 
hemodiafiltration,	EDD	=	extended	daily	dialysis,	SLED	=	sustained	low-efficiency	dialysis,	CVVHD	=	continuous	venovenous	hemodialysis.
aData	reported	as	mean	±	sd	(unless	otherwise	stated).
bCalculated	mean/median	from	reported	data.
cData	reported	as	median.
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TablE 1. Characteristics of the Selected Pharmacokinetic Studies
Drug/Reference (s)
Patient Characteristicsa
RRT Type  
(Duration)
RRT Settings
Population
No. of Patients 
(Male/Female) age Weight
acute Physiology  
and Chronic Health 
Evaluation
Sequential 
Organ Failure 
 assessment Filter Material
Surface  
area (m2)
Pre- or  
 Postdilution
Meropenem
  Thalhammer et al (17) Acute kidney injury, anuric 9 (6/3) 57.9 ± 5.7 86.7 ± 23.1 NA NA CVVH Polysulfone 0.4 Postdilution
  Krueger et al (18) Acute kidney injury, anuric 9 (5/4) 54.2 ± 19.7 69.4 ± 9.7 22.3 ± 5.3 NA CVVHDF Polyacrylonitrile 0.9 NA
  Meyer et al (19) Acute kidney injury, anuric 1 (1/0) 19.0 NA NA NA CVVHDF Polyacrylonitrile NA NA
  Tegeder et al (20) Acute kidney injury, anuric 9 (4/5) 65.7 ± 13.2b NA NA NA CVVH Polyacrylonitrile NA NA
  Valtonen et al (21) Acute kidney injury 6 (3/3) 45.0 ± 21.0 79.0 ± 11.0 NA NA CVVH/CVVHDF Polysulfone 0.7 NA
  Ververs et al (22) Acute kidney injury 5 (1/4) 46.6 ± 13.0b 85.8 ± 11.8 NA NA CVVH Polyacrylonitrile 0.6 Postdilution
  Giles et al (23) Acute kidney injury 10 (7/3) 64.9 ± 8.0b 79.8 ± 18.5b 26.7 ± 6.3b NA CVVH/CVVHDF Polyacrylonitrile 0.9 Postdilution
  Robatel et al (24) Renal failure 13 (8/5) 60.5 ± 8.3b 71.0 ± 16.3b NA NA CVVHDF Polyacrylonitrile 0.9 NA
  Krueger et al (25) Acute kidney injury 8 (5/3) 66.5 ± 9.4b 79.6 ± 14.5b 22.3 ± 3.2b NA CVVH Polyacrylonitrile 0.9 Pre/postdilution
  Isla et al (26) Renal failure 20 (15/5) 56.2 ± 20.5b 73.1 ± 6.9b 19.4 ± 6.8b 13.1 ± 4.0b CVVH/CVVHDF Polyacrylonitrile/polysulfone 0.9, 1.4 Predilution
  Langgartner et al (27) Renal failure 6 (5/1) 53.7 ± 7.9b 76.0 ± 16.7b NA NA CVVHDF Polysulfone 1.4 NA
  Bilgrami et al (28) Renal failure 10 (6/4) 57.0c 70.0c 25.0c NA CVVH Polyacrylonitrile 2.15 NA
  Seyler et al (8) Acute kidney injury 17 (NA) 62.0 ± 16.0 NA NA NA CVVH/CVVHDF Polyacrylonitrile NA NA
  Kielstein et al (29) Acute kidney injury, anuric 10 (6/4) 54.3 ± 9.4b 76.7 ± 15.0b NA NA EDD (8.0 hourly) Polysulfone 1.3 NA
  Deshpande et al (30) Renal failure 10 (8/2) 63.7 ± 11.7 88.9 ± 21.5 NA NA SLED (8.0 hourly) Polysulfone 0.7 NA
Piperacillin
  Joos et al (31) Acute kidney injury, anuric 8 (NA) NA NA NA NA CVVH Polyamide NA NA
  van der Werf et al (32) Acute kidney injury, anuric 9 (5/4) 56.4 ± 15.2b 86.6 ± 22.6b 30.1 ± 4.2b NA CVVH NA NA Predilution
  Capellier et al (33) Acute kidney injury 10 (NA) 70.0 ± 12.0 72.0 ± 20.0 74.0 ± 6.0 NA CVVH Polysulfone 0.5 NA
  Valtonen et al (34) Acute kidney injury 6 (5/1) 54.0 ± 13.0 90.0 ± 12.0 NA NA CVVH/CVVHDF Polysulfone 0.7 Postdilution
  Mueller et al (35) Acute kidney injury, anuric 8 (6/2) 66.0 ± 9.0 67.0 ± 21.0 NA NA CVVHD Polyacrylonitrile NA NA
  Arzuaga et al (36) Acute kidney injury 14 (11/3) 56.6 ± 6.9 75.6 ± 3.5 22.0 ± 2.8 11.0 ± 0.1 CVVH Polyacrylonitrile 0.9 Predilution
  Seyler et al (8) Acute kidney injury 8 (NA) 62.0 ± 16.0 NA NA NA CVVH/CVVHDF Polyacrylonitrile NA NA
  Bauer et al (37) Renal failure 42 (25/17) 56. 8 ± 15.5 95.1 ± 26.8 NA NA CVVHD/CVVHDF Polyacrylonitrile/polyethersulfone 0.6, 0.9, 1.5 NA
Vancomycin
  Santre et al (38) Acute kidney injury 3 (3/0) 58.7 ± 19.1b NA NA NA CVVHDF Polyacrylonitrile NA NA
  Boereboom et al (39) Acute kidney injury, anuric 2 (1/1) 46.0 ± 10.0b 82.5 ± 3.5b NA NA CVVH Polyacrylonitrile 0.6 Postdilution
  DelDot et al (40) Acute kidney injury 10 (6/4) 60.3 ± 8.7b 79.1 ± 17.1b 31.4 ± 11.1b 16.2 ± 4.8b CVVHDF Polyacrylonitrile NA NA
  Chaijamorn et al (41) Acute kidney injury 7 (7/0) 60.7 ± 16.9b 66.4 ± 12.1b 33.0 ± 6.9b 15.7 ± 2.6b CVVH Triacetate NA Predilution
  Petejova et al (42) Acute kidney injury 17 (11/6) 58.0c 90.0c 32.0c 17.0c CVVH Polysulfone 1.4, 1.8 Both
  Beumier et al (43) Septic, critically ill 32 (17/15) 55.0c 80.0c 21.0c 14.0c CVVH/CVVHDF Polyacrylonitrile/ Polysulfone NA NA
  Ahern et al (44) Acute kidney injury 11 (7/4) 54.5 ± 14.6 89.6 ± 23.4 25.9 ± 7.7 NA SLED (24.0 hourly) Polysulfone NA NA
  Kielstein et al (29) Acute kidney injury, anuric 10 (6/4) 55.0 ± 12.6b 84.5 ± 24.0b NA NA EDD (8.0 hourly) Polysulfone 1.3 NA
  Petejova et al (45) Acute kidney injury 9 (9/0) 63.8 ± 11.0b 82.1 ± 11.4b NA 15.0c EDD (6.0 hourly) Polysulfone 1.3, 1.5 NA
RRT	=	renal	replacement	therapy,	NA	=	data	not	available	or	not	applicable,	CVVH	=	continuous	venovenous	hemofiltration,	CVVHDF	=	continuous	venovenous	 
hemodiafiltration,	EDD	=	extended	daily	dialysis,	SLED	=	sustained	low-efficiency	dialysis,	CVVHD	=	continuous	venovenous	hemodialysis.
aData	reported	as	mean	±	sd	(unless	otherwise	stated).
bCalculated	mean/median	from	reported	data.
cData	reported	as	median.
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CL
total
 is the total clearance. The CL
RRT
 was estimated based on 
previously described calculation (9). An estimated body weight 
of 70 kg was used when mean or median data for patient weight 
were not available.
PD Calculations
PK/PD target attainment for reported dosing regimens was 
determined for each antibiotic. For meropenem and piper-
acillin, the PK/PD target (the percentage of time during the 
dosing interval that the drug concentration is in excess of the 
minimum inhibitory concentration [MIC] of the targeted 
pathogen [% T
>MIC
]) was determined according to previously 
established calculations (14). Target MIC values of 2 mg/L 
and 16 mg/L were chosen for 
meropenem and piperacillin, 
respectively, as these represent 
susceptibility breakpoints for 
Enterobacteriaceae and Pseudo-
monas aeruginosa (15). For van-
comycin, an AUC to MIC ratio 
(AUC
0–24
/MIC) of at least 400 
over a 24 hours dosing interval 
was considered as the optimal 
PK/PD target (16). A suscepti-
bility breakpoint of 1, 1.5, and 
2 mg/L for Staphylococcus spe-
cies was used in the vancomycin 
analysis (15).
Statistical analysis
Statistical analyses were per-
formed using Prism (Graph-
Pad, version 6.0; San Diego, CA) 
and Microsoft Excel (Microsoft 
Office 2011; Redmond, WA). 
Data are presented as the mean 
± sd or median (interquartile 
range, IQR) of the group data 
that were reported in indi-
vidual studies. The relation-
ship between summary data 
was determined by Spearman’s 
rank correlation coefficient (r
s
). 
The relationship (line of best 
fit) between blood flow rate or 
effluent flow rate and CL
total
 or 
CL
RRT
, as dependent variables, 
was determined by simple lin-
ear regression. A p value of less 
than 0.05 was considered statis-
tically significant.
RESUlTS
Thirty original articles describ-
ing the PK of meropenem, 
piperacillin, and vancomycin 
inclusive of 349 critically ill patients concurrently treated 
with varying types of RRT were reviewed for qualitative and 
quantitative analysis. The details of these studies are presented 
in Table 1. Meropenem PK was reported in 15 articles, using 
differing modes of continuous renal replacement therapy 
(CRRT) and hybrid techniques (EDD and SLED) (8, 17–30). 
Piperacillin PK during CRRT was investigated in eight studies 
(8, 31–37), while vancomycin data were reported in nine stud-
ies, using both CRRT and hybrid techniques (EDD and SLED) 
(29, 38–45). The mean age of included patient data was 55.3, 
60.3, and 56.8 years, while the median (IQR) sample size was 
9 (7–10), 8.5 (8–11), and 10 (7–12) in studies of meropenem, 
piperacillin, and vancomycin, respectively. The majority of 
Figure 2. The relationship between effluent flow intensity during continuous renal replacement therapy and 
clearance of meropenem (a), piperacillin (b), and vancomycin (C). A, Correlation between effluent flow rate and 
meropenem CLtotal (left) and CLRRT (right). B, Correlation between effluent flow rate and piperacillin CLtotal 
(left) and CLRRT (right). C, Correlation between effluent flow rate and vancomycin CLtotal (left)  
and CLRRT (right).
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studies examined changes in PK during CRRT (n = 26, 86.7%). 
The mean of the blood flow and effluent flow rates reported 
by the studies examining meropenem was 151.3 and 33.8 mL/
min. In studies investigating piperacillin and vancomycin, 
these were 131.8 and 27.0 mL/min and 189.3 and 35.6 mL/min, 
respectively.
Reported and calculated PK variables for meropenem, 
piperacillin, and vancomycin during RRT are summarized as 
in Supplemental Table 1 (Supplemental Digital Content 1, 
http://links.lww.com/CCM/A924). The median Vd was 31.6, 
33.2, and 43.7 L, respectively. Meropenem had an Sc of around 
0.9, while for piperacillin and vancomycin, this was approxi-
mately 0.5 and 0.8, respectively. Mean/median elimination via 
the extracorporeal circuit from the included studies varied for 
meropenem (15–58% of CL
total
) 
and piperacillin (13–47% of 
CL
total
) and was insignificant (< 
2% of CL
total
) in patients with 
residual renal function (26, 36). 
By contrast, CL
RRT
 for vancomy-
cin was significantly higher (> 
60% of CL
total
) in some studies 
(40, 42).
Based on mean or median 
CL
total
, CL
RRT
, blood flow, and 
effluent flow rates, relation-
ships between variables were 
examined using linear regres-
sion to determine the influence 
of CRRT intensity on antibiotic 
PK (Figs. 2 and 3). A statistically 
significant correlation was only 
observed between effluent flow 
rate and CL
total
 with piperacillin 
(r
s
 = 0.69, p = 0.02). However, 
visual correlations were noted 
between effluent flow rate and 
CL
RRT
 for all three antibiot-
ics (Fig. 2). The relationship 
between blood flow rate and 
both CL
total
 and CL
RRT
 was non-
significant for all three agents, 
possibly explained by limited 
available data (Fig. 3). However, 
positive trends were observed 
between blood flow rate and 
meropenem CL
total
 and CL
RRT
 
(r
s
 = 0.41 and r
s
 = 0.10, respec-
tively) and blood flow rate with 
vancomycin CL
RRT
, r
s
 = 0.66 
(p = 0.33).
PK/PD target attainment 
of meropenem and piperacil-
lin was calculated based on the 
reported dosing regimens and 
PK variables against selected 
susceptibility breakpoints (Table 2). Of these, 89% and 83% 
of the doses successfully achieved more than 100% T
>MIC
 for 
meropenem and piperacillin, respectively, against an MIC of 
2 mg/L and 16 mg/L. In the case of vancomycin, 60% of the 
evaluated doses achieved the desired AUC
0–24
/MIC ratio of 
at least 400 against an MIC value of 1 mg/L, while only 20% 
achieved the target at an MIC of 1.5 mg/L. All of the reported 
dosing regimens for vancomycin (ranging from 1 to 2 g/d) 
were insufficient to achieve the desired AUC
0–24
/MIC ratio at 
an MIC of 2 mg/L (Table 3).
DISCUSSION
Based on published data, this analysis has demonstrated that 
RRT intensity (as determined by effluent flow rate) increases 
Figure 3. The relationship between blood flow intensity during continuous renal replacement therapy and 
clearance of meropenem (a), piperacillin (b), and vancomycin (C). A, Correlation between blood flow rate and 
meropenem CLtotal (left) and CLRRT (right). B, Correlation between blood flow rate and piperacillin CLtotal (left) and 
CLRRT (right). C, Correlation between blood flow rate and vancomycin CLtotal (left) and CLRRT (right).
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the extracorporeal elimination of meropenem, piperacillin, 
and vancomycin. Although such a concept maybe taken for 
granted, this relationship has not been demonstrated across a 
wide range of studies for these commonly used antibiotics. As 
such, effluent flow rate could potentially be used to estimate 
the filter clearance of these agents during varying modes of 
RRT and, in particular, CRRT. Conversely, blood flow rate was 
largely unhelpful in predicting drug clearance. Our data are 
particularly interesting, as these strong correlations are present 
in spite of use of the different modalities (e.g., CVVHF and 
CVVHD) grouped together in this analysis. Our other major 
finding is the lack of efficacy of reported dosing regimens for 
vancomycin during RRT to achieve the target PK/PD index 
(16). These regimens often failed to provide an AUC
0–24
/MIC 
ratio of at least 400 using a susceptibility breakpoint of more 
than 1 mg/L. Meropenem dosing achieved the desired PK/PD 
index in 89% of studies, while piperacillin dosing regimens 
were sufficient in 83% of cases for the targeted MICs. Of note, 
however, is the exposure to high piperacillin and tazobactam 
trough concentrations, when the fixed combination prepara-
tion was used. This represents a concern given the potential 
accumulation of both compounds when using higher doses.
The role of effluent flow rate in differing modes of CRRT 
as a potential modifier of antibiotic prescription in future 
clinical practice requires substantial future validation. In this 
current work, a positive correlation was observed between 
effluent flow rate and CL
RRT
 for all three antibiotics (r
s
 = 0.44, 
r
s
 = 0.77, and r
s
 = 0.90), while similar relationships have been 
highlighted in previous studies (23, 28). In a prospective inves-
tigation of meropenem PK in 10 critically ill patients receiv-
ing CRRT (blood flow rate, 150 mL/min; ultrafiltration rate, 
16.7–33.3 mL/min), filter clearance was noted to be linearly 
correlated with effluent flow rate in CVVH and CVVHDF 
(r = 1.00 and 0.85, respectively) (23). In another study evaluat-
ing the influence of flow rate during CVVH on meropenem 
clearance, CL
RRT
 was found to be associated with ultrafiltration 
rate (r = 0.89), when the data were compared with previous 
studies (28).
TablE 2. The Pharmacokinetic/Pharmacodynamic Target attainments for  
Meropenem and Piperacillin
References RRT Type Dose
% T>MIC
References RRT type Dosea
% T>MIC
MIC 2 MIC 4 MIC 8 MIC 16
Meropenem Piperacillin
  Thalhammer et al (17) CVVH 1 g (single dose) 39.6 29.9   van der Werf et al (32) CVVH 4 g, 8 hourly 315.0 241.2
  Krueger et al (18) CVVHDF 1 g, 12 hourly 181.0 143.3   Capellier et al (33) CVVH 4 g (first dose) 81.1 59.8
  Meyer et al (19) CVVHDF 1 g, 8 hourly 190.9 139.7   Capellier et al (33) CVVH 4 g, 8 hourly 341.3 281.3
  Meyer et al (19) CVVHDF 1 g, 12 hourly 125.5 89.7   Valtonen et al (34) CVVH 4 g, 12 hourly 226.6 162.5
  Tegeder et al (20) CVVH 0.5 g, 8 hourly 476.7 366.7   Valtonen et al (34) CVVHDF 4 g, 12 hourly 184.5 128.7
  Valtonen et al (21) CVVH 1 g, 12 hourly 238.8 176.3   Valtonen et al (34) CVVHDF 4 g, 12 hourly 171.1 120.3
  Valtonen et al (21) CVVHDF 1 g, 12 hourly 173.3 126.6   Mueller et al (35) CVVHD 4 g, 12 hourly 164.4 128.5
  Valtonen et al (21) CVVHDF 1 g, 12 hourly 146.4 106.4   Arzuaga et al (36) CVVH 4 g, 8 hourly 445.9 348.4
  Ververs et al (22) CVVH 0.5 g, 12 hourly 158.2 105.1   Arzuaga et al (36) CVVH 4 g, 8 hourly 221.6 169.1
  Giles et al (23) CVVH/CVVHDF 1 g, 12 hourly 180.4 137.4   Arzuaga et al (36) CVVH 4 g, 8 hourly 113.0 80.5
  Robatel et al (24) CVVHDF 1 g, 12 hourly 167.3 124.5   Seyler et al (8) CVVH/CVVHDF 4 g, 6 hourly 278.8 209.5
  Krueger et al (25) CVVH 0.5 g, 12 hourly 105.5 75.2   Bauer et al (37) CVVHD/CVVHDF 3 g, 8 hourly 395.4 275.4
  Isla et al (26) CVVHDF 0.5 g, 6 hourly 157.9 95.9
  Isla et al (26) CVVH/CVVHDF 0.5 g, 6 hourly 148.8 103.3
  Isla et al (26) CVVH 2 g, 8 hourly 65.1 46.2
  Langgartner et al (27) CVVHDF 0.5 g (loading dose), 2 g 24 hourly 116.6 94.5
  Bilgrami et al (28) CVVH 1 g 8 hourly 230.6 176.6
  Seyler et al (8) CVVH/CVVHDF 1 g 12 hourly 145.9 109.3
  Kielstein et al (29) Extended daily dialysis 1 g (single dose) 192.3 130.6
RRT	=	renal	replacement	therapy,	%	T>MIC	=	percentage	of	time	during	dosing	interval	that	the	concentration	is	above	the	MIC	of	targeted	pathogen,	 
MIC	=	minimum	inhibitory	concentration	(mg/L),	CVVH	=	continuous	venovenous	hemofiltration,	CVVHDF	=	continuous	venovenous	hemodiafiltration,	 
CVVHD	=	continuous	venovenous	hemodialysis.
aDose	based	on	piperacillin	component.
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This relationship was also noted in a PK study of piperacil-
lin in nine anuric critically ill patients receiving CVVH (ultra-
filtration rate, 25.9 ± 9.8 mL/min) (32). Here ultrafiltration 
rate was significantly associated with piperacillin CL
tot
, r = 0.83 
(p < 0.001) (32). Similar data were also reported in recent van-
comycin PK studies during CRRT (43, 46). Of note, these find-
ings are in contrast to those reported in a multicenter study of 
CRRT intensity in critically ill patients (47), whereby the vari-
ability in antibiotic concentrations was not influenced by the 
effluent flow rates. This disparity is likely related to the small 
sample size and heterogeneity in patient characteristics, par-
ticularly the degree of residual native renal function, and filter 
lifespan. In this respect, while effluent flow intensity appears to 
predict extracorporeal drug elimination, modification of anti-
biotic doses will need to consider a variety of factors.
Blood flow rate was demonstrated to be nonsignificant in 
predicting CL
RRT
 and CL
total
 overall. However, a positive cor-
relation between blood flow rate and CL
total
 (r
s
 = 0.41) and 
CL
RRT
 (r
s
 = 0.10) was observed for meropenem. Given that 
two thirds of the meropenem patients (Supplemental Table 1, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
A924) received a RRT modality that used dialysis (CVVHD, 
CVVHDF), this relationship between meropenem CL and 
blood flow rate is not unexpected. Furthermore, for piper-
acillin and vancomycin, the relative proportion of patients 
receiving a RRT modality that included dialysis was reduced, 
and as such, a correlation of drug CL and blood flow rate was 
not observed.
Substantial amounts of meropenem and vancomycin are 
also eliminated with hybrid techniques (EDD and SLED), 
requiring additional consideration when prescribing these 
antibiotics (29, 30, 45). To date, limited data are available 
describing piperacillin PK during such therapy. Hybrid 
techniques combine the advantages of more efficient solute 
removal (as seen with traditional intermittent hemodialy-
sis), with longer treatment duration (over a period of 8–12 
hours), which is generally more tolerable in the unstable crit-
ically ill patient. This has significant potential ramifications 
TablE 2. The Pharmacokinetic/Pharmacodynamic Target attainments for  
Meropenem and Piperacillin
References RRT Type Dose
% T>MIC
References RRT type Dosea
% T>MIC
MIC 2 MIC 4 MIC 8 MIC 16
Meropenem Piperacillin
  Thalhammer et al (17) CVVH 1 g (single dose) 39.6 29.9   van der Werf et al (32) CVVH 4 g, 8 hourly 315.0 241.2
  Krueger et al (18) CVVHDF 1 g, 12 hourly 181.0 143.3   Capellier et al (33) CVVH 4 g (first dose) 81.1 59.8
  Meyer et al (19) CVVHDF 1 g, 8 hourly 190.9 139.7   Capellier et al (33) CVVH 4 g, 8 hourly 341.3 281.3
  Meyer et al (19) CVVHDF 1 g, 12 hourly 125.5 89.7   Valtonen et al (34) CVVH 4 g, 12 hourly 226.6 162.5
  Tegeder et al (20) CVVH 0.5 g, 8 hourly 476.7 366.7   Valtonen et al (34) CVVHDF 4 g, 12 hourly 184.5 128.7
  Valtonen et al (21) CVVH 1 g, 12 hourly 238.8 176.3   Valtonen et al (34) CVVHDF 4 g, 12 hourly 171.1 120.3
  Valtonen et al (21) CVVHDF 1 g, 12 hourly 173.3 126.6   Mueller et al (35) CVVHD 4 g, 12 hourly 164.4 128.5
  Valtonen et al (21) CVVHDF 1 g, 12 hourly 146.4 106.4   Arzuaga et al (36) CVVH 4 g, 8 hourly 445.9 348.4
  Ververs et al (22) CVVH 0.5 g, 12 hourly 158.2 105.1   Arzuaga et al (36) CVVH 4 g, 8 hourly 221.6 169.1
  Giles et al (23) CVVH/CVVHDF 1 g, 12 hourly 180.4 137.4   Arzuaga et al (36) CVVH 4 g, 8 hourly 113.0 80.5
  Robatel et al (24) CVVHDF 1 g, 12 hourly 167.3 124.5   Seyler et al (8) CVVH/CVVHDF 4 g, 6 hourly 278.8 209.5
  Krueger et al (25) CVVH 0.5 g, 12 hourly 105.5 75.2   Bauer et al (37) CVVHD/CVVHDF 3 g, 8 hourly 395.4 275.4
  Isla et al (26) CVVHDF 0.5 g, 6 hourly 157.9 95.9
  Isla et al (26) CVVH/CVVHDF 0.5 g, 6 hourly 148.8 103.3
  Isla et al (26) CVVH 2 g, 8 hourly 65.1 46.2
  Langgartner et al (27) CVVHDF 0.5 g (loading dose), 2 g 24 hourly 116.6 94.5
  Bilgrami et al (28) CVVH 1 g 8 hourly 230.6 176.6
  Seyler et al (8) CVVH/CVVHDF 1 g 12 hourly 145.9 109.3
  Kielstein et al (29) Extended daily dialysis 1 g (single dose) 192.3 130.6
RRT	=	renal	replacement	therapy,	%	T>MIC	=	percentage	of	time	during	dosing	interval	that	the	concentration	is	above	the	MIC	of	targeted	pathogen,	 
MIC	=	minimum	inhibitory	concentration	(mg/L),	CVVH	=	continuous	venovenous	hemofiltration,	CVVHDF	=	continuous	venovenous	hemodiafiltration,	 
CVVHD	=	continuous	venovenous	hemodialysis.
aDose	based	on	piperacillin	component.
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for antibiotic elimination. Specifically, in a study of criti-
cally ill patients treated with SLED over 8 hours, the median 
meropenem peak concentration was lower (21 mg/L vs 
55 mg/L) compared to those receiving CRRT, when similar 
doses were employed (23, 30). An additional factor when 
applying these therapies is the type of filter membrane, par-
ticularly with vancomycin extracorporeal elimination. In 
this respect, vancomycin clearance was higher when a high 
flux filter membrane was used (60.3 mL/min vs 29.0 mL/
min) compared to a low flux device (45). Additional studies 
are clearly required to better understand the PK of antibiot-
ics when using such modalities.
Achieving sufficient antibiotic concentrations at the site 
of infection is essential to maximize antibiotic efficacy. The 
associated PK/PD index is that variable defining optimal 
antibiotic exposure in terms of maximal bacterial killing. 
For β-lactams, it has been suggested that achieving 90–100% 
T
>MIC
 represents an appropriate PK/PD target for maximal 
efficacy (14, 48). Based on this, we determined the frequency 
with which current reported dosing regimens achieved 100% 
T
>MIC
 for meropenem and piperacillin against common ICU 
 Gram-negative pathogens. These doses were found to suffi-
ciently achieve the target for meropenem against susceptible 
pathogens (MIC ≤ 2 mg/L); however, they were only moder-
ately successful when a higher susceptibility breakpoint was 
used (e.g., 4 mg/L). This was particularly the case when doses 
less than 2 g/d were employed (17, 19, 25) and in patients 
with a large Vd (e.g., > 80 L) (26). As such, larger or more 
frequent doses may be mandated. Of concern, in patients 
with residual native renal function, higher doses (e.g., 6 g/d) 
were insufficient to achieve this target (26). Alternative dos-
ing strategies require consideration of meropenem as an 
extended or continuous infusion to improve meropenem 
PK/PD target attainment in this population (27).
Similarly, piperacillin doses between 8 and 24 g/d suffi-
ciently achieved the target PK/PD index for susceptible patho-
gens (MIC < 16 mg/L) (8, 32–37). However, such doses do 
predispose to accumulation of tazobactam, as has been high-
lighted in previous studies using the fixed combination prepa-
ration (32, 35). The degree of residual native renal function is 
clearly important in this scenario, where previous research has 
shown significantly higher tazobactam concentrations in those 
with a creatinine clearance less than 50 mL/min (36). Adding 
to this complexity is the impact of protein binding. In one 
recent PK study, it was highlighted that the probability of PD 
target attainment was higher when total drug concentration 
were employed, as compared to the unbound fraction (83% 
vs 77%) (37). This reinforces the importance of measuring the 
unbound fraction of piperacillin, as this will more closely rep-
resent the amount of pharmacologically active drug at the site 
of infection.
As previously noted, 80% of the reported vancomycin dos-
ing regimens failed to achieve the required PK/PD index when 
using a susceptibility breakpoint of greater than or equal to 
1.5 mg/L (40, 42, 43, 45). This raises major concerns about the 
validity of current dosing strategies, particularly as mortal-
ity associated with methicillin-resistant Staphylococcus aureus 
(MRSA) infection among critically ill patients is increasing 
(49). Of note, higher mortality rates and a greater risk of treat-
ment failure have also been demonstrated with MRSA infection 
where the vancomycin MIC is greater than or equal to 1.5 mg/L 
(50). Achieving an AUC/MIC ratio of at least 400 is consid-
ered essential to improve the possible outcome of vancomycin 
therapy (51). In the case of a vancomycin MIC greater than 
or equal to 1.5 mg/L, although vancomycin trough concen-
trations were ~22 mg/L (45), the observed AUC
0–24
 would be 
insufficient to achieve the target PK/PD index. Administration 
of higher loading doses followed by continuous infusion rep-
resents an evolving approach to improve drug dosing (43). 
Therapeutic drug monitoring (TDM) remains essential in this 
setting although consideration of alternative therapy may be 
required when impractically large doses are required.
We wish to acknowledge the following limitations of this 
study: 1) this is a secondary analysis of group data as individual 
patient data was unavailable; 2) data were extracted from stud-
ies using variable RRT techniques which were not all accurately 
defined; 3) the total number of patients included is small; 4) 
there was heterogeneity between the included ICU populations 
(anuric and nonanuric patients); 5) the approach to ICU man-
agement was not standardized; 6) variable dosing regimens 
TablE 3. The Pharmacokinetic/Pharmacodynamic Target attainments for Vancomycin
References
Renal Replacement  
Therapy Type Dose
aUC0–24/MIC
MIC 1 MIC 1.5 MIC 2
DelDot et al (40) Continuous venovenous 
hemodiafiltration
0.75 g, 12 hourly 525.0 350.0 262.5
Petejova et al (42) CVVH 1 g (first dose), 1 g 12 hourly 347.4 231.6 173.7
Beumier et al (43) CVVH 35 mg/kg (loading),  
then 14 mg/kg 24 hourly
652.0 434.7 326.0
Petejova et al (45) EDD ~11 mg/kg 324.0 216.0 162.0
Petejova et al (45) EDD ~11 mg/kg 555.5 370.3 277.8
AUC0–24	=	area	under	the	concentration-time	curve	from	0	to	24	hours,	MIC	=	minimum	inhibitory	concentration	(mg/L),	CVVH	=	continuous	venovenous	
hemofiltration,	EDD	=	extended	daily	dialysis.
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were employed; 7) PK analyses varied between studies (e.g., 
noncompartmental and compartmental); and 8) alternative 
calculations were used to estimate PK variables in the absence 
of reported PK data.
CONClUSIONS
In conclusion, based on our analyses of published data, efflu-
ent flow rate predicts extracorporeal drug clearance of merope-
nem, piperacillin, and vancomcyin during CRRT. Additional 
data from a well-designed large multicenter trial are now war-
ranted to further evaluate this finding. We observed that anti-
biotic PK data from hybrid forms of RRT (e.g., SLED or EDD) 
are scarce and further studies are urgently needed as solute 
removal is expected to be greatly different from CRRT (11). PK 
studies during different forms of RRT are recommended dur-
ing drug development clinical trials in future to overcome this 
problem (10, 11). As such, current data are not readily translat-
able to hybrid forms of RRT. Given the absence of any stan-
dard globally applicable guidelines on antibiotic dosing during 
RRT, TDM will remain the most accurate means of optimizing 
antibiotic therapy, where available. Additional studies explor-
ing other RRT settings, such as the use of anticoagulation, filter 
material and size, replacement fluid type, and placement, are 
also paramount in order to identify RRT factors that could also 
deleteriously affect antibiotic PK.
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Supplemental Table 1: Pharmacokinetic parameters of meropenem, piperacillin and vancomycin in critically ill patients receiving renal 
replacement therapy 
Reference (s) 
Dose/ 
No. of patients 
(n) 
Pharmacokinetic parameters
a
 
RRT 
Type 
RRT settings 
Cmax 
(mg/L) 
Cmin/Css 
(mg/L) 
AUC0-τ 
CLtotal 
(ml/min) 
CLRRT 
(ml/min) 
Vd 
(L) 
Sc 
Qb  
(ml/min) 
Qe 
(ml/min) 
Meropenem            
Thalhammer et al [17] 1g (single dose) 
(n=9) 
28.1 ± 2.7 6.6 ± 1.5 118.0 ± 15.8
b
 143.7 ± 18.6 49.7 ± 8.3 29.5 ± 2.7 1.1 ± 0.1 CVVH 150.0 45.8 ± 6.2 
Krueger et al [18]  1g 12H 
(n=9) 
103.2 ± 45.9 9.6 ± 3.8 344.0 ± 114.4 53.1 ± 16.8 30.4 ± 2.0 18.0 ± 6.2 1.1 CVVHDF 100.0 29.0 ± 1.8 
Meyer et al [19] 1g 8H 
(n=1) 
19.6 5.8 128.8 129.4 19.8 ± 5.3 37.8 1.0 ± 0.3 CVVHDF 200.0 33.3 
Meyer et al [19] 1g 12H 
(n=1) 
17.9 4.5 118.0 141.3 20.0 ± 7.6 44.1 1.1 ± 0.2 CVVHDF 200.0 33.3 
Tegeder et al [20] 0.5g 8-12H 
(n=9) 
38.9 ± 9.7 7.3 ± 1.3 NA 52.0 ± 8.4 22.0 ± 4.7 12.4 ± 1.8 1.2 ± 0.1 CVVH 150.0-170.0 18.3-19.2 
Valtonen et al [21]  1g 12H 
(n=6) 
NA NA NA 54.5 ± 38.3 NA NA NA CVVH 100.0 6.7 
Valtonen et al [21]  1g 12H 
(n=6) 
NA NA NA 78.7 ± 44.8 NA NA NA CVVHDF 100.0 23.3 
Valtonen et al [21]  1g 12H 
(n=6) 
NA NA NA 95.2 ± 59.7 NA NA NA CVVHDF 100.0 40.0 
Ververs et al [22]  0.5g 12H 
(n=5) 
24.5 ± 7.2 3.0 ± 0.9 129.5 ± 26.4 76.2 ± 14.8 17.2 ± 7.0 31.7 ± 12.9 0.6 ± 0.3 CVVH 200.0 25.0-30.0 
Giles et al [23]  1g 12H 
(n=10) 
55-128e 15.0 246.0 ± 97.1 70.6 ± 24.2 32.7 ± 11.2 27.3 ± 9.8 0.9 ± 0.1 CVVH/ 
CVVHDF 
150.0 
 
33.3 
Robatel et al [24]  0.5-1g 8-12H 
(n=13) 
34.7(0.5g), 
59.4(1g) 
4.1(0.5g), 
7.6(1g) 
NA 74.7 27.0 33.2 0.7 CVVHDF 119.0 ± 15.0 
 
28.3 
Krueger et al [25] 0.5g 12H 
(n=8) 
39.5 ± 10.5 2.4 ± 1.5 105.3 ± 21.7 82.9 ± 21.6 24.4 ± 8.0 22.3 ± 5.6 0.9 ± 0.1 CVVH 100.0 26.7 
Isla et al [26] 0.5-1g 6-8H 
(n=7) 
30.4 ± 10.3 7.7 ± 5.4 NA 150.3 ± 75.8 27.0 ± 6.9 42.8 ± 21.8 0.8 ± 0.1 CVVHDF 100.0-180.0 25.0 
Isla et al [26] 0.5-1g 6-8H 
(n=7) 
43.3 ± 20.1 4.4 ± 2.3 NA 134.4 ± 57.2 32.2 ± 7.2 25.9 ± 7.0 0.9 ± 0.1 CVVH/ 
CVVHDF 
150.0-220.0 
 
36.0 
Isla et al [26] 1-2g 6-8H 
(n=6) 
34.5 ± 18.6 1.0 ± 1.6 NA 1064.8 ± 662.3 16.4 ± 6.7 91.7 ± 63.0 NA CVVH 120.0-180.0 16.7 
Langgartner et al [27]  LD 0.5g, 1g 12H (IB) 
(n=6)  
62.8
d
 8.2
d
 NA 72.0
d
 31.3
c,d
 32.2
d
 1.0
d
 CVVHDF 150.0 31.3 
Langgartner et al [27] LD 0.5g, 2g 24H (CI) 20.0
d
 15.7
d
 NA 73.3
d
 28.2
c,d
 NA 0.9
d
 CVVHDF 150.0 31.3 
(n=6) 
Bilgrami et al [28] 1g 8H 
(n=10) 
56.6
d
 7.6
d
 166.5
d
 100.0
d
 58.3
d
 25.9
e
 0.9
d
 CVVH 275.0 73.3 
Seyler et al [8]  1g 12H 
(n=17) 
26.0 6.0 134.0 80.5
b
 NA 31.5
e
 NA CVVH/ 
CVVHDF 
150.0 ± 24.0     52.5
e
 
Kielstein et al [29] 1g (single dose) 
(n=10) 
NA NA NA NA 38.3 57.6 NA EDD (8.0H) 160.0 ± 3.0 160.0 ± 3.0 
Deshpande et al [30] 1g 12H 
(n=10) 
20.7 ± 8.2 4.0 ± 1.6
f
 NA NA NA NA NA SLED (8.0H) 160.0 ± 45.9 229.5 
Piperacillin
g
            
Joos et al [31] 1-4g 4-12H 
(n=8) 
NA NA NA 56.0
d
 10.0
d
 NA NA CVVH 100.0 13.2 ± 4.6 
van der Werf et al [32] 4g 8H 
(n=9) 
NA NA NA 42.0 ± 23.0 NA 25.9 ± 17.8 NA CVVH NA 25.9 ± 9.8 
Capellier et al [33]  4g (first dose) 
(n=6) 
125.0 ± 21.0 48.0 ± 8.0 964.0 ± 342.0 79.2 ± 23.7 NA 35.5 ± 17.8 NA CVVH 150.0 14.0 ± 1.0 
Capellier et al [33] 4g 8H 
(n=4) 
470.0 ± 127.0 188.0 ± 
71.0 
3352.0 ± 
1750.0 
24.8 ± 13.1 NA 9.7 ± 4.8 NA CVVH 150.0 10.8 ± 0.8 
Valtonen et al [34]  4g 12H 
(n=6) 
NA NA NA 64.8 ± 20.5 NA NA NA CVVH 100.0 13.3 
Valtonen et al [34]  4g 12H 
(n=6) 
NA NA NA 84.3 ± 28.0 NA NA NA CVVHDF 100.0 30.0 
Valtonen et al [34]  4g 12H 
(n=6) 
NA NA NA 91.3 ± 35.2 NA NA NA CVVHDF 100.0 46.6 
Mueller et al [35]  2-4g 8-24H 
(n=8) 
NA NA NA 47.0
d
 22.0 ± 5.0 20.8 ± 4.7 0.8 ± 0.2 CVVHD 150.0 25.3 
Arzuaga et al [36]  4g 6-8H 
(n=4) 
365.6 ± 232.3 NA 76143 ± 49748 50.0 ± 53.0 11.5 ± 6.5 21.0 ± 11.7 0.4 ± 0.3 CVVH 150.0-220.0 27.1 ± 7.8 
Arzuaga et al [36]  4g 6-8H 
(n=5) 
244.5 ± 122.1 NA 45445 ± 25525 90.6 ± 29.9 12.2 ± 13.2 26.8 ± 19.8 0.4 ± 0.4 CVVH 150.0-220.0 30.3 ± 4.3 
Arzuaga et al [36]  4g 6-8H 
(n=5) 
160.6 ± 93.2 NA 17328 ± 11134 265.2 ± 152.2 4.8 ± 3.3 44.9 ± 20.4 0.2 ± 0.1 CVVH 150.0-220.0 20.0 ± 7.5 
Seyler et al [8]  4g 6H 
(n=8) 
138.0
d
 60.0
d
 527.0
d
 80.5
e
 NA 30.8
e
 NA CVVH/ 
CVVHDF 
150.0 ± 24.0     52.5
e
 
Bauer et al [37]  2-3g 6-12H 
(n=42) 
115.0
d
 54.8
d
 NA 78.6
d
 33.2
d
 38.2
d
 NA CVVHD/ 
CVVHDF 
NA 40.7 ± 25.0 
Vancomycin            
Santre et al [38] 7.5mg/kg 
(n=3) 
27.3 3.6 216.7 ± 23.3
b
 38.9 ± 4.3 4.2 ± 1.3 47.4 ± 6.4 NA CVVHDF 100.0-150.0 16.7 
Boereboom et al [39]  1g (single dose) 
(n=1) 
NA NA 398.0 41.7 23.3 55.8 0.9 ± 0.0 CVVH 200.0 26.7 
Boereboom et al [39]  0.5g 12H 
(n=1) 
NA NA 175.0
b
 23.3 23.3 41.7 0.9 ± 0.0 CVVH 200.0 26.7 
DelDot et al [40]  0.75g 12H 
(n=10) 
45.4 ± 10.1 19.2 ± 5.2 262.5 ± 79.5 41.7 ± 11.7 30.0 ± 6.7 49.7 ± 29.1 0.7 ± 0.1 CVVHDF 200.0 50.0 
Chaijamorn et al [41]  1g (single dose) 
(n=7) 
NA NA 671.1 ± 181.1
b
 26.5 ± 7.8 12.1 ± 3.5 24.7 ± 11.0 0.7 ± 0.1 CVVH 200.0-250.0      13.3-20.0 
Petejova et al [42]  1g (1
st
 dose), 1g 12H 
(n=17) 
21.3
d
 10.0
d
 173.7
d
 49.5
d
 45.0
d
 36.9
d
 0.7
d
 CVVH 200.0 67.5 
Beumier et al [43] 35 mg/kg (loading), 
then 14 mg/kg 24H 
(n=41) 
44.0
d
 23.0
d
 652.0
d
 33.2
d
 NA NA NA CVVH/ 
CVVHDF 
150 45.3 
Ahern et al [44] 15 mg/kg 
(n=11) 
NA 16.5 ± 6.7 NA 24.3 ± 8.4 NA 75.3 ± 15.2 NA SLED (24H) 200.0 100.0 
Kielstein et al [29]  1g (single dose) 
(n=10) 
NA NA NA NA 35.0
d
 45.6
d
 NA EDD (8.0H) 160.0 160.0 
Petejova et al [45] ~11mg/kg 
(n=5) 
NA 11.7
d
 324.0
d
 NA 29.0
d
 28.0
d
 NA EDD (6.0H) 200.0 500.0 
Petejova et al [45] ~11mg/kg 
(n=4) 
NA 21.6
d
 555.5
d
 NA 60.3
d
 40.0
d
 NA EDD (6.0H) 200.0 500.0 
Abbreviations: H, Hourly; IB, Intermittent bolus; CI, Continuous infusion; CVVH, Continuous venovenous haemofiltration; CVVHDF, Continuous venovenous 
haemodiafiltration; CVVHD, Continuous venovenous haemodialysis; EDD, Extended daily dialysis; SLED, Sustained low efficiency dialysis; Qb, Blood flow rate; Qe, 
Effluent flow rate; Cmax, Maximum concentration; Cmin, Minimum concentration; Css, Concentration at steady state; AUC0-τ, Area under the curve of concentration versus 
time profile in one dosing interval; CLTotal, Total clearance; CLRRT, Clearance by RRT; Vd, Volume of distribution; Sc, Sieving coefficient and NA, Not available  
a
Data reported as mean ± standard deviation (unless otherwise stated) 
b
Data reported as AUC0-∞  
c
Calculated CLRRT based on alternative calculation 
d
Data reported as median 
e
Data calculated using estimated body weight = 70kg 
f
Concentration at the end of RRT therapy 
g
Based on piperacillin component 
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SUMMARY AT A GLANCE
A review of renal replacement therapy for
acute kidney injury in Malaysian intensive
care units. CRRT using CVVH was the
first-choice modality. Initiation of RRT was
undertaken by the intensivists.
ABSTRACT:
Objectives: To describe renal replacement therapy (RRT) prescribing prac-
tices in Malaysian intensive care units (ICU), and compare this with previ-
ously published data from other regions.
Method: A survey was sent to physicians responsible for prescribing RRT in
major ICU throughout Malaysia. The questionnaire sought information on
the physicians’ background, and detailed information regarding RRT
settings.
Results: Nineteen physicians from 24 sites throughout Malaysia responded
to the survey (response rate 79.2%). Sixteen respondents were intensivists
(84%), 2 were anaesthetists (11%) and one was a nephrologist (5%). The
majority (58%) used continuous venovenous haemofiltration (CVVH) as the
treatment of choice for acute kidney injury (AKI) in critically ill patients.
RRT prescription was predominantly practitioner-dependent (63%), while
37% reported use of a dedicated protocol. The mean blood flow rate and
effluent flow rate used for continuous RRT (CRRT) were 188.9 ± 28.9 mL/
min and 30.6 ± 4.7 mL/kg/h respectively. Replacement fluid solutions con-
taining both lactate and bicarbonate were commonly used during CRRT,
applied both pre- and post-dilution.
Conclusion: CRRT was the first-choice modality used to treat AKI in criti-
cally ill patients. CVVH was the most common CRRT technique used, while
other RRT modalities were used less frequently. Overall, RRT practices were
similar to those observed in other regions, although the modality and set-
tings used were slightly different, likely due to local availability.
Acute kidney injury (AKI) is a significant problem in criti-
cally ill patients. The reported incidence varies, but can be as
high as 65% in some ICU populations, depending on the
definition used.1,2 AKI is associated with mortality rates of
approximately 50%,2 and early management with renal
replacement therapy (RRT) is considered an essential inter-
vention. RRT modalities have evolved over time, in parallel
with technological advances, to offer better patient tolerabil-
ity and solute removal. However, ‘ideal’ RRT settings remain
controversial, and delivery of a standard RRT prescription
globally is unlikely. This is due, in part, to the high costs and
need for specialized staff, which are unlikely to be sustain-
able in resource-limited settings.
RRT can be given intermittently, lasting approximately 4 h
per session, such as occurs with conventional intermittent
haemodialysis (IHD). Prolonged intermittent RRT (PIRRT)
adapted from both intermittent and continuous modalities,
has a longer duration of treatment, lasting up to 18 h.3 Con-
tinuous RRT (CRRT) is perhaps most common in the ICU,
and is given over 24 h. Generally, the aims of treatment are
to control fluid volume, correct acid-base abnormalities,
improve uraemia, promote renal recovery and improve
bs_bs_banner
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mortality without causing complications.4 Solute removal
during RRT occurs by convection and/or diffusion. Conven-
tional dialysis uses diffusion for solute removal, whereas
haemofiltration techniques employ convection. In some
instances, both diffusion and convection are combined, as in
haemodiafiltration.
Describing RRT practice in the ICU is important, as signifi-
cant heterogeneity has been reported globally.5–13 A survey
conducted among nephrologists in the United States in 1995,
demonstrated that IHD and CRRT were both widely used in
ICU, while PIRRT was used infrequently.5 In contrast, a more
recent survey of ICU practitioners revealed increasing use of
CRRT and PIRRT in the critically ill, in preference to IHD.8 In
some countries, IHD is still used in the ICU although only for
select critically ill patients who are haemodynamically stable,
and approaching discharge to the ward.9 Variability in train-
ing and availability of resources between different ICU may
help to explain some of these inconsistencies in RRT
prescription.
Whilst some data exists from Western countries, limited
data are currently available describing RRT prescribing in
other regions. Advances in RRT technology are also likely to
have influenced RRT practice among ICU clinicians in
Malaysia, where the healthcare system is primarily govern-
ment funded. In a small number of University facilities a
co-payment is required from patients, although this is
thought not to influence RRT decisions. In this respect it is
important to provide baseline data on local practice, which
can then serve as a starting point to assess the impact of
alternative RRT methods in this setting.
The aims of this study were to describe RRT prescribing
practices in Malaysian ICU, and compare this with previously
published data from other regions.
METHODS
This study used a survey design and identified physicians who were
responsible for RRT prescribing in major ICU throughout Malaysia.
Based on local ICU registry data,14 from a total of 51 facilities, 24
were classified as major ICU. These were all tertiary centres, with at
least one ICU specialist, as well as an active in-house RRT service.
The reported number of admissions to these ICU was more than 500
per year.14 Therefore, we expected that responses from physicians at
these institutions would closely represent current RRT practices in
ICU across Malaysia.
Expressions of interest for involvement in the study were initially
sought from specialists attending a local ICU meeting in Malaysia.
They were typically the director, or a senior ICU specialist from one
of these centres. Subsequently a study questionnaire was developed
based on previous literature8,9 (Appendix S1), and was sent or
emailed in August 2013 to those willing to participate. These were
distributed to the physician responsible for RRT prescribing at each
unit/institution. The questionnaire sought detailed information on
institutional RRT prescribing and practice. In order to obtain suffi-
cient responses, contact was made with non-responders by email
and/or phone. Respondents could return the questionnaire to the
investigators via email or post.
Statistical analysis
Results were analysed using Microsoft Excel (Microsoft Office 2011;
Redmond, WA, USA) and Prism (GraphPad version 6.0; San Diego,
CA, USA), and are presented as the percentage of respondents, mean
(±standard deviation), or median (interquartile range), as appropri-
ate. A Fisher’s exact test was used to compare categorical data.
P-values of <0.05 were considered as statistically significant.
RESULTS
Respondents’ characteristics
Of the 24 ICU invited to participate, 19 physicians responded
to the questionnaire (79.2% response rate). The character-
istics of those facilities providing data are presented in
Table 1. The respondents were intensivists (84%), anaesthe-
tists (11%) and nephrologists (5%). Seventeen (90%) of the
respondents were physicians practicing in public hospitals
while the remaining were from university hospitals (10%).
The mean reported capacity of ICU and/or high dependency
unit beds available at the respondent’s institutions was
24.0 ± 8.7. The majority of respondents (89.5%) practiced
adult general critical care medicine. The mean estimated
number of AKI patients in ICU requiring RRT was
16.3 ± 10.3 per month. Eight (42%) respondents reported
that only an intensivist was able to commence RRT in ICU,
32% reported that this responsibility was with the
nephrologists, while 26% reported that either an intensivist
or nephrologist could prescribe RRT at their institution. RRT
prescription was mostly practitioner-dependent without a
unit protocol (63%). The majority of the respondents (58%)
reported continuous venovenous haemofiltration (CVVH) as
the treatment of choice for AKI in critically ill patients.
Continuous renal replacement therapy
Eighteen respondents (95%) reported that they prescribed
CRRT for AKI in the ICU (Table 2). Two types of appliances
were commonly used; the Aquarius (Edwards Lifesciences,
Saint-Prex, Switzerland) and Prismaflex (Gambro, Lund,
Table 1 ICU characteristics
Characteristics Respondents
(n = 19)
Non-respondents
(n = 5)
Public/university hospitals 17/2 4/1
ICU admissions (/year)† 1288.0 (1015.8–1611.3) 888.5 (573.5–1298.0)
ICU beds (/facility)† 20.5 (19.3–23.5) 16.0 (11.8–23.0)
Length of ICU stay (days)† 4.9 (4.2–5.4) 5.1 (4.6-5.3)
SAPS II† 39.1 (36.6–40.6) 39.8 (36.3–42.5)
SOFA† 6.9 (6.6–7.2) 7.2 (6.4–7.7)
†Data are presented as the median (interquartile range) from 2012.14 ICU,
intensive care unit; SAPS II, Simplified Acute Physiology Score II; SOFA,
Sequential Organ Failure Assessment.
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Sweden) machines. Most (67%) reported solely using
Prismaflex machines, while 17% reported both were avail-
able for CRRT at their institution. In practice, 61% of
respondents reported that they had used CRRT in more than
40% of AKI cases in the ICU. CRRT was prescribed on the
basis of body weight by most physicians (78%), with the
mean blood flow rate and targeted effluent flow rate being
188.9 ± 24.9 mL/min and 30.6 ± 4.7 mL/kg/h, respectively.
Solutions containing both lactate and bicarbonate were com-
monly used for replacement and dialysate fluid (Fig. 1).
Polyacrylonitrile and polysulfone filter membrane types
were the most commonly used (94%). The haemofilter
membrane surface area was reported as 0.9 m2.
Prolonged intermittent renal replacement therapy
Nine respondents (50%) used a PIRRT modality; with sus-
tained low efficiency dialysis (SLED) used exclusively by
78%, compared with the remainder of ICU which used
either SLED or extended daily diafiltration (EDD-f). The
mean reported percentage of AKI patients receiving this form
of RRT was 29.4 ± 13.6%. Mean blood flow rate and
dialysate flow rate used were 183.3 ± 25.0 mL/min and
294.4 ± 80.8 mL/min, respectively. A polysulfone haemo-
filter with a membrane surface area of 1.8 m2 was most
commonly used. The mean duration of treatment was
6.2 ± 1.8 h, although this was largely determined by pre-
scriber preference, as the treatment schedule varied (Fig. 2).
The most used treatment schedules were 3 times per week
and every other day, with the mean reported percentage of
patients treated with these schedules being 42.5 ± 32.2%,
and 56.3 ± 33.5% respectively.
Intermittent haemodialysis
Nine respondents (50%) prescribed IHD to treat AKI in the
ICU. These respondents included intensivists (78%), a neph-
rologist (11%) and an anaesthetist (11%). The mean
reported percentage of AKI cases in ICU treated with IHD
was 42.0 ± 20.4%. A blood flow rate between 100 and
300 mL/min (mean 263.6 ± 67.4) was commonly used.
Polysulfone haemofilters with a membrane surface area of
1.8 m2 were commonly used for IHD. The mean treatment
duration for IHD was 4.2 ± 0.6 h with a treatment schedule
that varied between the prescribers (Fig. 2). The most used
treatment schedule was 3 times per week and the mean
reported percentage of patients treated with this schedule
was 44.3 ± 23.0%.
Overall, there was no statistically significant association
between use of any RRT modality, including CRRT, IHD,
PIRRT, or at least 2 of these modalities, and the capacity of
the ICU (more than 20 beds or less than 20 beds) (Table 3).
DISCUSSION
This survey is the first report of RRT practices for AKI in
Malaysian ICU. The respondents that completed this survey
are clinicians who routinely care for critically ill patients with
AKI in Malaysia, and thus our findings are highly likely to
reflect current RRT practices in this setting. We found that
CRRT was the most frequently used RRT modality, with
CVVH being the most common technique (Table 3). Other
forms of RRT, such as IHD and PIRRT, were also practised in
some institutions, although this was less frequent.
The reported incidence of AKI within 24 h of ICU admis-
sion is approximately 14%, with 15% of all critically ill
patients receiving RRT at some point.14 Approximately half
of the patients that develop AKI (49.3%) receive RRT.14 The
commencement of RRT for AKI in critically ill patients is
varied, and is used more frequently (more than 60% of AKI
cases) in some region.15 In this population, AKI was associ-
ated with an in-hospital mortality rate of 41.4%, and is
encountered in up to 80% of patients presenting with severe
sepsis and multi-organ failure.14 As such, RRT is commonly
applied in ICU across Malaysia, particularly in high-acuity
patients. Of interest, our data suggest that RRT prescription
in Malaysian ICU is commonly based on practitioner prefer-
ence (more than 60%), while in less than 40%, a local
Table 2 RRT practices in Malaysia
Criteria Response
No. of respondents 19/24
Response rate (%) 79.2
Speciality
Intensivist (%) 84.0
Nephrologist (%) 5.0
Other (%) 11.0
First-choice modality
CRRT (%) 79.0
IHD (%) 15.7
PIRRT (%) 5.3
CRRT settings
Haemofiltration (%) 72
Haemodiafiltration (%) 56
Haemodialysis (%) 27.8
Prescribed dose (mL/kg/h)† 30.6 (± 4.6)
Blood flow rate (mL/min)† 188.9 (± 24.9)
Replacement fluid placement
Pre-dilution (%) 33.3
Post-dilution (%) 11.1
Both (%) 55.6
IHD settings
Blood flow rate (mL/min)† 263.6 (± 67.4)
Duration (h)† 4.2 (± 0.6)
PIRRT settings
Blood flow rate (mL/min)† 183.3 (± 25.0)
Dialysate flow rate (mL/min)† 294.4 (± 80.8)
Duration (h)† 6.2 (± 1.8)
†Data presented as mean (±standard deviation). CRRT, continuous renal
replacement therapy; IHD, intermittent haemodialysis; PIRRT, prolonged inter-
mittent renal replacement therapy; RRT, renal replacement therapy.
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unit/institutional protocol is used. This suggests significant
heterogeneity is likely in this population, which may greatly
influence further research in this area.
CRRT appears to be themost commonly used RRTmodality
in critically ill patients with AKI in Malaysia, a finding also
identified in other countries.6,7,9,12 Similarly, CVVH was
reported as the most common technique among respondents,
a finding consistent with ICU practice in other regions.10,12,13
In separate studies, continuous haemodiafiltration has been
reported as the main approach to treating AKI in the critically
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ill.9,12 The blood flow rate and effluent flow rate listed here are
similar to those reported by other ICU practitioners.8,10,12,13
Limited data are available to compare haemofilter material
and size, however it is expected to be variable between
different regions, as this is influencedmainly by product range
and availability.
The majority of respondents used a lactate-bicarbonate
containing solution as the replacement or dialysate fluid for
CRRT, where as using a lactate-based containing solution
alone may not be preferable in certain situations, particularly
critical illness.16 However, other types of solutions, such as
containing citrate or acetate, have been reported with CRRT
in other areas.8,9 Combining pre-dilution and post-dilution
replacement fluid during CVVH appears to be an increasingly
common practice in many ICU over recent years.12,13 Inter-
estingly, previous study has suggested that applying pre-
dilution is advantageous in increasing filter life span.17
PIRRT such as SLED and EDD-f techniques are alternative
forms of RRT that appear to be increasingly being used in the
critical care setting. In this manner, these techniques
combine the benefits of both traditional RRT modalities.18
Clear advantages include less haemodynamic instability,
more efficient solute removal, better resource allocation,
improved patient mobility (off-treatment), and greater cost-
benefit. As such, recent data support a growing trend
amongst ICU practitioners to use these modalities in treating
AKI in critically ill patients.7,8,11 Of note, the blood flow and
dialysate flow rate used by respondents in this survey, are
similar to those reported in a previous survey.8
IHD is a more conventional form of RRT that is commonly
used for hospitalized and ambulatory patients. The use of
IHD in the ICU setting is therefore somewhat variable. Spe-
cifically, although previous data suggests that some clinicians
employ IHD regularly in the ICU,7,8,11,12 many practitioners in
fact have minimal experience with this modality in the criti-
cally ill.10,13 Of interest, the IHD settings reported in this
survey are similar to those used in routine practice
elsewhere.8,12
We acknowledge that this survey has several limitations.
The number of respondents was low. However, all of them
are ICU physicians who currently manage RRT for AKI in
critically patients admitted to major ICU across Malaysia.
Thus their responses are likely to represent current practices
in this population. There is also potential survey bias, in that
the majority of respondents were critical care physicians (e.g.
intensivist and anaesthetist), as distinct from nephrologists.
Despite this, we believe that the respondents are suitably
qualified to report on RRT prescribing at their institution. We
acknowledge that these data are only applicable to Malaysian
critical care practice, and may not be representative of
current practice in other regions.
We believe these data are crucial in establishing baseline
critical care RRT practice in Malaysia. Benchmarking and
acquisition of quality metrics around such interventions are
essential to improve the quality of care delivered to critically
ill patients nationally. Issues of access to varying RRT modali-
ties, standards of practice, and any influence on clinical out-
comes are key future quality assurance activities linked to
these data. In addition, our results can be used to inform
future clinical research design, particularly in the develop-
ment of protocols applicable to the Malaysian context.
In conclusion, significant variability exists in RRT prescrib-
ing among ICU practitioners in Malaysia; however, CRRT
appears to be the first-choice for most survey respondents.
These data are similar to reports from other regions. CVVH is
the CRRT technique most commonly used, while other types
of RRT (such as IHD and PIRRT) are applied only in select
situations. Intensivists and nephrologists were mainly
responsible on RRT prescription. Further studies using these
data should now be considered.
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Appendix S1: 
A practice survey on renal replacement therapy in Malaysian intensive 
care units 
 
A. General information 
 
1. Which of the following best describes your specialty? 
[   ] Intensivist 
[   ] Nephrologist 
[   ] Anaesthetist 
[   ] Others, please specify:_________________ 
 
2. Who prescribes renal replacement therapy (RRT) in intensive care unit (ICU) patients with 
acute kidney injury (AKI) in your institution? 
[   ] Intensivist 
[   ] Nephrologist 
[   ] Others, please specify:_________________ 
 
3. How many ICU/high dependency unit (HDU) beds in your institution? 
[   ] ICU:______ beds 
[   ] HDU:______ beds 
 
4. What type of ICU is in your institution? 
[   ] General adult ICU 
[   ] General paediatric ICU 
[   ] Surgical ICU 
[   ] Neurosurgical ICU 
[   ] Others, please specify:________________ 
 
5. Approximately how many critically ill patients with AKI do you treat who require RRT? 
____ per month or _______ per year 
 
6. Which RRT modality does your unit use as treatment of first choice in critically ill patients 
with AKI? (please tick one only) 
[   ] Intermittent hemodialysis (IHD) 
[   ] Sustain low efficiency dialysis (SLED) 
[   ] Continuous arteriovenous hemofiltration (CAVH) 
[   ] Continuous arteriovenous hemodialysis (CAVHD) 
[   ] Continuous arteriovenous hemodiafiltration (CAVHDF) 
[   ] Continuous venovenous hemofiltration (CVVH) 
[   ] Continuous venovenous hemodialysis (CVVHD) 
[   ] Continuous venovenous hemodiafiltration (CVVHDF) 
 
7. Is RRT prescription practitioner-dependent or based on unit / institution protocol? 
[   ] practitioner-dependant 
[   ] based on unit/institution protocol 
 
 
 
 
B. Intermittent hemodialysis (IHD) 
 
1. Do you prescribe IHD for critically ill patients with AKI? 
[   ] Yes 
[   ] No (continue to section C) 
2. What RRT machines do you use for IHD? 
______________________ 
 
3. Approximately what percentage of critically ill patients with AKI who require RRT do you 
treat with IHD? 
_______________% 
 
4. For critically ill patients with AKI treated with IHD, estimate the percentage of patients for 
whom you prescribe each of the following treatment schedules: 
____% 2x/week 
____% 3x/week 
____% 4x/week 
____% 5x/week 
____% 6x/week 
____% every other day 
____% daily 
____% as required 
 
5. What is the typical prescription you use when prescribing IHD in critically ill patients with 
AKI? 
Blood flow rate   :_______ ml/min or _________L/h 
Treatment duration  :_______ hours 
Filter material   :_________________________ 
Filter membrane surface area :_______ m2 
 
C. Other forms slow hemodialysis – ‘Prolonged intermittent renal replacement therapy, 
PIRRT) 
 
6. Do you prescribe PIRRT for critically ill patients with AKI? 
[   ] Yes 
[   ] No (continue to section D) 
 
7. Please specify mode: 
[   ] SLED 
[   ] Extended daily diafiltration (EDD-f) 
[   ] Others, please specify:__________________ 
 
8. What RRT machines do you use for PIRRT? 
__________________________________ 
 
9. Approximately what percentage of critically ill patients with AKI who require RRT do you 
treat with PIRRT? 
________ % 
 
10. For critically ill patients with AKI treated with PIRRT, estimate the percentage of patients for 
whom you prescribe each of the following treatment schedules: 
____% 2x/week 
____% 3x/week 
____% 4x/week 
____% 5x/week 
____% 6x/week 
____% every other day 
____% daily 
____% as required 
 
11. What is the typical prescription you use when prescribing PIRRT in critically ill patients with 
AKI? 
Blood flow rate   :________ml/min or _________ L/h 
Dialysate flow rate  :________ ml/min or _________ L/h 
Treatment duration  :________ hours 
Filter material   :__________________________ 
Filter membrane surface area :________m2 
 
D. Continuous renal replacement therapy (CRRT) 
 
12. Do you prescribe CRRT for critically ill patients with AKI? 
[   ] Yes 
[   ] No (skip to question 24) 
 
13. What RRT machines do you use for CRRT? 
____________________ 
 
14. Approximately what percentage of critically ill patients with AKI who require RRT do you 
treat with CRRT? 
____________ % 
 
15. What modalities of CRRT do you utilize? 
[   ] CAVH 
[   ] CAVHD 
[   ] CAVHDF 
[   ] CVVH 
[   ] CVVHD 
[   ] CVVHDF 
 
16. What blood flow rate do you usually prescribe for patients treated with CRRT? 
______________ml/min 
[   ] arteriovenous therapy – blood flow rate not specified 
 
17. Do you prescribe CRRT based on patient weight? 
[   ] Yes 
[   ] No 
 
18. What effluent flow rate (sum of replacement fluid, dialysate and net ultrafiltration rate) do 
you aim for in patients treated with CRRT? 
________ ml/H or ________ ml/kg/H 
 
19. What fluid do you use for dialysate in patients treated with CRRT? 
[   ] Lactate-buffered dialysate 
[   ] Prismasate 
[   ] Normocarb 
[   ] Other, please specify:___________ 
[   ] Do not use dialysate 
 
20. If replacement fluid was given, where in relation to the filter was it given? 
[   ] before the filter (pre-dilution) 
[   ] after the filter (post-dilution) 
[   ] no fluid replacement (continue to question no. 22) 
 
21. What fluid do you use for replacement fluid in patients treated with CRRT? 
[   ] Lactate-buffered dialysate 
[   ] Prismasate 
[   ] Normocarb 
[   ] Other, please specify:___________ 
[   ] Do not use dialysate 
 
22. What is filter material that you commonly used? 
[   ] polyamide 
[   ] polyacrylnitrile 
[   ] polysulphone 
[   ] other, please specify:_____________ 
[   ] not sure 
 
23. What is the size of membrane surface area of filter that you commonly used? 
___________ m2 
 
24. Please identify your institution: 
[   ] Hospital Kangar, Perlis 
[   ] Hospital Sultanah Bahiyah, Kedah 
[   ] Hospital Pulau Pinang, Penang 
[   ] Hospital Ipoh, Perak 
[   ] Hospital Kuala Lumpur 
[   ] Hospital Putrajaya 
[   ] Hospital Selayang 
[   ] Hospital Serdang 
[   ] Hospital Sg. Buloh 
[   ] Hospital Ampang 
[   ] Hospital Melaka 
[   ] Hospital Seremban 
[   ] Hospital Sultanah Aminah, Johor Bahru 
[   ] Hospital Tg. Ampuan Afzan, Kuantan 
[   ] Hospital Sultanah Nur Zahirah, Kuala Terengganu 
[   ] Hospital Kota Bahru 
[   ] Hospital Universiti Kebangsaan Malaysia 
[   ] Pusat Perubatan Universiti Malaya 
[   ] Hospital Universiti Sains Malaysia, Kubang Kerian 
[   ] Other, please specify:___________________ 
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The objective of this study was to describe the pharmacokinetics of meropenem, administered by con-
tinuous infusion (CI) or intermittent bolus (IB), in critically ill patients receiving continuous venovenous
haemofiltration (CVVH) and to evaluate the frequency of pharmacokinetic/pharmacodynamic target
attainment with each dosing strategy. This was a prospective, randomised controlled trial in critically
ill patients receiving CVVH and administered meropenem by CI or IB. Serial meropenem concentra-
tions in plasma and ultrafiltrate were measured after administration of a standard total daily dose
(4 g/day onDay1, followedby3g/day thereafter) on twooccasions during antibiotic therapy.Meropenem
pharmacokinetic parameters were calculated using a non-compartmental approach. Sixteen critically
ill patients receiving CVVH concurrently treated with meropenem were randomised to CI (n=8) or IB
dosing (n=8). IB administration resulted in higher maximum concentrations (Cmax) [64.7 (58.9–80.3)
and 64.8 (48.5–81.8)mg/L, respectively] on both sampling occasions compared with CI (P<0.01 and
P=0.04, respectively). CI resulted in a higher meropenem steady-state concentration (Css) on occasion 1
[26.0 (24.5–41.6)mg/L] compared with the minimum concentration (Cmin) observed for IB patients [17.0
(15.7–19.8)mg/L; P<0.01]. CVVH contributed to ca. 50% of meropenem total clearance in these patients.
The administered meropenem doses resulted in plasma drug concentrations that were >4× the targeted
susceptibility breakpoint (2mg/L) for 100% of the dosing interval, for both groups, on both occasions. CI
could be an alternative to IB for meropenem administration in critically ill patients receiving CVVH.
© 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.. Introduction
Effective antibiotic dosing is considered one of the key inter-
entions to reduce mortality in critically ill patients with severe
epsis or septic shock [1]. Administration by continuous infusion
CI) is one of the approaches advocated to improve -lactam drug
xposure in critical illness [2–8], particularly in an era of emerging
∗ Corresponding author. Present address: Burns, Trauma and Critical Care
esearch Centre, Level 7, Block 6, Royal Brisbane and Women’s Hospital, Butter-
eld Street, Brisbane QLD 4029, Australia. Tel.: +61 7 3646 4108;
ax: +61 7 3646 3542.
E-mail address: janattul.jamal@uq.net.au (J.-A. Jamal).
ttp://dx.doi.org/10.1016/j.ijantimicag.2014.09.009
924-8579/© 2014 Elsevier B.V. and the International Society of Chemotherapy. All rightsbacterial resistance and limited availability of new antibiotics.
Multiple studies have evaluated this method of -lactam admin-
istration in various critically ill subgroups, demonstrating that CI
achieves the required drug concentrations more consistently than
conventional intermittent bolus (IB) dosing [6–10].
Existing literature on-lactamCI generally excludes critically ill
patients treated with renal replacement therapy (RRT), a group for
which additional data are urgently required as substantial amounts
of drug may be cleared by this extracorporeal technique [11].
Indeed, previous data have shown that standard carbapenem dos-
ing regimens were insufficient for critically ill patients receiving
RRT [12]. As such, CI may offer a more effective dosing option,
increasing the likelihood of achieving therapeutic concentrations
in this patient group.
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The objectives of this study were therefore to describe the
harmacokinetics of meropenem administered by CI or IB to criti-
ally ill patients receiving continuous venovenous haemofiltration
CVVH). We also aimed to describe the frequency of pharmacoki-
etic/pharmacodynamic (PK/PD) target attainment of meropenem
ith each method of administration.
. Patients and methods
This was a prospective, randomised controlled pharmacoki-
etic study performed in a 12-bed intensive care unit (ICU) of a
ajor tertiary hospital in Malaysia (Kuantan, Pahang, Malaysia).
he studywas approved by the local ethics committee, and consent
o participate was obtained from the patient’s legally authorised
epresentative.
.1. Patient selection and data collection
All adult patients (age ≥18 years) admitted to the ICU with
evere sepsis or septic shock and receiving CVVH for oligouric or
nuric renal impairment were eligible for enrolment. Meropenem
as prescribed at the discretion of the treating physician. Patients
ere randomised to receive the same dose of meropenem, admin-
stered by either CI or IB, using random allocations selected from
equentially numbered opaque sealed envelopes.
.2. Meropenem administration
All patients received meropenem (DBLTM Meropenem for Injec-
ion; Hospira Healthcare, Chennai, India). Patients in the CI group
n=8) were administered a loading dose of 1 g of meropenem
n 20mL of 0.9% sodium chloride over 30min via a central line,
ollowed immediately by CI over 24h (125mg/h). Owing to stabil-
ty issues, meropenem was prepared every 8h by diluting 1g of
eropenem in 100mL of 0.9% sodium chloride. Patients in the IB
roup (n=8) received 2g of meropenem as a 30-min infusion via a
entral line for the first dose, followed by 1g every 8h thereafter.
n both groups, meropenem was administered using a volumetric
nfusion pump controller, and all patients received a total dose of
eropenem of 4g/day on Day 1 and 3g/day thereafter.
.3. Continuous renal replacement therapy
CVVHwas performed in all patients using anAquariusTM system
Edwards Lifesciences, Saint-Prex, Switzerland). Polysulfone®-type
aemofilters with a surface area of 1.2m2 (Aquamax12TM; Bax-
er Healthcare, Zurich, Switzerland) were used. In all patients,
VVH was started at least 4h prior to the sampling period. Vas-
ular access was obtained via the internal jugular or femoral vein
sing a 14-French double-lumen catheter. The ultrafiltrate rate
as set at 2000mL/h [median effluent flow rate, 30.09mL/kg/h;
nterquartile range (IQR), 25.00–33.33mL/kg/h], combining pre-
nd post-dilution fluid replacement at a 1:1 ratio. The targeted
lood flow rate was 200mL/min. Net fluid removal was between
0mL/h and 100mL/h depending on the clinical circumstance.
actate-containing (PrismaSol®; Gambro, Sondalo, Italy) or lactate-
ree (DuosolTM; B. Braun, Glandorf, Germany) solutions were used
s the replacement solution, and the circuit was anticoagulated
ith heparin (100U/mL) at the discretion of the attending physi-
ian.
.4. Sample collectionPharmacokinetic sampling occurredduring one 8-h or 24-hdos-
ng interval betweenDays1–3of treatment (occasion1), andduring
n 8-h dosing interval between Days 4–6 of treatment (occasion 2).ntimicrobial Agents 45 (2015) 41–45
For each sample, 3mL of blood was collected in a lithium heparin
tube, pre-filter, at 0, 15, 30, 45, 60, 120, 240, 480 and 1440min
(CI only) and post-filter at 30, 120 and 480min on occasion 1.
For occasion 2, 3mL of blood was collected in a lithium heparin
tube, pre-filter or at arterial line, at 0, 15, 30, 45, 60, 120, 240, 480
and post-filter at 480min. Ultrafiltrate samples were collected and
measuredat120,240, 360and480min, and3mLaliquotswerekept
for analysis. All sampleswere immediately centrifuged at 3000 rpm
for 10min and plasma was separated and frozen at −80 ◦C.
2.5. Meropenem assay
Meropenem concentrations in plasma and ultrafiltrate were
determinedbyvalidated assaymethodsonaShimadzuProminence
(Shimadzu Corp., Kyoto, Japan) high-pressure liquid chromatogra-
phy (HPLC) system at the Burns, Trauma and Critical Care Research
Centre of The University of Queensland (Brisbane, Australia). The
assay was conducted alongside a standard curve and quality con-
trol replicates at high, medium and low concentrations. The limit
of quantification for meropenem was 0.2mg/L and linearity was
validated from 0.2mg/L to 100mg/L (plasma) and from 1mg/L to
200mg/L (ultrafiltrate). All results were within 5% for all matrices
at all levels, and the assay was validated and conducted according
to criteria specified by the US Food and Drug Administration (FDA)
guidance on bioanalysis [13].
2.6. Pharmacokinetic analysis
Pharmacokinetic parameter values were estimated using non-
compartmental methods. The area under the concentration–time
curve from0 to 8h in plasma (AUC0–8 plasma) or ultrafiltrate (AUC0–8
ultrafiltrate) was calculated using the linear trapezoidal rule. Total
body clearance (CLtotal) was calculated as dose/AUC0–8 plasma. The
maximumconcentration for the dosing period (Cmax) and themini-
mum concentration for the dosing period (Cmin) were the observed
values. The apparent terminal elimination rate constant (ke) was
determined from log-linear least-squares regression analysis of
concentrations from 2 to 8h (bolus dosing). The apparent volume
of distribution during the terminal phase (Vd) was calculated as
CLtotal/ke, and the half-life (t1/2) was calculated as ln(2)/ke (bolus
dosing). The extraction ratio (ER) across the filter was calculated
as the ratio of the meropenem post-filter blood sample concen-
tration to the pre-filter blood sample concentration. The sieving
coefficient (Sc) was calculated as the ratio of the concentration of
meropenem in the ultrafiltrate to the concentration in the pre-
filter blood. Clearance by CVVH (CLCVVH) was calculated using the
equation CLCVVH =ACVVH/AUC0–8 ultrafiltrate (where ACVVH is the total
amount of meropenem recovered in the ultrafiltrate in one dos-
ing interval). Clearance not mediated by CVVH (CLnon-CVVH) was
calculated using the equation CLnon-CVVH =CLtotal −CLCVVH.
2.7. Pharmacodynamic analysis
A susceptibility breakpoint of 2mg/L for meropenem against
common pathogens, based on the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST) 2013 database [14] was
used to determine the frequency of PK/PD target attainment. Based
on previous publications [15,16], for IB administration a plasma
drug concentration ≥4× the minimum inhibitory concentration
(MIC) for more than 40% of the dosing interval (40% T>4×MIC) was
considered as a suitable PK/PD target, whereas for CI administra-
tion a plasma concentration 5× the MIC breakpoint over the entire
dosing interval (100% T>5×MIC) was required.
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Table 1
Demographic and clinical data of patientsa
Characteristic Continuous infusion (n=8) Intermittent bolus (n=8) P valueb
Sex (male/female) (n) 7/1 4/4 0.28
Age (years) 47.5 (32.0–63.3) 44.5 (29.0–60.8) 0.90
Height (cm) 166.0 (161.5–170.8) 151.0 (150.0–158.3) 0.006*
Weight (kg) 80.0 (68.5–80.0) 60.0 (50.0–63.8) 0.003*
APACHE II score 30.0 (26.5–32.5) 32.5 (29.8–37.8) 0.13
SOFA score (upon ICU admission) 15.5 (13.3–18.5) 14.5 (14.0–17.8) 0.90
SOFA score (upon study inclusion) 16.0 (13.0–16.8) 17.5 (14.8–18.8) 0.11
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit.
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.8. Statistical analysis
Datawere analysed usingMicrosoft Excel (Microsoft Corp., Red-
ond, WA) and GraphPad Prism® v.6.0 (GraphPad Software Inc.,
an Diego, CA). Continuous data are presented as the median (IQR).
Fisher’s exact test was used to compare categorical data, and a
ann–Whitney test for continuous data. A Wilcoxon signed-rank
est was used for paired data. A P value of <0.05 was considered
tatistically significant.
. Results
.1. Patient demographics
In total, 16patientswere enrolled,with 8 randomised toCI and8
o IB. Studyparticipants’ demographics, illness severity and anthro-
ometric data are presented in Table 1. There were no significant
ifferences between the groups in terms of age, sex, severity of ill-
ess and organ dysfunction, although those receiving CI has greater
eight and height (see Table 1). Seven patients in the CI group and
ix in the IB group were still in the ICU on the second occasion of
ampling. However, of these, only three patients in the CI group
nd five in the IB group were receiving ongoing CVVH.
.2. Meropenem concentrationsThe observed plasma concentration–time profiles for
eropenem on occasion 1 of sampling (Days 1–3 of treat-
ent) and occasion 2 (Days 4–6 of treatment) in patients receiving
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CI and IB are shown in Fig. 1. IB administration resulted in a
significantly higher Cmax on both occasions. Conversely, CI resulted
in a significantly higher steady-state concentration (Css) compared
with the Cmin observed in IB patients on occasion 1 only (Table 2).
Table 3 summarises the pharmacokinetic parameters for
patients receiving CVVH on two sampling occasions. Overall, the
parameter estimates were numerically higher on occasion 1 for
both CI and IB, except for CLtotal, ER and CLnon-CVVH, as well as Sc in
patientswho received IB.However, all differenceswere statistically
insignificant (P>0.05) when comparing paired data. The median
(IQR) meropenem Vd and t1/2 in patients who received IB adminis-
tration were 0.43 (0.40–0.50) L/kg and 4.4 (4.1–5.1) h, respectively,
however these data were unable to be calculated in patients who
received CI.
3.3. Pharmacokinetic/pharmacodynamic target attainment
Overall, the meropenem dosing regimen used in this study
resulted in plasma concentrations that were >4× the targeted sus-
ceptibility breakpoint (2mg/L) for 100% of the dosing interval in
patients receiving IB administration on both occasions of sampling.
In the CI group, the plasma concentrations were all >10× the sus-
ceptibilitybreakpoint throughout theentiredosing interval onboth
occasions of sampling.4. Discussion
This prospective studyofmeropenempharmacokinetics in criti-
cally ill patients receiving CVVHhas demonstrated that CI produces
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nge) at an 8-h dosing interval during occasion 1 (Days 1–3, cumulative meropenem
=9–10g) by (a) continuous infusion and (b) intermittent bolus administration.
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Table 2
Meropenem pharmacokinetic parameters between continuous infusion (CI) and intermittent bolus (IB) dosing.
Parameter Occasion 1 (Days 1–3)a P valueb Occasion 2 (Days 4–6)a P valueb
CI (n=8) IB (n=8) CI (n=3) IB (n=5)
Cmax (mg/L) 34.51 (28.97–47.10) 64.66 (58.89–80.33) 0.0006* 24.80 (22.69–33.36) 64.80 (48.45–81.80) 0.04*
Cmin or Css (mg/L) 25.96 (24.51–41.64) 16.99 (15.67–19.83) 0.003* 21.91 (17.18–32.64) 16.86 (9.73–19.72) 0.14
AUC0–8 plasma (mgh/L) 215.28 (195.95–250.35) 250.82 (215.48–294.79) 0.27 186.30 (144.71–241.03) 234.79 (174.53–288.36) 0.36
CLtotal (mL/kg/min) 0.96 (0.86–1.01) 1.13 (0.88–1.60) 0.19 1.12 (0.86–1.69) 1.29 (1.07–1.49) 0.86
Sc 1.02 (0.93–1.14) 1.10 (1.04–1.31) 0.15 0.92 (0.81–1.07) 1.21 (1.02–1.40) 0.14
ER 0.89 (0.85–1.01) 0.95 (0.86–1.02) 0.70 0.93 (0.86–0.96) 0.97 (0.88–1.09) 0.45
AUC0–8 ultrafiltrate (mgh/L) 188.44 (182.93–208.80) 226.70 (192.08–342.25) 0.16 147.60 (122.64–218.28) 179.29 (167.39–288.55) 0.25
ACVVH (mg) 442.44 (410.92–481.34) 482.00 (422.06–540.08) 0.49 346.71 (335.51–482.43) 429.98 (378.85–576.02) 0.25
CLCVVH (mL/kg/min) 0.49 (0.43–0.58) 0.58 (0.52–0.67) 0.06 0.49 (0.46–0.67) 0.66 (0.56–0.67) 0.50
CLnon-CVVH (mL/kg/min) 0.45 (0.38–0.56) 0.55 (0.32–1.03) 0.56 0.63 (0.40–1.02) 0.63 (0.40–0.92) 0.85
Cmax, maximum concentration; Cmin, minimum concentration; Css, concentration at steady state; AUC0–8 plasma, area under the concentration–time curve from 0 to 8h in
plasma; CLtotal, total clearance; Sc, sieving coefficient; ER, extraction ratio; AUC0–8 ultrafiltrate, area under the concentration–time curve from 0 to 8h in ultrafiltrate; ACVVH, total
amount of meropenem recovered in ultrafiltrate in one dosing interval; CLCVVH, clearance by continuous venovenous haemofiltration; CLnon-CVVH, clearance not mediated by
continuous venovenous haemofiltration.
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significantly higher Css compared with the Cmin observed with IB
dministration when samples were drawn between Days 1–3 of
herapy. The dosing regimen chosen for this study is the same as
hat recommended by the product information for use in patients
ith ‘normal’ renal function. For both methods of administration,
his dose resulted in meropenem plasma concentrations that eas-
ly met the chosen PK/PD targets and were in fact greater than 4×
IC for the entire dosing intervalwhen considering a susceptibility
reakpoint of 2mg/L. These results demonstrate that lower doses
verall of meropenem could be used with the RRT settings [median
IQR) effluent flow rate, 30.09 (25.00–33.33)mL/kg/h] used in this
tudy.
In patients who continued to receive CVVH on Days 4–6,
eropenem concentrations tended to be lower than those
bserved earlier during treatment (Days 1–3). These changes were
ot statistically significant, although the fact many patients were
ot eligible for sampling on occasion 2 (due to discontinuation
f RRT) limits this analysis. Temporal variability in pharmacoki-
etic parameters can also be related to a number of patient factors,
ncluding recovering native renal function. Unfortunately, quan-
ifying such changes remains problematic, as ongoing RRT will
onfound the interpretation both of plasma biochemistry and of
athematical estimates of renal function. However, CLnon-CVVH
mproved during occasion 2 sampling both in the CI and IB groups,
hich might indicate recovering of intrinsic renal function or
pregulation of non-renal elimination pathways. For treatment of
able 3
eropenem pharmacokinetics in patients continuing to receive continuous venovenous
Parameter Continuous infusion (n=3)a
Occasion 1 Occasion 2
Cmax (mg/L) 37.34 (28.87–37.40) 24.80 (22.69–33.36)
Cmin or Css (mg/L) 27.75 (26.41–32.39) 21.91 (17.18–32.64)
AUC0–8 plasma (mgh/L) 231.38 (211.11–256.67) 186.30 (144.71–241.03)
CLtotal (mL/kg/min) 0.98 (0.87–1.01) 1.12 (0.86–1.69)
Sc 0.94 (0.92–1.05) 0.92 (0.81–1.07)
ER 0.88 (0.84–0.88) 0.93 (0.86–0.96)
AUC0–8 ultrafiltrate (mgh/L) 199.00 (183.62–212.07) 147.60 (122.64–218.28)
ACVVH (mg) 465.63 (448.47–486.57) 346.71 (335.51–482.43)
CLCVVH (mL/kg/min) 0.51 (0.46–0.60) 0.49 (0.46–0.67)
CLnon-CVVH (mL/kg/min) 0.42 (0.38–0.50) 0.63 (0.40–1.02)
max, maximum concentration; Cmin, minimum concentration; Css, concentration at stea
lasma; CLtotal, total clearance; Sc, sieving coefficient; ER, extraction ratio; AUC0–8 ultrafiltrat
mount of meropenem recovered in ultrafiltrate in one dosing interval; CLCVVH, clearance
ontinuous venovenous haemofiltration.
a Data are presented as the median (interquartile range).
b P values were calculated using the Wilcoxon signed-rank test, which compares pairedpathogens with higher MICs, this could represent an advantage for
CI in terms of more consistent achievement of therapeutic concen-
trations, although this observation appears to be more dependent
on dose rather than infusion duration.
The observed median meropenem CLtotal was similar to that
reported in previous studies [17–21]. Of note, CVVH accounted
for ca. 50% of meropenem CLtotal, either administered by CI or IB,
which is also in agreement with previous work [22,23]. In compar-
ison with data derived from studies using similar continuous renal
replacement therapy (CRRT) intensity [21,24,25],we found that the
impact of extracorporeal clearancewas slightly higher in this study.
This could be explained by differing patient factors, including the
presence of residual native renal function, as described in previous
reports [24,26]. This is highly likely given that in this study cohort,
all patients were oligo-anuric, such that significant intrinsic renal
clearance would be very unlikely.
Despite reported physiological differences in Asian patients
compared with Western patients [27], the observed median Vd in
patients who received IB dosing was comparable with previous
findings in critically ill patients receiving variable CRRT settings
(0.30–0.50 L/kg) [12,17–19,21,22,28,29].
The dosing regimen used in this study easily achieved the
selected PK/PD targets for meropenem administered by either CI
or IB. The result suggests that in critically ill patients receiving
CVVH, choice of dose rather than mode of administration may be
the more important consideration for clinicians. Earlier studies of
haemofiltration on both occasions.
P valueb Intermittent bolus (n=5)a P valueb
Occasion 1 Occasion 2
0.25 64.97 (61.42–86.92) 64.80 (48.45–81.80) 0.31
0.50 19.12 (16.78–24.42) 16.86 (9.73–19.72) 0.13
0.25 282.35 (250.82–351.09) 234.79 (174.53–288.36) 0.13
0.50 0.98 (0.84–1.14) 1.29 (1.07–1.49) 0.13
0.75 1.08 (0.95–1.27) 1.21 (1.02–1.40) 0.31
0.50 0.95 (0.78–1.06) 0.97 (0.88–1.09) 0.81
0.50 247.00 (194.45–373.27) 179.29 (167.39–288.55) 0.06
0.50 522.55 (482.01–666.66) 429.98 (378.85–576.02) 0.13
0.75 0.65 (0.50–0.68) 0.66 (0.56–0.67) 0.63
0.50 0.34 (0.22–0.56) 0.63 (0.40–0.92) 0.19
dy state; AUC0–8 plasma, area under the concentration–time curve from 0 to 8h in
e, area under the concentration–time curve from 0 to 8h in ultrafiltrate; ACVVH, total
by continuous venovenous haemofiltration; CLnon-CVVH, clearance not mediated by
data from patients sampled on both occasions.
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eropenem in CRRT demonstrated that lower meropenem doses
e.g. 1–2g/day) rarely enabled concentrations to be maintained
bove higher MICs (e.g. >2mg/L) [18,19,23,24,29], supporting the
eed for more aggressive meropenem dosing in this population
12]. Interestingly, despite higher meropenem dosing (e.g. 3 g/day)
n patients receiving higher-intensity CRRT, this was still subopti-
al for the desired therapeutic target [22].
Importantly, the current study has highlighted that unselected
pplication of meropenem CI in the ICU is unlikely to deliver addi-
ional benefits in some patient groups, such as those receiving
VVH.However, given the varying effects of different CRRT settings
n meropenem clearance [22,30], dose individualisation based on
ndividual patient circumstances should still be considered the best
pproach for optimal dosing.
We wish to acknowledge the following limitations. First, this
as a single-centre study from a patient population different to
hat encountered in other regions. Despite this, we believe these
ata provide useful insights into this area of practice. Second, local
CU management may be different to that used in other insti-
utions and therefore any recommendation from this work may
ot be directly transferable to other ICU populations. Third, the
UCAST database was used to evaluate achievement of the PK/PD
ndex during meropenem treatment and this may underestimate
he scenario in a clinical data set. However, in the absence of these
ata locally, these susceptibility breakpoints are a useful guide for
ntibiotic dosing. Finally, we did not specifically measure intrinsic
enal function, and therefore other than by examining CLnon-CVVH,
e cannot reliably quantify changes in intrinsic renal function over
ime.
. Conclusion
CI administration resulted in more rapid and sustained
eropenem concentrations compared with IB. The dosing regi-
en used in this study was associated with achievement of the
esiredmeropenemPK/PD target both for CI and IB, suggesting that
lower dose could be considered in this CRRT setting if susceptible
athogens are present. If more resistant pathogens are being tar-
eted then CI is likely to result in more consistent achievement of
K/PD targets.
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